"STUDY_ID","EVENTCATEGORYNAME","EVENTNAME","startdt","SHORTTITLE","STUDYNUMBER","enddt","EVENT"
50203,"Protocol Status","Closed to Follow Up","30-MAR-1992","AZT in KS","ACTG 001","","Closed to Follow Up"
50203,"Protocol Status","Concluded","05-MAY-1990","AZT in KS","ACTG 001","30-MAR-1992","Concluded"
50203,"Protocol Status","Closed to Accrual","13-NOV-1987","AZT in KS","ACTG 001","05-MAY-1990","Closed to Accrual"
50203,"Protocol Status","Open","20-NOV-1986","AZT in KS","ACTG 001","13-NOV-1987","Open"
50203,"Protocol Status","Pending","05-SEP-1986","AZT in KS","ACTG 001","20-NOV-1986","Pending"
50204,"Protocol Status","Concluded","01-MAR-2001","AZT for AIDS patients post first episode PCP","ACTG 002","","Concluded"
50204,"Protocol Status","Closed to Follow Up","14-MAY-1990","AZT for AIDS patients post first episode PCP","ACTG 002","01-MAR-2001","Closed to Follow Up"
50204,"Protocol Status","POS/PAC","01-MAY-1990","AZT for AIDS patients post first episode PCP","ACTG 002","14-MAY-1990","POS/PAC"
50204,"Protocol Status","Closed to Accrual","12-NOV-1987","AZT for AIDS patients post first episode PCP","ACTG 002","01-MAY-1990","Closed to Accrual"
50204,"Protocol Status","Open","02-DEC-1986","AZT for AIDS patients post first episode PCP","ACTG 002","12-NOV-1987","Open"
50204,"Protocol Status","Pending","10-NOV-1986","AZT for AIDS patients post first episode PCP","ACTG 002","02-DEC-1986","Pending"
50205,"Protocol Status","Concluded","15-JUL-1990","AZT/DHPG in CMV","ACTG 004","","Concluded"
50205,"Protocol Status","POS/PAC","14-FEB-1990","AZT/DHPG in CMV","ACTG 004","15-JUL-1990","POS/PAC"
50205,"Protocol Status","Closed to Follow Up","30-JAN-1990","AZT/DHPG in CMV","ACTG 004","14-FEB-1990","Closed to Follow Up"
50205,"Protocol Status","Closed to Accrual","26-SEP-1988","AZT/DHPG in CMV","ACTG 004","30-JAN-1990","Closed to Accrual"
50205,"Protocol Status","Open","23-APR-1987","AZT/DHPG in CMV","ACTG 004","26-SEP-1988","Open"
50205,"Protocol Status","Pending","16-JAN-1987","AZT/DHPG in CMV","ACTG 004","23-APR-1987","Pending"
50206,"Protocol Status","Concluded","01-APR-1993","AZT in ADC (placebo-control)","ACTG 005","","Concluded"
50206,"Protocol Status","POS/PAC","01-AUG-1990","AZT in ADC (placebo-control)","ACTG 005","01-APR-1993","POS/PAC"
50206,"Protocol Status","Closed to Follow Up","19-SEP-1989","AZT in ADC (placebo-control)","ACTG 005","01-AUG-1990","Closed to Follow Up"
50206,"Protocol Status","Closed to Accrual","16-JUN-1988","AZT in ADC (placebo-control)","ACTG 005","19-SEP-1989","Closed to Accrual"
50206,"Protocol Status","Open","17-JUL-1987","AZT in ADC (placebo-control)","ACTG 005","16-JUN-1988","Open"
50206,"Protocol Status","Pending","28-APR-1987","AZT in ADC (placebo-control)","ACTG 005","17-JUL-1987","Pending"
50207,"Protocol Status","Concluded","01-MAR-1993","Adriamycin in KS","ACTG 006","","Concluded"
50207,"Protocol Status","POS/PAC","02-JUN-1990","Adriamycin in KS","ACTG 006","01-MAR-1993","POS/PAC"
50207,"Protocol Status","Closed to Follow Up","26-DEC-1989","Adriamycin in KS","ACTG 006","02-JUN-1990","Closed to Follow Up"
50207,"Protocol Status","Closed to Accrual","11-JUL-1988","Adriamycin in KS","ACTG 006","26-DEC-1989","Closed to Accrual"
50207,"Protocol Status","Open","24-MAY-1987","Adriamycin in KS","ACTG 006","11-JUL-1988","Open"
50207,"Protocol Status","Pending","07-APR-1987","Adriamycin in KS","ACTG 006","24-MAY-1987","Pending"
50208,"Protocol Status","Withdrawn","04-OCT-1994","Phase I:  Desciclovir -> Desciclovir + AZT","ACTG 007","","Other"
50208,"Protocol Status","In Development","06-DEC-1988","Phase I:  Desciclovir -> Desciclovir + AZT","ACTG 007","04-OCT-1994","In Development"
50208,"Protocol Status","Deferred","06-DEC-1988","Phase I:  Desciclovir -> Desciclovir + AZT","ACTG 007","06-DEC-1988","Other"
50209,"Protocol Status","Concluded","03-JUL-1991","MBACOD/AZT +/- radiation in B-cell lymphoma","ACTG 008","","Concluded"
50209,"Protocol Status","Closed to Follow Up","01-MAY-1991","MBACOD/AZT +/- radiation in B-cell lymphoma","ACTG 008","03-JUL-1991","Closed to Follow Up"
50209,"Protocol Status","POS/PAC","31-MAR-1990","MBACOD/AZT +/- radiation in B-cell lymphoma","ACTG 008","01-MAY-1991","POS/PAC"
50209,"Protocol Status","Closed to Accrual","27-DEC-1988","MBACOD/AZT +/- radiation in B-cell lymphoma","ACTG 008","31-MAR-1990","Closed to Accrual"
50209,"Protocol Status","Open","26-JUN-1987","MBACOD/AZT +/- radiation in B-cell lymphoma","ACTG 008","27-DEC-1988","Open"
50209,"Protocol Status","Pending","30-APR-1987","MBACOD/AZT +/- radiation in B-cell lymphoma","ACTG 008","26-JUN-1987","Pending"
50210,"Protocol Status","Concluded","26-MAR-1990","Chemo./AZT/Rad. in Primary CNS lymphoma","ACTG 009","","Concluded"
50210,"Protocol Status","Concluded","14-FEB-1990","Chemo./AZT/Rad. in Primary CNS lymphoma","ACTG 009","26-MAR-1990","Concluded"
50210,"Protocol Status","Closed to Follow Up","28-SEP-1989","Chemo./AZT/Rad. in Primary CNS lymphoma","ACTG 009","14-FEB-1990","Closed to Follow Up"
50210,"Protocol Status","Closed to Accrual","20-JUN-1989","Chemo./AZT/Rad. in Primary CNS lymphoma","ACTG 009","28-SEP-1989","Closed to Accrual"
50210,"Protocol Status","Open","17-OCT-1987","Chemo./AZT/Rad. in Primary CNS lymphoma","ACTG 009","20-JUN-1989","Open"
50210,"Protocol Status","Pending","15-MAY-1987","Chemo./AZT/Rad. in Primary CNS lymphoma","ACTG 009","17-OCT-1987","Pending"
50211,"Protocol Status","Concluded","01-AUG-1998","AZT/ACV in AIDS/ARC","ACTG 010","","Concluded"
50211,"Protocol Status","POS/PAC","11-OCT-1990","AZT/ACV in AIDS/ARC","ACTG 010","01-AUG-1998","POS/PAC"
50211,"Protocol Status","Closed to Follow Up","16-NOV-1989","AZT/ACV in AIDS/ARC","ACTG 010","11-OCT-1990","Closed to Follow Up"
50211,"Protocol Status","Closed to Accrual","28-JUL-1989","AZT/ACV in AIDS/ARC","ACTG 010","16-NOV-1989","Closed to Accrual"
50211,"Protocol Status","Open","01-JUN-1987","AZT/ACV in AIDS/ARC","ACTG 010","28-JUL-1989","Open"
50211,"Protocol Status","Pending","23-APR-1987","AZT/ACV in AIDS/ARC","ACTG 010","01-JUN-1987","Pending"
50212,"Protocol Status","Concluded","06-DEC-1988","ddC PK in AIDS/ARC","ACTG 011","","Concluded"
50212,"Protocol Status","Closed to Follow Up","24-JUL-1987","ddC PK in AIDS/ARC","ACTG 011","06-DEC-1988","Closed to Follow Up"
50212,"Protocol Status","Closed to Accrual","13-JUL-1987","ddC PK in AIDS/ARC","ACTG 011","24-JUL-1987","Closed to Accrual"
50212,"Protocol Status","Open","11-MAY-1987","ddC PK in AIDS/ARC","ACTG 011","13-JUL-1987","Open"
50212,"Protocol Status","Pending","30-APR-1987","ddC PK in AIDS/ARC","ACTG 011","11-MAY-1987","Pending"
50213,"Protocol Status","POS/PAC","12-APR-1990","Dose ranging ddC in AIDS/Advanced ARC","ACTG 012","","POS/PAC"
50213,"Protocol Status","Closed to Follow Up","06-MAR-1990","Dose ranging ddC in AIDS/Advanced ARC","ACTG 012","12-APR-1990","Closed to Follow Up"
50213,"Protocol Status","Closed to Accrual","04-MAR-1988","Dose ranging ddC in AIDS/Advanced ARC","ACTG 012","06-MAR-1990","Closed to Accrual"
50213,"Protocol Status","Open","04-MAY-1987","Dose ranging ddC in AIDS/Advanced ARC","ACTG 012","04-MAR-1988","Open"
50213,"Protocol Status","Pending","15-APR-1987","Dose ranging ddC in AIDS/Advanced ARC","ACTG 012","04-MAY-1987","Pending"
50214,"Protocol Status","Concluded","01-JAN-1991","AZT/IFN in KS","ACTG 013","","Concluded"
50214,"Protocol Status","POS/PAC","06-FEB-1990","AZT/IFN in KS","ACTG 013","01-JAN-1991","POS/PAC"
50214,"Protocol Status","Closed to Follow Up","28-JUN-1989","AZT/IFN in KS","ACTG 013","06-FEB-1990","Closed to Follow Up"
50214,"Protocol Status","Closed to Accrual","24-MAR-1989","AZT/IFN in KS","ACTG 013","28-JUN-1989","Closed to Accrual"
50214,"Protocol Status","Open","11-MAY-1987","AZT/IFN in KS","ACTG 013","24-MAR-1989","Open"
50214,"Protocol Status","Pending","21-APR-1987","AZT/IFN in KS","ACTG 013","11-MAY-1987","Pending"
50215,"Protocol Status","Concluded","01-SEP-1991","AZT/IFN in KS","ACTG 014","","Concluded"
50215,"Protocol Status","Closed to Follow Up","08-APR-1990","AZT/IFN in KS","ACTG 014","01-SEP-1991","Closed to Follow Up"
50215,"Protocol Status","POS/PAC","31-MAR-1990","AZT/IFN in KS","ACTG 014","08-APR-1990","POS/PAC"
50215,"Protocol Status","Closed to Accrual","22-FEB-1989","AZT/IFN in KS","ACTG 014","31-MAR-1990","Closed to Accrual"
50215,"Protocol Status","Open","11-MAY-1987","AZT/IFN in KS","ACTG 014","22-FEB-1989","Open"
50215,"Protocol Status","Pending","21-APR-1987","AZT/IFN in KS","ACTG 014","11-MAY-1987","Pending"
50216,"Protocol Status","Concluded","01-MAY-1994","Foscarnet for CMV Retinitis","ACTG 015","","Concluded"
50216,"Protocol Status","POS/PAC","04-FEB-1992","Foscarnet for CMV Retinitis","ACTG 015","01-MAY-1994","POS/PAC"
50216,"Protocol Status","Closed to Follow Up","28-FEB-1990","Foscarnet for CMV Retinitis","ACTG 015","04-FEB-1992","Closed to Follow Up"
50216,"Protocol Status","Closed to Accrual","24-MAY-1989","Foscarnet for CMV Retinitis","ACTG 015","28-FEB-1990","Closed to Accrual"
50216,"Protocol Status","Open","17-NOV-1987","Foscarnet for CMV Retinitis","ACTG 015","24-MAY-1989","Open"
50216,"Protocol Status","Pending","16-JUL-1987","Foscarnet for CMV Retinitis","ACTG 015","17-NOV-1987","Pending"
50217,"Protocol Status","Concluded","01-JUN-2001","AZT for treat. of early ARC pts.","ACTG 016","","Concluded"
50217,"Protocol Status","Closed to Follow Up","03-APR-1995","AZT for treat. of early ARC pts.","ACTG 016","01-JUN-2001","Closed to Follow Up"
50217,"Protocol Status","POS/PAC","06-FEB-1995","AZT for treat. of early ARC pts.","ACTG 016","03-APR-1995","POS/PAC"
50217,"Protocol Status","Closed to Accrual","01-MAY-1989","AZT for treat. of early ARC pts.","ACTG 016","06-FEB-1995","Closed to Accrual"
50217,"Protocol Status","Open","16-JUL-1987","AZT for treat. of early ARC pts.","ACTG 016","01-MAY-1989","Open"
50217,"Protocol Status","Pending","22-JUN-1987","AZT for treat. of early ARC pts.","ACTG 016","16-JUL-1987","Pending"
50218,"Protocol Status","Concluded","01-OCT-1992","AZT PK in Hemophilia","ACTG 017","","Concluded"
50218,"Protocol Status","POS/PAC","16-MAR-1989","AZT PK in Hemophilia","ACTG 017","01-OCT-1992","POS/PAC"
50218,"Protocol Status","Closed to Follow Up","20-APR-1988","AZT PK in Hemophilia","ACTG 017","16-MAR-1989","Closed to Follow Up"
50218,"Protocol Status","Closed to Accrual","15-FEB-1988","AZT PK in Hemophilia","ACTG 017","20-APR-1988","Closed to Accrual"
50218,"Protocol Status","Open","10-JUN-1987","AZT PK in Hemophilia","ACTG 017","15-FEB-1988","Open"
50218,"Protocol Status","Pending","30-APR-1987","AZT PK in Hemophilia","ACTG 017","10-JUN-1987","Pending"
50219,"Protocol Status","Concluded","01-JAN-1990","TMTX for previously untreated PCP","ACTG 018","","Concluded"
50219,"Protocol Status","POS/PAC","05-APR-1989","TMTX for previously untreated PCP","ACTG 018","01-JAN-1990","POS/PAC"
50219,"Protocol Status","Closed to Accrual","06-DEC-1988","TMTX for previously untreated PCP","ACTG 018","05-APR-1989","Closed to Accrual"
50219,"Protocol Status","Closed to Follow Up","19-NOV-1987","TMTX for previously untreated PCP","ACTG 018","06-DEC-1988","Closed to Follow Up"
50219,"Protocol Status","Open","02-JUN-1987","TMTX for previously untreated PCP","ACTG 018","19-NOV-1987","Open"
50219,"Protocol Status","Pending","24-APR-1987","TMTX for previously untreated PCP","ACTG 018","02-JUN-1987","Pending"
50220,"Protocol Status","Concluded","30-OCT-2003","AZT for asymptomatic HIV-infected patients","ACTG 019","","Concluded"
50220,"Protocol Status","POS/PAC","01-FEB-1995","AZT for asymptomatic HIV-infected patients","ACTG 019","30-OCT-2003","POS/PAC"
50220,"Protocol Status","Closed to Follow Up","03-FEB-1994","AZT for asymptomatic HIV-infected patients","ACTG 019","01-FEB-1995","Closed to Follow Up"
50220,"Protocol Status","Closed to Accrual","14-JUL-1989","AZT for asymptomatic HIV-infected patients","ACTG 019","03-FEB-1994","Closed to Accrual"
50220,"Protocol Status","Open","17-JUN-1987","AZT for asymptomatic HIV-infected patients","ACTG 019","14-JUL-1989","Open"
50220,"Protocol Status","Pending","20-MAY-1987","AZT for asymptomatic HIV-infected patients","ACTG 019","17-JUN-1987","Pending"
50221,"Protocol Status","Concluded","01-MAR-2001","AZT for treat. of HIV infection in AIDS/ARC","ACTG 020","","Concluded"
50221,"Protocol Status","POS/PAC","27-FEB-1991","AZT for treat. of HIV infection in AIDS/ARC","ACTG 020","01-MAR-2001","POS/PAC"
50221,"Protocol Status","Closed to Follow Up","30-JAN-1990","AZT for treat. of HIV infection in AIDS/ARC","ACTG 020","27-FEB-1991","Closed to Follow Up"
50221,"Protocol Status","Closed to Accrual","12-DEC-1987","AZT for treat. of HIV infection in AIDS/ARC","ACTG 020","30-JAN-1990","Closed to Accrual"
50221,"Protocol Status","Open","29-MAY-1987","AZT for treat. of HIV infection in AIDS/ARC","ACTG 020","12-DEC-1987","Open"
50221,"Protocol Status","Pending","20-MAY-1987","AZT for treat. of HIV infection in AIDS/ARC","ACTG 020","29-MAY-1987","Pending"
50222,"Protocol Status","Concluded","30-OCT-2003","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","","Concluded"
50222,"Protocol Status","Closed to Follow Up","07-JAN-1992","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","30-OCT-2003","Closed to Follow Up"
50222,"Protocol Status","POS/PAC","28-AUG-1991","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","07-JAN-1992","POS/PAC"
50222,"Protocol Status","Closed to Accrual","30-NOV-1990","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","28-AUG-1991","Closed to Accrual"
50222,"Protocol Status","Open","25-JUL-1988","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","30-NOV-1990","Open"
50222,"Protocol Status","Pending","17-MAY-1988","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","25-JUL-1988","Pending"
50222,"Protocol Status","In Development","02-MAR-1988","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","17-MAY-1988","In Development"
50222,"Protocol Status","Pending","02-MAR-1988","TMP/SMX vs.Aerosolized Pentamidine for Prophylaxis of PCP in AIDS Patient on ZDV","ACTG 021","02-MAR-1988","Pending"
50223,"Protocol Status","Concluded","01-OCT-1991","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","","Concluded"
50223,"Protocol Status","POS/PAC","24-JAN-1990","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","01-OCT-1991","POS/PAC"
50223,"Protocol Status","Closed to Accrual","28-JUL-1989","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","24-JAN-1990","Closed to Accrual"
50223,"Protocol Status","Closed to Follow Up","19-MAY-1989","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","28-JUL-1989","Closed to Follow Up"
50223,"Protocol Status","Open","24-FEB-1989","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","19-MAY-1989","Open"
50223,"Protocol Status","Temporarily Closed","06-DEC-1988","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","24-FEB-1989","Other"
50223,"Protocol Status","Open","30-NOV-1987","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","06-DEC-1988","Open"
50223,"Protocol Status","Pending","26-JUN-1987","AL721 for pts. w/PGL & symptomatic HIV","ACTG 022","30-NOV-1987","Pending"
50224,"Protocol Status","Concluded","01-JAN-1992","ZDV & recombinant IL-2 combination in pts. w/PGL","ACTG 024","","Concluded"
50224,"Protocol Status","POS/PAC","12-APR-1990","ZDV & recombinant IL-2 combination in pts. w/PGL","ACTG 024","01-JAN-1992","POS/PAC"
50224,"Protocol Status","Closed to Follow Up","23-JAN-1990","ZDV & recombinant IL-2 combination in pts. w/PGL","ACTG 024","12-APR-1990","Closed to Follow Up"
50224,"Protocol Status","Closed to Accrual","03-AUG-1989","ZDV & recombinant IL-2 combination in pts. w/PGL","ACTG 024","23-JAN-1990","Closed to Accrual"
50224,"Protocol Status","Open","08-DEC-1987","ZDV & recombinant IL-2 combination in pts. w/PGL","ACTG 024","03-AUG-1989","Open"
50224,"Protocol Status","Pending","21-JUL-1987","ZDV & recombinant IL-2 combination in pts. w/PGL","ACTG 024","08-DEC-1987","Pending"
50225,"Protocol Status","Concluded","01-MAY-1992","Recombinant TNF & Recombinant IFN-gamma in ARC","ACTG 025","","Concluded"
50225,"Protocol Status","POS/PAC","14-FEB-1990","Recombinant TNF & Recombinant IFN-gamma in ARC","ACTG 025","01-MAY-1992","POS/PAC"
50225,"Protocol Status","Closed to Follow Up","02-OCT-1989","Recombinant TNF & Recombinant IFN-gamma in ARC","ACTG 025","14-FEB-1990","Closed to Follow Up"
50225,"Protocol Status","Closed to Accrual","26-JUL-1989","Recombinant TNF & Recombinant IFN-gamma in ARC","ACTG 025","02-OCT-1989","Closed to Accrual"
50225,"Protocol Status","Open","01-APR-1988","Recombinant TNF & Recombinant IFN-gamma in ARC","ACTG 025","26-JUL-1989","Open"
50225,"Protocol Status","Pending","20-JUL-1987","Recombinant TNF & Recombinant IFN-gamma in ARC","ACTG 025","01-APR-1988","Pending"
50226,"Protocol Status","Concluded","01-MAY-1994","Flu vs. Ampho B for maint. TX of crypt. mening","ACTG 026","","Concluded"
50226,"Protocol Status","Closed to Follow Up","01-JAN-1992","Flu vs. Ampho B for maint. TX of crypt. mening","ACTG 026","01-MAY-1994","Closed to Follow Up"
50226,"Protocol Status","POS/PAC","22-JUL-1991","Flu vs. Ampho B for maint. TX of crypt. mening","ACTG 026","01-JAN-1992","POS/PAC"
50226,"Protocol Status","Closed to Accrual","02-MAY-1990","Flu vs. Ampho B for maint. TX of crypt. mening","ACTG 026","22-JUL-1991","Closed to Accrual"
50226,"Protocol Status","Open","04-DEC-1987","Flu vs. Ampho B for maint. TX of crypt. mening","ACTG 026","02-MAY-1990","Open"
50227,"Protocol Status","Concluded","26-AUG-1989","AZT PK w/ Probenecid or Quinine","ACTG 027","","Concluded"
50227,"Protocol Status","POS/PAC","06-DEC-1988","AZT PK w/ Probenecid or Quinine","ACTG 027","26-AUG-1989","POS/PAC"
50227,"Protocol Status","Closed to Follow Up","16-FEB-1988","AZT PK w/ Probenecid or Quinine","ACTG 027","06-DEC-1988","Closed to Follow Up"
50227,"Protocol Status","Open","12-DEC-1987","AZT PK w/ Probenecid or Quinine","ACTG 027","16-FEB-1988","Open"
50227,"Protocol Status","Pending","15-JUL-1987","AZT PK w/ Probenecid or Quinine","ACTG 027","12-DEC-1987","Pending"
50228,"Protocol Status","Concluded","01-MAR-1994","Foscarnet dose response in HIV + w/PGL","ACTG 028","","Concluded"
50228,"Protocol Status","POS/PAC","15-JUN-1992","Foscarnet dose response in HIV + w/PGL","ACTG 028","01-MAR-1994","POS/PAC"
50228,"Protocol Status","Closed to Follow Up","02-FEB-1990","Foscarnet dose response in HIV + w/PGL","ACTG 028","15-JUN-1992","Closed to Follow Up"
50228,"Protocol Status","Closed to Accrual","06-NOV-1989","Foscarnet dose response in HIV + w/PGL","ACTG 028","02-FEB-1990","Closed to Accrual"
50228,"Protocol Status","Open","31-MAY-1988","Foscarnet dose response in HIV + w/PGL","ACTG 028","06-NOV-1989","Open"
50228,"Protocol Status","Pending","16-JUL-1987","Foscarnet dose response in HIV + w/PGL","ACTG 028","31-MAY-1988","Pending"
50229,"Protocol Status","Concluded","01-JUL-1994","TMTX vs. TMP/SMX for PCP followed by AP proph.","ACTG 029","","Concluded"
50229,"Protocol Status","POS/PAC","19-SEP-1991","TMTX vs. TMP/SMX for PCP followed by AP proph.","ACTG 029","01-JUL-1994","POS/PAC"
50229,"Protocol Status","Closed to Follow Up","24-JUN-1991","TMTX vs. TMP/SMX for PCP followed by AP proph.","ACTG 029","19-SEP-1991","Closed to Follow Up"
50229,"Protocol Status","Closed to Accrual","21-JUN-1989","TMTX vs. TMP/SMX for PCP followed by AP proph.","ACTG 029","24-JUN-1991","Closed to Accrual"
50229,"Protocol Status","Open","24-MAR-1988","TMTX vs. TMP/SMX for PCP followed by AP proph.","ACTG 029","21-JUN-1989","Open"
50229,"Protocol Status","Pending","31-JUL-1987","TMTX vs. TMP/SMX for PCP followed by AP proph.","ACTG 029","24-MAR-1988","Pending"
50230,"Protocol Status","Closed to Follow Up","15-JUL-1989","TMTX vs. TMP/SMX for refractory PCP","ACTG 030","","Closed to Follow Up"
50230,"Protocol Status","Concluded","14-MAR-1989","TMTX vs. TMP/SMX for refractory PCP","ACTG 030","15-JUL-1989","Concluded"
50230,"Protocol Status","Open","13-FEB-1989","TMTX vs. TMP/SMX for refractory PCP","ACTG 030","14-MAR-1989","Open"
50230,"Protocol Status","Pending","26-FEB-1988","TMTX vs. TMP/SMX for refractory PCP","ACTG 030","13-FEB-1989","Pending"
50231,"Protocol Status","Concluded","01-JUL-1994","TMTX vs TMP/S for severe PCP","ACTG 031","","Concluded"
50231,"Protocol Status","POS/PAC","15-SEP-1991","TMTX vs TMP/S for severe PCP","ACTG 031","01-JUL-1994","POS/PAC"
50231,"Protocol Status","Closed to Follow Up","27-MAR-1991","TMTX vs TMP/S for severe PCP","ACTG 031","15-SEP-1991","Closed to Follow Up"
50231,"Protocol Status","Closed to Accrual","08-MAY-1990","TMTX vs TMP/S for severe PCP","ACTG 031","27-MAR-1991","Closed to Accrual"
50231,"Protocol Status","Open","14-DEC-1988","TMTX vs TMP/S for severe PCP","ACTG 031","08-MAY-1990","Open"
50231,"Protocol Status","Pending","11-JAN-1988","TMTX vs TMP/S for severe PCP","ACTG 031","14-DEC-1988","Pending"
50232,"Protocol Status","Concluded","05-MAY-1990","AZT/Acetaminophen PK","ACTG 032","","Concluded"
50232,"Protocol Status","Closed to Accrual","15-AUG-1989","AZT/Acetaminophen PK","ACTG 032","05-MAY-1990","Closed to Accrual"
50232,"Protocol Status","Closed to Follow Up","03-AUG-1989","AZT/Acetaminophen PK","ACTG 032","15-AUG-1989","Closed to Follow Up"
50232,"Protocol Status","Open","18-MAR-1988","AZT/Acetaminophen PK","ACTG 032","03-AUG-1989","Open"
50232,"Protocol Status","Pending","11-SEP-1987","AZT/Acetaminophen PK","ACTG 032","18-MAR-1988","Pending"
50233,"Protocol Status","Concluded","05-MAY-1990","AZT/low-dose TMP/SMX PK","ACTG 033","","Concluded"
50233,"Protocol Status","Closed to Accrual","20-OCT-1989","AZT/low-dose TMP/SMX PK","ACTG 033","05-MAY-1990","Closed to Accrual"
50233,"Protocol Status","Closed to Follow Up","21-SEP-1989","AZT/low-dose TMP/SMX PK","ACTG 033","20-OCT-1989","Closed to Follow Up"
50233,"Protocol Status","Open","13-MAY-1988","AZT/low-dose TMP/SMX PK","ACTG 033","21-SEP-1989","Open"
50233,"Protocol Status","Pending","11-SEP-1987","AZT/low-dose TMP/SMX PK","ACTG 033","13-MAY-1988","Pending"
50234,"Protocol Status","Closed to Follow Up","11-OCT-1990","Ribavirin for AIDS/Advanced ARC patients","ACTG 034","","Closed to Follow Up"
50234,"Protocol Status","Concluded","02-JUN-1990","Ribavirin for AIDS/Advanced ARC patients","ACTG 034","11-OCT-1990","Concluded"
50234,"Protocol Status","Closed to Accrual","15-SEP-1989","Ribavirin for AIDS/Advanced ARC patients","ACTG 034","02-JUN-1990","Closed to Accrual"
50234,"Protocol Status","Open","28-APR-1988","Ribavirin for AIDS/Advanced ARC patients","ACTG 034","15-SEP-1989","Open"
50234,"Protocol Status","Pending","06-NOV-1987","Ribavirin for AIDS/Advanced ARC patients","ACTG 034","28-APR-1988","Pending"
50235,"Protocol Status","Concluded","01-OCT-1991","Ribavarin in PK","ACTG 035","","Concluded"
50235,"Protocol Status","POS/PAC","01-OCT-1991","Ribavarin in PK","ACTG 035","01-OCT-1991","POS/PAC"
50235,"Protocol Status","Closed to Accrual","09-AUG-1989","Ribavarin in PK","ACTG 035","01-OCT-1991","Closed to Accrual"
50235,"Protocol Status","Closed to Follow Up","01-MAY-1989","Ribavarin in PK","ACTG 035","09-AUG-1989","Closed to Follow Up"
50235,"Protocol Status","Open","26-JUL-1988","Ribavarin in PK","ACTG 035","01-MAY-1989","Open"
50235,"Protocol Status","Pending","06-NOV-1987","Ribavarin in PK","ACTG 035","26-JUL-1988","Pending"
50236,"Protocol Status","Concluded","01-OCT-1998","AZT in hemophiliacs","ACTG 036","","Concluded"
50236,"Protocol Status","Closed to Follow Up","30-JUN-1990","AZT in hemophiliacs","ACTG 036","01-OCT-1998","Closed to Follow Up"
50236,"Protocol Status","POS/PAC","12-FEB-1990","AZT in hemophiliacs","ACTG 036","30-JUN-1990","POS/PAC"
50236,"Protocol Status","Closed to Accrual","18-AUG-1989","AZT in hemophiliacs","ACTG 036","12-FEB-1990","Closed to Accrual"
50236,"Protocol Status","Open","12-APR-1988","AZT in hemophiliacs","ACTG 036","18-AUG-1989","Open"
50236,"Protocol Status","Pending","04-JAN-1988","AZT in hemophiliacs","ACTG 036","12-APR-1988","Pending"
50237,"Protocol Status","Concluded","05-MAY-1990","AZT/high-dose TMP/SMX PK","ACTG 037","","Concluded"
50237,"Protocol Status","Closed to Accrual","20-OCT-1989","AZT/high-dose TMP/SMX PK","ACTG 037","05-MAY-1990","Closed to Accrual"
50237,"Protocol Status","Closed to Follow Up","24-AUG-1989","AZT/high-dose TMP/SMX PK","ACTG 037","20-OCT-1989","Closed to Follow Up"
50237,"Protocol Status","Open","21-JUN-1988","AZT/high-dose TMP/SMX PK","ACTG 037","24-AUG-1989","Open"
50237,"Protocol Status","Pending","22-SEP-1987","AZT/high-dose TMP/SMX PK","ACTG 037","21-JUN-1988","Pending"
50238,"Protocol Status","POS/PAC","01-OCT-1992","Ampligen Phase I","ACTG 038","","POS/PAC"
50238,"Protocol Status","Concluded","01-OCT-1992","Ampligen Phase I","ACTG 038","01-OCT-1992","Concluded"
50238,"Protocol Status","Closed to Accrual","19-JUN-1991","Ampligen Phase I","ACTG 038","01-OCT-1992","Closed to Accrual"
50238,"Protocol Status","Closed to Follow Up","26-APR-1991","Ampligen Phase I","ACTG 038","19-JUN-1991","Closed to Follow Up"
50238,"Protocol Status","Temporarily Closed","15-APR-1991","Ampligen Phase I","ACTG 038","26-APR-1991","Other"
50238,"Protocol Status","Open","02-MAY-1988","Ampligen Phase I","ACTG 038","15-APR-1991","Open"
50238,"Protocol Status","Pending","09-MAR-1988","Ampligen Phase I","ACTG 038","02-MAY-1988","Pending"
50239,"Protocol Status","Concluded","01-APR-1995","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","","Concluded"
50239,"Protocol Status","POS/PAC","03-SEP-1991","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","01-APR-1995","POS/PAC"
50239,"Protocol Status","Closed to Follow Up","14-JAN-1990","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","03-SEP-1991","Closed to Follow Up"
50239,"Protocol Status","Closed to Accrual","31-MAY-1989","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","14-JAN-1990","Closed to Accrual"
50239,"Protocol Status","Open","25-MAY-1988","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","31-MAY-1989","Open"
50239,"Protocol Status","Pending","17-MAY-1988","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","25-MAY-1988","Pending"
50239,"Protocol Status","In Development","02-MAR-1988","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","17-MAY-1988","In Development"
50239,"Protocol Status","Pending","02-MAR-1988","AP vs. parenteral/oral TMP/SMX for PCP","ACTG 040","02-MAR-1988","Pending"
50240,"Protocol Status","Concluded","15-AUG-1997","AP vs. parenteral pentamidine","ACTG 041","","Concluded"
50240,"Protocol Status","POS/PAC","14-JUN-1991","AP vs. parenteral pentamidine","ACTG 041","15-AUG-1997","POS/PAC"
50240,"Protocol Status","Closed to Accrual","18-MAY-1990","AP vs. parenteral pentamidine","ACTG 041","14-JUN-1991","Closed to Accrual"
50240,"Protocol Status","Closed to Follow Up","04-APR-1990","AP vs. parenteral pentamidine","ACTG 041","18-MAY-1990","Closed to Follow Up"
50240,"Protocol Status","Open","01-DEC-1988","AP vs. parenteral pentamidine","ACTG 041","04-APR-1990","Open"
50240,"Protocol Status","Pending","23-AUG-1988","AP vs. parenteral pentamidine","ACTG 041","01-DEC-1988","Pending"
50240,"Protocol Status","In Development","07-MAR-1988","AP vs. parenteral pentamidine","ACTG 041","23-AUG-1988","In Development"
50241,"Protocol Status","Concluded","01-OCT-1998","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","","Concluded"
50241,"Protocol Status","POS/PAC","06-FEB-1995","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","01-OCT-1998","POS/PAC"
50241,"Protocol Status","Closed to Follow Up","06-AUG-1992","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","06-FEB-1995","Closed to Follow Up"
50241,"Protocol Status","Closed to Accrual","19-MAY-1992","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","06-AUG-1992","Closed to Accrual"
50241,"Protocol Status","Open","08-JUN-1988","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","19-MAY-1992","Open"
50241,"Protocol Status","Pending","11-MAY-1988","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","08-JUN-1988","Pending"
50241,"Protocol Status","In Development","11-FEB-1988","AZT/IL-2 in asymptomatic HIV with lymphadenopathy","ACTG 042","11-MAY-1988","In Development"
50242,"Protocol Status","Concluded","01-JUN-1994","clinda and primaquine for mild-mod PCP","ACTG 044","","Concluded"
50242,"Protocol Status","POS/PAC","27-NOV-1991","clinda and primaquine for mild-mod PCP","ACTG 044","01-JUN-1994","POS/PAC"
50242,"Protocol Status","Closed to Follow Up","27-NOV-1990","clinda and primaquine for mild-mod PCP","ACTG 044","27-NOV-1991","Closed to Follow Up"
50242,"Protocol Status","Closed to Accrual","20-AUG-1990","clinda and primaquine for mild-mod PCP","ACTG 044","27-NOV-1990","Closed to Accrual"
50242,"Protocol Status","Open","23-AUG-1988","clinda and primaquine for mild-mod PCP","ACTG 044","20-AUG-1990","Open"
50242,"Protocol Status","Pending","15-JUL-1988","clinda and primaquine for mild-mod PCP","ACTG 044","23-AUG-1988","Pending"
50242,"Protocol Status","In Development","23-MAR-1988","clinda and primaquine for mild-mod PCP","ACTG 044","15-JUL-1988","In Development"
50243,"Protocol Status","Concluded","01-MAR-1993","AS-101 Phase I","ACTG 046","","Concluded"
50243,"Protocol Status","Closed to Accrual","27-FEB-1990","AS-101 Phase I","ACTG 046","01-MAR-1993","Closed to Accrual"
50243,"Protocol Status","Closed to Follow Up","22-MAY-1989","AS-101 Phase I","ACTG 046","27-FEB-1990","Closed to Follow Up"
50243,"Protocol Status","Open","28-OCT-1988","AS-101 Phase I","ACTG 046","22-MAY-1989","Open"
50243,"Protocol Status","Temporarily Closed","04-AUG-1988","AS-101 Phase I","ACTG 046","28-OCT-1988","Other"
50243,"Protocol Status","Open","03-JUN-1988","AS-101 Phase I","ACTG 046","04-AUG-1988","Open"
50243,"Protocol Status","Pending","04-APR-1988","AS-101 Phase I","ACTG 046","03-JUN-1988","Pending"
50243,"Protocol Status","In Development","18-MAR-1988","AS-101 Phase I","ACTG 046","04-APR-1988","In Development"
50243,"Protocol Status","Pending","18-MAR-1988","AS-101 Phase I","ACTG 046","18-MAR-1988","Pending"
50244,"Protocol Status","Concluded","01-MAR-1997","AZT/ddC alternating","ACTG 047","","Concluded"
50244,"Protocol Status","POS/PAC","20-SEP-1991","AZT/ddC alternating","ACTG 047","01-MAR-1997","POS/PAC"
50244,"Protocol Status","Closed to Follow Up","08-MAY-1991","AZT/ddC alternating","ACTG 047","20-SEP-1991","Closed to Follow Up"
50244,"Protocol Status","Closed to Accrual","04-OCT-1989","AZT/ddC alternating","ACTG 047","08-MAY-1991","Closed to Accrual"
50244,"Protocol Status","Open","06-JUN-1988","AZT/ddC alternating","ACTG 047","04-OCT-1989","Open"
50244,"Protocol Status","Pending","24-MAY-1988","AZT/ddC alternating","ACTG 047","06-JUN-1988","Pending"
50244,"Protocol Status","In Development","27-MAR-1988","AZT/ddC alternating","ACTG 047","24-MAY-1988","In Development"
50245,"Protocol Status","POS/PAC","12-JUN-1991","AP for","ACTG 048","","POS/PAC"
50245,"Protocol Status","Concluded","01-APR-1991","AP for","ACTG 048","12-JUN-1991","Concluded"
50245,"Protocol Status","Closed to Accrual","21-FEB-1990","AP for","ACTG 048","01-APR-1991","Closed to Accrual"
50245,"Protocol Status","Closed to Follow Up","24-APR-1989","AP for","ACTG 048","21-FEB-1990","Closed to Follow Up"
50245,"Protocol Status","Open","15-MAR-1989","AP for","ACTG 048","24-APR-1989","Open"
50245,"Protocol Status","Pending","23-FEB-1989","AP for","ACTG 048","15-MAR-1989","Pending"
50245,"Protocol Status","FDA - IND Hold","01-FEB-1989","AP for","ACTG 048","23-FEB-1989","Other"
50245,"Protocol Status","Pending","30-DEC-1988","AP for","ACTG 048","01-FEB-1989","Pending"
50245,"Protocol Status","In Development","05-APR-1988","AP for","ACTG 048","30-DEC-1988","In Development"
50246,"Protocol Status","Concluded","01-MAR-1997","AZT/ddC alternating in AZT int.","ACTG 050","","Concluded"
50246,"Protocol Status","Concluded","06-FEB-1995","AZT/ddC alternating in AZT int.","ACTG 050","01-MAR-1997","Concluded"
50246,"Protocol Status","Closed to Follow Up","17-DEC-1990","AZT/ddC alternating in AZT int.","ACTG 050","06-FEB-1995","Closed to Follow Up"
50246,"Protocol Status","Closed to Accrual","15-JUN-1989","AZT/ddC alternating in AZT int.","ACTG 050","17-DEC-1990","Closed to Accrual"
50246,"Protocol Status","Open","15-JUN-1988","AZT/ddC alternating in AZT int.","ACTG 050","15-JUN-1989","Open"
50246,"Protocol Status","Pending","07-JUN-1988","AZT/ddC alternating in AZT int.","ACTG 050","15-JUN-1988","Pending"
50246,"Protocol Status","In Development","04-APR-1988","AZT/ddC alternating in AZT int.","ACTG 050","07-JUN-1988","In Development"
50247,"Protocol Status","Concluded","01-AUG-1992","Foscarnet for long-term AZT patients","ACTG 053","","Concluded"
50247,"Protocol Status","POS/PAC","01-JUN-1991","Foscarnet for long-term AZT patients","ACTG 053","01-AUG-1992","POS/PAC"
50247,"Protocol Status","Closed to Follow Up","16-FEB-1990","Foscarnet for long-term AZT patients","ACTG 053","01-JUN-1991","Closed to Follow Up"
50247,"Protocol Status","Closed to Accrual","30-SEP-1989","Foscarnet for long-term AZT patients","ACTG 053","16-FEB-1990","Closed to Accrual"
50247,"Protocol Status","Open","09-NOV-1988","Foscarnet for long-term AZT patients","ACTG 053","30-SEP-1989","Open"
50247,"Protocol Status","Pending","17-MAY-1988","Foscarnet for long-term AZT patients","ACTG 053","09-NOV-1988","Pending"
50247,"Protocol Status","In Development","08-APR-1988","Foscarnet for long-term AZT patients","ACTG 053","17-MAY-1988","In Development"
50248,"Protocol Status","Concluded","06-FEB-1990","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","","Concluded"
50248,"Protocol Status","Withdrawn","06-FEB-1990","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","06-FEB-1990","Other"
50248,"Protocol Status","Closed to Follow Up","15-NOV-1989","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","06-FEB-1990","Closed to Follow Up"
50248,"Protocol Status","Closed to Accrual","06-NOV-1989","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","15-NOV-1989","Closed to Accrual"
50248,"Protocol Status","Open","21-NOV-1988","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","06-NOV-1989","Open"
50248,"Protocol Status","Pending","17-JUN-1988","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","21-NOV-1988","Pending"
50248,"Protocol Status","In Development","05-APR-1988","Dose ranging ampligen for p24+ AIDS/ARC pts.","ACTG 054","17-JUN-1988","In Development"
50249,"Protocol Status","Concluded","01-JUN-1992","AZT/Methadone PK","ACTG 055","","Concluded"
50249,"Protocol Status","POS/PAC","29-MAR-1991","AZT/Methadone PK","ACTG 055","01-JUN-1992","POS/PAC"
50249,"Protocol Status","Closed to Accrual","22-FEB-1991","AZT/Methadone PK","ACTG 055","29-MAR-1991","Closed to Accrual"
50249,"Protocol Status","Closed to Follow Up","15-DEC-1990","AZT/Methadone PK","ACTG 055","22-FEB-1991","Closed to Follow Up"
50249,"Protocol Status","Open","03-FEB-1989","AZT/Methadone PK","ACTG 055","15-DEC-1990","Open"
50249,"Protocol Status","In Development","05-APR-1988","AZT/Methadone PK","ACTG 055","03-FEB-1989","In Development"
50250,"Protocol Status","Concluded","01-MAR-1993","Atvogen in healthy volunteers & HIV infected pts.","ACTG 056","","Concluded"
50250,"Protocol Status","POS/PAC","05-JAN-1990","Atvogen in healthy volunteers & HIV infected pts.","ACTG 056","01-MAR-1993","POS/PAC"
50250,"Protocol Status","Closed to Accrual","06-NOV-1989","Atvogen in healthy volunteers & HIV infected pts.","ACTG 056","05-JAN-1990","Closed to Accrual"
50250,"Protocol Status","Closed to Follow Up","26-MAY-1989","Atvogen in healthy volunteers & HIV infected pts.","ACTG 056","06-NOV-1989","Closed to Follow Up"
50250,"Protocol Status","Open","01-JUN-1988","Atvogen in healthy volunteers & HIV infected pts.","ACTG 056","26-MAY-1989","Open"
50250,"Protocol Status","In Development","05-APR-1988","Atvogen in healthy volunteers & HIV infected pts.","ACTG 056","01-JUN-1988","In Development"
50251,"Protocol Status","Concluded","01-MAR-1998","AZT/IFN-Beta (Phase I) in KS","ACTG 057","","Concluded"
50251,"Protocol Status","Closed to Follow Up","11-APR-1993","AZT/IFN-Beta (Phase I) in KS","ACTG 057","01-MAR-1998","Closed to Follow Up"
50251,"Protocol Status","POS/PAC","01-JUL-1991","AZT/IFN-Beta (Phase I) in KS","ACTG 057","11-APR-1993","POS/PAC"
50251,"Protocol Status","Closed to Accrual","05-MAR-1991","AZT/IFN-Beta (Phase I) in KS","ACTG 057","01-JUL-1991","Closed to Accrual"
50251,"Protocol Status","Open","29-MAR-1989","AZT/IFN-Beta (Phase I) in KS","ACTG 057","05-MAR-1991","Open"
50251,"Protocol Status","Pending","19-DEC-1988","AZT/IFN-Beta (Phase I) in KS","ACTG 057","29-MAR-1989","Pending"
50251,"Protocol Status","In Development","29-MAR-1988","AZT/IFN-Beta (Phase I) in KS","ACTG 057","19-DEC-1988","In Development"
50252,"Protocol Status","Withdrawn","07-FEB-1989"," ","ACTG 058","","Other"
50252,"Protocol Status","In Development","29-MAR-1988"," ","ACTG 058","07-FEB-1989","In Development"
50253,"Protocol Status","Concluded","01-MAY-1996","Fluconazole vs. Amp-B for acute crypt. meningitis","ACTG 059","","Concluded"
50253,"Protocol Status","POS/PAC","22-JUL-1991","Fluconazole vs. Amp-B for acute crypt. meningitis","ACTG 059","01-MAY-1996","POS/PAC"
50253,"Protocol Status","Closed to Follow Up","12-MAY-1990","Fluconazole vs. Amp-B for acute crypt. meningitis","ACTG 059","22-JUL-1991","Closed to Follow Up"
50253,"Protocol Status","Closed to Accrual","14-AUG-1989","Fluconazole vs. Amp-B for acute crypt. meningitis","ACTG 059","12-MAY-1990","Closed to Accrual"
50253,"Protocol Status","In Development","08-APR-1988","Fluconazole vs. Amp-B for acute crypt. meningitis","ACTG 059","14-AUG-1989","In Development"
50253,"Protocol Status","Open","08-APR-1988","Fluconazole vs. Amp-B for acute crypt. meningitis","ACTG 059","08-APR-1988","Open"
50254,"Protocol Status","Concluded","13-APR-1990","Dose ranging oral dextran sulfate in AIDS/ARC","ACTG 060","","Concluded"
50254,"Protocol Status","Closed to Follow Up","18-AUG-1989","Dose ranging oral dextran sulfate in AIDS/ARC","ACTG 060","13-APR-1990","Closed to Follow Up"
50254,"Protocol Status","Closed to Accrual","20-JUN-1989","Dose ranging oral dextran sulfate in AIDS/ARC","ACTG 060","18-AUG-1989","Closed to Accrual"
50254,"Protocol Status","Open","02-AUG-1988","Dose ranging oral dextran sulfate in AIDS/ARC","ACTG 060","20-JUN-1989","Open"
50254,"Protocol Status","Pending","17-JUN-1988","Dose ranging oral dextran sulfate in AIDS/ARC","ACTG 060","02-AUG-1988","Pending"
50254,"Protocol Status","In Development","25-APR-1988","Dose ranging oral dextran sulfate in AIDS/ARC","ACTG 060","17-JUN-1988","In Development"
50255,"Protocol Status","Concluded","14-FEB-1990","AZT in ADC (open-label)","ACTG 061","","Concluded"
50255,"Protocol Status","Closed to Follow Up","20-JAN-1990","AZT in ADC (open-label)","ACTG 061","14-FEB-1990","Closed to Follow Up"
50255,"Protocol Status","Closed to Accrual","22-SEP-1989","AZT in ADC (open-label)","ACTG 061","20-JAN-1990","Closed to Accrual"
50255,"Protocol Status","Open","03-FEB-1989","AZT in ADC (open-label)","ACTG 061","22-SEP-1989","Open"
50255,"Protocol Status","Pending","21-NOV-1988","AZT in ADC (open-label)","ACTG 061","03-FEB-1989","Pending"
50255,"Protocol Status","In Development","25-APR-1988","AZT in ADC (open-label)","ACTG 061","21-NOV-1988","In Development"
50256,"Protocol Status","Concluded","01-DEC-1995","AZT in Hepatic Insuff.","ACTG 062","","Concluded"
50256,"Protocol Status","POS/PAC","05-MAY-1990","AZT in Hepatic Insuff.","ACTG 062","01-DEC-1995","POS/PAC"
50256,"Protocol Status","Closed to Accrual","16-FEB-1990","AZT in Hepatic Insuff.","ACTG 062","05-MAY-1990","Closed to Accrual"
50256,"Protocol Status","Closed to Follow Up","15-FEB-1990","AZT in Hepatic Insuff.","ACTG 062","16-FEB-1990","Closed to Follow Up"
50256,"Protocol Status","Open","26-SEP-1988","AZT in Hepatic Insuff.","ACTG 062","15-FEB-1990","Open"
50256,"Protocol Status","Pending","21-JUL-1988","AZT in Hepatic Insuff.","ACTG 062","26-SEP-1988","Pending"
50256,"Protocol Status","In Development","25-APR-1988","AZT in Hepatic Insuff.","ACTG 062","21-JUL-1988","In Development"
50257,"Protocol Status","Concluded","01-AUG-1998","AZT/ACV","ACTG 063","","Concluded"
50257,"Protocol Status","POS/PAC","10-NOV-1994","AZT/ACV","ACTG 063","01-AUG-1998","POS/PAC"
50257,"Protocol Status","Closed to Follow Up","10-MAY-1993","AZT/ACV","ACTG 063","10-NOV-1994","Closed to Follow Up"
50257,"Protocol Status","Closed to Accrual","13-MAR-1992","AZT/ACV","ACTG 063","10-MAY-1993","Closed to Accrual"
50257,"Protocol Status","Open","08-FEB-1991","AZT/ACV","ACTG 063","13-MAR-1992","Open"
50257,"Protocol Status","Temporarily Closed","01-JAN-1991","AZT/ACV","ACTG 063","08-FEB-1991","Other"
50257,"Protocol Status","Open","17-FEB-1989","AZT/ACV","ACTG 063","01-JAN-1991","Open"
50257,"Protocol Status","Pending","23-MAY-1987","AZT/ACV","ACTG 063","17-FEB-1989","Pending"
50258,"Protocol Status","Concluded","01-DEC-1995","ddI Phase I","ACTG 064","","Concluded"
50258,"Protocol Status","Closed to Follow Up","06-AUG-1992","ddI Phase I","ACTG 064","01-DEC-1995","Closed to Follow Up"
50258,"Protocol Status","POS/PAC","01-MAY-1990","ddI Phase I","ACTG 064","06-AUG-1992","POS/PAC"
50258,"Protocol Status","Closed to Accrual","12-JAN-1990","ddI Phase I","ACTG 064","01-MAY-1990","Closed to Accrual"
50258,"Protocol Status","Open","03-OCT-1988","ddI Phase I","ACTG 064","12-JAN-1990","Open"
50258,"Protocol Status","Pending","16-AUG-1988","ddI Phase I","ACTG 064","03-OCT-1988","Pending"
50258,"Protocol Status","In Development","28-APR-1988","ddI Phase I","ACTG 064","16-AUG-1988","In Development"
50259,"Protocol Status","Concluded","01-MAR-1993","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","","Concluded"
50259,"Protocol Status","POS/PAC","05-MAY-1990","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","01-MAR-1993","POS/PAC"
50259,"Protocol Status","Closed to Accrual","01-DEC-1989","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","05-MAY-1990","Closed to Accrual"
50259,"Protocol Status","Closed to Follow Up","03-NOV-1989","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","01-DEC-1989","Closed to Follow Up"
50259,"Protocol Status","Open","03-FEB-1989","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","03-NOV-1989","Open"
50259,"Protocol Status","Pending","12-SEP-1988","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","03-FEB-1989","Pending"
50259,"Protocol Status","In Development","29-APR-1988","GM-CSF & ZDV in pts. w/ AIDS/Severe ARC","ACTG 065","12-SEP-1988","In Development"
50260,"Protocol Status","POS/PAC","29-MAR-1991","(high dose) CD4","ACTG 066","","POS/PAC"
50260,"Protocol Status","Closed to Follow Up","24-DEC-1990","(high dose) CD4","ACTG 066","29-MAR-1991","Closed to Follow Up"
50260,"Protocol Status","Closed to Accrual","18-SEP-1990","(high dose) CD4","ACTG 066","24-DEC-1990","Closed to Accrual"
50260,"Protocol Status","Concluded","01-SEP-1990","(high dose) CD4","ACTG 066","18-SEP-1990","Concluded"
50260,"Protocol Status","Open","07-FEB-1990","(high dose) CD4","ACTG 066","01-SEP-1990","Open"
50260,"Protocol Status","Temporarily Closed","25-MAY-1989","(high dose) CD4","ACTG 066","07-FEB-1990","Other"
50260,"Protocol Status","Open","14-OCT-1988","(high dose) CD4","ACTG 066","25-MAY-1989","Open"
50260,"Protocol Status","Pending","28-SEP-1988","(high dose) CD4","ACTG 066","14-OCT-1988","Pending"
50260,"Protocol Status","In Development","02-MAY-1988","(high dose) CD4","ACTG 066","28-SEP-1988","In Development"
50261,"Protocol Status","Concluded","01-JAN-1994","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","","Concluded"
50261,"Protocol Status","POS/PAC","01-JAN-1994","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","01-JAN-1994","POS/PAC"
50261,"Protocol Status","Closed to Accrual","26-NOV-1991","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","01-JAN-1994","Closed to Accrual"
50261,"Protocol Status","Closed to Follow Up","22-MAR-1991","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","26-NOV-1991","Closed to Follow Up"
50261,"Protocol Status","Open","16-FEB-1989","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","22-MAR-1991","Open"
50261,"Protocol Status","Pending","22-SEP-1988","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","16-FEB-1989","Pending"
50261,"Protocol Status","In Development","02-MAY-1988","Safety & immunology of ZDV + IL-2 in AIDS & ARC","ACTG 067","22-SEP-1988","In Development"
50262,"Protocol Status","Concluded","01-APR-1996","AZT+alpha interferon in symptomatic HIV disease","ACTG 068","","Concluded"
50262,"Protocol Status","POS/PAC","08-NOV-1993","AZT+alpha interferon in symptomatic HIV disease","ACTG 068","01-APR-1996","POS/PAC"
50262,"Protocol Status","Closed to Follow Up","18-FEB-1993","AZT+alpha interferon in symptomatic HIV disease","ACTG 068","08-NOV-1993","Closed to Follow Up"
50262,"Protocol Status","Closed to Accrual","30-OCT-1992","AZT+alpha interferon in symptomatic HIV disease","ACTG 068","18-FEB-1993","Closed to Accrual"
50262,"Protocol Status","Open","27-MAR-1989","AZT+alpha interferon in symptomatic HIV disease","ACTG 068","30-OCT-1992","Open"
50262,"Protocol Status","Pending","21-APR-1987","AZT+alpha interferon in symptomatic HIV disease","ACTG 068","27-MAR-1989","Pending"
50263,"Protocol Status","Withdrawn","09-MAY-1988","AP for secondary prophylaxis of PCP","ACTG 069","","Other"
50263,"Protocol Status","In Development","09-MAY-1988","AP for secondary prophylaxis of PCP","ACTG 069","09-MAY-1988","In Development"
50264,"Protocol Status","POS/PAC","01-MAR-1992","High-dose ACV & AZT for maint. TX","ACTG 070","","POS/PAC"
50264,"Protocol Status","Concluded","01-OCT-1991","High-dose ACV & AZT for maint. TX","ACTG 070","01-MAR-1992","Concluded"
50264,"Protocol Status","Closed to Accrual","20-JUL-1990","High-dose ACV & AZT for maint. TX","ACTG 070","01-OCT-1991","Closed to Accrual"
50264,"Protocol Status","Closed to Follow Up","05-JUL-1990","High-dose ACV & AZT for maint. TX","ACTG 070","20-JUL-1990","Closed to Follow Up"
50264,"Protocol Status","Open","04-AUG-1989","High-dose ACV & AZT for maint. TX","ACTG 070","05-JUL-1990","Open"
50264,"Protocol Status","Pending","01-MAR-1989","High-dose ACV & AZT for maint. TX","ACTG 070","04-AUG-1989","Pending"
50264,"Protocol Status","FDA - IND Hold","10-JAN-1989","High-dose ACV & AZT for maint. TX","ACTG 070","01-MAR-1989","Other"
50264,"Protocol Status","Pending","20-DEC-1988","High-dose ACV & AZT for maint. TX","ACTG 070","10-JAN-1989","Pending"
50264,"Protocol Status","In Development","04-MAY-1988","High-dose ACV & AZT for maint. TX","ACTG 070","20-DEC-1988","In Development"
50265,"Protocol Status","POS/PAC","06-FEB-1995","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","","POS/PAC"
50265,"Protocol Status","Concluded","01-SEP-1993","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","06-FEB-1995","Concluded"
50265,"Protocol Status","Closed to Accrual","03-OCT-1990","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","01-SEP-1993","Closed to Accrual"
50265,"Protocol Status","Closed to Follow Up","29-AUG-1990","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","03-OCT-1990","Closed to Follow Up"
50265,"Protocol Status","Open","23-MAR-1989","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","29-AUG-1990","Open"
50265,"Protocol Status","Pending","17-FEB-1989","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","23-MAR-1989","Pending"
50265,"Protocol Status","In Development","01-JUN-1988","immed. vs. delayed GCV TX for peripheral retinitis","ACTG 071","17-FEB-1989","In Development"
50266,"Protocol Status","Concluded","01-APR-1993","Phase I Study of Gamma-Interferon and AZT","ACTG 072","","Concluded"
50266,"Protocol Status","Closed to Accrual","27-FEB-1990","Phase I Study of Gamma-Interferon and AZT","ACTG 072","01-APR-1993","Closed to Accrual"
50266,"Protocol Status","Closed to Follow Up","11-AUG-1989","Phase I Study of Gamma-Interferon and AZT","ACTG 072","27-FEB-1990","Closed to Follow Up"
50266,"Protocol Status","Open","19-APR-1989","Phase I Study of Gamma-Interferon and AZT","ACTG 072","11-AUG-1989","Open"
50266,"Protocol Status","Pending","19-SEP-1988","Phase I Study of Gamma-Interferon and AZT","ACTG 072","19-APR-1989","Pending"
50266,"Protocol Status","In Development","01-JUN-1988","Phase I Study of Gamma-Interferon and AZT","ACTG 072","19-SEP-1988","In Development"
50267,"Protocol Status","Concluded","01-JUN-1994","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","","Concluded"
50267,"Protocol Status","POS/PAC","31-JUL-1992","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","01-JUN-1994","POS/PAC"
50267,"Protocol Status","Closed to Follow Up","04-FEB-1992","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","31-JUL-1992","Closed to Follow Up"
50267,"Protocol Status","Closed to Accrual","01-MAY-1991","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","04-FEB-1992","Closed to Accrual"
50267,"Protocol Status","Open","14-APR-1989","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","01-MAY-1991","Open"
50267,"Protocol Status","Pending","21-DEC-1988","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","14-APR-1989","Pending"
50267,"Protocol Status","In Development","19-JUN-1988","GCV +/- GMCSF for induction/maint. of retinitis","ACTG 073","21-DEC-1988","In Development"
50268,"Protocol Status","Closed to Follow Up","12-APR-1994","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","","Closed to Follow Up"
50268,"Protocol Status","Concluded","01-MAR-1993","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","12-APR-1994","Concluded"
50268,"Protocol Status","POS/PAC","14-MAR-1991","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","01-MAR-1993","POS/PAC"
50268,"Protocol Status","Closed to Accrual","20-MAR-1990","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","14-MAR-1991","Closed to Accrual"
50268,"Protocol Status","Open","12-JAN-1989","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","20-MAR-1990","Open"
50268,"Protocol Status","Pending","22-NOV-1988","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","12-JAN-1989","Pending"
50268,"Protocol Status","In Development","13-JUL-1988","mBACOD and GM-CSF in AIDS-associated lymphoma","ACTG 074","22-NOV-1988","In Development"
50269,"Protocol Status","Concluded","01-DEC-1994","AZT + ABV in KS (Phase I)","ACTG 075","","Concluded"
50269,"Protocol Status","POS/PAC","07-APR-1992","AZT + ABV in KS (Phase I)","ACTG 075","01-DEC-1994","POS/PAC"
50269,"Protocol Status","Closed to Accrual","18-NOV-1991","AZT + ABV in KS (Phase I)","ACTG 075","07-APR-1992","Closed to Accrual"
50269,"Protocol Status","Closed to Follow Up","20-OCT-1991","AZT + ABV in KS (Phase I)","ACTG 075","18-NOV-1991","Closed to Follow Up"
50269,"Protocol Status","Temporarily Closed","09-MAY-1991","AZT + ABV in KS (Phase I)","ACTG 075","20-OCT-1991","Other"
50269,"Protocol Status","Open","27-FEB-1989","AZT + ABV in KS (Phase I)","ACTG 075","09-MAY-1991","Open"
50269,"Protocol Status","Pending","22-NOV-1988","AZT + ABV in KS (Phase I)","ACTG 075","27-FEB-1989","Pending"
50269,"Protocol Status","In Development","13-JUL-1988","AZT + ABV in KS (Phase I)","ACTG 075","22-NOV-1988","In Development"
50270,"Protocol Status","Withdrawn","16-APR-1991","Clinda/pyr vs. sulfa/pyr for acute toxo","ACTG 077","","Other"
50270,"Protocol Status","In Development","24-AUG-1988","Clinda/pyr vs. sulfa/pyr for acute toxo","ACTG 077","16-APR-1991","In Development"
50271,"Protocol Status","Concluded","30-SEP-1993","Clinda/pyrimethamine for acute toxo","ACTG 077P","","Concluded"
50271,"Protocol Status","POS/PAC","28-AUG-1992","Clinda/pyrimethamine for acute toxo","ACTG 077P","30-SEP-1993","POS/PAC"
50271,"Protocol Status","Closed to Follow Up","24-DEC-1991","Clinda/pyrimethamine for acute toxo","ACTG 077P","28-AUG-1992","Closed to Follow Up"
50271,"Protocol Status","Closed to Accrual","21-DEC-1990","Clinda/pyrimethamine for acute toxo","ACTG 077P","24-DEC-1991","Closed to Accrual"
50271,"Protocol Status","Open","18-DEC-1989","Clinda/pyrimethamine for acute toxo","ACTG 077P","21-DEC-1990","Open"
50271,"Protocol Status","Pending","15-SEP-1989","Clinda/pyrimethamine for acute toxo","ACTG 077P","18-DEC-1989","Pending"
50271,"Protocol Status","FDA - IND Hold","18-AUG-1989","Clinda/pyrimethamine for acute toxo","ACTG 077P","15-SEP-1989","Other"
50271,"Protocol Status","Pending","15-AUG-1989","Clinda/pyrimethamine for acute toxo","ACTG 077P","18-AUG-1989","Pending"
50271,"Protocol Status","In Development","05-JUN-1989","Clinda/pyrimethamine for acute toxo","ACTG 077P","15-AUG-1989","In Development"
50272,"Protocol Status","Concluded","01-OCT-1989","Dextran sulfate PK (oral, IV)","ACTG 078","","Concluded"
50272,"Protocol Status","POS/PAC","01-OCT-1989","Dextran sulfate PK (oral, IV)","ACTG 078","01-OCT-1989","POS/PAC"
50272,"Protocol Status","Closed to Accrual","17-FEB-1989","Dextran sulfate PK (oral, IV)","ACTG 078","01-OCT-1989","Closed to Accrual"
50272,"Protocol Status","Closed to Follow Up","19-NOV-1988","Dextran sulfate PK (oral, IV)","ACTG 078","17-FEB-1989","Closed to Follow Up"
50272,"Protocol Status","Open","13-OCT-1988","Dextran sulfate PK (oral, IV)","ACTG 078","19-NOV-1988","Open"
50272,"Protocol Status","Pending","28-SEP-1988","Dextran sulfate PK (oral, IV)","ACTG 078","13-OCT-1988","Pending"
50272,"Protocol Status","In Development","13-JUL-1988","Dextran sulfate PK (oral, IV)","ACTG 078","28-SEP-1988","In Development"
50273,"Protocol Status","POS/PAC","29-JAN-1992","AP deposition in 021 and 081 pts.","ACTG 079","","POS/PAC"
50273,"Protocol Status","Closed to Follow Up","01-JUL-1991","AP deposition in 021 and 081 pts.","ACTG 079","29-JAN-1992","Closed to Follow Up"
50273,"Protocol Status","Closed to Accrual","11-APR-1991","AP deposition in 021 and 081 pts.","ACTG 079","01-JUL-1991","Closed to Accrual"
50273,"Protocol Status","Concluded","01-APR-1991","AP deposition in 021 and 081 pts.","ACTG 079","11-APR-1991","Concluded"
50273,"Protocol Status","Open","14-DEC-1988","AP deposition in 021 and 081 pts.","ACTG 079","01-APR-1991","Open"
50273,"Protocol Status","Pending","15-SEP-1988","AP deposition in 021 and 081 pts.","ACTG 079","14-DEC-1988","Pending"
50273,"Protocol Status","In Development","11-AUG-1988","AP deposition in 021 and 081 pts.","ACTG 079","15-SEP-1988","In Development"
50274,"Protocol Status","Concluded","01-SEP-1993","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","","Concluded"
50274,"Protocol Status","POS/PAC","01-APR-1993","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","01-SEP-1993","POS/PAC"
50274,"Protocol Status","Closed to Follow Up","24-FEB-1992","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","01-APR-1993","Closed to Follow Up"
50274,"Protocol Status","Closed to Accrual","05-NOV-1991","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","24-FEB-1992","Closed to Accrual"
50274,"Protocol Status","Open","21-DEC-1989","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","05-NOV-1991","Open"
50274,"Protocol Status","FDA - IND Hold","17-NOV-1989","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","21-DEC-1989","Other"
50274,"Protocol Status","Open","15-NOV-1989","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","17-NOV-1989","Open"
50274,"Protocol Status","Pending","13-NOV-1989","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","15-NOV-1989","Pending"
50274,"Protocol Status","FDA - IND Hold","24-OCT-1989","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","13-NOV-1989","Other"
50274,"Protocol Status","Pending","20-OCT-1989","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","24-OCT-1989","Pending"
50274,"Protocol Status","In Development","25-AUG-1988","CD8 w/ or w/out IL-2 for AIDS or ARC","ACTG 080","20-OCT-1989","In Development"
50275,"Protocol Status","Concluded","01-DEC-2001","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","","Concluded"
50275,"Protocol Status","POS/PAC","07-APR-1994","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","01-DEC-2001","POS/PAC"
50275,"Protocol Status","Closed to Follow Up","06-AUG-1993","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","07-APR-1994","Closed to Follow Up"
50275,"Protocol Status","Closed to Accrual","01-JUN-1990","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","06-AUG-1993","Closed to Accrual"
50275,"Protocol Status","Open","10-APR-1989","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","01-JUN-1990","Open"
50275,"Protocol Status","Pending","22-MAR-1989","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","10-APR-1989","Pending"
50275,"Protocol Status","FDA - IND Hold","21-MAR-1989","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","22-MAR-1989","Other"
50275,"Protocol Status","Pending","22-DEC-1988","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","21-MAR-1989","Pending"
50275,"Protocol Status","In Development","07-SEP-1988","AP vs. TMP/S vs. dapsone for primary proph. of PCP","ACTG 081","22-DEC-1988","In Development"
50276,"Protocol Status","Withdrawn","15-MAR-1989","Oral Acyclovir for Herpes zoster","ACTG 083","","Other"
50276,"Protocol Status","In Development","28-SEP-1988","Oral Acyclovir for Herpes zoster","ACTG 083","15-MAR-1989","In Development"
50277,"Protocol Status","Concluded","15-APR-1993","Itraconazole for maint. of dissem. histo.","ACTG 084","","Concluded"
50277,"Protocol Status","Closed to Follow Up","01-DEC-1992","Itraconazole for maint. of dissem. histo.","ACTG 084","15-APR-1993","Closed to Follow Up"
50277,"Protocol Status","POS/PAC","22-JUN-1992","Itraconazole for maint. of dissem. histo.","ACTG 084","01-DEC-1992","POS/PAC"
50277,"Protocol Status","Closed to Accrual","08-MAR-1990","Itraconazole for maint. of dissem. histo.","ACTG 084","22-JUN-1992","Closed to Accrual"
50277,"Protocol Status","Open","03-MAY-1989","Itraconazole for maint. of dissem. histo.","ACTG 084","08-MAR-1990","Open"
50277,"Protocol Status","Pending","17-APR-1989","Itraconazole for maint. of dissem. histo.","ACTG 084","03-MAY-1989","Pending"
50277,"Protocol Status","FDA - IND Hold","12-APR-1989","Itraconazole for maint. of dissem. histo.","ACTG 084","17-APR-1989","Other"
50277,"Protocol Status","Pending","11-APR-1989","Itraconazole for maint. of dissem. histo.","ACTG 084","12-APR-1989","Pending"
50277,"Protocol Status","In Development","28-SEP-1988","Itraconazole for maint. of dissem. histo.","ACTG 084","11-APR-1989","In Development"
50278,"Protocol Status","Concluded","01-NOV-1996","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","","Concluded"
50278,"Protocol Status","POS/PAC","04-MAY-1993","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","01-NOV-1996","POS/PAC"
50278,"Protocol Status","Closed to Accrual","01-MAY-1992","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","04-MAY-1993","Closed to Accrual"
50278,"Protocol Status","Closed to Follow Up","05-JUL-1991","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","01-MAY-1992","Closed to Follow Up"
50278,"Protocol Status","Open","04-JAN-1990","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","05-JUL-1991","Open"
50278,"Protocol Status","Pending","03-AUG-1989","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","04-JAN-1990","Pending"
50278,"Protocol Status","In Development","28-SEP-1988","Intravitreal GCV for Salvage TX of CMV Retinitis","ACTG 085","03-AUG-1989","In Development"
50279,"Protocol Status","Withdrawn","26-SEP-1989","AZT in HIV-related Thrombocytopenic Purpura","ACTG 087","","Other"
50279,"Protocol Status","Pending","15-MAY-1989","AZT in HIV-related Thrombocytopenic Purpura","ACTG 087","26-SEP-1989","Pending"
50279,"Protocol Status","FDA - IND Hold","24-MAR-1989","AZT in HIV-related Thrombocytopenic Purpura","ACTG 087","15-MAY-1989","Other"
50279,"Protocol Status","Pending","15-MAR-1989","AZT in HIV-related Thrombocytopenic Purpura","ACTG 087","24-MAR-1989","Pending"
50279,"Protocol Status","In Development","19-OCT-1988","AZT in HIV-related Thrombocytopenic Purpura","ACTG 087","15-MAR-1989","In Development"
50280,"Protocol Status","Withdrawn","01-FEB-1990","AZT PK in CAPD patients","ACTG 088","","Other"
50280,"Protocol Status","Open","27-SEP-1989","AZT PK in CAPD patients","ACTG 088","01-FEB-1990","Open"
50280,"Protocol Status","Pending","26-MAY-1989","AZT PK in CAPD patients","ACTG 088","27-SEP-1989","Pending"
50280,"Protocol Status","In Development","19-OCT-1988","AZT PK in CAPD patients","ACTG 088","26-MAY-1989","In Development"
50281,"Protocol Status","Concluded","01-MAR-1995","Min Effective dose of D4T","ACTG 089","","Concluded"
50281,"Protocol Status","POS/PAC","22-MAR-1994","Min Effective dose of D4T","ACTG 089","01-MAR-1995","POS/PAC"
50281,"Protocol Status","Closed to Follow Up","17-JUL-1992","Min Effective dose of D4T","ACTG 089","22-MAR-1994","Closed to Follow Up"
50281,"Protocol Status","Closed to Accrual","16-JAN-1991","Min Effective dose of D4T","ACTG 089","17-JUL-1992","Closed to Accrual"
50281,"Protocol Status","Open","23-MAR-1989","Min Effective dose of D4T","ACTG 089","16-JAN-1991","Open"
50281,"Protocol Status","Pending","21-NOV-1988","Min Effective dose of D4T","ACTG 089","23-MAR-1989","Pending"
50281,"Protocol Status","In Development","13-OCT-1988","Min Effective dose of D4T","ACTG 089","21-NOV-1988","In Development"
50282,"Protocol Status","Concluded","01-SEP-1997","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","","Concluded"
50282,"Protocol Status","POS/PAC","01-AUG-1992","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","01-SEP-1997","POS/PAC"
50282,"Protocol Status","Closed to Follow Up","05-NOV-1991","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","01-AUG-1992","Closed to Follow Up"
50282,"Protocol Status","Closed to Accrual","08-FEB-1991","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","05-NOV-1991","Closed to Accrual"
50282,"Protocol Status","Open","18-APR-1989","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","08-FEB-1991","Open"
50282,"Protocol Status","Pending","17-MAR-1989","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","18-APR-1989","Pending"
50282,"Protocol Status","In Development","09-NOV-1988","Interferon-alpha/GM-CSF/AZT: Phase I","ACTG 090","17-MAR-1989","In Development"
50283,"Protocol Status","Withdrawn","01-NOV-1989","N/A","ACTG 092","","Other"
50283,"Protocol Status","Open","07-JUL-1989","N/A","ACTG 092","01-NOV-1989","Open"
50283,"Protocol Status","Pending","31-JAN-1989","N/A","ACTG 092","07-JUL-1989","Pending"
50283,"Protocol Status","In Development","28-SEP-1988","N/A","ACTG 092","31-JAN-1989","In Development"
50284,"Protocol Status","Concluded","01-APR-1994","PFA for salvage TX of retinitis","ACTG 093","","Concluded"
50284,"Protocol Status","POS/PAC","15-AUG-1992","PFA for salvage TX of retinitis","ACTG 093","01-APR-1994","POS/PAC"
50284,"Protocol Status","Closed to Follow Up","23-JUL-1991","PFA for salvage TX of retinitis","ACTG 093","15-AUG-1992","Closed to Follow Up"
50284,"Protocol Status","Closed to Accrual","01-JUN-1990","PFA for salvage TX of retinitis","ACTG 093","23-JUL-1991","Closed to Accrual"
50284,"Protocol Status","Open","17-MAR-1989","PFA for salvage TX of retinitis","ACTG 093","01-JUN-1990","Open"
50284,"Protocol Status","Pending","02-FEB-1989","PFA for salvage TX of retinitis","ACTG 093","17-MAR-1989","Pending"
50284,"Protocol Status","In Development","28-SEP-1988","PFA for salvage TX of retinitis","ACTG 093","02-FEB-1989","In Development"
50285,"Protocol Status","Concluded","01-JAN-1997","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","","Concluded"
50285,"Protocol Status","POS/PAC","01-OCT-1993","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","01-JAN-1997","POS/PAC"
50285,"Protocol Status","Closed to Follow Up","02-JUL-1992","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","01-OCT-1993","Closed to Follow Up"
50285,"Protocol Status","Closed to Accrual","11-MAR-1992","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","02-JUL-1992","Closed to Accrual"
50285,"Protocol Status","Temporarily Closed","21-FEB-1992","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","11-MAR-1992","Other"
50285,"Protocol Status","Open","01-MAR-1991","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","21-FEB-1992","Open"
50285,"Protocol Status","Temporarily Closed","21-DEC-1990","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","01-MAR-1991","Other"
50285,"Protocol Status","Open","05-SEP-1989","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","21-DEC-1990","Open"
50285,"Protocol Status","Pending","08-MAY-1989","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","05-SEP-1989","Pending"
50285,"Protocol Status","In Development","08-DEC-1988","GM-CSF/AZT/ABV in KS (Phase I)","ACTG 094","08-MAY-1989","In Development"
50286,"Protocol Status","Concluded","01-JUN-1996","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","","Concluded"
50286,"Protocol Status","Closed to Follow Up","03-NOV-1990","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","01-JUN-1996","Closed to Follow Up"
50286,"Protocol Status","POS/PAC","22-OCT-1990","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","03-NOV-1990","POS/PAC"
50286,"Protocol Status","Temporarily Closed","23-MAY-1990","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","22-OCT-1990","Other"
50286,"Protocol Status","Open","26-MAY-1989","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","23-MAY-1990","Open"
50286,"Protocol Status","Pending","19-APR-1989","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","26-MAY-1989","Pending"
50286,"Protocol Status","In Development","19-OCT-1988","PFA vs. Ara-A for ACV-resistant Herpes simplex","ACTG 095","19-APR-1989","In Development"
50287,"Protocol Status","Concluded","01-SEP-1997","AZT/Interferon-alpha in KS (Phase II)","ACTG 096","","Concluded"
50287,"Protocol Status","POS/PAC","15-JUL-1993","AZT/Interferon-alpha in KS (Phase II)","ACTG 096","01-SEP-1997","POS/PAC"
50287,"Protocol Status","Closed to Follow Up","06-MAY-1992","AZT/Interferon-alpha in KS (Phase II)","ACTG 096","15-JUL-1993","Closed to Follow Up"
50287,"Protocol Status","Closed to Accrual","31-JAN-1991","AZT/Interferon-alpha in KS (Phase II)","ACTG 096","06-MAY-1992","Closed to Accrual"
50287,"Protocol Status","Open","19-JUL-1989","AZT/Interferon-alpha in KS (Phase II)","ACTG 096","31-JAN-1991","Open"
50287,"Protocol Status","Pending","21-APR-1987","AZT/Interferon-alpha in KS (Phase II)","ACTG 096","19-JUL-1989","Pending"
50288,"Protocol Status","Withdrawn","16-APR-1991","Clinda/pyr vs. sulfa/pyr for maint. treat. of toxo","ACTG 099","","Other"
50288,"Protocol Status","In Development","01-FEB-1989","Clinda/pyr vs. sulfa/pyr for maint. treat. of toxo","ACTG 099","16-APR-1991","In Development"
50289,"Protocol Status","Concluded","15-DEC-1995","N-butyl DNJ","ACTG 100","","Concluded"
50289,"Protocol Status","POS/PAC","01-FEB-1993","N-butyl DNJ","ACTG 100","15-DEC-1995","POS/PAC"
50289,"Protocol Status","Closed to Accrual","27-FEB-1991","N-butyl DNJ","ACTG 100","01-FEB-1993","Closed to Accrual"
50289,"Protocol Status","Closed to Follow Up","16-FEB-1991","N-butyl DNJ","ACTG 100","27-FEB-1991","Closed to Follow Up"
50289,"Protocol Status","Open","31-MAR-1989","N-butyl DNJ","ACTG 100","16-FEB-1991","Open"
50289,"Protocol Status","Pending","27-FEB-1989","N-butyl DNJ","ACTG 100","31-MAR-1989","Pending"
50289,"Protocol Status","In Development","27-FEB-1989","N-butyl DNJ","ACTG 100","27-FEB-1989","In Development"
50290,"Protocol Status","Concluded","01-JUN-1996","Pyrimethamine PK in AIDS/ARC","ACTG 102","","Concluded"
50290,"Protocol Status","POS/PAC","12-MAR-1995","Pyrimethamine PK in AIDS/ARC","ACTG 102","01-JUN-1996","POS/PAC"
50290,"Protocol Status","Closed to Follow Up","28-JAN-1992","Pyrimethamine PK in AIDS/ARC","ACTG 102","12-MAR-1995","Closed to Follow Up"
50290,"Protocol Status","Closed to Accrual","23-JAN-1992","Pyrimethamine PK in AIDS/ARC","ACTG 102","28-JAN-1992","Closed to Accrual"
50290,"Protocol Status","Open","09-OCT-1990","Pyrimethamine PK in AIDS/ARC","ACTG 102","23-JAN-1992","Open"
50290,"Protocol Status","Pending","16-AUG-1990","Pyrimethamine PK in AIDS/ARC","ACTG 102","09-OCT-1990","Pending"
50290,"Protocol Status","In Development","04-JUN-1990","Pyrimethamine PK in AIDS/ARC","ACTG 102","16-AUG-1990","In Development"
50290,"Protocol Status","Deferred","01-FEB-1990","Pyrimethamine PK in AIDS/ARC","ACTG 102","04-JUN-1990","Other"
50290,"Protocol Status","In Development","31-MAR-1989","Pyrimethamine PK in AIDS/ARC","ACTG 102","01-FEB-1990","In Development"
50291,"Protocol Status","Withdrawn","01-FEB-1990","AZT/ASA & Ibuprofen PKs","ACTG 104","","Other"
50291,"Protocol Status","Pending","10-OCT-1989","AZT/ASA & Ibuprofen PKs","ACTG 104","01-FEB-1990","Pending"
50291,"Protocol Status","In Development","31-MAR-1989","AZT/ASA & Ibuprofen PKs","ACTG 104","10-OCT-1989","In Development"
50292,"Protocol Status","Concluded","01-DEC-1995","Dextran sulfate IV","ACTG 105","","Concluded"
50292,"Protocol Status","POS/PAC","25-APR-1991","Dextran sulfate IV","ACTG 105","01-DEC-1995","POS/PAC"
50292,"Protocol Status","Closed to Accrual","25-JUL-1990","Dextran sulfate IV","ACTG 105","25-APR-1991","Closed to Accrual"
50292,"Protocol Status","Closed to Follow Up","14-JUN-1990","Dextran sulfate IV","ACTG 105","25-JUL-1990","Closed to Follow Up"
50292,"Protocol Status","Open","14-FEB-1990","Dextran sulfate IV","ACTG 105","14-JUN-1990","Open"
50292,"Protocol Status","Temporarily Closed","05-DEC-1989","Dextran sulfate IV","ACTG 105","14-FEB-1990","Other"
50292,"Protocol Status","Open","11-AUG-1989","Dextran sulfate IV","ACTG 105","05-DEC-1989","Open"
50292,"Protocol Status","Pending","01-JUN-1989","Dextran sulfate IV","ACTG 105","11-AUG-1989","Pending"
50292,"Protocol Status","In Development","10-APR-1989","Dextran sulfate IV","ACTG 105","01-JUN-1989","In Development"
50293,"Protocol Status","Concluded","01-JAN-1997","AZT/ddC combination","ACTG 106","","Concluded"
50293,"Protocol Status","Closed to Follow Up","30-NOV-1992","AZT/ddC combination","ACTG 106","01-JAN-1997","Closed to Follow Up"
50293,"Protocol Status","POS/PAC","01-JAN-1992","AZT/ddC combination","ACTG 106","30-NOV-1992","POS/PAC"
50293,"Protocol Status","Temporarily Closed","08-FEB-1991","AZT/ddC combination","ACTG 106","01-JAN-1992","Other"
50293,"Protocol Status","Open","15-MAY-1989","AZT/ddC combination","ACTG 106","08-FEB-1991","Open"
50293,"Protocol Status","In Development","14-APR-1989","AZT/ddC combination","ACTG 106","15-MAY-1989","In Development"
50294,"Protocol Status","Concluded","15-OCT-1990","AZT/Probenecid PK","ACTG 107","","Concluded"
50294,"Protocol Status","Closed to Accrual","26-SEP-1990","AZT/Probenecid PK","ACTG 107","15-OCT-1990","Closed to Accrual"
50294,"Protocol Status","Closed to Follow Up","21-AUG-1990","AZT/Probenecid PK","ACTG 107","26-SEP-1990","Closed to Follow Up"
50294,"Protocol Status","Open","02-AUG-1989","AZT/Probenecid PK","ACTG 107","21-AUG-1990","Open"
50294,"Protocol Status","Pending","03-JUL-1989","AZT/Probenecid PK","ACTG 107","02-AUG-1989","Pending"
50294,"Protocol Status","In Development","14-APR-1989","AZT/Probenecid PK","ACTG 107","03-JUL-1989","In Development"
50295,"Protocol Status","Concluded","01-JAN-1999","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","","Concluded"
50295,"Protocol Status","POS/PAC","08-SEP-1994","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","01-JAN-1999","POS/PAC"
50295,"Protocol Status","Closed to Follow Up","25-AUG-1993","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","08-SEP-1994","Closed to Follow Up"
50295,"Protocol Status","Closed to Accrual","01-JUL-1993","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","25-AUG-1993","Closed to Accrual"
50295,"Protocol Status","Open","25-APR-1991","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","01-JUL-1993","Open"
50295,"Protocol Status","Pending","04-FEB-1991","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","25-APR-1991","Pending"
50295,"Protocol Status","In Development","18-APR-1989","Dap/TMP & Clinda/Prima vs TMP/SMX for Mild-Mod. PC","ACTG 108","04-FEB-1991","In Development"
50296,"Protocol Status","Withdrawn","01-FEB-1990","AZT/BV/IFN in KS (Phases II/III)","ACTG 109","","Other"
50296,"Protocol Status","Pending","01-NOV-1989","AZT/BV/IFN in KS (Phases II/III)","ACTG 109","01-FEB-1990","Pending"
50296,"Protocol Status","In Development","18-APR-1989","AZT/BV/IFN in KS (Phases II/III)","ACTG 109","01-NOV-1989","In Development"
50297,"Protocol Status","Concluded","01-SEP-1997","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","","Concluded"
50297,"Protocol Status","Closed to Follow Up","30-SEP-1992","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","01-SEP-1997","Closed to Follow Up"
50297,"Protocol Status","POS/PAC","08-JUL-1992","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","30-SEP-1992","POS/PAC"
50297,"Protocol Status","Closed to Accrual","06-NOV-1991","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","08-JUL-1992","Closed to Accrual"
50297,"Protocol Status","Temporarily Closed","03-OCT-1991","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","06-NOV-1991","Other"
50297,"Protocol Status","Open","15-MAY-1990","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","03-OCT-1991","Open"
50297,"Protocol Status","Pending","14-DEC-1989","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","15-MAY-1990","Pending"
50297,"Protocol Status","In Development","18-APR-1989","Oral VP16 in KS: dose-escalating Phase I","ACTG 110","14-DEC-1989","In Development"
50298,"Protocol Status","Closed to Follow Up","16-JUL-1992","D4T in AZT-Intolerant-Phase I","ACTG 111","","Closed to Follow Up"
50298,"Protocol Status","Open","01-FEB-1990","D4T in AZT-Intolerant-Phase I","ACTG 111","16-JUL-1992","Open"
50298,"Protocol Status","Withdrawn","01-FEB-1990","D4T in AZT-Intolerant-Phase I","ACTG 111","01-FEB-1990","Other"
50298,"Protocol Status","Concluded","26-JAN-1990","D4T in AZT-Intolerant-Phase I","ACTG 111","01-FEB-1990","Concluded"
50298,"Protocol Status","Pending","31-MAY-1989","D4T in AZT-Intolerant-Phase I","ACTG 111","26-JAN-1990","Pending"
50298,"Protocol Status","In Development","18-APR-1989","D4T in AZT-Intolerant-Phase I","ACTG 111","31-MAY-1989","In Development"
50299,"Protocol Status","Concluded","01-OCT-1998","AZT vs ddC (002 f/u)","ACTG 112","","Concluded"
50299,"Protocol Status","Concluded","01-SEP-1992","AZT vs ddC (002 f/u)","ACTG 112","01-OCT-1998","Concluded"
50299,"Protocol Status","Closed to Follow Up","30-MAY-1990","AZT vs ddC (002 f/u)","ACTG 112","01-SEP-1992","Closed to Follow Up"
50299,"Protocol Status","Closed to Accrual","05-MAR-1990","AZT vs ddC (002 f/u)","ACTG 112","30-MAY-1990","Closed to Accrual"
50299,"Protocol Status","Open","26-JUN-1989","AZT vs ddC (002 f/u)","ACTG 112","05-MAR-1990","Open"
50299,"Protocol Status","Pending","09-MAY-1989","AZT vs ddC (002 f/u)","ACTG 112","26-JUN-1989","Pending"
50299,"Protocol Status","In Development","03-MAY-1989","AZT vs ddC (002 f/u)","ACTG 112","09-MAY-1989","In Development"
50300,"Protocol Status","Concluded","06-FEB-1995","Spiramycin IV for cryptosporidiosis","ACTG 113","","Concluded"
50300,"Protocol Status","Closed to Follow Up","15-DEC-1990","Spiramycin IV for cryptosporidiosis","ACTG 113","06-FEB-1995","Closed to Follow Up"
50300,"Protocol Status","Closed to Accrual","03-OCT-1990","Spiramycin IV for cryptosporidiosis","ACTG 113","15-DEC-1990","Closed to Accrual"
50300,"Protocol Status","Open","29-JUL-1989","Spiramycin IV for cryptosporidiosis","ACTG 113","03-OCT-1990","Open"
50300,"Protocol Status","In Development","14-JUN-1989","Spiramycin IV for cryptosporidiosis","ACTG 113","29-JUL-1989","In Development"
50301,"Protocol Status","Concluded","01-FEB-1994","ddC vs AZT in ARC/AIDS","ACTG 114","","Concluded"
50301,"Protocol Status","Closed to Follow Up","03-MAR-1992","ddC vs AZT in ARC/AIDS","ACTG 114","01-FEB-1994","Closed to Follow Up"
50301,"Protocol Status","Closed to Accrual","30-NOV-1990","ddC vs AZT in ARC/AIDS","ACTG 114","03-MAR-1992","Closed to Accrual"
50301,"Protocol Status","Open","18-SEP-1989","ddC vs AZT in ARC/AIDS","ACTG 114","30-NOV-1990","Open"
50301,"Protocol Status","In Development","20-JUN-1989","ddC vs AZT in ARC/AIDS","ACTG 114","18-SEP-1989","In Development"
50302,"Protocol Status","Concluded","01-DEC-1997","ddI vs. ZDV Therapy in Patients with HIV Infection","ACTG 116","","Concluded"
50302,"Protocol Status","POS/PAC","27-OCT-1992","ddI vs. ZDV Therapy in Patients with HIV Infection","ACTG 116","01-DEC-1997","POS/PAC"
50302,"Protocol Status","Closed to Follow Up","30-SEP-1992","ddI vs. ZDV Therapy in Patients with HIV Infection","ACTG 116","27-OCT-1992","Closed to Follow Up"
50302,"Protocol Status","Closed to Accrual","31-MAR-1991","ddI vs. ZDV Therapy in Patients with HIV Infection","ACTG 116","30-SEP-1992","Closed to Accrual"
50302,"Protocol Status","Open","26-JUL-1989","ddI vs. ZDV Therapy in Patients with HIV Infection","ACTG 116","31-MAR-1991","Open"
50302,"Protocol Status","In Development","17-JUL-1989","ddI vs. ZDV Therapy in Patients with HIV Infection","ACTG 116","26-JUL-1989","In Development"
50303,"Protocol Status","Concluded","01-JUN-1998","ddI vs. ZDV in Patients on Long Term ZDV Treatment","ACTG 117","","Concluded"
50303,"Protocol Status","Closed to Follow Up","24-OCT-1992","ddI vs. ZDV in Patients on Long Term ZDV Treatment","ACTG 117","01-JUN-1998","Closed to Follow Up"
50303,"Protocol Status","POS/PAC","27-MAR-1992","ddI vs. ZDV in Patients on Long Term ZDV Treatment","ACTG 117","24-OCT-1992","POS/PAC"
50303,"Protocol Status","Closed to Accrual","31-MAR-1991","ddI vs. ZDV in Patients on Long Term ZDV Treatment","ACTG 117","27-MAR-1992","Closed to Accrual"
50303,"Protocol Status","Open","26-JUL-1989","ddI vs. ZDV in Patients on Long Term ZDV Treatment","ACTG 117","31-MAR-1991","Open"
50303,"Protocol Status","In Development","17-JUL-1989","ddI vs. ZDV in Patients on Long Term ZDV Treatment","ACTG 117","26-JUL-1989","In Development"
50304,"Protocol Status","Concluded","17-FEB-1993","ddI in ZDV intolerant","ACTG 118","","Concluded"
50304,"Protocol Status","Closed to Follow Up","08-MAY-1992","ddI in ZDV intolerant","ACTG 118","17-FEB-1993","Closed to Follow Up"
50304,"Protocol Status","Closed to Accrual","31-MAR-1991","ddI in ZDV intolerant","ACTG 118","08-MAY-1992","Closed to Accrual"
50304,"Protocol Status","Open","26-JUL-1989","ddI in ZDV intolerant","ACTG 118","31-MAR-1991","Open"
50304,"Protocol Status","In Development","17-JUL-1989","ddI in ZDV intolerant","ACTG 118","26-JUL-1989","In Development"
50305,"Protocol Status","Concluded","15-MAY-1993","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","","Concluded"
50305,"Protocol Status","POS/PAC","13-JUL-1992","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","15-MAY-1993","POS/PAC"
50305,"Protocol Status","Closed to Follow Up","16-DEC-1991","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","13-JUL-1992","Closed to Follow Up"
50305,"Protocol Status","Closed to Accrual","12-NOV-1990","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","16-DEC-1991","Closed to Accrual"
50305,"Protocol Status","Open","21-DEC-1989","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","12-NOV-1990","Open"
50305,"Protocol Status","Pending","21-SEP-1989","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","21-DEC-1989","Pending"
50305,"Protocol Status","In Development","19-JUL-1989","AZT vs ddC in long-term AZT ARC/AIDS pts.","ACTG 119","21-SEP-1989","In Development"
50306,"Protocol Status","Concluded","01-JAN-1997","Itraconazole for acute treatment of dissem. histo.","ACTG 120","","Concluded"
50306,"Protocol Status","POS/PAC","16-SEP-1994","Itraconazole for acute treatment of dissem. histo.","ACTG 120","01-JAN-1997","POS/PAC"
50306,"Protocol Status","Closed to Follow Up","23-FEB-1993","Itraconazole for acute treatment of dissem. histo.","ACTG 120","16-SEP-1994","Closed to Follow Up"
50306,"Protocol Status","Closed to Accrual","15-JUL-1991","Itraconazole for acute treatment of dissem. histo.","ACTG 120","23-FEB-1993","Closed to Accrual"
50306,"Protocol Status","Open","10-APR-1990","Itraconazole for acute treatment of dissem. histo.","ACTG 120","15-JUL-1991","Open"
50306,"Protocol Status","Pending","31-JAN-1990","Itraconazole for acute treatment of dissem. histo.","ACTG 120","10-APR-1990","Pending"
50306,"Protocol Status","In Development","07-AUG-1989","Itraconazole for acute treatment of dissem. histo.","ACTG 120","31-JAN-1990","In Development"
50307,"Protocol Status","Concluded","01-JAN-1995","CD4-IgG Phase I","ACTG 121","","Concluded"
50307,"Protocol Status","POS/PAC","27-JUN-1991","CD4-IgG Phase I","ACTG 121","01-JAN-1995","POS/PAC"
50307,"Protocol Status","Closed to Follow Up","09-APR-1991","CD4-IgG Phase I","ACTG 121","27-JUN-1991","Closed to Follow Up"
50307,"Protocol Status","Closed to Accrual","13-FEB-1991","CD4-IgG Phase I","ACTG 121","09-APR-1991","Closed to Accrual"
50307,"Protocol Status","Temporarily Closed","22-JAN-1991","CD4-IgG Phase I","ACTG 121","13-FEB-1991","Other"
50307,"Protocol Status","Open","27-OCT-1989","CD4-IgG Phase I","ACTG 121","22-JAN-1991","Open"
50307,"Protocol Status","In Development","18-AUG-1989","CD4-IgG Phase I","ACTG 121","27-OCT-1989","In Development"
50308,"Protocol Status","Concluded","01-FEB-1993","Tolerance of oral FIAU for HIV+ pts with Herpes","ACTG 122","","Concluded"
50308,"Protocol Status","Closed to Follow Up","27-JUL-1992","Tolerance of oral FIAU for HIV+ pts with Herpes","ACTG 122","01-FEB-1993","Closed to Follow Up"
50308,"Protocol Status","Closed to Accrual","23-JUL-1992","Tolerance of oral FIAU for HIV+ pts with Herpes","ACTG 122","27-JUL-1992","Closed to Accrual"
50308,"Protocol Status","Open","31-AUG-1989","Tolerance of oral FIAU for HIV+ pts with Herpes","ACTG 122","23-JUL-1992","Open"
50308,"Protocol Status","In Development","18-AUG-1989","Tolerance of oral FIAU for HIV+ pts with Herpes","ACTG 122","31-AUG-1989","In Development"
50309,"Protocol Status","Withdrawn","21-JAN-1992","IFN-gamma and pyr/sulfa for acute toxo","ACTG 123","","Other"
50309,"Protocol Status","In Development","26-AUG-1989","IFN-gamma and pyr/sulfa for acute toxo","ACTG 123","21-JAN-1992","In Development"
50310,"Protocol Status","POS/PAC","01-JAN-1993","AZT/Oxazepam PK","ACTG 124","","POS/PAC"
50310,"Protocol Status","Concluded","01-JAN-1993","AZT/Oxazepam PK","ACTG 124","01-JAN-1993","Concluded"
50310,"Protocol Status","Closed to Accrual","28-OCT-1991","AZT/Oxazepam PK","ACTG 124","01-JAN-1993","Closed to Accrual"
50310,"Protocol Status","Closed to Follow Up","09-NOV-1990","AZT/Oxazepam PK","ACTG 124","28-OCT-1991","Closed to Follow Up"
50310,"Protocol Status","Temporarily Closed","01-NOV-1990","AZT/Oxazepam PK","ACTG 124","09-NOV-1990","Other"
50310,"Protocol Status","Open","13-MAR-1990","AZT/Oxazepam PK","ACTG 124","01-NOV-1990","Open"
50310,"Protocol Status","Pending","13-FEB-1990","AZT/Oxazepam PK","ACTG 124","13-MAR-1990","Pending"
50310,"Protocol Status","In Development","06-SEP-1989","AZT/Oxazepam PK","ACTG 124","13-FEB-1990","In Development"
50311,"Protocol Status","Concluded","29-SEP-1991","SCH 39304 for acute TX of crypt. meningitis","ACTG 125","","Concluded"
50311,"Protocol Status","Closed to Follow Up","07-MAR-1991","SCH 39304 for acute TX of crypt. meningitis","ACTG 125","29-SEP-1991","Closed to Follow Up"
50311,"Protocol Status","Closed to Accrual","18-JAN-1991","SCH 39304 for acute TX of crypt. meningitis","ACTG 125","07-MAR-1991","Closed to Accrual"
50311,"Protocol Status","Open","12-JAN-1990","SCH 39304 for acute TX of crypt. meningitis","ACTG 125","18-JAN-1991","Open"
50311,"Protocol Status","Pending","14-OCT-1989","SCH 39304 for acute TX of crypt. meningitis","ACTG 125","12-JAN-1990","Pending"
50311,"Protocol Status","In Development","04-AUG-1989","SCH 39304 for acute TX of crypt. meningitis","ACTG 125","14-OCT-1989","In Development"
50312,"Protocol Status","Withdrawn","13-JUN-2002","IVDU Enrollment","ACTG 126","","Other"
50312,"Protocol Status","Deferred","13-FEB-1990","IVDU Enrollment","ACTG 126","13-JUN-2002","Other"
50312,"Protocol Status","In Development","06-SEP-1989","IVDU Enrollment","ACTG 126","13-FEB-1990","In Development"
50313,"Protocol Status","Concluded","01-JUN-1995","PK/Tolerance study of p.o. GCV for CMV","ACTG 127","","Concluded"
50313,"Protocol Status","POS/PAC","06-FEB-1995","PK/Tolerance study of p.o. GCV for CMV","ACTG 127","01-JUN-1995","POS/PAC"
50313,"Protocol Status","Closed to Follow Up","15-AUG-1991","PK/Tolerance study of p.o. GCV for CMV","ACTG 127","06-FEB-1995","Closed to Follow Up"
50313,"Protocol Status","Closed to Accrual","12-MAR-1991","PK/Tolerance study of p.o. GCV for CMV","ACTG 127","15-AUG-1991","Closed to Accrual"
50313,"Protocol Status","Open","26-JAN-1990","PK/Tolerance study of p.o. GCV for CMV","ACTG 127","12-MAR-1991","Open"
50313,"Protocol Status","In Development","25-SEP-1989","PK/Tolerance study of p.o. GCV for CMV","ACTG 127","26-JAN-1990","In Development"
50314,"Protocol Status","Concluded","01-SEP-1995","PFA vs. GCV for CMV retinitis","ACTG 129","","Concluded"
50314,"Protocol Status","Closed to Follow Up","06-AUG-1994","PFA vs. GCV for CMV retinitis","ACTG 129","01-SEP-1995","Closed to Follow Up"
50314,"Protocol Status","POS/PAC","01-APR-1992","PFA vs. GCV for CMV retinitis","ACTG 129","06-AUG-1994","POS/PAC"
50314,"Protocol Status","Closed to Accrual","09-OCT-1991","PFA vs. GCV for CMV retinitis","ACTG 129","01-APR-1992","Closed to Accrual"
50314,"Protocol Status","Open","13-MAR-1990","PFA vs. GCV for CMV retinitis","ACTG 129","09-OCT-1991","Open"
50314,"Protocol Status","In Development","05-OCT-1989","PFA vs. GCV for CMV retinitis","ACTG 129","13-MAR-1990","In Development"
50315,"Protocol Status","Withdrawn","01-MAR-1990","ddI in ADC","ACTG 132","","Other"
50315,"Protocol Status","Deferred","01-FEB-1990","ddI in ADC","ACTG 132","01-MAR-1990","Other"
50315,"Protocol Status","In Development","03-NOV-1989","ddI in ADC","ACTG 132","01-FEB-1990","In Development"
50316,"Protocol Status","Withdrawn","18-JUL-1990","Comination AZT and soluble CD4 in AIDS and ARC","ACTG 133","","Other"
50316,"Protocol Status","Open","27-NOV-1989","Comination AZT and soluble CD4 in AIDS and ARC","ACTG 133","18-JUL-1990","Open"
50316,"Protocol Status","In Development","03-NOV-1989","Comination AZT and soluble CD4 in AIDS and ARC","ACTG 133","27-NOV-1989","In Development"
50317,"Protocol Status","Concluded","01-FEB-1995","rCD4-IgG with Oral ZDV in AIDS and ARC","ACTG 134","","Concluded"
50317,"Protocol Status","POS/PAC","13-DEC-1994","rCD4-IgG with Oral ZDV in AIDS and ARC","ACTG 134","01-FEB-1995","POS/PAC"
50317,"Protocol Status","Closed to Follow Up","15-OCT-1991","rCD4-IgG with Oral ZDV in AIDS and ARC","ACTG 134","13-DEC-1994","Closed to Follow Up"
50317,"Protocol Status","Closed to Accrual","22-JAN-1991","rCD4-IgG with Oral ZDV in AIDS and ARC","ACTG 134","15-OCT-1991","Closed to Accrual"
50317,"Protocol Status","Open","04-MAY-1990","rCD4-IgG with Oral ZDV in AIDS and ARC","ACTG 134","22-JAN-1991","Open"
50317,"Protocol Status","In Development","11-DEC-1989","rCD4-IgG with Oral ZDV in AIDS and ARC","ACTG 134","04-MAY-1990","In Development"
50318,"Protocol Status","Concluded","24-DEC-1998","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","","Concluded"
50318,"Protocol Status","POS/PAC","15-DEC-1994","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","24-DEC-1998","POS/PAC"
50318,"Protocol Status","Closed to Follow Up","01-NOV-1993","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","15-DEC-1994","Closed to Follow Up"
50318,"Protocol Status","Closed to Accrual","09-OCT-1992","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","01-NOV-1993","Closed to Accrual"
50318,"Protocol Status","Open","25-MAR-1991","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","09-OCT-1992","Open"
50318,"Protocol Status","Pending","14-JAN-1991","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","25-MAR-1991","Pending"
50318,"Protocol Status","In Development","09-FEB-1990","5 Drug Combo vs. 4 Drugs for MAI","ACTG 135","14-JAN-1991","In Development"
50319,"Protocol Status","Concluded","28-OCT-1990","Gastric pH on Bioavailability of Foscarnet","ACTG 136","","Concluded"
50319,"Protocol Status","Closed to Follow Up","28-AUG-1990","Gastric pH on Bioavailability of Foscarnet","ACTG 136","28-OCT-1990","Closed to Follow Up"
50319,"Protocol Status","Closed to Accrual","28-AUG-1990","Gastric pH on Bioavailability of Foscarnet","ACTG 136","28-AUG-1990","Closed to Accrual"
50319,"Protocol Status","Open","27-JUL-1990","Gastric pH on Bioavailability of Foscarnet","ACTG 136","28-AUG-1990","Open"
50319,"Protocol Status","Pending","17-JUL-1990","Gastric pH on Bioavailability of Foscarnet","ACTG 136","27-JUL-1990","Pending"
50319,"Protocol Status","In Development","09-FEB-1990","Gastric pH on Bioavailability of Foscarnet","ACTG 136","17-JUL-1990","In Development"
50320,"Protocol Status","Concluded","01-DEC-1999","Intramuscular gp160","ACTG 137","","Concluded"
50320,"Protocol Status","Closed to Follow Up","14-OCT-1993","Intramuscular gp160","ACTG 137","01-DEC-1999","Closed to Follow Up"
50320,"Protocol Status","POS/PAC","14-MAY-1993","Intramuscular gp160","ACTG 137","14-OCT-1993","POS/PAC"
50320,"Protocol Status","Closed to Accrual","15-JUL-1991","Intramuscular gp160","ACTG 137","14-MAY-1993","Closed to Accrual"
50320,"Protocol Status","Open","16-OCT-1990","Intramuscular gp160","ACTG 137","15-JUL-1991","Open"
50320,"Protocol Status","Pending","17-JUL-1990","Intramuscular gp160","ACTG 137","16-OCT-1990","Pending"
50320,"Protocol Status","In Development","09-FEB-1990","Intramuscular gp160","ACTG 137","17-JUL-1990","In Development"
50321,"Protocol Status","Concluded","25-SEP-1992","ddI vs AZT for AIDS Dementia Complex (ADC)","ACTG 140","","Concluded"
50321,"Protocol Status","Closed to Follow Up","19-FEB-1992","ddI vs AZT for AIDS Dementia Complex (ADC)","ACTG 140","25-SEP-1992","Closed to Follow Up"
50321,"Protocol Status","Closed to Accrual","09-DEC-1991","ddI vs AZT for AIDS Dementia Complex (ADC)","ACTG 140","19-FEB-1992","Closed to Accrual"
50321,"Protocol Status","Open","04-FEB-1991","ddI vs AZT for AIDS Dementia Complex (ADC)","ACTG 140","09-DEC-1991","Open"
50321,"Protocol Status","Pending","26-JUL-1990","ddI vs AZT for AIDS Dementia Complex (ADC)","ACTG 140","04-FEB-1991","Pending"
50321,"Protocol Status","In Development","09-FEB-1990","ddI vs AZT for AIDS Dementia Complex (ADC)","ACTG 140","26-JUL-1990","In Development"
50322,"Protocol Status","POS/PAC","01-MAR-1993","AZT/PEG-IL-2 (IMM)","ACTG 141","","POS/PAC"
50322,"Protocol Status","Concluded","01-MAR-1993","AZT/PEG-IL-2 (IMM)","ACTG 141","01-MAR-1993","Concluded"
50322,"Protocol Status","Closed to Accrual","26-DEC-1992","AZT/PEG-IL-2 (IMM)","ACTG 141","01-MAR-1993","Closed to Accrual"
50322,"Protocol Status","Closed to Follow Up","21-DEC-1992","AZT/PEG-IL-2 (IMM)","ACTG 141","26-DEC-1992","Closed to Follow Up"
50322,"Protocol Status","Open","30-AUG-1990","AZT/PEG-IL-2 (IMM)","ACTG 141","21-DEC-1992","Open"
50322,"Protocol Status","Pending","19-JUN-1990","AZT/PEG-IL-2 (IMM)","ACTG 141","30-AUG-1990","Pending"
50322,"Protocol Status","In Development","09-FEB-1990","AZT/PEG-IL-2 (IMM)","ACTG 141","19-JUN-1990","In Development"
50323,"Protocol Status","Concluded","01-NOV-1998","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","","Concluded"
50323,"Protocol Status","Closed to Follow Up","10-MAY-1996","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","01-NOV-1998","Closed to Follow Up"
50323,"Protocol Status","POS/PAC","02-FEB-1996","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","10-MAY-1996","POS/PAC"
50323,"Protocol Status","Closed to Accrual","07-NOV-1994","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","02-FEB-1996","Closed to Accrual"
50323,"Protocol Status","Open","13-DEC-1990","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","07-NOV-1994","Open"
50323,"Protocol Status","Pending","14-SEP-1990","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","13-DEC-1990","Pending"
50323,"Protocol Status","In Development","09-FEB-1990","mBACOD + rGM-CSF vs. low-dose mBACOD in NHL","ACTG 142","14-SEP-1990","In Development"
50324,"Protocol Status","Concluded","01-JUN-1998","PILOT ddI vs. AZT/ddI","ACTG 143","","Concluded"
50324,"Protocol Status","POS/PAC","17-NOV-1993","PILOT ddI vs. AZT/ddI","ACTG 143","01-JUN-1998","POS/PAC"
50324,"Protocol Status","Closed to Follow Up","11-MAY-1993","PILOT ddI vs. AZT/ddI","ACTG 143","17-NOV-1993","Closed to Follow Up"
50324,"Protocol Status","Closed to Accrual","19-JUL-1991","PILOT ddI vs. AZT/ddI","ACTG 143","11-MAY-1993","Closed to Accrual"
50324,"Protocol Status","Temporarily Closed","31-MAY-1991","PILOT ddI vs. AZT/ddI","ACTG 143","19-JUL-1991","Other"
50324,"Protocol Status","Open","14-SEP-1990","PILOT ddI vs. AZT/ddI","ACTG 143","31-MAY-1991","Open"
50324,"Protocol Status","Pending","02-AUG-1990","PILOT ddI vs. AZT/ddI","ACTG 143","14-SEP-1990","Pending"
50324,"Protocol Status","In Development","09-FEB-1990","PILOT ddI vs. AZT/ddI","ACTG 143","02-AUG-1990","In Development"
50325,"Protocol Status","Concluded","15-FEB-2004","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","","Concluded"
50325,"Protocol Status","POS/PAC","29-FEB-1996","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","15-FEB-2004","POS/PAC"
50325,"Protocol Status","Closed to Follow Up","02-FEB-1995","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","29-FEB-1996","Closed to Follow Up"
50325,"Protocol Status","Closed to Accrual","30-APR-1994","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","02-FEB-1995","Closed to Accrual"
50325,"Protocol Status","Open","25-SEP-1991","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","30-APR-1994","Open"
50325,"Protocol Status","Pending","31-MAY-1991","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","25-SEP-1991","Pending"
50325,"Protocol Status","FDA - IND Hold","11-MAR-1991","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","31-MAY-1991","Other"
50325,"Protocol Status","In Development","09-FEB-1990","PCN or Ceftriazone for Neurosyph in HIV+ Patients","ACTG 145","11-MAR-1991","In Development"
50326,"Protocol Status","Withdrawn","04-DEC-1990","AZT/Interferon-alpha/rsCD4","ACTG 147","","Other"
50326,"Protocol Status","In Development","09-FEB-1990","AZT/Interferon-alpha/rsCD4","ACTG 147","04-DEC-1990","In Development"
50327,"Protocol Status","Concluded","15-JUL-1993","DTH and immunogenicity of gp160 w/ CD4+  400","ACTG 148","","Concluded"
50327,"Protocol Status","Closed to Follow Up","03-OCT-1991","DTH and immunogenicity of gp160 w/ CD4+  400","ACTG 148","15-JUL-1993","Closed to Follow Up"
50327,"Protocol Status","Closed to Accrual","12-JUL-1991","DTH and immunogenicity of gp160 w/ CD4+  400","ACTG 148","03-OCT-1991","Closed to Accrual"
50327,"Protocol Status","Open","16-OCT-1990","DTH and immunogenicity of gp160 w/ CD4+  400","ACTG 148","12-JUL-1991","Open"
50327,"Protocol Status","Pending","17-JUL-1990","DTH and immunogenicity of gp160 w/ CD4+  400","ACTG 148","16-OCT-1990","Pending"
50327,"Protocol Status","In Development","02-MAR-1990","DTH and immunogenicity of gp160 w/ CD4+  400","ACTG 148","17-JUL-1990","In Development"
50328,"Protocol Status","Concluded","15-AUG-2000","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","","Concluded"
50328,"Protocol Status","Closed to Follow Up","14-APR-1999","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","15-AUG-2000","Closed to Follow Up"
50328,"Protocol Status","POS/PAC","19-FEB-1999","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","14-APR-1999","POS/PAC"
50328,"Protocol Status","Closed to Accrual","02-OCT-1996","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","19-FEB-1999","Closed to Accrual"
50328,"Protocol Status","Open","08-JAN-1992","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","02-OCT-1996","Open"
50328,"Protocol Status","Pending","09-OCT-1991","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","08-JAN-1992","Pending"
50328,"Protocol Status","In Development","10-APR-1990","ABVD + G-CSF in AIDS/Hodgkin's","ACTG 149","09-OCT-1991","In Development"
50329,"Protocol Status","Concluded","16-MAR-1999","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","","Concluded"
50329,"Protocol Status","POS/PAC","15-OCT-1994","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","16-MAR-1999","POS/PAC"
50329,"Protocol Status","Closed to Accrual","24-SEP-1993","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","15-OCT-1994","Closed to Accrual"
50329,"Protocol Status","Closed to Follow Up","01-JUL-1993","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","24-SEP-1993","Closed to Follow Up"
50329,"Protocol Status","Open","16-JUN-1992","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","01-JUL-1993","Open"
50329,"Protocol Status","Temporarily Closed","31-JAN-1992","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","16-JUN-1992","Other"
50329,"Protocol Status","Open","30-SEP-1991","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","31-JAN-1992","Open"
50329,"Protocol Status","Pending","12-AUG-1991","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","30-SEP-1991","Pending"
50329,"Protocol Status","FDA - IND Hold","30-NOV-1990","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","12-AUG-1991","Other"
50329,"Protocol Status","Pending","31-OCT-1990","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","30-NOV-1990","Pending"
50329,"Protocol Status","In Development","26-JUL-1990","Hypericin in HIV-Infected Pts. w/CD4","ACTG 150","31-OCT-1990","In Development"
50330,"Protocol Status","Concluded","01-APR-1995","Alternating PFA & GCV for CMV retinitis","ACTG 151","","Concluded"
50330,"Protocol Status","Closed to Follow Up","20-JAN-1995","Alternating PFA & GCV for CMV retinitis","ACTG 151","01-APR-1995","Closed to Follow Up"
50330,"Protocol Status","POS/PAC","16-JUN-1993","Alternating PFA & GCV for CMV retinitis","ACTG 151","20-JAN-1995","POS/PAC"
50330,"Protocol Status","Closed to Accrual","20-NOV-1992","Alternating PFA & GCV for CMV retinitis","ACTG 151","16-JUN-1993","Closed to Accrual"
50330,"Protocol Status","Open","20-MAR-1991","Alternating PFA & GCV for CMV retinitis","ACTG 151","20-NOV-1992","Open"
50330,"Protocol Status","Pending","28-DEC-1990","Alternating PFA & GCV for CMV retinitis","ACTG 151","20-MAR-1991","Pending"
50330,"Protocol Status","In Development","26-JUL-1990","Alternating PFA & GCV for CMV retinitis","ACTG 151","28-DEC-1990","In Development"
50331,"Protocol Status","Concluded","01-MAY-2001","Pyrimethamine for proph. of cerebral toxo","ACTG 154","","Concluded"
50331,"Protocol Status","POS/PAC","01-MAY-1994","Pyrimethamine for proph. of cerebral toxo","ACTG 154","01-MAY-2001","POS/PAC"
50331,"Protocol Status","Closed to Follow Up","17-JUN-1993","Pyrimethamine for proph. of cerebral toxo","ACTG 154","01-MAY-1994","Closed to Follow Up"
50331,"Protocol Status","Closed to Accrual","31-MAR-1992","Pyrimethamine for proph. of cerebral toxo","ACTG 154","17-JUN-1993","Closed to Accrual"
50331,"Protocol Status","Open","14-MAR-1991","Pyrimethamine for proph. of cerebral toxo","ACTG 154","31-MAR-1992","Open"
50331,"Protocol Status","Pending","05-FEB-1991","Pyrimethamine for proph. of cerebral toxo","ACTG 154","14-MAR-1991","Pending"
50331,"Protocol Status","In Development","26-JUL-1990","Pyrimethamine for proph. of cerebral toxo","ACTG 154","05-FEB-1991","In Development"
50332,"Protocol Status","Concluded","23-JAN-2005","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","","Concluded"
50332,"Protocol Status","POS/PAC","28-MAY-1993","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","23-JAN-2005","POS/PAC"
50332,"Protocol Status","Closed to Follow Up","31-MAR-1993","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","28-MAY-1993","Closed to Follow Up"
50332,"Protocol Status","Closed to Accrual","02-AUG-1991","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","31-MAR-1993","Closed to Accrual"
50332,"Protocol Status","Open","14-DEC-1990","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","02-AUG-1991","Open"
50332,"Protocol Status","Pending","14-SEP-1990","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","14-DEC-1990","Pending"
50332,"Protocol Status","In Development","13-AUG-1990","ddC + AZT vs AZT or ddC in HIV+ pts.w/prior AZT tx","ACTG 155","14-SEP-1990","In Development"
50333,"Protocol Status","Concluded","31-MAR-2001","Azithromycin and Pyrimethamine for Toxo","ACTG 156","","Concluded"
50333,"Protocol Status","POS/PAC","15-DEC-1993","Azithromycin and Pyrimethamine for Toxo","ACTG 156","31-MAR-2001","POS/PAC"
50333,"Protocol Status","Closed to Follow Up","17-SEP-1993","Azithromycin and Pyrimethamine for Toxo","ACTG 156","15-DEC-1993","Closed to Follow Up"
50333,"Protocol Status","Closed to Accrual","05-AUG-1993","Azithromycin and Pyrimethamine for Toxo","ACTG 156","17-SEP-1993","Closed to Accrual"
50333,"Protocol Status","Open","20-AUG-1991","Azithromycin and Pyrimethamine for Toxo","ACTG 156","05-AUG-1993","Open"
50333,"Protocol Status","Pending","06-MAY-1991","Azithromycin and Pyrimethamine for Toxo","ACTG 156","20-AUG-1991","Pending"
50333,"Protocol Status","In Development","15-OCT-1990","Azithromycin and Pyrimethamine for Toxo","ACTG 156","06-MAY-1991","In Development"
50334,"Protocol Status","Concluded","01-NOV-1997","Safety/Efficacy of Clarithromycin on Disseminated MAC Infection in AIDs","ACTG 157","","Concluded"
50334,"Protocol Status","Closed to Follow Up","01-SEP-1993","Safety/Efficacy of Clarithromycin on Disseminated MAC Infection in AIDs","ACTG 157","01-NOV-1997","Closed to Follow Up"
50334,"Protocol Status","POS/PAC","15-DEC-1992","Safety/Efficacy of Clarithromycin on Disseminated MAC Infection in AIDs","ACTG 157","01-SEP-1993","POS/PAC"
50334,"Protocol Status","Closed to Accrual","30-NOV-1991","Safety/Efficacy of Clarithromycin on Disseminated MAC Infection in AIDs","ACTG 157","15-DEC-1992","Closed to Accrual"
50334,"Protocol Status","Open","06-MAR-1991","Safety/Efficacy of Clarithromycin on Disseminated MAC Infection in AIDs","ACTG 157","30-NOV-1991","Open"
50334,"Protocol Status","In Development","08-OCT-1990","Safety/Efficacy of Clarithromycin on Disseminated MAC Infection in AIDs","ACTG 157","06-MAR-1991","In Development"
50335,"Protocol Status","Withdrawn","27-AUG-1991","Phase II/III Clarithro vs ACV for MAC& CMV","ACTG 158","","Other"
50335,"Protocol Status","In Development","09-NOV-1990","Phase II/III Clarithro vs ACV for MAC& CMV","ACTG 158","27-AUG-1991","In Development"
50336,"Protocol Status","Concluded","01-JAN-2000","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","","Concluded"
50336,"Protocol Status","POS/PAC","05-SEP-1997","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","01-JAN-2000","POS/PAC"
50336,"Protocol Status","Closed to Follow Up","01-MAR-1996","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","05-SEP-1997","Closed to Follow Up"
50336,"Protocol Status","Closed to Accrual","31-AUG-1994","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","01-MAR-1996","Closed to Accrual"
50336,"Protocol Status","Open","19-SEP-1991","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","31-AUG-1994","Open"
50336,"Protocol Status","Pending","25-JUL-1991","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","19-SEP-1991","Pending"
50336,"Protocol Status","In Development","23-AUG-1990","Ampho B + 5FC/Ampho B for Crypto. Meningitis","ACTG 159","25-JUL-1991","In Development"
50337,"Protocol Status","Concluded","01-JUN-1995","Pentoxifylline as modulator of TNF, HIV replicatio","ACTG 160","","Concluded"
50337,"Protocol Status","Closed to Follow Up","25-FEB-1994","Pentoxifylline as modulator of TNF, HIV replicatio","ACTG 160","01-JUN-1995","Closed to Follow Up"
50337,"Protocol Status","POS/PAC","12-MAR-1993","Pentoxifylline as modulator of TNF, HIV replicatio","ACTG 160","25-FEB-1994","POS/PAC"
50337,"Protocol Status","Open","06-JUN-1991","Pentoxifylline as modulator of TNF, HIV replicatio","ACTG 160","12-MAR-1993","Open"
50337,"Protocol Status","Pending","01-MAY-1991","Pentoxifylline as modulator of TNF, HIV replicatio","ACTG 160","06-JUN-1991","Pending"
50337,"Protocol Status","In Development","10-JAN-1991","Pentoxifylline as modulator of TNF, HIV replicatio","ACTG 160","01-MAY-1991","In Development"
50338,"Protocol Status","Concluded","01-JUL-1994","ZDVPt PK in HIV-Infected Pts.","ACTG 161","","Concluded"
50338,"Protocol Status","POS/PAC","16-AUG-1993","ZDVPt PK in HIV-Infected Pts.","ACTG 161","01-JUL-1994","POS/PAC"
50338,"Protocol Status","Closed to Follow Up","05-MAY-1993","ZDVPt PK in HIV-Infected Pts.","ACTG 161","16-AUG-1993","Closed to Follow Up"
50338,"Protocol Status","Closed to Accrual","30-DEC-1992","ZDVPt PK in HIV-Infected Pts.","ACTG 161","05-MAY-1993","Closed to Accrual"
50338,"Protocol Status","Open","18-JUN-1991","ZDVPt PK in HIV-Infected Pts.","ACTG 161","30-DEC-1992","Open"
50338,"Protocol Status","Pending","23-MAY-1991","ZDVPt PK in HIV-Infected Pts.","ACTG 161","18-JUN-1991","Pending"
50338,"Protocol Status","In Development","10-JAN-1991","ZDVPt PK in HIV-Infected Pts.","ACTG 161","23-MAY-1991","In Development"
50339,"Protocol Status","Concluded","01-JUL-1998","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","","Concluded"
50339,"Protocol Status","POS/PAC","26-JUL-1994","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","01-JUL-1998","POS/PAC"
50339,"Protocol Status","Closed to Follow Up","01-JUN-1994","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","26-JUL-1994","Closed to Follow Up"
50339,"Protocol Status","Closed to Accrual","10-SEP-1993","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","01-JUN-1994","Closed to Accrual"
50339,"Protocol Status","Open","17-MAR-1992","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","10-SEP-1993","Open"
50339,"Protocol Status","Pending","19-DEC-1991","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","17-MAR-1992","Pending"
50339,"Protocol Status","FDA - IND Hold","18-OCT-1991","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","19-DEC-1991","Other"
50339,"Protocol Status","Pending","18-SEP-1991","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","18-OCT-1991","Pending"
50339,"Protocol Status","In Development","10-JAN-1991","Nimodipine for Neuro as Concurrent Therapy w/AZT","ACTG 162","18-SEP-1991","In Development"
50340,"Protocol Status","Concluded","26-SEP-1996","ABV & ddI or ddC in Treat of AIDS-Related KS","ACTG 163","","Concluded"
50340,"Protocol Status","Closed to Follow Up","07-MAR-1996","ABV & ddI or ddC in Treat of AIDS-Related KS","ACTG 163","26-SEP-1996","Closed to Follow Up"
50340,"Protocol Status","Closed to Accrual","02-AUG-1994","ABV & ddI or ddC in Treat of AIDS-Related KS","ACTG 163","07-MAR-1996","Closed to Accrual"
50340,"Protocol Status","Open","22-OCT-1991","ABV & ddI or ddC in Treat of AIDS-Related KS","ACTG 163","02-AUG-1994","Open"
50340,"Protocol Status","Pending","26-AUG-1991","ABV & ddI or ddC in Treat of AIDS-Related KS","ACTG 163","22-OCT-1991","Pending"
50340,"Protocol Status","In Development","10-JAN-1991","ABV & ddI or ddC in Treat of AIDS-Related KS","ACTG 163","26-AUG-1991","In Development"
50341,"Protocol Status","Concluded","01-JAN-1996","Safety, Tolerance, and Activity of NVP in HIV Infection","ACTG 164","","Concluded"
50341,"Protocol Status","Closed to Follow Up","11-JAN-1994","Safety, Tolerance, and Activity of NVP in HIV Infection","ACTG 164","01-JAN-1996","Closed to Follow Up"
50341,"Protocol Status","POS/PAC","01-JUL-1993","Safety, Tolerance, and Activity of NVP in HIV Infection","ACTG 164","11-JAN-1994","POS/PAC"
50341,"Protocol Status","Open","07-MAY-1991","Safety, Tolerance, and Activity of NVP in HIV Infection","ACTG 164","01-JUL-1993","Open"
50341,"Protocol Status","In Development","10-JAN-1991","Safety, Tolerance, and Activity of NVP in HIV Infection","ACTG 164","07-MAY-1991","In Development"
50342,"Protocol Status","Concluded","26-SEP-1996","DTC in HIV-infected Patients","ACTG 166","","Concluded"
50342,"Protocol Status","Closed to Accrual","26-JAN-1993","DTC in HIV-infected Patients","ACTG 166","26-SEP-1996","Closed to Accrual"
50342,"Protocol Status","Closed to Follow Up","13-NOV-1992","DTC in HIV-infected Patients","ACTG 166","26-JAN-1993","Closed to Follow Up"
50342,"Protocol Status","Open","21-APR-1992","DTC in HIV-infected Patients","ACTG 166","13-NOV-1992","Open"
50342,"Protocol Status","Pending","15-OCT-1991","DTC in HIV-infected Patients","ACTG 166","21-APR-1992","Pending"
50342,"Protocol Status","FDA - IND Hold","27-JUN-1991","DTC in HIV-infected Patients","ACTG 166","15-OCT-1991","Other"
50342,"Protocol Status","Pending","06-JUN-1991","DTC in HIV-infected Patients","ACTG 166","27-JUN-1991","Pending"
50342,"Protocol Status","In Development","10-JAN-1991","DTC in HIV-infected Patients","ACTG 166","06-JUN-1991","In Development"
50343,"Protocol Status","Concluded","01-MAY-1995","566C80 vs TMP/SMX for Treat. of PCP in AIDS Pts.","ACTG 167","","Concluded"
50343,"Protocol Status","POS/PAC","01-JAN-1992","566C80 vs TMP/SMX for Treat. of PCP in AIDS Pts.","ACTG 167","01-MAY-1995","POS/PAC"
50343,"Protocol Status","Closed to Follow Up","30-OCT-1991","566C80 vs TMP/SMX for Treat. of PCP in AIDS Pts.","ACTG 167","01-JAN-1992","Closed to Follow Up"
50343,"Protocol Status","Closed to Accrual","16-AUG-1991","566C80 vs TMP/SMX for Treat. of PCP in AIDS Pts.","ACTG 167","30-OCT-1991","Closed to Accrual"
50343,"Protocol Status","Open","19-FEB-1991","566C80 vs TMP/SMX for Treat. of PCP in AIDS Pts.","ACTG 167","16-AUG-1991","Open"
50343,"Protocol Status","In Development","10-JAN-1991","566C80 vs TMP/SMX for Treat. of PCP in AIDS Pts.","ACTG 167","19-FEB-1991","In Development"
50344,"Protocol Status","Concluded","01-JAN-1996","PK, Safety, Tolerance of NVP + ZDV","ACTG 168","","Concluded"
50344,"Protocol Status","Closed to Follow Up","05-FEB-1995","PK, Safety, Tolerance of NVP + ZDV","ACTG 168","01-JAN-1996","Closed to Follow Up"
50344,"Protocol Status","POS/PAC","09-JUN-1993","PK, Safety, Tolerance of NVP + ZDV","ACTG 168","05-FEB-1995","POS/PAC"
50344,"Protocol Status","Open","09-JUL-1991","PK, Safety, Tolerance of NVP + ZDV","ACTG 168","09-JUN-1993","Open"
50344,"Protocol Status","In Development","01-FEB-1991","PK, Safety, Tolerance of NVP + ZDV","ACTG 168","09-JUL-1991","In Development"
50345,"Protocol Status","Concluded","01-MAY-1998","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","","Concluded"
50345,"Protocol Status","POS/PAC","04-SEP-1996","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","01-MAY-1998","POS/PAC"
50345,"Protocol Status","Closed to Follow Up","31-MAY-1995","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","04-SEP-1996","Closed to Follow Up"
50345,"Protocol Status","Closed to Accrual","27-MAY-1994","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","31-MAY-1995","Closed to Accrual"
50345,"Protocol Status","Open","31-JUL-1991","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","27-MAY-1994","Open"
50345,"Protocol Status","Pending","24-MAY-1991","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","31-JUL-1991","Pending"
50345,"Protocol Status","In Development","13-FEB-1991","BV-ARA-U vs Acyclovir in Localized Zoster","ACTG 169","24-MAY-1991","In Development"
50346,"Protocol Status","Withdrawn","02-JUN-1992","AP Distribution in Pts. undergoing PCP Prophylaxis","ACTG 171","","Other"
50346,"Protocol Status","Pending","05-NOV-1991","AP Distribution in Pts. undergoing PCP Prophylaxis","ACTG 171","02-JUN-1992","Pending"
50346,"Protocol Status","In Development","08-MAR-1991","AP Distribution in Pts. undergoing PCP Prophylaxis","ACTG 171","05-NOV-1991","In Development"
50347,"Protocol Status","Concluded","01-JUN-1996","Trifluorothymidine for ACV-Resistant HSV","ACTG 172","","Concluded"
50347,"Protocol Status","Closed to Follow Up","01-MAR-1993","Trifluorothymidine for ACV-Resistant HSV","ACTG 172","01-JUN-1996","Closed to Follow Up"
50347,"Protocol Status","POS/PAC","30-APR-1992","Trifluorothymidine for ACV-Resistant HSV","ACTG 172","01-MAR-1993","POS/PAC"
50347,"Protocol Status","Open","20-AUG-1991","Trifluorothymidine for ACV-Resistant HSV","ACTG 172","30-APR-1992","Open"
50347,"Protocol Status","Pending","05-JUL-1991","Trifluorothymidine for ACV-Resistant HSV","ACTG 172","20-AUG-1991","Pending"
50347,"Protocol Status","In Development","05-MAR-1991","Trifluorothymidine for ACV-Resistant HSV","ACTG 172","05-JUL-1991","In Development"
50348,"Protocol Status","Concluded","01-MAY-1999","WR 6026 in HIV-Infected Patients","ACTG 173","","Concluded"
50348,"Protocol Status","POS/PAC","30-SEP-1993","WR 6026 in HIV-Infected Patients","ACTG 173","01-MAY-1999","POS/PAC"
50348,"Protocol Status","Closed to Follow Up","09-JUL-1993","WR 6026 in HIV-Infected Patients","ACTG 173","30-SEP-1993","Closed to Follow Up"
50348,"Protocol Status","Closed to Accrual","18-JUN-1993","WR 6026 in HIV-Infected Patients","ACTG 173","09-JUL-1993","Closed to Accrual"
50348,"Protocol Status","Open","20-MAR-1992","WR 6026 in HIV-Infected Patients","ACTG 173","18-JUN-1993","Open"
50348,"Protocol Status","Pending","28-JAN-1992","WR 6026 in HIV-Infected Patients","ACTG 173","20-MAR-1992","Pending"
50348,"Protocol Status","FDA - IND Hold","15-JAN-1992","WR 6026 in HIV-Infected Patients","ACTG 173","28-JAN-1992","Other"
50348,"Protocol Status","Pending","09-DEC-1991","WR 6026 in HIV-Infected Patients","ACTG 173","15-JAN-1992","Pending"
50348,"Protocol Status","In Development","08-MAR-1991","WR 6026 in HIV-Infected Patients","ACTG 173","09-DEC-1991","In Development"
50349,"Protocol Status","Concluded","01-DEC-2001","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","","Concluded"
50349,"Protocol Status","POS/PAC","15-NOV-1994","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","01-DEC-2001","POS/PAC"
50349,"Protocol Status","Closed to Follow Up","29-NOV-1993","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","15-NOV-1994","Closed to Follow Up"
50349,"Protocol Status","Closed to Accrual","01-MAR-1993","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","29-NOV-1993","Closed to Accrual"
50349,"Protocol Status","Open","30-OCT-1991","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","01-MAR-1993","Open"
50349,"Protocol Status","Pending","27-AUG-1991","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","30-OCT-1991","Pending"
50349,"Protocol Status","In Development","08-MAR-1991","Fluconazole for Treatment & Suppression of Histo.","ACTG 174","27-AUG-1991","In Development"
50350,"Protocol Status","Concluded","01-JAN-2003","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","","Concluded"
50350,"Protocol Status","POS/PAC","21-NOV-1995","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","01-JAN-2003","POS/PAC"
50350,"Protocol Status","Closed to Follow Up","25-MAY-1995","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","21-NOV-1995","Closed to Follow Up"
50350,"Protocol Status","Closed to Accrual","16-OCT-1992","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","25-MAY-1995","Closed to Accrual"
50350,"Protocol Status","Open","12-DEC-1991","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","16-OCT-1992","Open"
50350,"Protocol Status","Pending","05-NOV-1991","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","12-DEC-1991","Pending"
50350,"Protocol Status","In Development","08-MAR-1991","Monotherapy vs. Combination Therapy with Nucleoside Analogues","ACTG 175","05-NOV-1991","In Development"
50351,"Protocol Status","Concluded","15-MAR-2000","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","","Concluded"
50351,"Protocol Status","POS/PAC","20-SEP-1999","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","15-MAR-2000","POS/PAC"
50351,"Protocol Status","Closed to Follow Up","03-JUL-1996","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","20-SEP-1999","Closed to Follow Up"
50351,"Protocol Status","Closed to Accrual","29-MAR-1996","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","03-JUL-1996","Closed to Accrual"
50351,"Protocol Status","Open","31-OCT-1991","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","29-MAR-1996","Open"
50351,"Protocol Status","Pending","06-AUG-1991","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","31-OCT-1991","Pending"
50351,"Protocol Status","In Development","27-MAR-1991","Rif/PZA vs. INH for TB prophylaxis","ACTG 177","06-AUG-1991","In Development"
50352,"Protocol Status","Closed to Follow Up","01-JUL-1993","Natural History:  Substudy 081/981","ACTG 181","","Closed to Follow Up"
50353,"Protocol Status","POS/PAC","01-AUG-1998","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","","POS/PAC"
50353,"Protocol Status","Concluded","01-AUG-1998","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","01-AUG-1998","Concluded"
50353,"Protocol Status","Closed to Follow Up","05-AUG-1997","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","01-AUG-1998","Closed to Follow Up"
50353,"Protocol Status","Closed to Accrual","20-NOV-1996","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","05-AUG-1997","Closed to Accrual"
50353,"Protocol Status","Open","02-JUN-1995","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","20-NOV-1996","Open"
50353,"Protocol Status","Temporarily Closed","31-AUG-1994","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","02-JUN-1995","Other"
50353,"Protocol Status","Open","31-JAN-1994","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","31-AUG-1994","Open"
50353,"Protocol Status","Pending","07-APR-1993","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","31-JAN-1994","Pending"
50353,"Protocol Status","FDA - IND Hold","17-MAR-1993","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","07-APR-1993","Other"
50353,"Protocol Status","Pending","29-JAN-1993","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","17-MAR-1993","Pending"
50353,"Protocol Status","In Development","16-MAY-1991","PK study of oral GCV, 3 dose levels, w/wo acid","ACTG 183","29-JAN-1993","In Development"
50354,"Protocol Status","Concluded","01-AUG-1996","Pk of L-697,661 alone and with AZT","ACTG 184","","Concluded"
50354,"Protocol Status","POS/PAC","15-AUG-1993","Pk of L-697,661 alone and with AZT","ACTG 184","01-AUG-1996","POS/PAC"
50354,"Protocol Status","Closed to Follow Up","28-MAY-1992","Pk of L-697,661 alone and with AZT","ACTG 184","15-AUG-1993","Closed to Follow Up"
50354,"Protocol Status","Closed to Accrual","13-FEB-1992","Pk of L-697,661 alone and with AZT","ACTG 184","28-MAY-1992","Closed to Accrual"
50354,"Protocol Status","Open","13-NOV-1991","Pk of L-697,661 alone and with AZT","ACTG 184","13-FEB-1992","Open"
50354,"Protocol Status","Pending","07-OCT-1991","Pk of L-697,661 alone and with AZT","ACTG 184","13-NOV-1991","Pending"
50354,"Protocol Status","In Development","03-JUL-1991","Pk of L-697,661 alone and with AZT","ACTG 184","07-OCT-1991","In Development"
50355,"Protocol Status","Withdrawn","11-FEB-1993","Multi drug prophylaxis for sinusitis","ACTG 186","","Other"
50355,"Protocol Status","Open","12-NOV-1992","Multi drug prophylaxis for sinusitis","ACTG 186","11-FEB-1993","Open"
50355,"Protocol Status","Pending","03-AUG-1992","Multi drug prophylaxis for sinusitis","ACTG 186","12-NOV-1992","Pending"
50355,"Protocol Status","In Development","06-SEP-1991","Multi drug prophylaxis for sinusitis","ACTG 186","03-AUG-1992","In Development"
50356,"Protocol Status","Concluded","01-JAN-2000","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","","Concluded"
50356,"Protocol Status","POS/PAC","01-FEB-1995","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","01-JAN-2000","POS/PAC"
50356,"Protocol Status","Closed to Follow Up","18-JUL-1994","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","01-FEB-1995","Closed to Follow Up"
50356,"Protocol Status","Closed to Accrual","16-DEC-1993","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","18-JUL-1994","Closed to Accrual"
50356,"Protocol Status","Open","14-APR-1993","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","16-DEC-1993","Open"
50356,"Protocol Status","Pending","05-NOV-1991","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","14-APR-1993","Pending"
50356,"Protocol Status","In Development","23-SEP-1991","Ph I Study ATV, ZDV ddI or ddC","ACTG 187","05-NOV-1991","In Development"
50357,"Protocol Status","Concluded","01-SEP-1994","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","","Concluded"
50357,"Protocol Status","POS/PAC","26-FEB-1993","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","01-SEP-1994","POS/PAC"
50357,"Protocol Status","Closed to Accrual","27-JAN-1993","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","26-FEB-1993","Closed to Accrual"
50357,"Protocol Status","Closed to Follow Up","02-JUL-1992","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","27-JAN-1993","Closed to Follow Up"
50357,"Protocol Status","Open","08-NOV-1991","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","02-JUL-1992","Open"
50357,"Protocol Status","Pending","07-NOV-1991","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","08-NOV-1991","Pending"
50357,"Protocol Status","In Development","24-OCT-1991","Effect of Valproic Acid on AZT Glucuronidation, pk","ACTG 191","07-NOV-1991","In Development"
50358,"Protocol Status","Concluded","31-OCT-2000","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","","Concluded"
50358,"Protocol Status","POS/PAC","26-SEP-1996","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","31-OCT-2000","POS/PAC"
50358,"Protocol Status","Closed to Follow Up","02-NOV-1995","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","26-SEP-1996","Closed to Follow Up"
50358,"Protocol Status","Closed to Accrual","09-AUG-1995","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","02-NOV-1995","Closed to Accrual"
50358,"Protocol Status","Temporarily Closed","09-JUN-1995","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","09-AUG-1995","Other"
50358,"Protocol Status","Open","16-SEP-1993","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","09-JUN-1995","Open"
50358,"Protocol Status","Pending","24-SEP-1992","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","16-SEP-1993","Pending"
50358,"Protocol Status","In Development","07-NOV-1991","Paromomycin as Tx of Cryptosporidiosis in AIDS","ACTG 192","24-SEP-1992","In Development"
50359,"Protocol Status","Concluded","01-MAR-1998","AZT + ddI or ddC vs Alt. AZT & ddI - CD4","ACTG 193","","Concluded"
50359,"Protocol Status","Closed to Follow Up","10-JUN-1994","AZT + ddI or ddC vs Alt. AZT & ddI - CD4","ACTG 193","01-MAR-1998","Closed to Follow Up"
50359,"Protocol Status","Concluded","04-MAY-1993","AZT + ddI or ddC vs Alt. AZT & ddI - CD4","ACTG 193","10-JUN-1994","Concluded"
50359,"Protocol Status","Open","06-JAN-1993","AZT + ddI or ddC vs Alt. AZT & ddI - CD4","ACTG 193","04-MAY-1993","Open"
50359,"Protocol Status","Pending","04-SEP-1992","AZT + ddI or ddC vs Alt. AZT & ddI - CD4","ACTG 193","06-JAN-1993","Pending"
50359,"Protocol Status","In Development","07-NOV-1991","AZT + ddI or ddC vs Alt. AZT & ddI - CD4","ACTG 193","04-SEP-1992","In Development"
50360,"Protocol Status","Concluded","01-OCT-1999","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","","Concluded"
50360,"Protocol Status","POS/PAC","09-SEP-1996","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","01-OCT-1999","POS/PAC"
50360,"Protocol Status","Closed to Follow Up","14-JUN-1996","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","09-SEP-1996","Closed to Follow Up"
50360,"Protocol Status","Closed to Accrual","07-NOV-1995","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","14-JUN-1996","Closed to Accrual"
50360,"Protocol Status","Open","08-JUL-1994","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","07-NOV-1995","Open"
50360,"Protocol Status","Temporarily Closed","24-JUN-1994","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","08-JUL-1994","Other"
50360,"Protocol Status","Open","18-JUN-1993","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","24-JUN-1994","Open"
50360,"Protocol Status","Pending","10-MAY-1993","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","18-JUN-1993","Pending"
50360,"Protocol Status","In Development","15-MAR-1993","2 2-drug NRT tx v. Alt. NRT tx vs. 3-drug NRT tx","ACTG 193A","10-MAY-1993","In Development"
50361,"Protocol Status","Concluded","22-MAY-1995","Short-Term Clin. & Vir. Significance of AZT Resist","ACTG 194","","Concluded"
50361,"Protocol Status","Closed to Follow Up","02-FEB-1995","Short-Term Clin. & Vir. Significance of AZT Resist","ACTG 194","22-MAY-1995","Closed to Follow Up"
50361,"Protocol Status","Closed to Accrual","22-APR-1994","Short-Term Clin. & Vir. Significance of AZT Resist","ACTG 194","02-FEB-1995","Closed to Accrual"
50361,"Protocol Status","Open","09-JUL-1992","Short-Term Clin. & Vir. Significance of AZT Resist","ACTG 194","22-APR-1994","Open"
50361,"Protocol Status","Pending","26-MAY-1992","Short-Term Clin. & Vir. Significance of AZT Resist","ACTG 194","09-JUL-1992","Pending"
50361,"Protocol Status","In Development","07-NOV-1991","Short-Term Clin. & Vir. Significance of AZT Resist","ACTG 194","26-MAY-1992","In Development"
50362,"Protocol Status","Withdrawn","20-OCT-1993","BI-RG-587 + AZT Versus AZT Alone","ACTG 195","","Other"
50362,"Protocol Status","In Development","07-NOV-1991","BI-RG-587 + AZT Versus AZT Alone","ACTG 195","20-OCT-1993","In Development"
50363,"Protocol Status","Concluded","01-JUN-2001","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","","Concluded"
50363,"Protocol Status","POS/PAC","17-JUN-1996","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","01-JUN-2001","POS/PAC"
50363,"Protocol Status","Closed to Follow Up","01-DEC-1995","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","17-JUN-1996","Closed to Follow Up"
50363,"Protocol Status","Closed to Accrual","31-JAN-1994","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","01-DEC-1995","Closed to Accrual"
50363,"Protocol Status","Open","19-APR-1993","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","31-JAN-1994","Open"
50363,"Protocol Status","Pending","21-DEC-1992","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","19-APR-1993","Pending"
50363,"Protocol Status","In Development","23-OCT-1991","Clari vs Rifabutin vs Comb for MAC prophylaxis","ACTG 196","21-DEC-1992","In Development"
50364,"Protocol Status","Concluded","01-DEC-1997","AZT + ddC +/- IFN-A","ACTG 197","","Concluded"
50364,"Protocol Status","POS/PAC","01-FEB-1995","AZT + ddC +/- IFN-A","ACTG 197","01-DEC-1997","POS/PAC"
50364,"Protocol Status","Closed to Follow Up","28-FEB-1994","AZT + ddC +/- IFN-A","ACTG 197","01-FEB-1995","Closed to Follow Up"
50364,"Protocol Status","Closed to Accrual","26-MAR-1993","AZT + ddC +/- IFN-A","ACTG 197","28-FEB-1994","Closed to Accrual"
50364,"Protocol Status","Open","01-OCT-1992","AZT + ddC +/- IFN-A","ACTG 197","26-MAR-1993","Open"
50364,"Protocol Status","Pending","20-JUL-1992","AZT + ddC +/- IFN-A","ACTG 197","01-OCT-1992","Pending"
50364,"Protocol Status","In Development","25-NOV-1991","AZT + ddC +/- IFN-A","ACTG 197","20-JUL-1992","In Development"
50365,"Protocol Status","Concluded","06-FEB-1995","Letrazuril for Cryptosporidiosis","ACTG 198","","Concluded"
50365,"Protocol Status","Closed to Follow Up","28-JUN-1993","Letrazuril for Cryptosporidiosis","ACTG 198","06-FEB-1995","Closed to Follow Up"
50365,"Protocol Status","Closed to Accrual","01-OCT-1992","Letrazuril for Cryptosporidiosis","ACTG 198","28-JUN-1993","Closed to Accrual"
50365,"Protocol Status","Open","28-JAN-1992","Letrazuril for Cryptosporidiosis","ACTG 198","01-OCT-1992","Open"
50365,"Protocol Status","In Development","12-DEC-1991","Letrazuril for Cryptosporidiosis","ACTG 198","28-JAN-1992","In Development"
50366,"Protocol Status","Concluded","01-JAN-2000","AZT, U-87201E and ddI viral susceptibility","ACTG 199","","Concluded"
50366,"Protocol Status","Closed to Follow Up","26-JAN-1994","AZT, U-87201E and ddI viral susceptibility","ACTG 199","01-JAN-2000","Closed to Follow Up"
50366,"Protocol Status","POS/PAC","05-OCT-1993","AZT, U-87201E and ddI viral susceptibility","ACTG 199","26-JAN-1994","POS/PAC"
50366,"Protocol Status","Closed to Accrual","16-OCT-1992","AZT, U-87201E and ddI viral susceptibility","ACTG 199","05-OCT-1993","Closed to Accrual"
50366,"Protocol Status","Open","14-MAY-1992","AZT, U-87201E and ddI viral susceptibility","ACTG 199","16-OCT-1992","Open"
50366,"Protocol Status","Pending","26-MAR-1992","AZT, U-87201E and ddI viral susceptibility","ACTG 199","14-MAY-1992","Pending"
50366,"Protocol Status","In Development","20-DEC-1991","AZT, U-87201E and ddI viral susceptibility","ACTG 199","26-MAR-1992","In Development"
50367,"Protocol Status","Concluded","01-DEC-1999","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","","Concluded"
50367,"Protocol Status","POS/PAC","08-APR-1998","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","01-DEC-1999","POS/PAC"
50367,"Protocol Status","Closed to Follow Up","30-JUN-1997","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","08-APR-1998","Closed to Follow Up"
50367,"Protocol Status","Closed to Accrual","31-DEC-1996","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","30-JUN-1997","Closed to Accrual"
50367,"Protocol Status","Open","21-JAN-1993","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","31-DEC-1996","Open"
50367,"Protocol Status","Pending","01-OCT-1992","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","21-JAN-1993","Pending"
50367,"Protocol Status","In Development","10-JAN-1992","Topical Vaginal Fluorouracil vs Obser after Tx for High Grade Cervical Dysplasia","ACTG 200","01-OCT-1992","In Development"
50368,"Protocol Status","Concluded","15-MAY-1995","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","","Concluded"
50368,"Protocol Status","Closed to Accrual","27-FEB-1995","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","15-MAY-1995","Closed to Accrual"
50368,"Protocol Status","Closed to Follow Up","09-SEP-1994","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","27-FEB-1995","Closed to Follow Up"
50368,"Protocol Status","Open","22-MAY-1992","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","09-SEP-1994","Open"
50368,"Protocol Status","Pending","16-APR-1992","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","22-MAY-1992","Pending"
50368,"Protocol Status","FDA - IND Hold","06-APR-1992","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","16-APR-1992","Other"
50368,"Protocol Status","Pending","11-MAR-1992","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","06-APR-1992","Pending"
50368,"Protocol Status","In Development","01-DEC-1991","Safety of sCD4-PE40 in HIV-Infected Patients","ACTG 201","11-MAR-1992","In Development"
50369,"Protocol Status","Concluded","26-SEP-1996","Dexamethasone in Cryptococcal Meningitis","ACTG 202","","Concluded"
50369,"Protocol Status","Closed to Accrual","10-FEB-1995","Dexamethasone in Cryptococcal Meningitis","ACTG 202","26-SEP-1996","Closed to Accrual"
50369,"Protocol Status","Closed to Follow Up","17-JAN-1995","Dexamethasone in Cryptococcal Meningitis","ACTG 202","10-FEB-1995","Closed to Follow Up"
50369,"Protocol Status","Open","27-MAY-1993","Dexamethasone in Cryptococcal Meningitis","ACTG 202","17-JAN-1995","Open"
50369,"Protocol Status","Pending","15-JAN-1993","Dexamethasone in Cryptococcal Meningitis","ACTG 202","27-MAY-1993","Pending"
50369,"Protocol Status","In Development","10-JAN-1992","Dexamethasone in Cryptococcal Meningitis","ACTG 202","15-JAN-1993","In Development"
50370,"Protocol Status","Closed to Follow Up","29-AUG-1995","IFN-a + Nucleoside Analogue in HCV+/HIV+ Pts","ACTG 203","","Closed to Follow Up"
50370,"Protocol Status","Withdrawn","19-DEC-1994","IFN-a + Nucleoside Analogue in HCV+/HIV+ Pts","ACTG 203","29-AUG-1995","Other"
50370,"Protocol Status","Deferred","02-JUL-1992","IFN-a + Nucleoside Analogue in HCV+/HIV+ Pts","ACTG 203","19-DEC-1994","Other"
50370,"Protocol Status","In Development","10-JAN-1992","IFN-a + Nucleoside Analogue in HCV+/HIV+ Pts","ACTG 203","02-JUL-1992","In Development"
50371,"Protocol Status","Concluded","26-SEP-1996","Pilot:  IFN-a + AZT, ddI, or ddC in HCV+/HIV+ Pts","ACTG 203P","","Concluded"
50371,"Protocol Status","Closed to Follow Up","29-AUG-1995","Pilot:  IFN-a + AZT, ddI, or ddC in HCV+/HIV+ Pts","ACTG 203P","26-SEP-1996","Closed to Follow Up"
50371,"Protocol Status","Closed to Accrual","31-DEC-1994","Pilot:  IFN-a + AZT, ddI, or ddC in HCV+/HIV+ Pts","ACTG 203P","29-AUG-1995","Closed to Accrual"
50371,"Protocol Status","Open","02-JUL-1993","Pilot:  IFN-a + AZT, ddI, or ddC in HCV+/HIV+ Pts","ACTG 203P","31-DEC-1994","Open"
50371,"Protocol Status","Pending","10-DEC-1992","Pilot:  IFN-a + AZT, ddI, or ddC in HCV+/HIV+ Pts","ACTG 203P","02-JUL-1993","Pending"
50371,"Protocol Status","In Development","01-JUL-1992","Pilot:  IFN-a + AZT, ddI, or ddC in HCV+/HIV+ Pts","ACTG 203P","10-DEC-1992","In Development"
50372,"Protocol Status","Concluded","01-SEP-2003","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","","Concluded"
50372,"Protocol Status","POS/PAC","15-MAY-1996","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","01-SEP-2003","POS/PAC"
50372,"Protocol Status","Closed to Follow Up","31-JUL-1995","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","15-MAY-1996","Closed to Follow Up"
50372,"Protocol Status","Closed to Accrual","30-SEP-1994","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","31-JUL-1995","Closed to Accrual"
50372,"Protocol Status","Open","06-JAN-1993","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","30-SEP-1994","Open"
50372,"Protocol Status","Pending","21-OCT-1992","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","06-JAN-1993","Pending"
50372,"Protocol Status","In Development","10-JAN-1992","BW256 vs high ACV vs low ACV for CMV prophylaxis","ACTG 204","21-OCT-1992","In Development"
50373,"Protocol Status","Concluded","30-OCT-1998","Safety and immunogenicity of Immuno gp160","ACTG 205","","Concluded"
50373,"Protocol Status","Closed to Follow Up","23-JAN-1995","Safety and immunogenicity of Immuno gp160","ACTG 205","30-OCT-1998","Closed to Follow Up"
50373,"Protocol Status","Closed to Accrual","19-FEB-1993","Safety and immunogenicity of Immuno gp160","ACTG 205","23-JAN-1995","Closed to Accrual"
50373,"Protocol Status","Open","30-APR-1992","Safety and immunogenicity of Immuno gp160","ACTG 205","19-FEB-1993","Open"
50373,"Protocol Status","Pending","08-APR-1992","Safety and immunogenicity of Immuno gp160","ACTG 205","30-APR-1992","Pending"
50373,"Protocol Status","In Development","16-JAN-1992","Safety and immunogenicity of Immuno gp160","ACTG 205","08-APR-1992","In Development"
50374,"Protocol Status","Concluded","01-MAR-2002","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","","Concluded"
50374,"Protocol Status","POS/PAC","03-MAR-2000","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","01-MAR-2002","POS/PAC"
50374,"Protocol Status","Closed to Follow Up","29-MAY-1998","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","03-MAR-2000","Closed to Follow Up"
50374,"Protocol Status","Closed to Accrual","30-SEP-1997","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","29-MAY-1998","Closed to Accrual"
50374,"Protocol Status","Open","29-JUL-1992","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","30-SEP-1997","Open"
50374,"Protocol Status","Pending","15-JUN-1992","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","29-JUL-1992","Pending"
50374,"Protocol Status","In Development","14-JAN-1992","Two Doses of IFN-Alpha + ddI in KS","ACTG 206","15-JUN-1992","In Development"
50375,"Protocol Status","Withdrawn","30-JUN-1994","Albendazole as Tx for Microsporidiosis","ACTG 207","","Other"
50375,"Protocol Status","In Development","05-MAR-1992","Albendazole as Tx for Microsporidiosis","ACTG 207","30-JUN-1994","In Development"
50376,"Protocol Status","Concluded","01-NOV-1995","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","","Concluded"
50376,"Protocol Status","POS/PAC","09-DEC-1994","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","01-NOV-1995","POS/PAC"
50376,"Protocol Status","Closed to Follow Up","29-NOV-1994","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","09-DEC-1994","Closed to Follow Up"
50376,"Protocol Status","Closed to Accrual","31-JAN-1994","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","29-NOV-1994","Closed to Accrual"
50376,"Protocol Status","Open","14-JUL-1992","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","31-JAN-1994","Open"
50376,"Protocol Status","Pending","10-JUL-1992","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","14-JUL-1992","Pending"
50376,"Protocol Status","In Development","05-MAR-1992","Nevirapine in HIV+ Pts w/ CD4 = 500","ACTG 208","10-JUL-1992","In Development"
50377,"Protocol Status","Concluded","01-NOV-2000","PhI/II vaccine trial w/ CD4s 50-500","ACTG 209","","Concluded"
50377,"Protocol Status","Closed to Follow Up","02-MAR-1995","PhI/II vaccine trial w/ CD4s 50-500","ACTG 209","01-NOV-2000","Closed to Follow Up"
50377,"Protocol Status","POS/PAC","28-JUL-1994","PhI/II vaccine trial w/ CD4s 50-500","ACTG 209","02-MAR-1995","POS/PAC"
50377,"Protocol Status","Closed to Accrual","28-JUL-1994","PhI/II vaccine trial w/ CD4s 50-500","ACTG 209","28-JUL-1994","Closed to Accrual"
50377,"Protocol Status","Open","03-MAR-1993","PhI/II vaccine trial w/ CD4s 50-500","ACTG 209","28-JUL-1994","Open"
50378,"Protocol Status","Withdrawn","10-SEP-1992","Ro 31-8959 in HIV-infected Patients","ACTG 212","","Other"
50378,"Protocol Status","In Development","20-APR-1992","Ro 31-8959 in HIV-infected Patients","ACTG 212","10-SEP-1992","In Development"
50379,"Protocol Status","POS/PAC","30-OCT-1998","Ro 24-7429 activity, safety, tolerance in HIV inf","ACTG 213","","POS/PAC"
50379,"Protocol Status","Concluded","01-MAR-1997","Ro 24-7429 activity, safety, tolerance in HIV inf","ACTG 213","30-OCT-1998","Concluded"
50379,"Protocol Status","Closed to Follow Up","16-AUG-1993","Ro 24-7429 activity, safety, tolerance in HIV inf","ACTG 213","01-MAR-1997","Closed to Follow Up"
50379,"Protocol Status","Closed to Accrual","24-FEB-1993","Ro 24-7429 activity, safety, tolerance in HIV inf","ACTG 213","16-AUG-1993","Closed to Accrual"
50379,"Protocol Status","Open","01-DEC-1992","Ro 24-7429 activity, safety, tolerance in HIV inf","ACTG 213","24-FEB-1993","Open"
50379,"Protocol Status","In Development","20-APR-1992","Ro 24-7429 activity, safety, tolerance in HIV inf","ACTG 213","01-DEC-1992","In Development"
50380,"Protocol Status","Concluded","01-NOV-2000","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","","Concluded"
50380,"Protocol Status","POS/PAC","28-SEP-1996","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","01-NOV-2000","POS/PAC"
50380,"Protocol Status","Closed to Follow Up","15-FEB-1996","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","28-SEP-1996","Closed to Follow Up"
50380,"Protocol Status","Closed to Accrual","18-SEP-1995","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","15-FEB-1996","Closed to Accrual"
50380,"Protocol Status","Open","09-DEC-1994","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","18-SEP-1995","Open"
50380,"Protocol Status","Temporarily Closed","06-DEC-1994","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","09-DEC-1994","Other"
50380,"Protocol Status","Open","07-OCT-1993","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","06-DEC-1994","Open"
50380,"Protocol Status","Pending","17-MAY-1993","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","07-OCT-1993","Pending"
50380,"Protocol Status","In Development","05-JUN-1992","HIV-1 Derived Immunogens in Pts w/ /=  500 CD4","ACTG 214","17-MAY-1993","In Development"
50381,"Protocol Status","Concluded","01-SEP-2000","TNP-470 for KS","ACTG 215","","Concluded"
50381,"Protocol Status","POS/PAC","02-FEB-1997","TNP-470 for KS","ACTG 215","01-SEP-2000","POS/PAC"
50381,"Protocol Status","Closed to Accrual","08-NOV-1996","TNP-470 for KS","ACTG 215","02-FEB-1997","Closed to Accrual"
50381,"Protocol Status","Closed to Follow Up","05-NOV-1996","TNP-470 for KS","ACTG 215","08-NOV-1996","Closed to Follow Up"
50381,"Protocol Status","Open","14-MAY-1993","TNP-470 for KS","ACTG 215","05-NOV-1996","Open"
50381,"Protocol Status","Pending","15-DEC-1992","TNP-470 for KS","ACTG 215","14-MAY-1993","Pending"
50381,"Protocol Status","In Development","05-JUN-1992","TNP-470 for KS","ACTG 215","15-DEC-1992","In Development"
50382,"Protocol Status","Concluded","01-JAN-1997","Chemoprevention of Anal Neoplasia","ACTG 216","","Concluded"
50382,"Protocol Status","Closed to Follow Up","16-SEP-1996","Chemoprevention of Anal Neoplasia","ACTG 216","01-JAN-1997","Closed to Follow Up"
50382,"Protocol Status","Closed to Accrual","29-JUL-1996","Chemoprevention of Anal Neoplasia","ACTG 216","16-SEP-1996","Closed to Accrual"
50382,"Protocol Status","Temporarily Closed","08-MAR-1996","Chemoprevention of Anal Neoplasia","ACTG 216","29-JUL-1996","Other"
50382,"Protocol Status","Open","06-JUL-1994","Chemoprevention of Anal Neoplasia","ACTG 216","08-MAR-1996","Open"
50382,"Protocol Status","Pending","21-DEC-1992","Chemoprevention of Anal Neoplasia","ACTG 216","06-JUL-1994","Pending"
50382,"Protocol Status","In Development","14-JUL-1992","Chemoprevention of Anal Neoplasia","ACTG 216","21-DEC-1992","In Development"
50383,"Protocol Status","Withdrawn","06-AUG-1993","Phase II Study of Ro 24-7429 + ZDV + ddCvs Ro 24-7","ACTG 217","","Other"
50383,"Protocol Status","In Development","14-JUL-1992","Phase II Study of Ro 24-7429 + ZDV + ddCvs Ro 24-7","ACTG 217","06-AUG-1993","In Development"
50384,"Protocol Status","Concluded","01-DEC-1999","DTH Reactions to Intradermal HIV Env Antigen","ACTG 221","","Concluded"
50384,"Protocol Status","POS/PAC","24-OCT-1996","DTH Reactions to Intradermal HIV Env Antigen","ACTG 221","01-DEC-1999","POS/PAC"
50384,"Protocol Status","Closed to Accrual","02-NOV-1995","DTH Reactions to Intradermal HIV Env Antigen","ACTG 221","24-OCT-1996","Closed to Accrual"
50384,"Protocol Status","Open","26-JUN-1995","DTH Reactions to Intradermal HIV Env Antigen","ACTG 221","02-NOV-1995","Open"
50384,"Protocol Status","Closed to Follow Up","27-FEB-1995","DTH Reactions to Intradermal HIV Env Antigen","ACTG 221","26-JUN-1995","Closed to Follow Up"
50385,"Protocol Status","Concluded","01-DEC-1999","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","","Concluded"
50385,"Protocol Status","Closed to Follow Up","15-SEP-1997","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","01-DEC-1999","Closed to Follow Up"
50385,"Protocol Status","POS/PAC","31-JUL-1997","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","15-SEP-1997","POS/PAC"
50385,"Protocol Status","Closed to Accrual","16-FEB-1996","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","31-JUL-1997","Closed to Accrual"
50385,"Protocol Status","Open","05-APR-1993","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","16-FEB-1996","Open"
50385,"Protocol Status","Pending","22-DEC-1992","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","05-APR-1993","Pending"
50385,"Protocol Status","In Development","14-JUL-1992","4 drug vs 4 drug + levofloxicin for TB treat","ACTG 222","22-DEC-1992","In Development"
50386,"Protocol Status","Concluded","01-NOV-2003","Clarithromycin/Ethambutol vs Clari/Rif vs Clari/Ethamb/Rif","ACTG 223","","Concluded"
50386,"Protocol Status","POS/PAC","20-JAN-1999","Clarithromycin/Ethambutol vs Clari/Rif vs Clari/Ethamb/Rif","ACTG 223","01-NOV-2003","POS/PAC"
50386,"Protocol Status","Closed to Follow Up","15-JUN-1998","Clarithromycin/Ethambutol vs Clari/Rif vs Clari/Ethamb/Rif","ACTG 223","20-JAN-1999","Closed to Follow Up"
50386,"Protocol Status","Closed to Accrual","10-JUN-1998","Clarithromycin/Ethambutol vs Clari/Rif vs Clari/Ethamb/Rif","ACTG 223","15-JUN-1998","Closed to Accrual"
50386,"Protocol Status","Open","23-NOV-1994","Clarithromycin/Ethambutol vs Clari/Rif vs Clari/Ethamb/Rif","ACTG 223","10-JUN-1998","Open"
50386,"Protocol Status","Pending","04-NOV-1993","Clarithromycin/Ethambutol vs Clari/Rif vs Clari/Ethamb/Rif","ACTG 223","23-NOV-1994","Pending"
50387,"Protocol Status","Concluded","02-NOV-2002","IL-4 for KS","ACTG 224","","Concluded"
50387,"Protocol Status","POS/PAC","27-APR-1998","IL-4 for KS","ACTG 224","02-NOV-2002","POS/PAC"
50387,"Protocol Status","Closed to Follow Up","16-OCT-1996","IL-4 for KS","ACTG 224","27-APR-1998","Closed to Follow Up"
50387,"Protocol Status","Closed to Accrual","18-APR-1996","IL-4 for KS","ACTG 224","16-OCT-1996","Closed to Accrual"
50387,"Protocol Status","Open","26-DEC-1995","IL-4 for KS","ACTG 224","18-APR-1996","Open"
50387,"Protocol Status","Temporarily Closed","10-FEB-1995","IL-4 for KS","ACTG 224","26-DEC-1995","Other"
50387,"Protocol Status","Open","26-MAR-1993","IL-4 for KS","ACTG 224","10-FEB-1995","Open"
50387,"Protocol Status","Pending","29-JAN-1993","IL-4 for KS","ACTG 224","26-MAR-1993","Pending"
50387,"Protocol Status","In Development","11-AUG-1992","IL-4 for KS","ACTG 224","29-JAN-1993","In Development"
50388,"Protocol Status","Closed to Follow Up","08-AUG-1996","CMV Retinitis Retreatment Trial","ACTG 228","","Closed to Follow Up"
50388,"Protocol Status","Concluded","01-JAN-1996","CMV Retinitis Retreatment Trial","ACTG 228","08-AUG-1996","Concluded"
50388,"Protocol Status","POS/PAC","30-SEP-1995","CMV Retinitis Retreatment Trial","ACTG 228","01-JAN-1996","POS/PAC"
50388,"Protocol Status","Closed to Accrual","06-MAR-1995","CMV Retinitis Retreatment Trial","ACTG 228","30-SEP-1995","Closed to Accrual"
50388,"Protocol Status","Open","24-JUL-1992","CMV Retinitis Retreatment Trial","ACTG 228","06-MAR-1995","Open"
50388,"Protocol Status","Pending","10-JUL-1992","CMV Retinitis Retreatment Trial","ACTG 228","24-JUL-1992","Pending"
50389,"Protocol Status","Concluded","01-JAN-1999","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","","Concluded"
50389,"Protocol Status","Closed to Follow Up","31-MAY-1994","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","01-JAN-1999","Closed to Follow Up"
50389,"Protocol Status","POS/PAC","26-MAY-1994","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","31-MAY-1994","POS/PAC"
50389,"Protocol Status","Closed to Accrual","16-JUL-1993","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","26-MAY-1994","Closed to Accrual"
50389,"Protocol Status","Open","09-MAR-1993","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","16-JUL-1993","Open"
50389,"Protocol Status","Pending","23-DEC-1992","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","09-MAR-1993","Pending"
50389,"Protocol Status","In Development","10-SEP-1992","SQV + ZDV vs. ZDV+ ddC vs. SQV + ZDV + ddC","ACTG 229","23-DEC-1992","In Development"
50390,"Protocol Status","Concluded","01-NOV-1996","ddI + Ribavirin in HIV+ Individuals","ACTG 231","","Concluded"
50390,"Protocol Status","POS/PAC","01-FEB-1995","ddI + Ribavirin in HIV+ Individuals","ACTG 231","01-NOV-1996","POS/PAC"
50390,"Protocol Status","Closed to Follow Up","22-SEP-1994","ddI + Ribavirin in HIV+ Individuals","ACTG 231","01-FEB-1995","Closed to Follow Up"
50390,"Protocol Status","Closed to Accrual","27-JUN-1994","ddI + Ribavirin in HIV+ Individuals","ACTG 231","22-SEP-1994","Closed to Accrual"
50390,"Protocol Status","Open","05-MAY-1993","ddI + Ribavirin in HIV+ Individuals","ACTG 231","27-JUN-1994","Open"
50390,"Protocol Status","Pending","04-MAR-1993","ddI + Ribavirin in HIV+ Individuals","ACTG 231","05-MAY-1993","Pending"
50390,"Protocol Status","In Development","07-OCT-1992","ddI + Ribavirin in HIV+ Individuals","ACTG 231","04-MAR-1993","In Development"
50391,"Protocol Status","Concluded","01-MAY-1998","F105 for the Treatment of HIV","ACTG 232","","Concluded"
50391,"Protocol Status","POS/PAC","15-MAR-1996","F105 for the Treatment of HIV","ACTG 232","01-MAY-1998","POS/PAC"
50391,"Protocol Status","Closed to Accrual","29-FEB-1996","F105 for the Treatment of HIV","ACTG 232","15-MAR-1996","Closed to Accrual"
50391,"Protocol Status","Open","01-DEC-1994","F105 for the Treatment of HIV","ACTG 232","29-FEB-1996","Open"
50391,"Protocol Status","Temporarily Closed","15-AUG-1994","F105 for the Treatment of HIV","ACTG 232","01-DEC-1994","Other"
50391,"Protocol Status","Closed to Follow Up","28-JUN-1994","F105 for the Treatment of HIV","ACTG 232","15-AUG-1994","Closed to Follow Up"
50391,"Protocol Status","Open","21-DEC-1993","F105 for the Treatment of HIV","ACTG 232","28-JUN-1994","Open"
50391,"Protocol Status","Pending","05-NOV-1993","F105 for the Treatment of HIV","ACTG 232","21-DEC-1993","Pending"
50391,"Protocol Status","FDA - IND Hold","25-MAY-1993","F105 for the Treatment of HIV","ACTG 232","05-NOV-1993","Other"
50391,"Protocol Status","Pending","29-APR-1993","F105 for the Treatment of HIV","ACTG 232","25-MAY-1993","Pending"
50391,"Protocol Status","In Development","07-OCT-1992","F105 for the Treatment of HIV","ACTG 232","29-APR-1993","In Development"
50392,"Protocol Status","POS/PAC","09-SEP-1996","Thymosin Alpha, PEG IL-2, & ZDV or ddI for HIV","ACTG 236","","POS/PAC"
50392,"Protocol Status","Concluded","01-APR-1996","Thymosin Alpha, PEG IL-2, & ZDV or ddI for HIV","ACTG 236","09-SEP-1996","Concluded"
50392,"Protocol Status","Closed to Accrual","08-MAR-1995","Thymosin Alpha, PEG IL-2, & ZDV or ddI for HIV","ACTG 236","01-APR-1996","Closed to Accrual"
50392,"Protocol Status","Closed to Follow Up","15-NOV-1994","Thymosin Alpha, PEG IL-2, & ZDV or ddI for HIV","ACTG 236","08-MAR-1995","Closed to Follow Up"
50392,"Protocol Status","Open","03-MAR-1993","Thymosin Alpha, PEG IL-2, & ZDV or ddI for HIV","ACTG 236","15-NOV-1994","Open"
50392,"Protocol Status","In Development","16-DEC-1992","Thymosin Alpha, PEG IL-2, & ZDV or ddI for HIV","ACTG 236","03-MAR-1993","In Development"
50393,"Protocol Status","Concluded","01-MAY-2002","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","","Concluded"
50393,"Protocol Status","POS/PAC","08-APR-1998","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","01-MAY-2002","POS/PAC"
50393,"Protocol Status","Closed to Follow Up","14-OCT-1997","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","08-APR-1998","Closed to Follow Up"
50393,"Protocol Status","Closed to Accrual","18-DEC-1996","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","14-OCT-1997","Closed to Accrual"
50393,"Protocol Status","Open","03-APR-1996","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","18-DEC-1996","Open"
50393,"Protocol Status","Temporarily Closed","22-DEC-1995","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","03-APR-1996","Other"
50393,"Protocol Status","Open","18-JUL-1994","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","22-DEC-1995","Open"
50393,"Protocol Status","Pending","14-JAN-1994","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","18-JUL-1994","Pending"
50393,"Protocol Status","In Development","16-DEC-1992","Atovaquone + Pyr. vs Atovaquone + Sulfa. for toxo","ACTG 237","14-JAN-1994","In Development"
50394,"Protocol Status","Concluded","01-JAN-1999","Pilot study for MDRTB","ACTG 238","","Concluded"
50394,"Protocol Status","POS/PAC","30-OCT-1998","Pilot study for MDRTB","ACTG 238","01-JAN-1999","POS/PAC"
50394,"Protocol Status","Closed to Follow Up","02-JUL-1996","Pilot study for MDRTB","ACTG 238","30-OCT-1998","Closed to Follow Up"
50394,"Protocol Status","Closed to Accrual","05-JAN-1996","Pilot study for MDRTB","ACTG 238","02-JUL-1996","Closed to Accrual"
50394,"Protocol Status","Open","04-FEB-1994","Pilot study for MDRTB","ACTG 238","05-JAN-1996","Open"
50394,"Protocol Status","Pending","16-JUN-1993","Pilot study for MDRTB","ACTG 238","04-FEB-1994","Pending"
50394,"Protocol Status","In Development","16-DEC-1992","Pilot study for MDRTB","ACTG 238","16-JUN-1993","In Development"
50395,"Protocol Status","Concluded","20-SEP-2000","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","","Concluded"
50395,"Protocol Status","Closed to Follow Up","19-JUN-1995","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","20-SEP-2000","Closed to Follow Up"
50395,"Protocol Status","POS/PAC","17-NOV-1994","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","19-JUN-1995","POS/PAC"
50395,"Protocol Status","Closed to Accrual","22-JUL-1993","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","17-NOV-1994","Closed to Accrual"
50395,"Protocol Status","Open","10-MAY-1993","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","22-JUL-1993","Open"
50395,"Protocol Status","Pending","12-APR-1993","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","10-MAY-1993","Pending"
50395,"Protocol Status","In Development","16-DEC-1992","ZDV + ddI + NVP vs. ZDV + ddI","ACTG 241","12-APR-1993","In Development"
50396,"Protocol Status","Concluded","01-DEC-1998","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","","Concluded"
50396,"Protocol Status","Concluded","01-DEC-1998","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","01-DEC-1998","Concluded"
50396,"Protocol Status","POS/PAC","15-OCT-1997","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","01-DEC-1998","POS/PAC"
50396,"Protocol Status","Closed to Follow Up","15-JAN-1997","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","15-OCT-1997","Closed to Follow Up"
50396,"Protocol Status","Closed to Accrual","12-DEC-1996","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","15-JAN-1997","Closed to Accrual"
50396,"Protocol Status","Open","16-FEB-1994","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","12-DEC-1996","Open"
50396,"Protocol Status","Pending","24-NOV-1993","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","16-FEB-1994","Pending"
50396,"Protocol Status","In Development","08-FEB-1993","Amitriptyline vs. Mexilitine in Painful Neuropathy","ACTG 242","24-NOV-1993","In Development"
50397,"Protocol Status","Concluded","01-DEC-1999","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","","Concluded"
50397,"Protocol Status","POS/PAC","28-APR-1997","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","01-DEC-1999","POS/PAC"
50397,"Protocol Status","Closed to Follow Up","04-SEP-1996","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","28-APR-1997","Closed to Follow Up"
50397,"Protocol Status","Closed to Accrual","02-JUL-1996","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","04-SEP-1996","Closed to Accrual"
50397,"Protocol Status","Open","05-APR-1994","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","02-JUL-1996","Open"
50397,"Protocol Status","Pending","01-DEC-1993","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","05-APR-1994","Pending"
50397,"Protocol Status","In Development","08-FEB-1993","IV Ara-C + Rx vs. Intrathecal Ara-C + Rx vs. Rx","ACTG 243","01-DEC-1993","In Development"
50398,"Protocol Status","Concluded","30-OCT-1998","AZT vs. AZT + ddI vs. AZT + ddI + Nevirapine","ACTG 244","","Concluded"
50398,"Protocol Status","Closed to Follow Up","23-DEC-1996","AZT vs. AZT + ddI vs. AZT + ddI + Nevirapine","ACTG 244","30-OCT-1998","Closed to Follow Up"
50398,"Protocol Status","Closed to Accrual","21-MAR-1996","AZT vs. AZT + ddI vs. AZT + ddI + Nevirapine","ACTG 244","23-DEC-1996","Closed to Accrual"
50398,"Protocol Status","Open","14-JAN-1994","AZT vs. AZT + ddI vs. AZT + ddI + Nevirapine","ACTG 244","21-MAR-1996","Open"
50398,"Protocol Status","Pending","29-JUN-1993","AZT vs. AZT + ddI vs. AZT + ddI + Nevirapine","ACTG 244","14-JAN-1994","Pending"
50398,"Protocol Status","In Development","08-FEB-1993","AZT vs. AZT + ddI vs. AZT + ddI + Nevirapine","ACTG 244","29-JUN-1993","In Development"
50399,"Protocol Status","Concluded","10-OCT-2001","Stratum I+/vaccine, Stratum 2+-vaccine +ART","ACTG 246","","Concluded"
50399,"Protocol Status","POS/PAC","13-MAY-1999","Stratum I+/vaccine, Stratum 2+-vaccine +ART","ACTG 246","10-OCT-2001","POS/PAC"
50399,"Protocol Status","Closed to Follow Up","13-JAN-1998","Stratum I+/vaccine, Stratum 2+-vaccine +ART","ACTG 246","13-MAY-1999","Closed to Follow Up"
50399,"Protocol Status","Closed to Accrual","05-APR-1997","Stratum I+/vaccine, Stratum 2+-vaccine +ART","ACTG 246","13-JAN-1998","Closed to Accrual"
50399,"Protocol Status","Open","20-SEP-1995","Stratum I+/vaccine, Stratum 2+-vaccine +ART","ACTG 246","05-APR-1997","Open"
50399,"Protocol Status","Pending","12-APR-1995","Stratum I+/vaccine, Stratum 2+-vaccine +ART","ACTG 246","20-SEP-1995","Pending"
50400,"Protocol Status","Concluded","20-APR-2004","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","","Concluded"
50400,"Protocol Status","POS/PAC","01-MAR-2002","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","20-APR-2004","POS/PAC"
50400,"Protocol Status","Closed to Follow Up","29-APR-1998","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","01-MAR-2002","Closed to Follow Up"
50400,"Protocol Status","Closed to Accrual","30-JUN-1997","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","29-APR-1998","Closed to Accrual"
50400,"Protocol Status","Open","08-SEP-1995","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","30-JUN-1997","Open"
50400,"Protocol Status","Pending","01-MAR-1995","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","08-SEP-1995","Pending"
50400,"Protocol Status","In Development","12-MAY-1993","Low-Dose IL-2 SQ + ART vs. ART Alone in Patients on Stable ART 2 Months","ACTG 248","01-MAR-1995","In Development"
50401,"Protocol Status","Concluded","01-OCT-2001","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","","Concluded"
50401,"Protocol Status","POS/PAC","30-OCT-1998","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","01-OCT-2001","POS/PAC"
50401,"Protocol Status","Closed to Follow Up","07-NOV-1997","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","30-OCT-1998","Closed to Follow Up"
50401,"Protocol Status","Closed to Accrual","04-NOV-1996","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","07-NOV-1997","Closed to Accrual"
50401,"Protocol Status","Open","03-MAR-1994","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","04-NOV-1996","Open"
50401,"Protocol Status","Pending","27-OCT-1993","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","03-MAR-1994","Pending"
50401,"Protocol Status","In Development","12-JUL-1993","Thalidomide for Oral & Esophageal Aphthous Ulcers & HIV Viremia","ACTG 251","27-OCT-1993","In Development"
50402,"Protocol Status","Concluded","15-APR-1997","CHOD + GCSF for CNS Lymphoma","ACTG 252","","Concluded"
50402,"Protocol Status","Withdrawn","15-APR-1997","CHOD + GCSF for CNS Lymphoma","ACTG 252","15-APR-1997","Other"
50402,"Protocol Status","Closed to Accrual","06-FEB-1997","CHOD + GCSF for CNS Lymphoma","ACTG 252","15-APR-1997","Closed to Accrual"
50402,"Protocol Status","Closed to Follow Up","04-AUG-1996","CHOD + GCSF for CNS Lymphoma","ACTG 252","06-FEB-1997","Closed to Follow Up"
50402,"Protocol Status","Open","12-SEP-1994","CHOD + GCSF for CNS Lymphoma","ACTG 252","04-AUG-1996","Open"
50402,"Protocol Status","Pending","25-MAY-1994","CHOD + GCSF for CNS Lymphoma","ACTG 252","12-SEP-1994","Pending"
50402,"Protocol Status","In Development","12-JUL-1993","CHOD + GCSF for CNS Lymphoma","ACTG 252","25-MAY-1994","In Development"
50403,"Protocol Status","Withdrawn","21-JUL-1995","MOPP Regimens for PCP, Toxo, Diss. MAC, Diss. Fung","ACTG 257","","Other"
50403,"Protocol Status","In Development","13-SEP-1993","MOPP Regimens for PCP, Toxo, Diss. MAC, Diss. Fung","ACTG 257","21-JUL-1995","In Development"
50404,"Protocol Status","Concluded","16-MAR-1999","Oral Hypericin for HIV Infection","ACTG 258","","Concluded"
50404,"Protocol Status","Withdrawn","30-OCT-1995","Oral Hypericin for HIV Infection","ACTG 258","16-MAR-1999","Other"
50404,"Protocol Status","POS/PAC","03-JAN-1995","Oral Hypericin for HIV Infection","ACTG 258","30-OCT-1995","POS/PAC"
50404,"Protocol Status","Closed to Follow Up","14-SEP-1994","Oral Hypericin for HIV Infection","ACTG 258","03-JAN-1995","Closed to Follow Up"
50404,"Protocol Status","Temporarily Closed","06-JUL-1994","Oral Hypericin for HIV Infection","ACTG 258","14-SEP-1994","Other"
50404,"Protocol Status","Open","10-MAR-1994","Oral Hypericin for HIV Infection","ACTG 258","06-JUL-1994","Open"
50404,"Protocol Status","Pending","15-DEC-1993","Oral Hypericin for HIV Infection","ACTG 258","10-MAR-1994","Pending"
50404,"Protocol Status","In Development","13-SEP-1993","Oral Hypericin for HIV Infection","ACTG 258","15-DEC-1993","In Development"
50405,"Protocol Status","Closed to Follow Up","21-AUG-1995","SC-49483 + AZT vs. AZT in Pts with CD4 150-350","ACTG 259","","Closed to Follow Up"
50405,"Protocol Status","Concluded","10-JUL-1995","SC-49483 + AZT vs. AZT in Pts with CD4 150-350","ACTG 259","21-AUG-1995","Concluded"
50405,"Protocol Status","Closed to Accrual","01-JUN-1995","SC-49483 + AZT vs. AZT in Pts with CD4 150-350","ACTG 259","10-JUL-1995","Closed to Accrual"
50405,"Protocol Status","Open","31-JAN-1994","SC-49483 + AZT vs. AZT in Pts with CD4 150-350","ACTG 259","01-JUN-1995","Open"
50405,"Protocol Status","Pending","15-DEC-1993","SC-49483 + AZT vs. AZT in Pts with CD4 150-350","ACTG 259","31-JAN-1994","Pending"
50405,"Protocol Status","In Development","13-SEP-1993","SC-49483 + AZT vs. AZT in Pts with CD4 150-350","ACTG 259","15-DEC-1993","In Development"
50406,"Protocol Status","Concluded","01-JAN-2005","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","","Concluded"
50406,"Protocol Status","POS/PAC","01-JAN-1996","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","01-JAN-2005","POS/PAC"
50406,"Protocol Status","Closed to Follow Up","13-OCT-1995","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","01-JAN-1996","Closed to Follow Up"
50406,"Protocol Status","Closed to Accrual","26-JUL-1995","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","13-OCT-1995","Closed to Accrual"
50406,"Protocol Status","Open","13-OCT-1994","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","26-JUL-1995","Open"
50406,"Protocol Status","Pending","13-SEP-1994","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","13-OCT-1994","Pending"
50406,"Protocol Status","In Development","13-SEP-1993","Dose Ranging Trial of the Anti-HIV Activity of Delavirdine Mesylate","ACTG 260","13-SEP-1994","In Development"
50407,"Protocol Status","Concluded","01-JAN-2005","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","","Concluded"
50407,"Protocol Status","POS/PAC","27-MAR-1997","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","01-JAN-2005","POS/PAC"
50407,"Protocol Status","Closed to Follow Up","09-DEC-1996","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","27-MAR-1997","Closed to Follow Up"
50407,"Protocol Status","Closed to Accrual","15-SEP-1995","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","09-DEC-1996","Closed to Accrual"
50407,"Protocol Status","Open","29-AUG-1994","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","15-SEP-1995","Open"
50407,"Protocol Status","Pending","20-JUL-1994","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","29-AUG-1994","Pending"
50407,"Protocol Status","In Development","19-OCT-1993","DLV + ZDV +/-ddI vs.ZDV + ddI","ACTG 261","20-JUL-1994","In Development"
50408,"Protocol Status","POS/PAC","30-OCT-1998","Effects of Methadone on ZDV Disposition","ACTG 262","","POS/PAC"
50408,"Protocol Status","Concluded","15-AUG-1998","Effects of Methadone on ZDV Disposition","ACTG 262","30-OCT-1998","Concluded"
50408,"Protocol Status","Closed to Accrual","09-SEP-1996","Effects of Methadone on ZDV Disposition","ACTG 262","15-AUG-1998","Closed to Accrual"
50408,"Protocol Status","Closed to Follow Up","23-JUL-1996","Effects of Methadone on ZDV Disposition","ACTG 262","09-SEP-1996","Closed to Follow Up"
50408,"Protocol Status","Open","24-MAY-1994","Effects of Methadone on ZDV Disposition","ACTG 262","23-JUL-1996","Open"
50408,"Protocol Status","Pending","03-MAY-1994","Effects of Methadone on ZDV Disposition","ACTG 262","24-MAY-1994","Pending"
50408,"Protocol Status","In Development","19-OCT-1993","Effects of Methadone on ZDV Disposition","ACTG 262","03-MAY-1994","In Development"
50409,"Protocol Status","Withdrawn","14-SEP-1995","p24-VLP in Asymptomatics with CD4 >500/mm3","ACTG 263","","Other"
50409,"Protocol Status","Deferred","14-DEC-1994","p24-VLP in Asymptomatics with CD4 >500/mm3","ACTG 263","14-SEP-1995","Other"
50409,"Protocol Status","In Development","09-NOV-1993","p24-VLP in Asymptomatics with CD4 >500/mm3","ACTG 263","14-DEC-1994","In Development"
50410,"Protocol Status","Withdrawn","22-OCT-1996","Phase I Procysteine","ACTG 264","","Other"
50410,"Protocol Status","In Development","09-NOV-1993","Phase I Procysteine","ACTG 264","22-OCT-1996","In Development"
50411,"Protocol Status","Concluded","01-JAN-2005","MSL 109 in CMV","ACTG 266","","Concluded"
50411,"Protocol Status","Concluded","01-NOV-2004","MSL 109 in CMV","ACTG 266","01-JAN-2005","Concluded"
50411,"Protocol Status","POS/PAC","11-MAR-1998","MSL 109 in CMV","ACTG 266","01-NOV-2004","POS/PAC"
50411,"Protocol Status","Closed to Accrual","15-MAR-1997","MSL 109 in CMV","ACTG 266","11-MAR-1998","Closed to Accrual"
50411,"Protocol Status","Closed to Follow Up","12-MAR-1997","MSL 109 in CMV","ACTG 266","15-MAR-1997","Closed to Follow Up"
50411,"Protocol Status","Open","28-DEC-1996","MSL 109 in CMV","ACTG 266","12-MAR-1997","Open"
50411,"Protocol Status","Temporarily Closed","03-SEP-1996","MSL 109 in CMV","ACTG 266","28-DEC-1996","Other"
50411,"Protocol Status","Open","06-JUL-1995","MSL 109 in CMV","ACTG 266","03-SEP-1996","Open"
50411,"Protocol Status","Pending","07-APR-1995","MSL 109 in CMV","ACTG 266","06-JUL-1995","Pending"
50411,"Protocol Status","In Development","09-DEC-1993","MSL 109 in CMV","ACTG 266","07-APR-1995","In Development"
50412,"Protocol Status","Concluded","01-MAY-2002","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","","Concluded"
50412,"Protocol Status","POS/PAC","03-JUL-2000","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","01-MAY-2002","POS/PAC"
50412,"Protocol Status","Closed to Follow Up","17-DEC-1998","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","03-JUL-2000","Closed to Follow Up"
50412,"Protocol Status","Closed to Accrual","17-SEP-1998","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","17-DEC-1998","Closed to Accrual"
50412,"Protocol Status","Open","23-DEC-1996","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","17-SEP-1998","Open"
50412,"Protocol Status","Temporarily Closed","25-OCT-1996","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","23-DEC-1996","Other"
50412,"Protocol Status","Open","12-AUG-1996","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","25-OCT-1996","Open"
50412,"Protocol Status","Temporarily Closed","10-JUL-1996","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","12-AUG-1996","Other"
50412,"Protocol Status","Open","03-MAR-1995","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","10-JUL-1996","Open"
50412,"Protocol Status","Pending","22-SEP-1994","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","03-MAR-1995","Pending"
50412,"Protocol Status","In Development","09-DEC-1993","Dose-Escalation & Safety, Tolerability, & PK of Thalidomide in HIV-1 Infection","ACTG 267","22-SEP-1994","In Development"
50413,"Protocol Status","Concluded","01-AUG-2000","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","","Concluded"
50413,"Protocol Status","POS/PAC","26-SEP-1996","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","01-AUG-2000","POS/PAC"
50413,"Protocol Status","Closed to Follow Up","02-JUL-1996","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","26-SEP-1996","Closed to Follow Up"
50413,"Protocol Status","Closed to Accrual","29-MAR-1996","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","02-JUL-1996","Closed to Accrual"
50413,"Protocol Status","Open","23-NOV-1994","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","29-MAR-1996","Open"
50413,"Protocol Status","Pending","20-OCT-1994","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","23-NOV-1994","Pending"
50413,"Protocol Status","In Development","09-DEC-1993","TMP/SMX as Primary PCP Prophylaxis","ACTG 268","20-OCT-1994","In Development"
50414,"Protocol Status","Concluded","01-AUG-2002","Etoposide for Relapsed or Progressed KS","ACTG 269","","Concluded"
50414,"Protocol Status","POS/PAC","30-JUL-2000","Etoposide for Relapsed or Progressed KS","ACTG 269","01-AUG-2002","POS/PAC"
50414,"Protocol Status","Closed to Follow Up","16-JUN-1998","Etoposide for Relapsed or Progressed KS","ACTG 269","30-JUL-2000","Closed to Follow Up"
50414,"Protocol Status","Closed to Accrual","15-MAY-1998","Etoposide for Relapsed or Progressed KS","ACTG 269","16-JUN-1998","Closed to Accrual"
50414,"Protocol Status","Open","04-OCT-1994","Etoposide for Relapsed or Progressed KS","ACTG 269","15-MAY-1998","Open"
50414,"Protocol Status","Pending","23-AUG-1994","Etoposide for Relapsed or Progressed KS","ACTG 269","04-OCT-1994","Pending"
50414,"Protocol Status","In Development","09-DEC-1993","Etoposide for Relapsed or Progressed KS","ACTG 269","23-AUG-1994","In Development"
50415,"Protocol Status","Withdrawn","14-FEB-1996","Pentoxifylline in HIV positive TB","ACTG 270","","Other"
50415,"Protocol Status","In Development","13-JAN-1994","Pentoxifylline in HIV positive TB","ACTG 270","14-FEB-1996","In Development"
50416,"Protocol Status","Concluded","09-SEP-1999","Prednisone vs. Placebo for HIVAN","ACTG 271","","Concluded"
50416,"Protocol Status","Closed to Accrual","13-MAY-1996","Prednisone vs. Placebo for HIVAN","ACTG 271","09-SEP-1999","Closed to Accrual"
50416,"Protocol Status","Closed to Follow Up","16-JAN-1996","Prednisone vs. Placebo for HIVAN","ACTG 271","13-MAY-1996","Closed to Follow Up"
50416,"Protocol Status","Open","09-JUN-1995","Prednisone vs. Placebo for HIVAN","ACTG 271","16-JAN-1996","Open"
50416,"Protocol Status","Pending","20-JAN-1995","Prednisone vs. Placebo for HIVAN","ACTG 271","09-JUN-1995","Pending"
50416,"Protocol Status","In Development","13-JAN-1994","Prednisone vs. Placebo for HIVAN","ACTG 271","20-JAN-1995","In Development"
50417,"Protocol Status","Withdrawn","06-APR-1995","Low dose alpha interferon","ACTG 272","","Other"
50417,"Protocol Status","In Development","23-JAN-1994","Low dose alpha interferon","ACTG 272","06-APR-1995","In Development"
50418,"Protocol Status","Closed to Follow Up","28-SEP-1995","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","","Closed to Follow Up"
50418,"Protocol Status","Concluded","08-MAY-1995","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","28-SEP-1995","Concluded"
50418,"Protocol Status","Withdrawn","08-MAY-1995","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","08-MAY-1995","Other"
50418,"Protocol Status","Temporarily Closed","04-MAY-1995","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","08-MAY-1995","Other"
50418,"Protocol Status","Open","18-NOV-1994","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","04-MAY-1995","Open"
50418,"Protocol Status","Pending","28-SEP-1994","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","18-NOV-1994","Pending"
50418,"Protocol Status","In Development","12-APR-1994","Virologic Effects of ZDV VS ZDV + DDI in Pts w/ CD","ACTG 275","28-SEP-1994","In Development"
50419,"Protocol Status","Concluded","07-APR-2007","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","","Concluded"
50419,"Protocol Status","POS/PAC","15-FEB-2000","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","07-APR-2007","POS/PAC"
50419,"Protocol Status","Closed to Follow Up","22-JUL-1997","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","15-FEB-2000","Closed to Follow Up"
50419,"Protocol Status","Closed to Accrual","31-DEC-1996","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","22-JUL-1997","Closed to Accrual"
50419,"Protocol Status","Open","06-NOV-1995","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","31-DEC-1996","Open"
50419,"Protocol Status","Temporarily Closed","18-OCT-1995","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","06-NOV-1995","Other"
50419,"Protocol Status","Open","17-JUL-1995","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","18-OCT-1995","Open"
50419,"Protocol Status","Pending","19-APR-1995","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","17-JUL-1995","Pending"
50419,"Protocol Status","In Development","12-APR-1994","Diff. Among Antiretrovirals on Quant. Meas. of Vir","ACTG 276","19-APR-1995","In Development"
50420,"Protocol Status","Concluded","24-DEC-1998","PCP-INT","ACTG 277","","Concluded"
50420,"Protocol Status","POS/PAC","18-JUL-1997","PCP-INT","ACTG 277","24-DEC-1998","POS/PAC"
50420,"Protocol Status","Closed to Follow Up","31-MAY-1997","PCP-INT","ACTG 277","18-JUL-1997","Closed to Follow Up"
50420,"Protocol Status","Closed to Accrual","05-MAY-1995","PCP-INT","ACTG 277","31-MAY-1997","Closed to Accrual"
50420,"Protocol Status","Open","23-SEP-1994","PCP-INT","ACTG 277","05-MAY-1995","Open"
50420,"Protocol Status","Pending","20-JUL-1994","PCP-INT","ACTG 277","23-SEP-1994","Pending"
50420,"Protocol Status","In Development","25-APR-1994","PCP-INT","ACTG 277","20-JUL-1994","In Development"
50421,"Protocol Status","Concluded","10-JAN-1998","Alternating Oral and IV Ganciclovir for CMV Retini","ACTG 278","","Concluded"
50421,"Protocol Status","Closed to Follow Up","15-APR-1997","Alternating Oral and IV Ganciclovir for CMV Retini","ACTG 278","10-JAN-1998","Closed to Follow Up"
50421,"Protocol Status","Closed to Accrual","10-DEC-1996","Alternating Oral and IV Ganciclovir for CMV Retini","ACTG 278","15-APR-1997","Closed to Accrual"
50421,"Protocol Status","Open","18-DEC-1995","Alternating Oral and IV Ganciclovir for CMV Retini","ACTG 278","10-DEC-1996","Open"
50421,"Protocol Status","Pending","04-APR-1995","Alternating Oral and IV Ganciclovir for CMV Retini","ACTG 278","18-DEC-1995","Pending"
50421,"Protocol Status","In Development","10-MAY-1994","Alternating Oral and IV Ganciclovir for CMV Retini","ACTG 278","04-APR-1995","In Development"
50422,"Protocol Status","Withdrawn","04-NOV-1994","SC-52151 vs AZT vs AZT + SC-52151 in Pts w/ CD4 10","ACTG 280","","Other"
50422,"Protocol Status","In Development","24-MAY-1994","SC-52151 vs AZT vs AZT + SC-52151 in Pts w/ CD4 10","ACTG 280","04-NOV-1994","In Development"
50423,"Protocol Status","Concluded","15-FEB-1997","HPMPC for Peripheral CMV Retinitis","ACTG 281","","Concluded"
50423,"Protocol Status","Closed to Follow Up","28-NOV-1996","HPMPC for Peripheral CMV Retinitis","ACTG 281","15-FEB-1997","Closed to Follow Up"
50423,"Protocol Status","POS/PAC","10-APR-1996","HPMPC for Peripheral CMV Retinitis","ACTG 281","28-NOV-1996","POS/PAC"
50423,"Protocol Status","Closed to Accrual","11-MAR-1996","HPMPC for Peripheral CMV Retinitis","ACTG 281","10-APR-1996","Closed to Accrual"
50423,"Protocol Status","Open","27-OCT-1994","HPMPC for Peripheral CMV Retinitis","ACTG 281","11-MAR-1996","Open"
50423,"Protocol Status","FDA - IND Hold","03-AUG-1994","HPMPC for Peripheral CMV Retinitis","ACTG 281","27-OCT-1994","Other"
50423,"Protocol Status","Open","10-APR-1994","HPMPC for Peripheral CMV Retinitis","ACTG 281","03-AUG-1994","Open"
50424,"Protocol Status","Concluded","01-MAY-1997","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","","Concluded"
50424,"Protocol Status","POS/PAC","01-FEB-1995","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","01-MAY-1997","POS/PAC"
50424,"Protocol Status","Closed to Follow Up","07-OCT-1994","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","01-FEB-1995","Closed to Follow Up"
50424,"Protocol Status","Closed to Accrual","01-SEP-1994","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","07-OCT-1994","Closed to Accrual"
50424,"Protocol Status","Open","04-AUG-1994","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","01-SEP-1994","Open"
50424,"Protocol Status","Pending","06-JUL-1994","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","04-AUG-1994","Pending"
50424,"Protocol Status","In Development","23-JUN-1994","Phase I SC-52151 Study:  Elixir vs. SEDDS","ACTG 282","06-JUL-1994","In Development"
50425,"Protocol Status","Concluded","01-DEC-2004","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","","Concluded"
50425,"Protocol Status","POS/PAC","15-MAY-1999","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","01-DEC-2004","POS/PAC"
50425,"Protocol Status","Closed to Accrual","19-AUG-1997","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","15-MAY-1999","Closed to Accrual"
50425,"Protocol Status","Closed to Follow Up","05-AUG-1997","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","19-AUG-1997","Closed to Follow Up"
50425,"Protocol Status","Open","31-OCT-1995","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","05-AUG-1997","Open"
50425,"Protocol Status","Pending","24-APR-1995","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","31-OCT-1995","Pending"
50425,"Protocol Status","In Development","23-JUN-1994","Effects of Flucon, Clari, & Rifab on Dapsone & SMX","ACTG 283","24-APR-1995","In Development"
50426,"Protocol Status","Concluded","01-OCT-2000","ACTG 122 followup","ACTG 284","","Concluded"
50426,"Protocol Status","Closed to Follow Up","16-SEP-1997","ACTG 122 followup","ACTG 284","01-OCT-2000","Closed to Follow Up"
50426,"Protocol Status","Closed to Accrual","07-AUG-1996","ACTG 122 followup","ACTG 284","16-SEP-1997","Closed to Accrual"
50426,"Protocol Status","Open","26-JAN-1995","ACTG 122 followup","ACTG 284","07-AUG-1996","Open"
50426,"Protocol Status","Pending","26-SEP-1994","ACTG 122 followup","ACTG 284","26-JAN-1995","Pending"
50426,"Protocol Status","In Development","23-JUN-1994","ACTG 122 followup","ACTG 284","26-SEP-1994","In Development"
50427,"Protocol Status","Concluded","01-DEC-2004","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","","Concluded"
50427,"Protocol Status","POS/PAC","30-OCT-1998","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","01-DEC-2004","POS/PAC"
50427,"Protocol Status","Closed to Follow Up","17-JUL-1998","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","30-OCT-1998","Closed to Follow Up"
50427,"Protocol Status","Closed to Accrual","01-JAN-1998","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","17-JUL-1998","Closed to Accrual"
50427,"Protocol Status","Open","20-MAR-1996","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","01-JAN-1998","Open"
50427,"Protocol Status","Pending","20-NOV-1995","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","20-MAR-1996","Pending"
50427,"Protocol Status","In Development","17-JUL-1994","Stem Cell Mobilization: Harvesting from PBMCs Using G-CSF","ACTG 285","20-NOV-1995","In Development"
50428,"Protocol Status","Concluded","10-AUG-1998","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","","Concluded"
50428,"Protocol Status","Closed to Follow Up","28-APR-1998","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","10-AUG-1998","Closed to Follow Up"
50428,"Protocol Status","Closed to Accrual","30-AUG-1996","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","28-APR-1998","Closed to Accrual"
50428,"Protocol Status","Open","15-MAY-1995","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","30-AUG-1996","Open"
50428,"Protocol Status","Pending","04-APR-1995","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","15-MAY-1995","Pending"
50428,"Protocol Status","FDA - IND Hold","08-MAR-1995","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","04-APR-1995","Other"
50428,"Protocol Status","Pending","06-FEB-1995","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","08-MAR-1995","Pending"
50428,"Protocol Status","In Development","18-JUL-1994","Dox-SL +/- Bleo & vincristine for Advanced KS","ACTG 286","06-FEB-1995","In Development"
50429,"Protocol Status","Withdrawn","30-OCT-1996","Aerosol.  Recombinant Human IFN-Gamma for TB","ACTG 289","","Other"
50429,"Protocol Status","In Development","17-OCT-1994","Aerosol.  Recombinant Human IFN-Gamma for TB","ACTG 289","30-OCT-1996","In Development"
50430,"Protocol Status","Concluded","01-JUL-2000","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","","Concluded"
50430,"Protocol Status","POS/PAC","05-NOV-1997","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","01-JUL-2000","POS/PAC"
50430,"Protocol Status","POS/PAC","05-NOV-1997","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","05-NOV-1997","POS/PAC"
50430,"Protocol Status","Closed to Follow Up","29-APR-1997","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","05-NOV-1997","Closed to Follow Up"
50430,"Protocol Status","Closed to Accrual","01-NOV-1996","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","29-APR-1997","Closed to Accrual"
50430,"Protocol Status","Open","16-JUN-1995","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","01-NOV-1996","Open"
50430,"Protocol Status","Pending","04-APR-1995","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","16-JUN-1995","Pending"
50430,"Protocol Status","In Development","17-OCT-1994","d4T vs. ddI vs. AZT+d4T vs. AZT+ddI w/ CD4 300-600","ACTG 290","04-APR-1995","In Development"
50431,"Protocol Status","Concluded","15-FEB-2002","rhNGF for HIV-Associated Neuropathy","ACTG 291","","Concluded"
50431,"Protocol Status","POS/PAC","03-FEB-1999","rhNGF for HIV-Associated Neuropathy","ACTG 291","15-FEB-2002","POS/PAC"
50431,"Protocol Status","Closed to Follow Up","03-FEB-1999","rhNGF for HIV-Associated Neuropathy","ACTG 291","03-FEB-1999","Closed to Follow Up"
50431,"Protocol Status","Closed to Accrual","07-JUL-1997","rhNGF for HIV-Associated Neuropathy","ACTG 291","03-FEB-1999","Closed to Accrual"
50431,"Protocol Status","Open","15-APR-1997","rhNGF for HIV-Associated Neuropathy","ACTG 291","07-JUL-1997","Open"
50431,"Protocol Status","Temporarily Closed","19-FEB-1997","rhNGF for HIV-Associated Neuropathy","ACTG 291","15-APR-1997","Other"
50431,"Protocol Status","Open","11-JUL-1996","rhNGF for HIV-Associated Neuropathy","ACTG 291","19-FEB-1997","Open"
50431,"Protocol Status","Pending","12-FEB-1996","rhNGF for HIV-Associated Neuropathy","ACTG 291","11-JUL-1996","Pending"
50431,"Protocol Status","In Development","24-OCT-1994","rhNGF for HIV-Associated Neuropathy","ACTG 291","12-FEB-1996","In Development"
50432,"Protocol Status","Concluded","15-DEC-2002","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","","Concluded"
50432,"Protocol Status","POS/PAC","26-MAR-2001","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","15-DEC-2002","POS/PAC"
50432,"Protocol Status","Closed to Follow Up","21-AUG-2000","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","26-MAR-2001","Closed to Follow Up"
50432,"Protocol Status","Closed to Accrual","12-NOV-1999","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","21-AUG-2000","Closed to Accrual"
50432,"Protocol Status","Open","01-OCT-1998","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","12-NOV-1999","Open"
50432,"Protocol Status","Open","27-MAR-1996","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","01-OCT-1998","Open"
50432,"Protocol Status","Pending","03-JAN-1996","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","27-MAR-1996","Pending"
50432,"Protocol Status","In Development","04-NOV-1994","Oral Isotretinoin vs.Observation for Low Grade Squamous Intraepithelial Lesions","ACTG 293","03-JAN-1996","In Development"
50433,"Protocol Status","POS/PAC","17-AUG-1998","MSL 109 for CMV Retinitis - SOCA Collaboration","ACTG 294","","POS/PAC"
50433,"Protocol Status","Concluded","01-DEC-1997","MSL 109 for CMV Retinitis - SOCA Collaboration","ACTG 294","17-AUG-1998","Concluded"
50433,"Protocol Status","Closed to Follow Up","30-JAN-1997","MSL 109 for CMV Retinitis - SOCA Collaboration","ACTG 294","01-DEC-1997","Closed to Follow Up"
50433,"Protocol Status","Closed to Accrual","15-AUG-1996","MSL 109 for CMV Retinitis - SOCA Collaboration","ACTG 294","30-JAN-1997","Closed to Accrual"
50433,"Protocol Status","Open","28-APR-1995","MSL 109 for CMV Retinitis - SOCA Collaboration","ACTG 294","15-AUG-1996","Open"
50433,"Protocol Status","In Development","04-NOV-1994","MSL 109 for CMV Retinitis - SOCA Collaboration","ACTG 294","28-APR-1995","In Development"
50434,"Protocol Status","POS/PAC","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","","POS/PAC"
50434,"Protocol Status","Concluded","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","Concluded"
50434,"Protocol Status","Concluded","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","Concluded"
50434,"Protocol Status","POS/PAC","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","POS/PAC"
50434,"Protocol Status","POS/PAC","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","POS/PAC"
50434,"Protocol Status","POS/PAC","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","POS/PAC"
50434,"Protocol Status","POS/PAC","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","POS/PAC"
50434,"Protocol Status","Concluded","01-MAY-2000","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","Concluded"
50434,"Protocol Status","POS/PAC","04-APR-1998","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-2000","POS/PAC"
50434,"Protocol Status","Closed to Follow Up","24-SEP-1997","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","04-APR-1998","Closed to Follow Up"
50434,"Protocol Status","Closed to Accrual","26-MAR-1997","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","24-SEP-1997","Closed to Accrual"
50434,"Protocol Status","Open","14-SEP-1995","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","26-MAR-1997","Open"
50434,"Protocol Status","Pending","01-MAY-1995","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","14-SEP-1995","Pending"
50434,"Protocol Status","In Development","04-NOV-1994","Ampho B for Fluconazole-Resistant Candidiasis","ACTG 295","01-MAY-1995","In Development"
50435,"Protocol Status","Withdrawn","13-SEP-1995","Incidence/Characteristics of Malignant Disease","ACTG 297","","Other"
50435,"Protocol Status","In Development","15-DEC-1994","Incidence/Characteristics of Malignant Disease","ACTG 297","13-SEP-1995","In Development"
50436,"Protocol Status","Concluded","01-JUL-2002","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","","Concluded"
50436,"Protocol Status","POS/PAC","20-NOV-1997","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","01-JUL-2002","POS/PAC"
50436,"Protocol Status","Closed to Follow Up","23-APR-1997","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","20-NOV-1997","Closed to Follow Up"
50436,"Protocol Status","Closed to Accrual","01-NOV-1996","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","23-APR-1997","Closed to Accrual"
50436,"Protocol Status","Open","29-AUG-1995","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","01-NOV-1996","Open"
50436,"Protocol Status","Pending","13-JUL-1995","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","29-AUG-1995","Pending"
50436,"Protocol Status","In Development","30-DEC-1994","ZDV v d4T v ZDV+d4T in CD4 300-600 & no Nucl Exper","ACTG 298","13-JUL-1995","In Development"
50437,"Protocol Status","Concluded","01-SEP-2008","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","","Concluded"
50437,"Protocol Status","POS/PAC","20-JUL-2001","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","01-SEP-2008","POS/PAC"
50437,"Protocol Status","Closed to Follow Up","20-JUL-2001","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","20-JUL-2001","Closed to Follow Up"
50437,"Protocol Status","Closed to Accrual","30-DEC-1999","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","20-JUL-2001","Closed to Accrual"
50437,"Protocol Status","Open","18-DEC-1996","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","30-DEC-1999","Open"
50437,"Protocol Status","Pending","23-JUL-1996","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","18-DEC-1996","Pending"
50437,"Protocol Status","In Development","31-JAN-1995","Memantine for AIDS Dementia Complex (ADC) Alone or with ART","ACTG 301","23-JUL-1996","In Development"
50438,"Protocol Status","Concluded","15-AUG-2003","Virologic Response to New Nucleoside Regimens","ACTG 302","","Concluded"
50438,"Protocol Status","POS/PAC","04-MAY-1998","Virologic Response to New Nucleoside Regimens","ACTG 302","15-AUG-2003","POS/PAC"
50438,"Protocol Status","Closed to Follow Up","17-NOV-1997","Virologic Response to New Nucleoside Regimens","ACTG 302","04-MAY-1998","Closed to Follow Up"
50438,"Protocol Status","Closed to Accrual","12-JAN-1996","Virologic Response to New Nucleoside Regimens","ACTG 302","17-NOV-1997","Closed to Accrual"
50438,"Protocol Status","Open","28-SEP-1995","Virologic Response to New Nucleoside Regimens","ACTG 302","12-JAN-1996","Open"
50438,"Protocol Status","Pending","04-AUG-1995","Virologic Response to New Nucleoside Regimens","ACTG 302","28-SEP-1995","Pending"
50438,"Protocol Status","In Development","31-MAR-1995","Virologic Response to New Nucleoside Regimens","ACTG 302","04-AUG-1995","In Development"
50439,"Protocol Status","Concluded","15-AUG-2003","Influence of Risk Status on ART Response","ACTG 303","","Concluded"
50439,"Protocol Status","POS/PAC","30-OCT-1998","Influence of Risk Status on ART Response","ACTG 303","15-AUG-2003","POS/PAC"
50439,"Protocol Status","Closed to Follow Up","16-SEP-1997","Influence of Risk Status on ART Response","ACTG 303","30-OCT-1998","Closed to Follow Up"
50439,"Protocol Status","Closed to Accrual","12-JAN-1996","Influence of Risk Status on ART Response","ACTG 303","16-SEP-1997","Closed to Accrual"
50439,"Protocol Status","Open","28-SEP-1995","Influence of Risk Status on ART Response","ACTG 303","12-JAN-1996","Open"
50439,"Protocol Status","Pending","04-AUG-1995","Influence of Risk Status on ART Response","ACTG 303","28-SEP-1995","Pending"
50439,"Protocol Status","In Development","30-MAR-1995","Influence of Risk Status on ART Response","ACTG 303","04-AUG-1995","In Development"
50440,"Protocol Status","Concluded","27-MAR-2000","Effect of Antiretroviral Cessation on HIV-RNA","ACTG 304","","Concluded"
50440,"Protocol Status","Closed to Accrual","27-DEC-1996","Effect of Antiretroviral Cessation on HIV-RNA","ACTG 304","27-MAR-2000","Closed to Accrual"
50440,"Protocol Status","Closed to Follow Up","01-OCT-1996","Effect of Antiretroviral Cessation on HIV-RNA","ACTG 304","27-DEC-1996","Closed to Follow Up"
50440,"Protocol Status","Open","23-JAN-1996","Effect of Antiretroviral Cessation on HIV-RNA","ACTG 304","01-OCT-1996","Open"
50440,"Protocol Status","Pending","05-DEC-1995","Effect of Antiretroviral Cessation on HIV-RNA","ACTG 304","23-JAN-1996","Pending"
50440,"Protocol Status","In Development","31-MAR-1995","Effect of Antiretroviral Cessation on HIV-RNA","ACTG 304","05-DEC-1995","In Development"
50441,"Protocol Status","Withdrawn","15-JAN-1999","Pilot of CSF Penetration & Response to Ganc & Fosc","ACTG 305","","Other"
50441,"Protocol Status","Deferred","20-JUL-1997","Pilot of CSF Penetration & Response to Ganc & Fosc","ACTG 305","15-JAN-1999","Other"
50441,"Protocol Status","Open","02-JAN-1997","Pilot of CSF Penetration & Response to Ganc & Fosc","ACTG 305","20-JUL-1997","Open"
50441,"Protocol Status","Pending","20-MAY-1996","Pilot of CSF Penetration & Response to Ganc & Fosc","ACTG 305","02-JAN-1997","Pending"
50441,"Protocol Status","In Development","17-APR-1995","Pilot of CSF Penetration & Response to Ganc & Fosc","ACTG 305","20-MAY-1996","In Development"
50442,"Protocol Status","Concluded","01-SEP-2007","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","","Concluded"
50442,"Protocol Status","POS/PAC","30-MAR-1998","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","01-SEP-2007","POS/PAC"
50442,"Protocol Status","Closed to Follow Up","15-JAN-1998","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","30-MAR-1998","Closed to Follow Up"
50442,"Protocol Status","Closed to Accrual","19-JUL-1996","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","15-JAN-1998","Closed to Accrual"
50442,"Protocol Status","Open","24-NOV-1995","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","19-JUL-1996","Open"
50442,"Protocol Status","Pending","02-OCT-1995","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","24-NOV-1995","Pending"
50442,"Protocol Status","In Development","17-APR-1995","Interaction of 3TC + ZDV, d4T, or ddI vs. Monotherapy ddI or d4T in HIV Subjects","ACTG 306","02-OCT-1995","In Development"
50443,"Protocol Status","Concluded","01-NOV-2007","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","","Concluded"
50443,"Protocol Status","POS/PAC","05-JAN-2000","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","01-NOV-2007","POS/PAC"
50443,"Protocol Status","Closed to Follow Up","17-FEB-1999","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","05-JAN-2000","Closed to Follow Up"
50443,"Protocol Status","Closed to Accrual","09-JAN-1998","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","17-FEB-1999","Closed to Accrual"
50443,"Protocol Status","Open","03-SEP-1996","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","09-JAN-1998","Open"
50443,"Protocol Status","Pending","01-FEB-1996","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","03-SEP-1996","Pending"
50443,"Protocol Status","In Development","26-APR-1995","Hydroxyurea/ddI vs ddI Monotherapy","ACTG 307","01-FEB-1996","In Development"
50444,"Protocol Status","On Hold","01-OCT-1999","Human Monoclonal Antibodies 2F5 & 2G12 HIV Treatmt","ACTG 308","","Other"
50444,"Protocol Status","Withdrawn","01-JUN-1999","Human Monoclonal Antibodies 2F5 & 2G12 HIV Treatmt","ACTG 308","01-OCT-1999","Other"
50444,"Protocol Status","FDA - IND Hold","04-MAR-1999","Human Monoclonal Antibodies 2F5 & 2G12 HIV Treatmt","ACTG 308","01-JUN-1999","Other"
50444,"Protocol Status","In Development","15-OCT-1998","Human Monoclonal Antibodies 2F5 & 2G12 HIV Treatmt","ACTG 308","04-MAR-1999","In Development"
50444,"Protocol Status","Withdrawn","04-AUG-1998","Human Monoclonal Antibodies 2F5 & 2G12 HIV Treatmt","ACTG 308","15-OCT-1998","Other"
50444,"Protocol Status","In Development","01-JUN-1995","Human Monoclonal Antibodies 2F5 & 2G12 HIV Treatmt","ACTG 308","04-AUG-1998","In Development"
50445,"Protocol Status","Concluded","01-DEC-2005","PK of TB Drugs in HIV/TB Patients","ACTG 309","","Concluded"
50445,"Protocol Status","POS/PAC","06-MAY-2002","PK of TB Drugs in HIV/TB Patients","ACTG 309","01-DEC-2005","POS/PAC"
50445,"Protocol Status","Closed to Accrual","11-DEC-1999","PK of TB Drugs in HIV/TB Patients","ACTG 309","06-MAY-2002","Closed to Accrual"
50445,"Protocol Status","Closed to Follow Up","02-NOV-1999","PK of TB Drugs in HIV/TB Patients","ACTG 309","11-DEC-1999","Closed to Follow Up"
50445,"Protocol Status","Open","11-JAN-1996","PK of TB Drugs in HIV/TB Patients","ACTG 309","02-NOV-1999","Open"
50445,"Protocol Status","Pending","01-SEP-1995","PK of TB Drugs in HIV/TB Patients","ACTG 309","11-JAN-1996","Pending"
50445,"Protocol Status","In Development","08-APR-1995","PK of TB Drugs in HIV/TB Patients","ACTG 309","01-SEP-1995","In Development"
50446,"Protocol Status","Withdrawn","26-SEP-1996","HIV RNA Threshold for Monitoring Change of HIV RNA","ACTG 312","","Other"
50446,"Protocol Status","In Development","31-JUL-1995","HIV RNA Threshold for Monitoring Change of HIV RNA","ACTG 312","26-SEP-1996","In Development"
50447,"Protocol Status","Concluded","01-FEB-2007","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","","Concluded"
50447,"Protocol Status","POS/PAC","19-DEC-2002","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","01-FEB-2007","POS/PAC"
50447,"Protocol Status","Closed to Follow Up","29-SEP-1998","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","19-DEC-2002","Closed to Follow Up"
50447,"Protocol Status","Closed to Accrual","13-MAR-1998","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","29-SEP-1998","Closed to Accrual"
50447,"Protocol Status","Open","23-DEC-1996","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","13-MAR-1998","Open"
50447,"Protocol Status","Pending","16-SEP-1996","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","23-DEC-1996","Pending"
50447,"Protocol Status","In Development","03-AUG-1995","Megestrol Acetate+Testosterone vs. Megestrol Acetate+Placebo in HIV-Wasting","ACTG 313","16-SEP-1996","In Development"
50448,"Protocol Status","Withdrawn","01-JUL-1998","Phase II Study of WR 6026 for PCP","ACTG 314","","Other"
50448,"Protocol Status","Closed to Follow Up","28-JAN-1998","Phase II Study of WR 6026 for PCP","ACTG 314","01-JUL-1998","Closed to Follow Up"
50448,"Protocol Status","Concluded","10-DEC-1997","Phase II Study of WR 6026 for PCP","ACTG 314","28-JAN-1998","Concluded"
50448,"Protocol Status","Closed to Accrual","10-DEC-1997","Phase II Study of WR 6026 for PCP","ACTG 314","10-DEC-1997","Closed to Accrual"
50448,"Protocol Status","Open","30-JAN-1997","Phase II Study of WR 6026 for PCP","ACTG 314","10-DEC-1997","Open"
50448,"Protocol Status","Pending","18-OCT-1996","Phase II Study of WR 6026 for PCP","ACTG 314","30-JAN-1997","Pending"
50448,"Protocol Status","In Development","03-AUG-1995","Phase II Study of WR 6026 for PCP","ACTG 314","18-OCT-1996","In Development"
50449,"Protocol Status","Concluded","01-JUL-2007","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","","Concluded"
50449,"Protocol Status","POS/PAC","30-OCT-1998","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","01-JUL-2007","POS/PAC"
50449,"Protocol Status","Closed to Follow Up","06-JAN-1998","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","30-OCT-1998","Closed to Follow Up"
50449,"Protocol Status","Closed to Accrual","22-NOV-1996","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","06-JAN-1998","Closed to Accrual"
50449,"Protocol Status","Open","05-MAR-1996","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","22-NOV-1996","Open"
50449,"Protocol Status","Pending","05-JAN-1996","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","05-MAR-1996","Pending"
50449,"Protocol Status","In Development","23-AUG-1995","Immune Consequences of RTV/ZDV/3TC in Moderately Advanced HIV-1 Disease","ACTG 315","05-JAN-1996","In Development"
50450,"Protocol Status","Concluded","11-SEP-2006","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","","Concluded"
50450,"Protocol Status","POS/PAC","28-OCT-2005","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","11-SEP-2006","POS/PAC"
50450,"Protocol Status","Closed to Accrual","31-JAN-2002","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","28-OCT-2005","Closed to Accrual"
50450,"Protocol Status","Closed to Follow Up","11-DEC-2001","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","31-JAN-2002","Closed to Follow Up"
50450,"Protocol Status","Open","20-JAN-1998","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","11-DEC-2001","Open"
50450,"Protocol Status","Pending","19-AUG-1997","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","20-JAN-1998","Pending"
50450,"Protocol Status","In Development","15-SEP-1995","Effects of Oral +Injectable Contraceptives +Gender on Plasma + Intracell ZDV PK","ACTG 317","19-AUG-1997","In Development"
50451,"Protocol Status","Concluded","01-AUG-2004","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","","Concluded"
50451,"Protocol Status","POS/PAC","03-JUN-1997","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","01-AUG-2004","POS/PAC"
50451,"Protocol Status","Closed to Follow Up","28-MAR-1997","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","03-JUN-1997","Closed to Follow Up"
50451,"Protocol Status","Closed to Accrual","20-FEB-1997","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","28-MAR-1997","Closed to Accrual"
50451,"Protocol Status","Open","26-JAN-1996","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","20-FEB-1997","Open"
50451,"Protocol Status","Pending","19-DEC-1995","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","26-JAN-1996","Pending"
50451,"Protocol Status","In Development","29-SEP-1995","IDV + ZDV or d4T + 3TC in HIV Infection w/CD4","ACTG 320","19-DEC-1995","In Development"
50452,"Protocol Status","Withdrawn","28-JAN-1997","Influence of Immune Activation on Viral Burden","ACTG 322","","Other"
50452,"Protocol Status","In Development","26-OCT-1995","Influence of Immune Activation on Viral Burden","ACTG 322","28-JAN-1997","In Development"
50453,"Protocol Status","Concluded","15-NOV-2005","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","","Concluded"
50453,"Protocol Status","POS/PAC","15-MAY-2002","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","15-NOV-2005","POS/PAC"
50453,"Protocol Status","Closed to Follow Up","29-JAN-2001","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","15-MAY-2002","Closed to Follow Up"
50453,"Protocol Status","Closed to Accrual","31-MAR-2000","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","29-JAN-2001","Closed to Accrual"
50453,"Protocol Status","Open","21-APR-1997","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","31-MAR-2000","Open"
50453,"Protocol Status","Pending","20-NOV-1996","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","21-APR-1997","Pending"
50453,"Protocol Status","In Development","26-OCT-1995","FLU as Chronic vs Episodic Tx for Recurrent OPC","ACTG 323","20-NOV-1996","In Development"
50454,"Protocol Status","Concluded","24-MAY-2002","Safety/Tolerance IL-12 In Subj with No Active OIs","ACTG 325","","Concluded"
50454,"Protocol Status","POS/PAC","08-JUN-2001","Safety/Tolerance IL-12 In Subj with No Active OIs","ACTG 325","24-MAY-2002","POS/PAC"
50454,"Protocol Status","Closed to Follow Up","05-JAN-2000","Safety/Tolerance IL-12 In Subj with No Active OIs","ACTG 325","08-JUN-2001","Closed to Follow Up"
50454,"Protocol Status","Closed to Accrual","24-NOV-1999","Safety/Tolerance IL-12 In Subj with No Active OIs","ACTG 325","05-JAN-2000","Closed to Accrual"
50454,"Protocol Status","Open","25-JUL-1996","Safety/Tolerance IL-12 In Subj with No Active OIs","ACTG 325","24-NOV-1999","Open"
50454,"Protocol Status","Pending","25-JUL-1996","Safety/Tolerance IL-12 In Subj with No Active OIs","ACTG 325","25-JUL-1996","Pending"
50455,"Protocol Status","Concluded","26-MAR-2007","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","","Concluded"
50455,"Protocol Status","POS/PAC","01-JUL-2002","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","26-MAR-2007","POS/PAC"
50455,"Protocol Status","Closed to Follow Up","22-JAN-2001","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","01-JUL-2002","Closed to Follow Up"
50455,"Protocol Status","Closed to Accrual","10-FEB-1999","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","22-JAN-2001","Closed to Accrual"
50455,"Protocol Status","Open","06-MAY-1997","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","10-FEB-1999","Open"
50455,"Protocol Status","Open","10-APR-1997","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","06-MAY-1997","Open"
50455,"Protocol Status","Pending","12-FEB-1997","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","10-APR-1997","Pending"
50455,"Protocol Status","In Development","15-JAN-1996","Intermittent rhIL-2 IV or SQ in Subjects w/HIV Infection on HAART or HAART Alone","ACTG 328","12-FEB-1997","In Development"
50456,"Protocol Status","Concluded","14-MAR-2005","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","","Concluded"
50456,"Protocol Status","Concluded","14-MAR-2005","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","14-MAR-2005","Concluded"
50456,"Protocol Status","POS/PAC","19-MAY-2003","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","14-MAR-2005","POS/PAC"
50456,"Protocol Status","POS/PAC","25-APR-2001","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","19-MAY-2003","POS/PAC"
50456,"Protocol Status","Closed to Follow Up","24-MAR-2000","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","25-APR-2001","Closed to Follow Up"
50456,"Protocol Status","Closed to Accrual","20-AUG-1999","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","24-MAR-2000","Closed to Accrual"
50456,"Protocol Status","Open","17-MAR-1997","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","20-AUG-1999","Open"
50456,"Protocol Status","Pending","16-SEP-1996","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","17-MAR-1997","Pending"
50456,"Protocol Status","In Development","29-JAN-1996","Nandrolone Decanoate in Women with HIV-Associated Weight Loss","ACTG 329","16-SEP-1996","In Development"
50457,"Protocol Status","Concluded","01-SEP-2000","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","","Concluded"
50457,"Protocol Status","POS/PAC","11-JUN-1999","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","01-SEP-2000","POS/PAC"
50457,"Protocol Status","Closed to Follow Up","20-AUG-1997","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","11-JUN-1999","Closed to Follow Up"
50457,"Protocol Status","Closed to Accrual","07-MAR-1997","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","20-AUG-1997","Closed to Accrual"
50457,"Protocol Status","Open","15-JUL-1996","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","07-MAR-1997","Open"
50457,"Protocol Status","Pending","31-MAY-1996","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","15-JUL-1996","Pending"
50457,"Protocol Status","In Development","15-MAR-1996","Anti-Viral Effect:  Saquinavir/Indinavir","ACTG 333","31-MAY-1996","In Development"
50458,"Protocol Status","Concluded","01-APR-2002","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","","Concluded"
50458,"Protocol Status","POS/PAC","04-MAY-2000","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","01-APR-2002","POS/PAC"
50458,"Protocol Status","Closed to Follow Up","16-JUN-1999","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","04-MAY-2000","Closed to Follow Up"
50458,"Protocol Status","Closed to Accrual","15-APR-1999","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","16-JUN-1999","Closed to Accrual"
50458,"Protocol Status","Open","25-JUN-1997","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","15-APR-1999","Open"
50458,"Protocol Status","Pending","06-DEC-1996","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","25-JUN-1997","Pending"
50458,"Protocol Status","In Development","22-MAR-1996","Cyclosporine Effect on Immune Activation & HIV Expression in Early HIV Disease","ACTG 334","06-DEC-1996","In Development"
50459,"Protocol Status","POS/PAC","06-NOV-2000","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","","POS/PAC"
50459,"Protocol Status","Concluded","01-SEP-1998","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","06-NOV-2000","Concluded"
50459,"Protocol Status","Closed to Follow Up","23-MAY-1998","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","01-SEP-1998","Closed to Follow Up"
50459,"Protocol Status","Closed to Accrual","15-MAY-1998","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","23-MAY-1998","Closed to Accrual"
50459,"Protocol Status","Open","30-JAN-1997","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","15-MAY-1998","Open"
50459,"Protocol Status","Pending","28-OCT-1996","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","30-JAN-1997","Pending"
50459,"Protocol Status","In Development","10-APR-1996","Nitazoxanide in Patients with Cryptosporidiosis","ACTG 336","28-OCT-1996","In Development"
50460,"Protocol Status","Withdrawn","25-JUN-1996","PK and PD of Saquinavir and Ritonavir","ACTG 337","","Other"
50460,"Protocol Status","In Development","02-MAY-1996","PK and PD of Saquinavir and Ritonavir","ACTG 337","25-JUN-1996","In Development"
50461,"Protocol Status","Withdrawn","23-APR-1997","Viral Turnover:  Response to Lymphocyte Activation","ACTG 340","","Other"
50461,"Protocol Status","Open","09-JAN-1997","Viral Turnover:  Response to Lymphocyte Activation","ACTG 340","23-APR-1997","Open"
50461,"Protocol Status","Pending","12-NOV-1996","Viral Turnover:  Response to Lymphocyte Activation","ACTG 340","09-JAN-1997","Pending"
50461,"Protocol Status","In Development","12-JUN-1996","Viral Turnover:  Response to Lymphocyte Activation","ACTG 340","12-NOV-1996","In Development"
50462,"Protocol Status","Concluded","01-AUG-2005","Natural History & Pathogenesis of MAC Disease","ACTG 341","","Concluded"
50462,"Protocol Status","POS/PAC","17-AUG-2001","Natural History & Pathogenesis of MAC Disease","ACTG 341","01-AUG-2005","POS/PAC"
50462,"Protocol Status","Closed to Follow Up","22-MAR-2001","Natural History & Pathogenesis of MAC Disease","ACTG 341","17-AUG-2001","Closed to Follow Up"
50462,"Protocol Status","Closed to Accrual","19-MAR-2000","Natural History & Pathogenesis of MAC Disease","ACTG 341","22-MAR-2001","Closed to Accrual"
50462,"Protocol Status","Open","30-JAN-1998","Natural History & Pathogenesis of MAC Disease","ACTG 341","19-MAR-2000","Open"
50462,"Protocol Status","Pending","21-OCT-1997","Natural History & Pathogenesis of MAC Disease","ACTG 341","30-JAN-1998","Pending"
50463,"Protocol Status","Withdrawn","06-OCT-1997","Observational Study of CMV Antiviral Resistance","ACTG 342","","Other"
50463,"Protocol Status","Deferred","16-SEP-1997","Observational Study of CMV Antiviral Resistance","ACTG 342","06-OCT-1997","Other"
50463,"Protocol Status","In Development","25-JUL-1996","Observational Study of CMV Antiviral Resistance","ACTG 342","16-SEP-1997","In Development"
50464,"Protocol Status","Concluded","15-AUG-2002","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","","Concluded"
50464,"Protocol Status","Closed to Follow Up","19-FEB-1999","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","15-AUG-2002","Closed to Follow Up"
50464,"Protocol Status","POS/PAC","05-DEC-1997","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","19-FEB-1999","POS/PAC"
50464,"Protocol Status","Closed to Accrual","01-MAY-1997","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","05-DEC-1997","Closed to Accrual"
50464,"Protocol Status","Open","19-FEB-1997","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","01-MAY-1997","Open"
50464,"Protocol Status","Pending","02-JAN-1997","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","19-FEB-1997","Pending"
50464,"Protocol Status","In Development","25-JUL-1996","Three Maintenance Regimens for HIV Infected Patients Receiving ZDV, 3TC, and IDV","ACTG 343","02-JAN-1997","In Development"
50465,"Protocol Status","Withdrawn","15-APR-1998","HIV Inhibition in Pts w/High CD4 & Low Viral Load","ACTG 344","","Other"
50465,"Protocol Status","In Development","31-JUL-1996","HIV Inhibition in Pts w/High CD4 & Low Viral Load","ACTG 344","15-APR-1998","In Development"
50466,"Protocol Status","Withdrawn","07-NOV-1996","IL-2 in Combo w/HAART (Indinavir+ZDV+3TC)","ACTG 346","","Other"
50466,"Protocol Status","In Development","16-AUG-1996","IL-2 in Combo w/HAART (Indinavir+ZDV+3TC)","ACTG 346","07-NOV-1996","In Development"
50467,"Protocol Status","Concluded","01-MAY-2000","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","","Concluded"
50467,"Protocol Status","Closed to Follow Up","25-SEP-1998","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","01-MAY-2000","Closed to Follow Up"
50467,"Protocol Status","POS/PAC","24-SEP-1998","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","25-SEP-1998","POS/PAC"
50467,"Protocol Status","Closed to Accrual","25-JUN-1997","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","24-SEP-1998","Closed to Accrual"
50467,"Protocol Status","Open","24-FEB-1997","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","25-JUN-1997","Open"
50467,"Protocol Status","Pending","18-DEC-1996","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","24-FEB-1997","Pending"
50467,"Protocol Status","In Development","15-AUG-1996","Phase II of VX-478 Monotherapy vs VX-478 plus ZDV+3TC in HIV Infected Individual","ACTG 347","18-DEC-1996","In Development"
50468,"Protocol Status","Withdrawn","10-APR-1997","Imm Consequences of HAART--ZDV+3TC+IDV in LTNPs","ACTG 348","","Other"
50468,"Protocol Status","In Development","30-AUG-1996","Imm Consequences of HAART--ZDV+3TC+IDV in LTNPs","ACTG 348","10-APR-1997","In Development"
50469,"Protocol Status","Concluded","01-MAR-2003","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","","Concluded"
50469,"Protocol Status","POS/PAC","10-JUN-2002","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","01-MAR-2003","POS/PAC"
50469,"Protocol Status","Closed to Follow Up","29-AUG-2001","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","10-JUN-2002","Closed to Follow Up"
50469,"Protocol Status","Closed to Accrual","04-APR-2000","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","29-AUG-2001","Closed to Accrual"
50469,"Protocol Status","Temporarily Closed","03-DEC-1999","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","04-APR-2000","Other"
50469,"Protocol Status","Open","12-FEB-1999","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","03-DEC-1999","Open"
50469,"Protocol Status","Pending","09-DEC-1998","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","12-FEB-1999","Pending"
50469,"Protocol Status","In Development","30-AUG-1996","Immunologic and Virologic Effects of Prednisone on HIV Infection","ACTG 349","09-DEC-1998","In Development"
50470,"Protocol Status","Concluded","30-JUN-2000","Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","ACTG 350","","Concluded"
50470,"Protocol Status","Closed to Accrual","28-APR-2000","Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","ACTG 350","30-JUN-2000","Closed to Accrual"
50470,"Protocol Status","Closed to Follow Up","07-JAN-2000","Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","ACTG 350","28-APR-2000","Closed to Follow Up"
50470,"Protocol Status","Open","20-APR-1997","Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","ACTG 350","07-JAN-2000","Open"
50470,"Protocol Status","Pending","14-APR-1997","Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","ACTG 350","20-APR-1997","Pending"
50470,"Protocol Status","In Development","25-AUG-1996","Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","ACTG 350","14-APR-1997","In Development"
50471,"Protocol Status","Withdrawn","15-MAR-1997","Strategic Timing of Antiretroviral Rx Trial-START","ACTG 355","","Other"
50471,"Protocol Status","In Development","11-OCT-1996","Strategic Timing of Antiretroviral Rx Trial-START","ACTG 355","15-MAR-1997","In Development"
50472,"Protocol Status","Concluded","22-APR-2008","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","","Concluded"
50472,"Protocol Status","Closed to Follow Up","07-OCT-1999","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","22-APR-2008","Closed to Follow Up"
50472,"Protocol Status","POS/PAC","27-AUG-1999","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","07-OCT-1999","POS/PAC"
50472,"Protocol Status","Closed to Accrual","02-OCT-1998","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","27-AUG-1999","Closed to Accrual"
50472,"Protocol Status","Open","26-AUG-1997","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","02-OCT-1998","Open"
50472,"Protocol Status","Pending","25-JUN-1997","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","26-AUG-1997","Pending"
50472,"Protocol Status","In Development","22-NOV-1996","Soft Gelatin SQV + RTV or NFV + DLV +/- Adefovir Dipivoxil in HIV Infection","ACTG 359","25-JUN-1997","In Development"
50473,"Protocol Status","Concluded","15-FEB-2006","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","","Concluded"
50473,"Protocol Status","POS/PAC","01-FEB-2002","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","15-FEB-2006","POS/PAC"
50473,"Protocol Status","Closed to Follow Up","20-FEB-2001","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","01-FEB-2002","Closed to Follow Up"
50473,"Protocol Status","Closed to Accrual","29-DEC-1997","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","20-FEB-2001","Closed to Accrual"
50473,"Protocol Status","Open","13-AUG-1997","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","29-DEC-1997","Open"
50473,"Protocol Status","Pending","06-JUN-1997","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","13-AUG-1997","Pending"
50473,"Protocol Status","In Development","04-DEC-1996","HIV and CMV Viral Burden and Development of CMV End-Organ Disease","ACTG 360","06-JUN-1997","In Development"
50474,"Protocol Status","Withdrawn","20-SEP-1999","Lobucavir Peripheral CMV Retinitis Trial (LPCRT)","ACTG 361","","Other"
50474,"Protocol Status","In Development","04-DEC-1996","Lobucavir Peripheral CMV Retinitis Trial (LPCRT)","ACTG 361","20-SEP-1999","In Development"
50475,"Protocol Status","Concluded","11-MAY-2011","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","","Concluded"
50475,"Protocol Status","POS/PAC","03-APR-2007","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","11-MAY-2011","POS/PAC"
50475,"Protocol Status","Closed to Follow Up","01-APR-2007","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","03-APR-2007","Closed to Follow Up"
50475,"Protocol Status","Closed to Accrual","30-APR-1999","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","01-APR-2007","Closed to Accrual"
50475,"Protocol Status","Open","09-OCT-1997","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","30-APR-1999","Open"
50475,"Protocol Status","Pending","30-JUN-1997","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","09-OCT-1997","Pending"
50475,"Protocol Status","In Development","11-DEC-1996","Metabolic, Cardio, & Neuro Complications in HIV w/Past CD4100 on HAART","ACTG 362","30-JUN-1997","In Development"
50476,"Protocol Status","Concluded","12-SEP-2008","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","","Concluded"
50476,"Protocol Status","Concluded","06-SEP-2002","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","12-SEP-2008","Concluded"
50476,"Protocol Status","POS/PAC","23-MAR-2001","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","06-SEP-2002","POS/PAC"
50476,"Protocol Status","Closed to Follow Up","05-MAY-2000","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","23-MAR-2001","Closed to Follow Up"
50476,"Protocol Status","Closed to Accrual","16-DEC-1999","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","05-MAY-2000","Closed to Accrual"
50476,"Protocol Status","Open","03-MAR-1998","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","16-DEC-1999","Open"
50476,"Protocol Status","Pending","09-DEC-1997","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","03-MAR-1998","Pending"
50476,"Protocol Status","In Development","12-DEC-1996","Cidofovir For  Treatment of Progressive Multifocal Leukoencephalopathy","ACTG 363","09-DEC-1997","In Development"
50477,"Protocol Status","Concluded","01-DEC-2006","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","","Concluded"
50477,"Protocol Status","POS/PAC","28-JUL-2000","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","01-DEC-2006","POS/PAC"
50477,"Protocol Status","Closed to Follow Up","27-JUL-2000","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","28-JUL-2000","Closed to Follow Up"
50477,"Protocol Status","Closed to Accrual","12-SEP-1997","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","27-JUL-2000","Closed to Accrual"
50477,"Protocol Status","Open","14-JUL-1997","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","12-SEP-1997","Open"
50477,"Protocol Status","Pending","22-MAY-1997","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","14-JUL-1997","Pending"
50477,"Protocol Status","In Development","12-DEC-1996","Virologic Efficacy of NFV and/or EFV + 1 or 2 Nucleosides","ACTG 364","22-MAY-1997","In Development"
50478,"Protocol Status","Concluded","01-MAR-2003","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","","Concluded"
50478,"Protocol Status","POS/PAC","04-OCT-2000","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","01-MAR-2003","POS/PAC"
50478,"Protocol Status","Closed to Follow Up","03-JUN-1999","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","04-OCT-2000","Closed to Follow Up"
50478,"Protocol Status","Closed to Accrual","01-JUN-1999","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","03-JUN-1999","Closed to Accrual"
50478,"Protocol Status","Open","15-OCT-1997","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","01-JUN-1999","Open"
50478,"Protocol Status","Pending","22-MAY-1997","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","15-OCT-1997","Pending"
50478,"Protocol Status","In Development","16-DEC-1996","Pharmacokinetic Study of Indinavir and Rifabutin","ACTG 365","22-MAY-1997","In Development"
50479,"Protocol Status","Concluded","01-JAN-2008","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","","Concluded"
50479,"Protocol Status","POS/PAC","02-SEP-1999","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","01-JAN-2008","POS/PAC"
50479,"Protocol Status","Closed to Follow Up","26-AUG-1999","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","02-SEP-1999","Closed to Follow Up"
50479,"Protocol Status","Closed to Accrual","13-MAR-1998","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","26-AUG-1999","Closed to Accrual"
50479,"Protocol Status","Open","22-APR-1997","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","13-MAR-1998","Open"
50479,"Protocol Status","Pending","05-MAR-1997","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","22-APR-1997","Pending"
50479,"Protocol Status","In Development","24-FEB-1997","ABC + IDV and EFV in HIV-Infected Subjects w/NRTI Experience","ACTG 368","05-MAR-1997","In Development"
50480,"Protocol Status","Concluded","20-APR-2004","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","","Concluded"
50480,"Protocol Status","Closed to Follow Up","01-NOV-1999","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","20-APR-2004","Closed to Follow Up"
50480,"Protocol Status","POS/PAC","04-MAY-1999","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","01-NOV-1999","POS/PAC"
50480,"Protocol Status","Closed to Accrual","31-DEC-1997","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","04-MAY-1999","Closed to Accrual"
50480,"Protocol Status","Open","19-AUG-1997","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","31-DEC-1997","Open"
50480,"Protocol Status","Pending","25-JUN-1997","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","19-AUG-1997","Pending"
50480,"Protocol Status","In Development","04-MAR-1997","Activity of 3TC vs Delavirdine (DLV)+IDV & ZDV or d4T in 3TC-Experience Patients","ACTG 370","25-JUN-1997","In Development"
50481,"Protocol Status","Concluded","16-DEC-2011","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","","Concluded"
50481,"Protocol Status","POS/PAC","30-JUL-2008","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","16-DEC-2011","POS/PAC"
50481,"Protocol Status","Closed to Follow Up","01-OCT-2006","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","30-JUL-2008","Closed to Follow Up"
50481,"Protocol Status","Closed to Accrual","10-SEP-2003","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","01-OCT-2006","Closed to Accrual"
50481,"Protocol Status","Open","11-MAY-1999","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","10-SEP-2003","Open"
50481,"Protocol Status","Pending","05-APR-1999","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","11-MAY-1999","Pending"
50481,"Protocol Status","In Development","28-MAR-1997","Safety/Efficacy of Induction Tx w/3TC+d4T+ABC+APV/RTV + STI in Acute Infection","ACTG 371","05-APR-1999","In Development"
50482,"Protocol Status","POS/PAC","25-JUN-2003","Prolongation of Virologic Success/Option for Failure in Subj Receiving IDV+NRTIs","ACTG 372","","POS/PAC"
50482,"Protocol Status","Closed to Follow Up","31-MAR-2003","Prolongation of Virologic Success/Option for Failure in Subj Receiving IDV+NRTIs","ACTG 372","25-JUN-2003","Closed to Follow Up"
50482,"Protocol Status","Closed to Accrual","06-MAY-1998","Prolongation of Virologic Success/Option for Failure in Subj Receiving IDV+NRTIs","ACTG 372","31-MAR-2003","Closed to Accrual"
50482,"Protocol Status","Open","26-SEP-1997","Prolongation of Virologic Success/Option for Failure in Subj Receiving IDV+NRTIs","ACTG 372","06-MAY-1998","Open"
50482,"Protocol Status","Pending","25-JUL-1997","Prolongation of Virologic Success/Option for Failure in Subj Receiving IDV+NRTIs","ACTG 372","26-SEP-1997","Pending"
50482,"Protocol Status","In Development","10-APR-1997","Prolongation of Virologic Success/Option for Failure in Subj Receiving IDV+NRTIs","ACTG 372","25-JUL-1997","In Development"
50483,"Protocol Status","Concluded","01-MAR-2001","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","","Concluded"
50483,"Protocol Status","POS/PAC","28-JUL-2000","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","01-MAR-2001","POS/PAC"
50483,"Protocol Status","Closed to Follow Up","28-JUL-2000","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","28-JUL-2000","Closed to Follow Up"
50483,"Protocol Status","Closed to Accrual","18-OCT-1999","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","28-JUL-2000","Closed to Accrual"
50483,"Protocol Status","Closed to Accrual","04-OCT-1999","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","18-OCT-1999","Closed to Accrual"
50483,"Protocol Status","Closed to Accrual","15-OCT-1998","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","04-OCT-1999","Closed to Accrual"
50483,"Protocol Status","Open","06-OCT-1997","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","15-OCT-1998","Open"
50483,"Protocol Status","Pending","25-JUL-1997","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","06-OCT-1997","Pending"
50483,"Protocol Status","In Development","14-APR-1997","APV+3TC+ZDV(or d4T) vs.IDV+NVP+3TC+d4T vs.Other Tx with Previously APV Tx","ACTG 373","25-JUL-1997","In Development"
50484,"Protocol Status","Withdrawn","10-APR-1998","Protease Inhibitors in Combo with ZDV/3TC","ACTG 374","","Other"
50484,"Protocol Status","Pending","02-FEB-1998","Protease Inhibitors in Combo with ZDV/3TC","ACTG 374","10-APR-1998","Pending"
50484,"Protocol Status","In Development","15-APR-1997","Protease Inhibitors in Combo with ZDV/3TC","ACTG 374","02-FEB-1998","In Development"
50485,"Protocol Status","POS/PAC","06-MAY-2004","Immune & Viral Consequences of Long-Term HAART","ACTG 375","","POS/PAC"
50485,"Protocol Status","Closed to Follow Up","23-JUL-2002","Immune & Viral Consequences of Long-Term HAART","ACTG 375","06-MAY-2004","Closed to Follow Up"
50485,"Protocol Status","Closed to Accrual","27-FEB-1998","Immune & Viral Consequences of Long-Term HAART","ACTG 375","23-JUL-2002","Closed to Accrual"
50485,"Protocol Status","Open","09-OCT-1997","Immune & Viral Consequences of Long-Term HAART","ACTG 375","27-FEB-1998","Open"
50485,"Protocol Status","Pending","14-AUG-1997","Immune & Viral Consequences of Long-Term HAART","ACTG 375","09-OCT-1997","Pending"
50485,"Protocol Status","In Development","25-APR-1997","Immune & Viral Consequences of Long-Term HAART","ACTG 375","14-AUG-1997","In Development"
50486,"Protocol Status","Concluded","01-MAY-2003","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","","Concluded"
50486,"Protocol Status","POS/PAC","15-MAY-2000","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","01-MAY-2003","POS/PAC"
50486,"Protocol Status","Closed to Accrual","12-OCT-1998","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","15-MAY-2000","Closed to Accrual"
50486,"Protocol Status","Closed to Follow Up","02-OCT-1998","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","12-OCT-1998","Closed to Follow Up"
50486,"Protocol Status","Open","29-MAY-1998","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","02-OCT-1998","Open"
50486,"Protocol Status","Pending","06-FEB-1998","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","29-MAY-1998","Pending"
50486,"Protocol Status","In Development","16-JUL-1997","Effect of Staggered Dosing of Protease Inhibitors on PK","ACTG 378","06-FEB-1998","In Development"
50487,"Protocol Status","Concluded","15-MAY-2005","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","","Concluded"
50487,"Protocol Status","POS/PAC","18-MAR-2003","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","15-MAY-2005","POS/PAC"
50487,"Protocol Status","Closed to Follow Up","01-JAN-2001","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","18-MAR-2003","Closed to Follow Up"
50487,"Protocol Status","Closed to Accrual","01-MAY-2000","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","01-JAN-2001","Closed to Accrual"
50487,"Protocol Status","Open","13-AUG-1998","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","01-MAY-2000","Open"
50487,"Protocol Status","Pending","02-JUN-1998","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","13-AUG-1998","Pending"
50487,"Protocol Status","In Development","23-JUL-1997","Safety, Virology, Immunology of D/C Maintenance Tx for CMV Retinitis after HAART","ACTG 379","02-JUN-1998","In Development"
50488,"Protocol Status","Concluded","20-MAY-2002","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","","Concluded"
50488,"Protocol Status","POS/PAC","25-OCT-2001","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","20-MAY-2002","POS/PAC"
50488,"Protocol Status","Closed to Follow Up","14-FEB-2001","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","25-OCT-2001","Closed to Follow Up"
50488,"Protocol Status","Closed to Accrual","15-FEB-2000","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","14-FEB-2001","Closed to Accrual"
50488,"Protocol Status","Open","01-APR-1998","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","15-FEB-2000","Open"
50488,"Protocol Status","Pending","10-FEB-1998","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","01-APR-1998","Pending"
50488,"Protocol Status","In Development","23-JUL-1997","Effect of Combined Cytoreductive Chemotherapy","ACTG 380","10-FEB-1998","In Development"
50489,"Protocol Status","Concluded","15-APR-2004","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","","Concluded"
50489,"Protocol Status","POS/PAC","21-SEP-2001","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","15-APR-2004","POS/PAC"
50489,"Protocol Status","Closed to Follow Up","26-OCT-2000","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","21-SEP-2001","Closed to Follow Up"
50489,"Protocol Status","Closed to Accrual","11-AUG-2000","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","26-OCT-2000","Closed to Accrual"
50489,"Protocol Status","Open","16-APR-1998","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","11-AUG-2000","Open"
50489,"Protocol Status","Pending","12-FEB-1998","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","16-APR-1998","Pending"
50489,"Protocol Status","In Development","26-AUG-1997","Dynamics of Hepatitis C Infection in Subjects with HCV/HIV Receiving HAART","ACTG 383","12-FEB-1998","In Development"
50490,"Protocol Status","POS/PAC","30-NOV-2002","PI +/- NNRTI with Dual Nucleosides in Initial Therapy of HIV Infection","ACTG 384","","POS/PAC"
50490,"Protocol Status","Closed to Follow Up","08-FEB-2002","PI +/- NNRTI with Dual Nucleosides in Initial Therapy of HIV Infection","ACTG 384","30-NOV-2002","Closed to Follow Up"
50490,"Protocol Status","Closed to Accrual","30-NOV-1999","PI +/- NNRTI with Dual Nucleosides in Initial Therapy of HIV Infection","ACTG 384","08-FEB-2002","Closed to Accrual"
50490,"Protocol Status","Open","08-OCT-1998","PI +/- NNRTI with Dual Nucleosides in Initial Therapy of HIV Infection","ACTG 384","30-NOV-1999","Open"
50490,"Protocol Status","Pending","27-AUG-1998","PI +/- NNRTI with Dual Nucleosides in Initial Therapy of HIV Infection","ACTG 384","08-OCT-1998","Pending"
50490,"Protocol Status","In Development","28-AUG-1997","PI +/- NNRTI with Dual Nucleosides in Initial Therapy of HIV Infection","ACTG 384","27-AUG-1998","In Development"
50491,"Protocol Status","Concluded","30-OCT-2000","Effect of 4 drugs + GM-CSF or IL-12 on viral decay","ACTG 387","","Concluded"
50491,"Protocol Status","Closed to Accrual","01-DEC-1999","Effect of 4 drugs + GM-CSF or IL-12 on viral decay","ACTG 387","30-OCT-2000","Closed to Accrual"
50491,"Protocol Status","Closed to Follow Up","24-NOV-1999","Effect of 4 drugs + GM-CSF or IL-12 on viral decay","ACTG 387","01-DEC-1999","Closed to Follow Up"
50491,"Protocol Status","Open","17-MAR-1998","Effect of 4 drugs + GM-CSF or IL-12 on viral decay","ACTG 387","24-NOV-1999","Open"
50491,"Protocol Status","Pending","24-NOV-1997","Effect of 4 drugs + GM-CSF or IL-12 on viral decay","ACTG 387","17-MAR-1998","Pending"
50491,"Protocol Status","In Development","23-SEP-1997","Effect of 4 drugs + GM-CSF or IL-12 on viral decay","ACTG 387","24-NOV-1997","In Development"
50492,"Protocol Status","Concluded","15-OCT-2005","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","","Concluded"
50492,"Protocol Status","Closed to Follow Up","02-OCT-2001","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","15-OCT-2005","Closed to Follow Up"
50492,"Protocol Status","POS/PAC","10-JUL-2001","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","02-OCT-2001","POS/PAC"
50492,"Protocol Status","Closed to Accrual","08-JAN-1999","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","10-JUL-2001","Closed to Accrual"
50492,"Protocol Status","Open","01-JUN-1998","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","08-JAN-1999","Open"
50492,"Protocol Status","Pending","20-APR-1998","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","01-JUN-1998","Pending"
50492,"Protocol Status","In Development","21-OCT-1997","EFV or NFV + Fixed-Dose Combination 3TC/ZDV + IDV","ACTG 388","20-APR-1998","In Development"
50493,"Protocol Status","Concluded","01-NOV-2008","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","","Concluded"
50493,"Protocol Status","POS/PAC","10-JUN-2003","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","01-NOV-2008","POS/PAC"
50493,"Protocol Status","POS/PAC","31-MAY-2001","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","10-JUN-2003","POS/PAC"
50493,"Protocol Status","Closed to Follow Up","02-MAR-2000","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","31-MAY-2001","Closed to Follow Up"
50493,"Protocol Status","Closed to Accrual","14-DEC-1999","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","02-MAR-2000","Closed to Accrual"
50493,"Protocol Status","Open","29-APR-1999","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","14-DEC-1999","Open"
50493,"Protocol Status","Pending","19-FEB-1999","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","29-APR-1999","Pending"
50493,"Protocol Status","In Development","03-DEC-1998","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","19-FEB-1999","In Development"
50493,"Protocol Status","In Development","03-DEC-1997","High Protein Supplementation in HIV-1-Positive Subjects with Stable Weight Loss","ACTG 392","03-DEC-1998","In Development"
50494,"Protocol Status","Concluded","15-APR-2003","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","","Concluded"
50494,"Protocol Status","POS/PAC","03-OCT-2001","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","15-APR-2003","POS/PAC"
50494,"Protocol Status","Closed to Follow Up","02-APR-2001","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","03-OCT-2001","Closed to Follow Up"
50494,"Protocol Status","Closed to Accrual","29-SEP-2000","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","02-APR-2001","Closed to Accrual"
50494,"Protocol Status","Open","27-AUG-1998","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","29-SEP-2000","Open"
50494,"Protocol Status","Pending","18-JUN-1998","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","27-AUG-1998","Pending"
50494,"Protocol Status","In Development","11-DEC-1997","Discontinuing Maintenance Therapy in Subjects with Disseminated MAC","ACTG 393","18-JUN-1998","In Development"
50495,"Protocol Status","Withdrawn","02-MAR-1998","ALLRT Protocol","ACTG 396","","Other"
50495,"Protocol Status","In Development","21-JAN-1998","ALLRT Protocol","ACTG 396","02-MAR-1998","In Development"
50496,"Protocol Status","POS/PAC","01-MAY-2000","APV+ABC/EFV/Adefovir vs. APV Alone in PI-Experienced Subjects with Viral Failure","ACTG 398","","POS/PAC"
50496,"Protocol Status","Closed to Follow Up","03-APR-2000","APV+ABC/EFV/Adefovir vs. APV Alone in PI-Experienced Subjects with Viral Failure","ACTG 398","01-MAY-2000","Closed to Follow Up"
50496,"Protocol Status","Closed to Accrual","09-APR-1999","APV+ABC/EFV/Adefovir vs. APV Alone in PI-Experienced Subjects with Viral Failure","ACTG 398","03-APR-2000","Closed to Accrual"
50496,"Protocol Status","Open","13-OCT-1998","APV+ABC/EFV/Adefovir vs. APV Alone in PI-Experienced Subjects with Viral Failure","ACTG 398","09-APR-1999","Open"
50496,"Protocol Status","Pending","11-AUG-1998","APV+ABC/EFV/Adefovir vs. APV Alone in PI-Experienced Subjects with Viral Failure","ACTG 398","13-OCT-1998","Pending"
50496,"Protocol Status","In Development","26-JAN-1998","APV+ABC/EFV/Adefovir vs. APV Alone in PI-Experienced Subjects with Viral Failure","ACTG 398","11-AUG-1998","In Development"
50497,"Protocol Status","Withdrawn","24-MAR-1998","PK & Viral Effects of Various RTV doses on SQV PK","ACTG 399","","Other"
50497,"Protocol Status","In Development","28-JAN-1998","PK & Viral Effects of Various RTV doses on SQV PK","ACTG 399","24-MAR-1998","In Development"
50498,"Protocol Status","Concluded","27-FEB-2002","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","","Concluded"
50498,"Protocol Status","Closed to Follow Up","10-MAY-2000","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","27-FEB-2002","Closed to Follow Up"
50498,"Protocol Status","Closed to Accrual","19-NOV-1999","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","10-MAY-2000","Closed to Accrual"
50498,"Protocol Status","Open","16-NOV-1998","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","19-NOV-1999","Open"
50498,"Protocol Status","Pending","12-NOV-1998","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","16-NOV-1998","Pending"
50498,"Protocol Status","Pending","24-AUG-1998","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","12-NOV-1998","Pending"
50498,"Protocol Status","In Development","28-JAN-1998","Salvage Therapies for Nelfinavir Treatment Failures","ACTG 400","24-AUG-1998","In Development"
50499,"Protocol Status","Concluded","01-JUN-2001","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","","Concluded"
50499,"Protocol Status","POS/PAC","26-SEP-2000","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","01-JUN-2001","POS/PAC"
50499,"Protocol Status","Closed to Follow Up","23-SEP-1999","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","26-SEP-2000","Closed to Follow Up"
50499,"Protocol Status","Closed to Accrual","25-AUG-1999","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","23-SEP-1999","Closed to Accrual"
50499,"Protocol Status","Open","05-FEB-1999","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","25-AUG-1999","Open"
50499,"Protocol Status","Pending","26-JUN-1998","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","05-FEB-1999","Pending"
50499,"Protocol Status","In Development","29-JAN-1998","Effect of PIs on Stereospecific Metabolism of Methadone in HIV Infected Subjects","ACTG 401","26-JUN-1998","In Development"
50500,"Protocol Status","Concluded","01-SEP-2008","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","","Concluded"
50500,"Protocol Status","POS/PAC","22-FEB-2002","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","01-SEP-2008","POS/PAC"
50500,"Protocol Status","Closed to Follow Up","22-APR-2000","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","22-FEB-2002","Closed to Follow Up"
50500,"Protocol Status","Closed to Accrual","30-DEC-1999","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","22-APR-2000","Closed to Accrual"
50500,"Protocol Status","Open","27-JAN-1998","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","30-DEC-1999","Open"
50500,"Protocol Status","Pending","07-NOV-1997","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","27-JAN-1998","Pending"
50500,"Protocol Status","In Development","09-APR-1997","InVivo Proton Magnetic Resonance Spectroscopy of Cerebral Injury in HIV Dementia","ACTG 700","07-NOV-1997","In Development"
50501,"Protocol Status","Closed to Follow Up","31-MAR-2003","ACTG 372 Tissue Compart./Vir Subst. (Group A only)","ACTG 701","","Closed to Follow Up"
50502,"Protocol Status","Closed to Follow Up","31-MAR-2003","Virology Substudy of ACTG 372 (Group A subjects)","ACTG 702","","Closed to Follow Up"
50503,"Protocol Status","Closed to Follow Up","30-MAR-1999","Virology Substudy of ACTG 372 (Group B&D subjects)","ACTG 703","","Closed to Follow Up"
50504,"Protocol Status","Closed to Follow Up","28-JUL-2000","CSF Substudy of ACTG 373","ACTG 704","","Closed to Follow Up"
50505,"Protocol Status","Closed to Follow Up","28-JUL-2000","Genital Secretions Substudy of ACTG 373","ACTG 705","","Closed to Follow Up"
50506,"Protocol Status","Closed to Follow Up","06-JAN-1998","PK/PD Substudy of ACTG 372 (Groups A&B only)","ACTG 706","","Closed to Follow Up"
50508,"Protocol Status","Concluded","01-SEP-2011","Immunology Substudy of ACTG 371","ACTG 709","","Concluded"
50508,"Protocol Status","Closed to Follow Up","18-APR-2006","Immunology Substudy of ACTG 371","ACTG 709","01-SEP-2011","Closed to Follow Up"
50509,"Protocol Status","Closed to Follow Up","22-SEP-2006","Compartment Substudy of ACTG 371","ACTG 710","","Closed to Follow Up"
50510,"Protocol Status","Closed to Follow Up","12-SEP-2000","Pharmacology Substudy of ACTG 371","ACTG 711","","Closed to Follow Up"
50518,"Protocol Status","Closed to Follow Up","30-NOV-1998","Lymphoid Tissue Substudy of ACTG 343","ACTG 719","","Closed to Follow Up"
50521,"Protocol Status","Closed to Follow Up","24-JAN-2001","Evaluating the Predictive Value of Viral Load (VL)","ACTG 722","","Closed to Follow Up"
50522,"Protocol Status","Concluded","02-OCT-2009","ART Effect on Viral Burden & Immune Function in the Lungs","ACTG 723","","Concluded"
50522,"Protocol Status","POS/PAC","15-APR-2006","ART Effect on Viral Burden & Immune Function in the Lungs","ACTG 723","02-OCT-2009","POS/PAC"
50522,"Protocol Status","Closed to Follow Up","15-APR-2003","ART Effect on Viral Burden & Immune Function in the Lungs","ACTG 723","15-APR-2006","Closed to Follow Up"
50522,"Protocol Status","Closed to Accrual","05-NOV-2002","ART Effect on Viral Burden & Immune Function in the Lungs","ACTG 723","15-APR-2003","Closed to Accrual"
50522,"Protocol Status","Open","17-AUG-1999","ART Effect on Viral Burden & Immune Function in the Lungs","ACTG 723","05-NOV-2002","Open"
50522,"Protocol Status","In Development","15-JUL-1997","ART Effect on Viral Burden & Immune Function in the Lungs","ACTG 723","17-AUG-1999","In Development"
50524,"Protocol Status","Closed to Follow Up","19-NOV-2002","Medication Compliance Substudy of ACTG 371","ACTG 729","","Closed to Follow Up"
50526,"Protocol Status","Closed to Follow Up","24-MAY-2000","Limited Adherence Substudy of ACTG 384","ACTG 731","","Closed to Follow Up"
50527,"Protocol Status","Closed to Follow Up","14-AUG-2001","Compartmental Substudy of ACTG 388","ACTG 732","","Closed to Follow Up"
50528,"Protocol Status","Closed to Follow Up","01-MAY-1999","PK Substudy of ACTG 388","ACTG 733","","Closed to Follow Up"
50529,"Protocol Status","Closed to Follow Up","06-JUN-2000","Treatment Failures Substudy","ACTG 734","","Closed to Follow Up"
50530,"Protocol Status","Closed to Follow Up","30-MAY-2001","Viral Dynamics Substudy of ACTG 388","ACTG 735","","Closed to Follow Up"
50531,"Protocol Status","Concluded","11-MAY-2011","Cerebrospinal Fluid HIV & Cognitive Function in Individuals Receiving ART","ACTG 736","","Concluded"
50531,"Protocol Status","POS/PAC","13-NOV-2007","Cerebrospinal Fluid HIV & Cognitive Function in Individuals Receiving ART","ACTG 736","11-MAY-2011","POS/PAC"
50531,"Protocol Status","Closed to Follow Up","12-JUL-2005","Cerebrospinal Fluid HIV & Cognitive Function in Individuals Receiving ART","ACTG 736","13-NOV-2007","Closed to Follow Up"
50531,"Protocol Status","Closed to Accrual","18-JUN-2004","Cerebrospinal Fluid HIV & Cognitive Function in Individuals Receiving ART","ACTG 736","12-JUL-2005","Closed to Accrual"
50531,"Protocol Status","Open","18-OCT-1999","Cerebrospinal Fluid HIV & Cognitive Function in Individuals Receiving ART","ACTG 736","18-JUN-2004","Open"
50531,"Protocol Status","In Development","12-DEC-1997","Cerebrospinal Fluid HIV & Cognitive Function in Individuals Receiving ART","ACTG 736","18-OCT-1999","In Development"
50532,"Protocol Status","Closed to Follow Up","10-JUL-2001","ACTG 388 Immunology Substudy","ACTG 737","","Closed to Follow Up"
50533,"Protocol Status","Closed to Follow Up","27-NOV-2001","CSF Substudy of ACTG 371","ACTG 738","","Closed to Follow Up"
50535,"Protocol Status","Closed to Follow Up","25-NOV-2003","Female Genital Secretions Substudy of ACTG 371","ACTG 740","","Closed to Follow Up"
50536,"Protocol Status","Closed to Follow Up","18-FEB-2004","Male Genital Secretions Substudy of ACTG 371","ACTG 741","","Closed to Follow Up"
50537,"Protocol Status","Closed to Follow Up","16-MAY-1995","Myopathy substudy of ACTG 175","ACTG 801","","Closed to Follow Up"
50538,"Protocol Status","Closed to Follow Up","04-MAY-1994","MEMS Compliance substudy of ACTG 175","ACTG 802","","Closed to Follow Up"
50539,"Protocol Status","Closed to Follow Up","06-MAY-1994","PK substudy of ACTG 229","ACTG 804","","Closed to Follow Up"
50540,"Protocol Status","Closed to Follow Up","31-MAY-1994","Immunology substudy of ACTG 229","ACTG 805","","Closed to Follow Up"
50541,"Protocol Status","Closed to Follow Up","10-JUN-1994","Compliance Monitoring-Random Drug Levels/ACTG 175","ACTG 806","","Closed to Follow Up"
50542,"Protocol Status","Closed to Follow Up","01-AUG-1995","Virology substudy for CMV in ACTG 228","ACTG 807","","Closed to Follow Up"
50543,"Protocol Status","Closed to Follow Up","08-MAY-1995","virology substudy for 241","ACTG 808","","Closed to Follow Up"
50544,"Protocol Status","Closed to Follow Up","16-MAR-1995","pk study for 241","ACTG 809","","Closed to Follow Up"
50545,"Protocol Status","Closed to Follow Up","14-JUN-1996","Microneurologic Substudy of ACTG 193A","ACTG 810","","Closed to Follow Up"
50546,"Protocol Status","Closed to Follow Up","22-NOV-1996","Macroneurology substudy of ACTG 193A","ACTG 811","","Closed to Follow Up"
50547,"Protocol Status","Closed to Follow Up","28-MAY-1996","PK substudy of ACTG 193A","ACTG 812","","Closed to Follow Up"
50548,"Protocol Status","Closed to Follow Up","13-JUN-1996","Virology Substudy of ACTG 193A","ACTG 813","","Closed to Follow Up"
50549,"Protocol Status","Closed to Follow Up","21-APR-1997","Pharmacokinetics of Thalidomide Substudy","ACTG 814","","Closed to Follow Up"
50550,"Protocol Status","Closed to Follow Up","19-OCT-1995","Epidemiology Substudy in ACTG 196 and 204","ACTG 815","","Closed to Follow Up"
50551,"Protocol Status","Concluded","01-SEP-2000","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","","Concluded"
50551,"Protocol Status","POS/PAC","30-JAN-1998","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","01-SEP-2000","POS/PAC"
50551,"Protocol Status","Closed to Follow Up","12-SEP-1997","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","30-JAN-1998","Closed to Follow Up"
50551,"Protocol Status","Closed to Accrual","31-AUG-1995","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","12-SEP-1997","Closed to Accrual"
50551,"Protocol Status","Open","06-MAY-1994","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","31-AUG-1995","Open"
50551,"Protocol Status","Pending","06-APR-1994","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","06-MAY-1994","Pending"
50551,"Protocol Status","In Development","20-OCT-1993","Nat. History of Resistant Mucosal Candidiasis","ACTG 816","06-APR-1994","In Development"
50554,"Protocol Status","Closed to Follow Up","04-MAR-1998","Intensive immunology for ACTG 248","ACTG 819","","Closed to Follow Up"
50555,"Protocol Status","Closed to Follow Up","04-MAR-1998","HIV-specific CTL Substudy of ACTG 248","ACTG 820","","Closed to Follow Up"
50558,"Protocol Status","Closed to Follow Up","17-JUN-1996","Pharmacokinetic Substudy of ACTG 223","ACTG 823","","Closed to Follow Up"
50559,"Protocol Status","Closed to Follow Up","09-JUN-1998","Pharmacodynamic Substudy of ACTG 223","ACTG 824","","Closed to Follow Up"
50560,"Protocol Status","Closed to Follow Up","09-DEC-1996","ACTG 261 Intensive Virology","ACTG 825","","Closed to Follow Up"
50561,"Protocol Status","Closed to Follow Up","09-DEC-1996","ACTG 261 Population PK","ACTG 826","","Closed to Follow Up"
50562,"Protocol Status","Closed to Follow Up","13-FEB-1997","MSL 109 on ADCC to CMV-ACTG 266 Substudy","ACTG 827","","Closed to Follow Up"
50563,"Protocol Status","Closed to Follow Up","16-JAN-1996","prod. of IL-1, -6, TNF-a, and lymph. prolif. assay","ACTG 828","","Closed to Follow Up"
50566,"Protocol Status","Closed to Follow Up","24-JUL-1996","mRNA TNF Substudy of ACTG 251","ACTG 831","","Closed to Follow Up"
50567,"Protocol Status","Closed to Follow Up","28-SEP-1995","Immunology Substudy I to ACTG 275","ACTG 832","","Closed to Follow Up"
50571,"Protocol Status","Closed to Follow Up","04-FEB-1997","PK substudy in ACTG 266","ACTG 837","","Closed to Follow Up"
50574,"Protocol Status","Closed to Follow Up","16-OCT-1997","Women Substudy for 251 - Prev of Genital Ulcers","ACTG 842","","Closed to Follow Up"
50576,"Protocol Status","Closed to Follow Up","06-JAN-1998","Tonsillar Biopsy Virology Substudy of ACTG 315","ACTG 846","","Closed to Follow Up"
50577,"Protocol Status","Closed to Follow Up","22-JAN-1998","Substudy of ACTG 347 to Evaluate CSF","ACTG 847","","Closed to Follow Up"
50580,"Protocol Status","Closed to Follow Up","30-DEC-1997","Semen Substudy of ACTG 347","ACTG 850","","Closed to Follow Up"
50581,"Protocol Status","Closed to Follow Up","28-SEP-1995","Immunology substudy to ACTG 275","ACTG 851","","Closed to Follow Up"
50582,"Protocol Status","Concluded","01-APR-2000","Effects of MAC Treatment on Cytokine Expression","ACTG 853","","Concluded"
50582,"Protocol Status","POS/PAC","04-JUN-1999","Effects of MAC Treatment on Cytokine Expression","ACTG 853","01-APR-2000","POS/PAC"
50582,"Protocol Status","Closed to Accrual","01-DEC-1997","Effects of MAC Treatment on Cytokine Expression","ACTG 853","04-JUN-1999","Closed to Accrual"
50582,"Protocol Status","Closed to Follow Up","26-OCT-1997","Effects of MAC Treatment on Cytokine Expression","ACTG 853","01-DEC-1997","Closed to Follow Up"
50582,"Protocol Status","Open","02-AUG-1995","Effects of MAC Treatment on Cytokine Expression","ACTG 853","26-OCT-1997","Open"
50582,"Protocol Status","Pending","22-MAY-1995","Effects of MAC Treatment on Cytokine Expression","ACTG 853","02-AUG-1995","Pending"
50582,"Protocol Status","In Development","04-NOV-1994","Effects of MAC Treatment on Cytokine Expression","ACTG 853","22-MAY-1995","In Development"
50583,"Protocol Status","Closed to Follow Up","05-JUN-1996","ACTG 276 Substudy: Intracellular PKs of ZDVTP","ACTG 854","","Closed to Follow Up"
50584,"Protocol Status","Closed to Follow Up","22-JUL-1997","Phenotypic/Immunol Studies w/Combo ZDV ddI Therapy","ACTG 855","","Closed to Follow Up"
50585,"Protocol Status","Closed to Follow Up","03-JUN-1997","Functional/Immunol Studies w/Combo ZDV/ddI Therapy","ACTG 856","","Closed to Follow Up"
50586,"Protocol Status","Closed to Follow Up","11-JUL-1996","Rate of HIV RNA Clearance: ZDV vs d4T vs ZDV + d4T","ACTG 857","","Closed to Follow Up"
50587,"Protocol Status","Closed to Follow Up","18-DEC-1996","Viral Dynamics Substudy of ACTG 276","ACTG 858","","Closed to Follow Up"
50588,"Protocol Status","Closed to Follow Up","24-JUL-1997","ACTG 303 substudy of viral dynamics","ACTG 859","","Closed to Follow Up"
50589,"Protocol Status","Closed to Follow Up","20-NOV-1998","ACTG 291 Nerve BX substudy","ACTG 860","","Closed to Follow Up"
50591,"Protocol Status","Closed to Follow Up","17-DEC-1997","Clinical Pharmacology Substudy of ACTG 306","ACTG 862","","Closed to Follow Up"
50592,"Protocol Status","Closed to Follow Up","16-JUL-1998","ACTG 307 immunology substudy","ACTG 863","","Closed to Follow Up"
50593,"Protocol Status","Closed to Follow Up","07-MAY-1998","Virology substudy in ACTG 307","ACTG 864","","Closed to Follow Up"
50594,"Protocol Status","Closed to Follow Up","17-APR-1998","PCR to Detect MAC Bacteremia: Substudy of ACTG 223","ACTG 865","","Closed to Follow Up"
50595,"Protocol Status","Closed to Follow Up","27-MAR-1997","Incid. of Cervical Dysplasia in ACTG 320 subjects","ACTG 866","","Closed to Follow Up"
50596,"Protocol Status","Closed to Follow Up","26-MAR-1997","Virologic Analysis of Surrogate Markers - IDV","ACTG 867","","Closed to Follow Up"
50597,"Protocol Status","Closed to Follow Up","21-FEB-1997","Eval. of HIV Load in Blood and Lymph Compartments","ACTG 868","","Closed to Follow Up"
50598,"Protocol Status","Closed to Follow Up","26-MAR-1997","Effect of Indinavir on Weight Gain","ACTG 869","","Closed to Follow Up"
50599,"Protocol Status","Closed to Follow Up","26-MAR-1997","Substudy  of ACTG 320:  Lymphocyte Subset Analyses","ACTG 870","","Closed to Follow Up"
50601,"Protocol Status","Closed to Follow Up","20-NOV-2000","Immunology Substudy of ACTG 328","ACTG 872","","Closed to Follow Up"
50602,"Protocol Status","Closed to Follow Up","08-JAN-2001","Virology Substudy of ACTG 328","ACTG 873","","Closed to Follow Up"
50603,"Protocol Status","Closed to Follow Up","11-OCT-2000","Substudy of ACTG 328 Viral/Immune Activation in Lymph Node","ACTG 874","","Closed to Follow Up"
50604,"Protocol Status","Closed to Follow Up","16-MAY-1995","Women's health substudy of ACTG 175","ACTG 875","","Closed to Follow Up"
50606,"Protocol Status","Closed to Follow Up","09-DEC-1999","Viral Burden:(Lymph/CSF/GenSec) Substudy ACTG 343","ACTG 877","","Closed to Follow Up"
50607,"Protocol Status","Closed to Follow Up","22-MAY-1998","PK/PD Substudy ACTG 343","ACTG 878","","Closed to Follow Up"
50608,"Protocol Status","Closed to Follow Up","31-DEC-1998","Immunology Substudy  of ACTG 343","ACTG 879","","Closed to Follow Up"
50609,"Protocol Status","Closed to Follow Up","26-JUL-2000","Virologic studies in ACTG 293","ACTG 880","","Closed to Follow Up"
50610,"Protocol Status","Closed to Follow Up","20-FEB-1997","Pharmacology Substudy of ACTG 290","ACTG 881","","Closed to Follow Up"
50612,"Protocol Status","Closed to Follow Up","13-JAN-1999","Pharmacology Substudy of ACTG 359","ACTG 884","","Closed to Follow Up"
50613,"Protocol Status","Closed to Follow Up","19-JUL-1999","MEMS Caps Substudy of ACTG 359","ACTG 885","","Closed to Follow Up"
50614,"Protocol Status","Closed to Follow Up","25-AUG-1999","Pharmacology Substudy of ACTG 368","ACTG 886","","Closed to Follow Up"
50615,"Protocol Status","Closed to Follow Up","25-AUG-1999","Virology Substudy of ACTG 368","ACTG 887","","Closed to Follow Up"
50616,"Protocol Status","POS/PAC","17-AUG-2001","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","","POS/PAC"
50616,"Protocol Status","Concluded","17-AUG-2001","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","17-AUG-2001","Concluded"
50616,"Protocol Status","Closed to Follow Up","23-MAY-2001","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","17-AUG-2001","Closed to Follow Up"
50616,"Protocol Status","POS/PAC","01-APR-2001","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","23-MAY-2001","POS/PAC"
50616,"Protocol Status","Closed to Accrual","29-OCT-1999","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","01-APR-2001","Closed to Accrual"
50616,"Protocol Status","Open","09-OCT-1997","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","29-OCT-1999","Open"
50616,"Protocol Status","Pending","01-JUL-1997","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","09-OCT-1997","Pending"
50616,"Protocol Status","In Development","27-FEB-1997","D/C of Primary PCP Prophylaxis in Subjects Receiving ART with Increased CD4>200","ACTG 888","01-JUL-1997","In Development"
50617,"Protocol Status","Closed to Follow Up","18-APR-2001","Substudy of ACTG 362: Immunology","ACTG 889","","Closed to Follow Up"
50618,"Protocol Status","Closed to Follow Up","25-AUG-1999","Immunology Substudy of ACTG 368","ACTG 890","","Closed to Follow Up"
50619,"Protocol Status","Concluded","14-APR-2000","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","","Concluded"
50619,"Protocol Status","POS/PAC","17-MAR-1999","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","14-APR-2000","POS/PAC"
50619,"Protocol Status","Closed to Accrual","08-JAN-1999","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","17-MAR-1999","Closed to Accrual"
50619,"Protocol Status","Closed to Follow Up","29-OCT-1998","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","08-JAN-1999","Closed to Follow Up"
50619,"Protocol Status","Open","25-SEP-1997","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","29-OCT-1998","Open"
50619,"Protocol Status","Pending","01-JUL-1997","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","25-SEP-1997","Pending"
50619,"Protocol Status","In Development","10-MAR-1997","Impact of Intercurrent Illness on HIV Viral Load","ACTG 891","01-JUL-1997","In Development"
50620,"Protocol Status","Concluded","15-OCT-2004","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","","Concluded"
50620,"Protocol Status","Concluded","15-OCT-2004","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","15-OCT-2004","Concluded"
50620,"Protocol Status","POS/PAC","13-AUG-2002","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","15-OCT-2004","POS/PAC"
50620,"Protocol Status","Closed to Follow Up","22-MAR-2000","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","13-AUG-2002","Closed to Follow Up"
50620,"Protocol Status","Closed to Accrual","10-MAY-1999","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","22-MAR-2000","Closed to Accrual"
50620,"Protocol Status","Open","03-NOV-1997","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","10-MAY-1999","Open"
50620,"Protocol Status","Pending","13-AUG-1997","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","03-NOV-1997","Pending"
50620,"Protocol Status","In Development","10-MAR-1997","Effect of Highly Active Antiretroviral Therapy on Lean Body Mass","ACTG 892","13-AUG-1997","In Development"
50621,"Protocol Status","Closed to Follow Up","10-JUN-1994","Micro-Neuro Substudy of ACTG 193","ACTG 893","","Closed to Follow Up"
50622,"Protocol Status","Closed to Follow Up","10-JUN-1994","Macro-Neuro Substudy of ACTG 193","ACTG 894","","Closed to Follow Up"
50623,"Protocol Status","Closed to Follow Up","09-SEP-1993","PK substudy of ACTG 193","ACTG 895","","Closed to Follow Up"
50624,"Protocol Status","Closed to Follow Up","06-APR-1994","Virology substudy of ACTG 193","ACTG 896","","Closed to Follow Up"
50627,"Protocol Status","Closed to Follow Up","10-FEB-2000","MAS Skin Testing Substudy of ACTG 362","ACTG 899","","Closed to Follow Up"
50628,"Protocol Status","Concluded","01-DEC-1999","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","","Concluded"
50628,"Protocol Status","POS/PAC","24-OCT-1996","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","01-DEC-1999","POS/PAC"
50628,"Protocol Status","Closed to Accrual","02-NOV-1995","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","24-OCT-1996","Closed to Accrual"
50628,"Protocol Status","Closed to Follow Up","29-SEP-1995","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","02-NOV-1995","Closed to Follow Up"
50628,"Protocol Status","Open","08-AUG-1995","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","29-SEP-1995","Open"
50628,"Protocol Status","Pending","10-APR-1995","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","08-AUG-1995","Pending"
50628,"Protocol Status","In Development","16-FEB-1995","DTH Reactions to Intradermal HIV Envelope Antigen","ACTG 921","10-APR-1995","In Development"
50629,"Protocol Status","Concluded","10-JUN-2002","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","","Concluded"
50629,"Protocol Status","POS/PAC","14-JUN-2000","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","10-JUN-2002","POS/PAC"
50629,"Protocol Status","Closed to Follow Up","14-AUG-1999","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","14-JUN-2000","Closed to Follow Up"
50629,"Protocol Status","Closed to Accrual","19-APR-1999","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","14-AUG-1999","Closed to Accrual"
50629,"Protocol Status","Open","12-FEB-1998","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","19-APR-1999","Open"
50629,"Protocol Status","Pending","16-DEC-1997","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","12-FEB-1998","Pending"
50629,"Protocol Status","In Development","25-APR-1997","Effect of TNFR:Fc on TNF alpha & Immune Markers","ACTG 928","16-DEC-1997","In Development"
50630,"Protocol Status","Concluded","10-OCT-2001","ART and HIV-1 MN rgp 160 or Vaccine Control","ACTG 946","","Concluded"
50630,"Protocol Status","POS/PAC","13-MAY-1999","ART and HIV-1 MN rgp 160 or Vaccine Control","ACTG 946","10-OCT-2001","POS/PAC"
50630,"Protocol Status","Closed to Follow Up","06-AUG-1998","ART and HIV-1 MN rgp 160 or Vaccine Control","ACTG 946","13-MAY-1999","Closed to Follow Up"
50630,"Protocol Status","Closed to Accrual","25-JAN-1998","ART and HIV-1 MN rgp 160 or Vaccine Control","ACTG 946","06-AUG-1998","Closed to Accrual"
50630,"Protocol Status","Open","04-MAR-1997","ART and HIV-1 MN rgp 160 or Vaccine Control","ACTG 946","25-JAN-1998","Open"
50630,"Protocol Status","In Development","27-SEP-1996","ART and HIV-1 MN rgp 160 or Vaccine Control","ACTG 946","04-MAR-1997","In Development"
50631,"Protocol Status","Withdrawn","16-FEB-1999","ACTG 248 Treatment Extension","ACTG 948","","Other"
50631,"Protocol Status","FDA - IND Hold","18-DEC-1998","ACTG 248 Treatment Extension","ACTG 948","16-FEB-1999","Other"
50631,"Protocol Status","In Development","15-AUG-1997","ACTG 248 Treatment Extension","ACTG 948","18-DEC-1998","In Development"
50632,"Protocol Status","Concluded","01-AUG-1997","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","","Concluded"
50632,"Protocol Status","POS/PAC","23-NOV-1993","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","01-AUG-1997","POS/PAC"
50632,"Protocol Status","Closed to Follow Up","06-AUG-1993","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","23-NOV-1993","Closed to Follow Up"
50632,"Protocol Status","Closed to Accrual","30-JUN-1993","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","06-AUG-1993","Closed to Accrual"
50632,"Protocol Status","Open","20-SEP-1989","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","30-JUN-1993","Open"
50632,"Protocol Status","Pending","28-AUG-1989","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","20-SEP-1989","Pending"
50632,"Protocol Status","In Development","31-JUL-1989","Fluconazole vs. clotrimazole for fungal proph.","ACTG 981","28-AUG-1989","In Development"
50783,"Protocol Status","Closed to Accrual","28-OCT-2011","ACTG Longitudinal Linked Randomized Trials (ALLRT) Protocol","A5001","","Closed to Accrual"
50783,"Protocol Status","Enrolling","19-JAN-2000","ACTG Longitudinal Linked Randomized Trials (ALLRT) Protocol","A5001","28-OCT-2011","Enrolling"
50783,"Protocol Status","Open","14-DEC-1999","ACTG Longitudinal Linked Randomized Trials (ALLRT) Protocol","A5001","19-JAN-2000","Open"
50783,"Protocol Status","Pending","03-DEC-1999","ACTG Longitudinal Linked Randomized Trials (ALLRT) Protocol","A5001","14-DEC-1999","Pending"
50783,"Protocol Status","In Development","21-JAN-1998","ACTG Longitudinal Linked Randomized Trials (ALLRT) Protocol","A5001","03-DEC-1999","In Development"
50786,"Protocol Status","Closed to Follow Up","14-AUG-2001","Adherence Substudy of ACTG 388","ACTG 746","","Closed to Follow Up"
50792,"Protocol Status","Concluded","04-JAN-2001","T-Lymphocyte Synthesis: A Nested Study of ACTG 375","A5002s","","Concluded"
50792,"Protocol Status","Closed to Accrual","29-DEC-2000","T-Lymphocyte Synthesis: A Nested Study of ACTG 375","A5002s","04-JAN-2001","Closed to Accrual"
50792,"Protocol Status","Closed to Follow Up","21-DEC-2000","T-Lymphocyte Synthesis: A Nested Study of ACTG 375","A5002s","29-DEC-2000","Closed to Follow Up"
50793,"Protocol Status","Closed to Follow Up","29-MAR-2000","ACTG 398 Pharmacokinetics Substudy","A5003s","","Closed to Follow Up"
50794,"Protocol Status","Closed to Follow Up","14-FEB-2000","ACTG 398 Immunology Substudy","A5004s","","Closed to Follow Up"
50803,"Protocol Status","Concluded","20-AUG-2008","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","","Concluded"
50803,"Protocol Status","POS/PAC","31-JUL-2004","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","20-AUG-2008","POS/PAC"
50803,"Protocol Status","Closed to Follow Up","02-DEC-2002","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","31-JUL-2004","Closed to Follow Up"
50803,"Protocol Status","Closed to Accrual","30-NOV-1999","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","02-DEC-2002","Closed to Accrual"
50803,"Protocol Status","Enrolling","02-NOV-1998","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","30-NOV-1999","Enrolling"
50803,"Protocol Status","Open","09-OCT-1998","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","02-NOV-1998","Open"
50803,"Protocol Status","Pending","27-AUG-1998","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","09-OCT-1998","Pending"
50803,"Protocol Status","In Development","15-APR-1998","Metabolic, Lipid & Body Composition Substudy of ACTG 384 (NFV or EFZ)","A5005s","27-AUG-1998","In Development"
50804,"Protocol Status","Closed to Follow Up","20-NOV-2002","Pharmacology and Adherence Substudy of ACTG 384","A5006s","","Closed to Follow Up"
50805,"Protocol Status","Concluded","03-MAY-2011","Immunology Substudy of ACTG 384","A5007s","","Concluded"
50805,"Protocol Status","Closed to Follow Up","24-JAN-2002","Immunology Substudy of ACTG 384","A5007s","03-MAY-2011","Closed to Follow Up"
50808,"Protocol Status","Closed to Follow Up","20-MAY-1999","A substudy of ACTG 349 Tonsillar Biopsy/Lymph Node Tissue","A5010s","","Closed to Follow Up"
50818,"Protocol Status","Closed to Follow Up","09-MAY-2000","Pilot PK Substudy of ACTG 400","A5013s","","Closed to Follow Up"
50820,"Protocol Status","Concluded","15-APR-2009","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","","Concluded"
50820,"Protocol Status","POS/PAC","23-JUL-2002","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","15-APR-2009","POS/PAC"
50820,"Protocol Status","Closed to Follow Up","06-MAR-2002","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","23-JUL-2002","Closed to Follow Up"
50820,"Protocol Status","Closed to Accrual","12-MAR-2001","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","06-MAR-2002","Closed to Accrual"
50820,"Protocol Status","Open","15-FEB-2000","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","12-MAR-2001","Open"
50820,"Protocol Status","Pending","26-NOV-1999","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","15-FEB-2000","Pending"
50820,"Protocol Status","In Development","12-MAY-1998","Cellular Dynamics & Immune Restoration with PI (LPV) or 3 NRTIs (d4T/3TC/ABC)","A5014","26-NOV-1999","In Development"
50821,"Protocol Status","POS/PAC","01-NOV-2005","Immunologic & Virologic Indices of Disease Progression Associated with Aging","A5015","","POS/PAC"
50821,"Protocol Status","Closed to Follow Up","11-APR-2005","Immunologic & Virologic Indices of Disease Progression Associated with Aging","A5015","01-NOV-2005","Closed to Follow Up"
50821,"Protocol Status","Closed to Accrual","22-AUG-2001","Immunologic & Virologic Indices of Disease Progression Associated with Aging","A5015","11-APR-2005","Closed to Accrual"
50821,"Protocol Status","Open","10-OCT-2000","Immunologic & Virologic Indices of Disease Progression Associated with Aging","A5015","22-AUG-2001","Open"
50821,"Protocol Status","Pending","18-MAY-2000","Immunologic & Virologic Indices of Disease Progression Associated with Aging","A5015","10-OCT-2000","Pending"
50822,"Protocol Status","Closed to Follow Up","14-JAN-2005","Immunology Laboratory Substudy of A5015","A5016s","","Closed to Follow Up"
50826,"Protocol Status","Closed to Follow Up","11-APR-2005","Viral Load in Genital Secretions Substudy of A5015","A5020s","","Closed to Follow Up"
50829,"Protocol Status","Withdrawn","20-NOV-1998","Longitudinal Study of Ocular Comp. of AIDS (LSOCA)","A5021","","Other"
50829,"Protocol Status","Withdrawn","29-OCT-1998","Longitudinal Study of Ocular Comp. of AIDS (LSOCA)","A5021","20-NOV-1998","Other"
50829,"Protocol Status","Pending","07-AUG-1998","Longitudinal Study of Ocular Comp. of AIDS (LSOCA)","A5021","29-OCT-1998","Pending"
50830,"Protocol Status","Closed to Follow Up","03-MAY-2000","Drug Exposure Substudy of ACTG 400","A5022s","","Closed to Follow Up"
50832,"Protocol Status","Concluded","01-AUG-2004","Safety & Efficacy of Hydroxyurea in Patients on ART","A5025","","Concluded"
50832,"Protocol Status","POS/PAC","14-FEB-2002","Safety & Efficacy of Hydroxyurea in Patients on ART","A5025","01-AUG-2004","POS/PAC"
50832,"Protocol Status","Closed to Follow Up","10-FEB-2000","Safety & Efficacy of Hydroxyurea in Patients on ART","A5025","14-FEB-2002","Closed to Follow Up"
50832,"Protocol Status","Closed to Accrual","01-JUL-1999","Safety & Efficacy of Hydroxyurea in Patients on ART","A5025","10-FEB-2000","Closed to Accrual"
50832,"Protocol Status","Open","02-NOV-1998","Safety & Efficacy of Hydroxyurea in Patients on ART","A5025","01-JUL-1999","Open"
50832,"Protocol Status","Pending","01-SEP-1998","Safety & Efficacy of Hydroxyurea in Patients on ART","A5025","02-NOV-1998","Pending"
50834,"Protocol Status","Closed to Follow Up","08-NOV-1999","Immunology Substudy of A5025","A5026s","","Closed to Follow Up"
50835,"Protocol Status","Closed to Follow Up","19-JAN-2000","PK Substudy of A5025","A5027s","","Closed to Follow Up"
50837,"Protocol Status","Concluded","15-DEC-2006","Potent ART, HIV Immunization, & IL-2 Cycles to Control Viral Replication","A5024","","Concluded"
50837,"Protocol Status","POS/PAC","10-OCT-2005","Potent ART, HIV Immunization, & IL-2 Cycles to Control Viral Replication","A5024","15-DEC-2006","POS/PAC"
50837,"Protocol Status","Closed to Follow Up","10-OCT-2005","Potent ART, HIV Immunization, & IL-2 Cycles to Control Viral Replication","A5024","10-OCT-2005","Closed to Follow Up"
50837,"Protocol Status","Closed to Accrual","28-MAY-2003","Potent ART, HIV Immunization, & IL-2 Cycles to Control Viral Replication","A5024","10-OCT-2005","Closed to Accrual"
50837,"Protocol Status","Open","30-AUG-2000","Potent ART, HIV Immunization, & IL-2 Cycles to Control Viral Replication","A5024","28-MAY-2003","Open"
50837,"Protocol Status","Pending","18-MAY-2000","Potent ART, HIV Immunization, & IL-2 Cycles to Control Viral Replication","A5024","30-AUG-2000","Pending"
50839,"Protocol Status","Concluded","01-JUL-2009","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","","Concluded"
50839,"Protocol Status","POS/PAC","21-NOV-2006","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","01-JUL-2009","POS/PAC"
50839,"Protocol Status","Closed to Follow Up","22-AUG-2005","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","21-NOV-2006","Closed to Follow Up"
50839,"Protocol Status","Closed to Accrual","16-MAY-2003","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","22-AUG-2005","Closed to Accrual"
50839,"Protocol Status","Open","16-NOV-2000","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","16-MAY-2003","Open"
50839,"Protocol Status","Pending","21-SEP-2000","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","16-NOV-2000","Pending"
50839,"Protocol Status","In Development","12-JUN-1998","Prevalence & Persistence of HPV DNA in PI Naive Women on HAART","A5029","21-SEP-2000","In Development"
50840,"Protocol Status","Concluded","18-JUN-2011","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","","Concluded"
50840,"Protocol Status","POS/PAC","10-FEB-2006","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","18-JUN-2011","POS/PAC"
50840,"Protocol Status","Closed to Follow Up","03-OCT-2005","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","10-FEB-2006","Closed to Follow Up"
50840,"Protocol Status","Closed to Accrual","01-APR-2004","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","03-OCT-2005","Closed to Accrual"
50840,"Protocol Status","Open","10-AUG-2000","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","01-APR-2004","Open"
50840,"Protocol Status","Pending","24-MAR-2000","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","10-AUG-2000","Pending"
50840,"Protocol Status","In Development","12-JUN-1998","Pre-Emptive Valganciclovir Therapy for CMV Viremia","A5030","24-MAR-2000","In Development"
50841,"Protocol Status","Closed to Follow Up","27-NOV-2002","Adherence Substudy for ACTG 384","A5031s","","Closed to Follow Up"
50843,"Protocol Status","Closed to Follow Up","11-OCT-2000","Frequency of Latently Infected T Cells in ACTG 328","A5033s","","Closed to Follow Up"
50847,"Protocol Status","Withdrawn","08-SEP-2000","Comparison of Intraocular & Systemic CMV Resistance Mutations","A5034","","Other"
50847,"Protocol Status","FDA - IND Hold","11-JAN-1999","Comparison of Intraocular & Systemic CMV Resistance Mutations","A5034","08-SEP-2000","Other"
50847,"Protocol Status","In Development","26-JUN-1998","Comparison of Intraocular & Systemic CMV Resistance Mutations","A5034","11-JAN-1999","In Development"
50848,"Protocol Status","Concluded","01-MAR-2000","Oncogenic Viral Pathogenesis & Cancer Risk Factors","A5035","","Concluded"
50848,"Protocol Status","Closed to Follow Up","01-MAR-2000","Oncogenic Viral Pathogenesis & Cancer Risk Factors","A5035","01-MAR-2000","Closed to Follow Up"
50848,"Protocol Status","Temporarily Closed","22-NOV-1999","Oncogenic Viral Pathogenesis & Cancer Risk Factors","A5035","01-MAR-2000","Other"
50848,"Protocol Status","Open","03-SEP-1999","Oncogenic Viral Pathogenesis & Cancer Risk Factors","A5035","22-NOV-1999","Open"
50849,"Protocol Status","Closed to Follow Up","13-FEB-2001","Substudy of A5014 Viral Dynamics Substudy","A5036s","","Closed to Follow Up"
50854,"Protocol Status","Concluded","15-MAY-2004","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","","Concluded"
50854,"Protocol Status","Concluded","15-MAY-2004","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","15-MAY-2004","Concluded"
50854,"Protocol Status","POS/PAC","25-JUL-2003","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","15-MAY-2004","POS/PAC"
50854,"Protocol Status","Closed to Follow Up","09-AUG-2002","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","25-JUL-2003","Closed to Follow Up"
50854,"Protocol Status","Closed to Accrual","27-SEP-2001","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","09-AUG-2002","Closed to Accrual"
50854,"Protocol Status","Open","06-MAY-1999","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","27-SEP-2001","Open"
50854,"Protocol Status","Pending","01-MAR-1999","Discontinuation of Antifungal Therapy for Histoplasmosis Following ART","A5038","06-MAY-1999","Pending"
50858,"Protocol Status","Concluded","24-JAN-2000","Maintenance ARV for HIV RNA","A5039","","Concluded"
50858,"Protocol Status","Closed to Follow Up","29-DEC-1999","Maintenance ARV for HIV RNA","A5039","24-JAN-2000","Closed to Follow Up"
50858,"Protocol Status","Closed to Accrual","29-NOV-1999","Maintenance ARV for HIV RNA","A5039","29-DEC-1999","Closed to Accrual"
50858,"Protocol Status","Temporarily Closed","24-SEP-1999","Maintenance ARV for HIV RNA","A5039","29-NOV-1999","Other"
50858,"Protocol Status","Open","18-MAY-1999","Maintenance ARV for HIV RNA","A5039","24-SEP-1999","Open"
50858,"Protocol Status","Pending","09-APR-1999","Maintenance ARV for HIV RNA","A5039","18-MAY-1999","Pending"
50867,"Protocol Status","Concluded","15-DEC-2003","Effects of GM-CSF on HIV RNA & Chemokine Receptor Expression","A5041","","Concluded"
50867,"Protocol Status","POS/PAC","17-SEP-2002","Effects of GM-CSF on HIV RNA & Chemokine Receptor Expression","A5041","15-DEC-2003","POS/PAC"
50867,"Protocol Status","Closed to Follow Up","02-OCT-2001","Effects of GM-CSF on HIV RNA & Chemokine Receptor Expression","A5041","17-SEP-2002","Closed to Follow Up"
50867,"Protocol Status","Closed to Accrual","04-OCT-2000","Effects of GM-CSF on HIV RNA & Chemokine Receptor Expression","A5041","02-OCT-2001","Closed to Accrual"
50867,"Protocol Status","Open","27-OCT-1999","Effects of GM-CSF on HIV RNA & Chemokine Receptor Expression","A5041","04-OCT-2000","Open"
50867,"Protocol Status","In Development","13-AUG-1998","Effects of GM-CSF on HIV RNA & Chemokine Receptor Expression","A5041","27-OCT-1999","In Development"
50868,"Protocol Status","Closed to Follow Up","02-OCT-2001","Core Immunology Substudy of A5041","A5042s","","Closed to Follow Up"
50871,"Protocol Status","Concluded","01-JAN-2008","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","","Concluded"
50871,"Protocol Status","POS/PAC","03-MAY-2004","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","01-JAN-2008","POS/PAC"
50871,"Protocol Status","Closed to Follow Up","13-JUN-2003","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","03-MAY-2004","Closed to Follow Up"
50871,"Protocol Status","Closed to Accrual","21-MAY-2003","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","13-JUN-2003","Closed to Accrual"
50871,"Protocol Status","Open","12-MAR-2001","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","21-MAY-2003","Open"
50871,"Protocol Status","Pending","12-DEC-2000","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","12-MAR-2001","Pending"
50871,"Protocol Status","Pending","23-NOV-1999","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","12-DEC-2000","Pending"
50871,"Protocol Status","On Hold","23-NOV-1999","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","23-NOV-1999","Other"
50871,"Protocol Status","In Development","25-SEP-1998","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","23-NOV-1999","In Development"
50871,"Protocol Status","In Development","19-AUG-1998","PK Interation Studies of APV, EFV, & A Second PI in Seronegative Volunteers","A5043","25-SEP-1998","In Development"
50872,"Protocol Status","Withdrawn","14-FEB-2000","Phase I/II Trial of PN401 for Sensory Neuropathy","A5044","","Other"
50872,"Protocol Status","On Hold","26-MAR-1999","Phase I/II Trial of PN401 for Sensory Neuropathy","A5044","14-FEB-2000","Other"
50872,"Protocol Status","In Development","20-AUG-1998","Phase I/II Trial of PN401 for Sensory Neuropathy","A5044","26-MAR-1999","In Development"
50886,"Protocol Status","Concluded","08-MAR-2002","Pharmacokinetic Interactions Between PIs & Lipid Lowering Agents","A5047","","Concluded"
50886,"Protocol Status","POS/PAC","27-OCT-2000","Pharmacokinetic Interactions Between PIs & Lipid Lowering Agents","A5047","08-MAR-2002","POS/PAC"
50886,"Protocol Status","Closed to Accrual","02-NOV-1999","Pharmacokinetic Interactions Between PIs & Lipid Lowering Agents","A5047","27-OCT-2000","Closed to Accrual"
50886,"Protocol Status","Closed to Follow Up","26-OCT-1999","Pharmacokinetic Interactions Between PIs & Lipid Lowering Agents","A5047","02-NOV-1999","Closed to Follow Up"
50886,"Protocol Status","Open","12-JUL-1999","Pharmacokinetic Interactions Between PIs & Lipid Lowering Agents","A5047","26-OCT-1999","Open"
50886,"Protocol Status","In Development","28-SEP-1998","Pharmacokinetic Interactions Between PIs & Lipid Lowering Agents","A5047","12-JUL-1999","In Development"
50888,"Protocol Status","Closed to Follow Up","09-FEB-2001","Core Immunology Substudy of ACTG 349","A5048s","","Closed to Follow Up"
50890,"Protocol Status","Concluded","21-MAY-2004","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","","Concluded"
50890,"Protocol Status","POS/PAC","28-OCT-2002","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","21-MAY-2004","POS/PAC"
50890,"Protocol Status","Closed to Follow Up","15-APR-2002","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","28-OCT-2002","Closed to Follow Up"
50890,"Protocol Status","Closed to Accrual","06-JUN-2001","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","15-APR-2002","Closed to Accrual"
50890,"Protocol Status","Open","04-OCT-2000","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","06-JUN-2001","Open"
50890,"Protocol Status","Pending","12-SEP-2000","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","04-OCT-2000","Pending"
50890,"Protocol Status","FDA - IND Hold","17-SEP-1999","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","12-SEP-2000","Other"
50890,"Protocol Status","In Development","08-OCT-1998","A Phase I Trial of Polyvalent Peptide HIV Vaccine C4-V3 with IL-12","A5049","17-SEP-1999","In Development"
50900,"Protocol Status","Concluded","30-JUL-2010","Treatment Extension for ACTG 328 with SC IL-2 in Combination with Potent ART","A5051","","Concluded"
50900,"Protocol Status","POS/PAC","17-SEP-2004","Treatment Extension for ACTG 328 with SC IL-2 in Combination with Potent ART","A5051","30-JUL-2010","POS/PAC"
50900,"Protocol Status","Closed to Follow Up","13-JUN-2002","Treatment Extension for ACTG 328 with SC IL-2 in Combination with Potent ART","A5051","17-SEP-2004","Closed to Follow Up"
50900,"Protocol Status","Closed to Accrual","07-FEB-2001","Treatment Extension for ACTG 328 with SC IL-2 in Combination with Potent ART","A5051","13-JUN-2002","Closed to Accrual"
50900,"Protocol Status","Open","25-MAR-1999","Treatment Extension for ACTG 328 with SC IL-2 in Combination with Potent ART","A5051","07-FEB-2001","Open"
50900,"Protocol Status","In Development","30-OCT-1998","Treatment Extension for ACTG 328 with SC IL-2 in Combination with Potent ART","A5051","25-MAR-1999","In Development"
50901,"Protocol Status","Closed to Follow Up","13-JUN-2002","Comparison of Immunologic Changes Induced by Potent ART +/- rhIL-2","A5052s","","Closed to Follow Up"
50902,"Protocol Status","Closed to Follow Up","13-JUN-2002","Comparison of Virologic Changes Induced by HAART +/- rhIL-2","A5053s","","Closed to Follow Up"
50903,"Protocol Status","Closed to Follow Up","13-JUN-2002","Longitudinal Study of Measurement of Freq of Latent Inf T-Cells","A5054s","","Closed to Follow Up"
50904,"Protocol Status","Concluded","01-AUG-2006","Safety & PK of IDV+RTV in Subjects Failing APV, NFV, SQV, or NFV+SQV","A5055","","Concluded"
50904,"Protocol Status","POS/PAC","22-SEP-2004","Safety & PK of IDV+RTV in Subjects Failing APV, NFV, SQV, or NFV+SQV","A5055","01-AUG-2006","POS/PAC"
50904,"Protocol Status","Closed to Follow Up","23-MAY-2002","Safety & PK of IDV+RTV in Subjects Failing APV, NFV, SQV, or NFV+SQV","A5055","22-SEP-2004","Closed to Follow Up"
50904,"Protocol Status","Closed to Accrual","03-DEC-2001","Safety & PK of IDV+RTV in Subjects Failing APV, NFV, SQV, or NFV+SQV","A5055","23-MAY-2002","Closed to Accrual"
50904,"Protocol Status","Open","06-JAN-2000","Safety & PK of IDV+RTV in Subjects Failing APV, NFV, SQV, or NFV+SQV","A5055","03-DEC-2001","Open"
50904,"Protocol Status","In Development","13-NOV-1998","Safety & PK of IDV+RTV in Subjects Failing APV, NFV, SQV, or NFV+SQV","A5055","06-JAN-2000","In Development"
50906,"Protocol Status","Concluded","08-JUL-2008","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","","Concluded"
50906,"Protocol Status","POS/PAC","21-SEP-2005","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","08-JUL-2008","POS/PAC"
50906,"Protocol Status","Closed to Follow Up","08-AUG-2001","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","21-SEP-2005","Closed to Follow Up"
50906,"Protocol Status","Closed to Accrual","26-FEB-2001","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","08-AUG-2001","Closed to Accrual"
50906,"Protocol Status","Open","31-AUG-2000","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","26-FEB-2001","Open"
50906,"Protocol Status","Pending","04-AUG-2000","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","31-AUG-2000","Pending"
50906,"Protocol Status","Closed to Accrual","06-JUN-2000","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","04-AUG-2000","Closed to Accrual"
50906,"Protocol Status","Open","18-MAY-2000","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","06-JUN-2000","Open"
50906,"Protocol Status","Pending","23-NOV-1999","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","18-MAY-2000","Pending"
50906,"Protocol Status","In Development","02-DEC-1998","Vaccine-Induced Immune Responses to HIV on Time to Virologic Relapse","A5057","23-NOV-1999","In Development"
50912,"Protocol Status","Withdrawn","15-MAR-1999","A Nested HIV Vaccine study of ACTG 375","A5059","","Other"
50912,"Protocol Status","In Development","16-DEC-1998","A Nested HIV Vaccine study of ACTG 375","A5059","15-MAR-1999","In Development"
50913,"Protocol Status","Closed to Follow Up","19-OCT-1999","Arm III Intensive PK Substudy of ACTG 388","A5060s","","Closed to Follow Up"
50922,"Protocol Status","Concluded","13-AUG-2002","Treatment Intensification in Early Virologic Failure","A5061","","Concluded"
50922,"Protocol Status","Closed to Follow Up","12-AUG-2002","Treatment Intensification in Early Virologic Failure","A5061","13-AUG-2002","Closed to Follow Up"
50922,"Protocol Status","Closed to Accrual","01-APR-2002","Treatment Intensification in Early Virologic Failure","A5061","12-AUG-2002","Closed to Accrual"
50922,"Protocol Status","Open","27-DEC-2000","Treatment Intensification in Early Virologic Failure","A5061","01-APR-2002","Open"
50922,"Protocol Status","Pending","10-SEP-1999","Treatment Intensification in Early Virologic Failure","A5061","27-DEC-2000","Pending"
50922,"Protocol Status","In Development","01-FEB-1999","Treatment Intensification in Early Virologic Failure","A5061","10-SEP-1999","In Development"
50925,"Protocol Status","Withdrawn","15-FEB-2002","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","","Other"
50925,"Protocol Status","Concluded","15-FEB-2002","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","15-FEB-2002","Concluded"
50925,"Protocol Status","Closed to Follow Up","24-JAN-2002","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","15-FEB-2002","Closed to Follow Up"
50925,"Protocol Status","Closed to Accrual","14-DEC-2001","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","24-JAN-2002","Closed to Accrual"
50925,"Protocol Status","Open","08-FEB-2000","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","14-DEC-2001","Open"
50925,"Protocol Status","Pending","13-DEC-1999","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","08-FEB-2000","Pending"
50925,"Protocol Status","In Development","23-FEB-1999","Viral & Immune Dynamics in HIV-Infected Patients with TB","A5062","13-DEC-1999","In Development"
50928,"Protocol Status","Withdrawn","20-APR-2000","Repeated Interruptions of ARV Tx & Exposure to Quantifiable Levels of HIV-1 RNA","A5063","","Other"
50928,"Protocol Status","In Development","17-MAR-1999","Repeated Interruptions of ARV Tx & Exposure to Quantifiable Levels of HIV-1 RNA","A5063","20-APR-2000","In Development"
50937,"Protocol Status","Concluded","01-JUN-2003","A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy","A5064","","Concluded"
50937,"Protocol Status","POS/PAC","24-AUG-2001","A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy","A5064","01-JUN-2003","POS/PAC"
50937,"Protocol Status","Closed to Follow Up","23-AUG-2001","A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy","A5064","24-AUG-2001","Closed to Follow Up"
50937,"Protocol Status","Closed to Accrual","15-JUN-2001","A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy","A5064","23-AUG-2001","Closed to Accrual"
50937,"Protocol Status","Open","03-NOV-1999","A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy","A5064","15-JUN-2001","Open"
50937,"Protocol Status","In Development","31-MAR-1999","A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy","A5064","03-NOV-1999","In Development"
50938,"Protocol Status","Closed to Follow Up","30-OCT-2001","Paradoxical Clinical Reaction in TB Patients Treated with Potent ART","A5065s","","Closed to Follow Up"
50944,"Protocol Status","Concluded","01-MAR-2005","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","","Concluded"
50944,"Protocol Status","POS/PAC","16-APR-2003","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","01-MAR-2005","POS/PAC"
50944,"Protocol Status","Closed to Follow Up","03-JAN-2002","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","16-APR-2003","Closed to Follow Up"
50944,"Protocol Status","Closed to Accrual","26-NOV-2001","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","03-JAN-2002","Closed to Accrual"
50944,"Protocol Status","Open","17-APR-2000","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","26-NOV-2001","Open"
50944,"Protocol Status","Pending","27-MAR-2000","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","17-APR-2000","Pending"
50944,"Protocol Status","In Development","16-APR-1999","Study of Pathogen -Specific Responses & General Immune Competence In OI","A5067","27-MAR-2000","In Development"
50945,"Protocol Status","Closed to Follow Up","04-OCT-2006","ALVAC-HIVvCP1452 +/- Intermittent ART Withdrawal as an Immunization Strategy","A5068","","Closed to Follow Up"
50945,"Protocol Status","POS/PAC","04-OCT-2006","ALVAC-HIVvCP1452 +/- Intermittent ART Withdrawal as an Immunization Strategy","A5068","04-OCT-2006","POS/PAC"
50945,"Protocol Status","Closed to Accrual","22-OCT-2003","ALVAC-HIVvCP1452 +/- Intermittent ART Withdrawal as an Immunization Strategy","A5068","04-OCT-2006","Closed to Accrual"
50945,"Protocol Status","Open","23-FEB-2001","ALVAC-HIVvCP1452 +/- Intermittent ART Withdrawal as an Immunization Strategy","A5068","22-OCT-2003","Open"
50945,"Protocol Status","Pending","19-DEC-2000","ALVAC-HIVvCP1452 +/- Intermittent ART Withdrawal as an Immunization Strategy","A5068","23-FEB-2001","Pending"
50945,"Protocol Status","In Development","20-APR-1999","ALVAC-HIVvCP1452 +/- Intermittent ART Withdrawal as an Immunization Strategy","A5068","19-DEC-2000","In Development"
50947,"Protocol Status","Withdrawn","29-MAR-2001","HU & ddI in Advanced HIV-Infected Subjects Failing Standard Therapy","A5069","","Other"
50947,"Protocol Status","Closed to Accrual","29-MAR-2001","HU & ddI in Advanced HIV-Infected Subjects Failing Standard Therapy","A5069","29-MAR-2001","Closed to Accrual"
50947,"Protocol Status","Withdrawn","29-MAR-2001","HU & ddI in Advanced HIV-Infected Subjects Failing Standard Therapy","A5069","29-MAR-2001","Other"
50947,"Protocol Status","Open","09-JAN-2001","HU & ddI in Advanced HIV-Infected Subjects Failing Standard Therapy","A5069","29-MAR-2001","Open"
50947,"Protocol Status","Pending","11-OCT-2000","HU & ddI in Advanced HIV-Infected Subjects Failing Standard Therapy","A5069","09-JAN-2001","Pending"
50947,"Protocol Status","In Development","05-MAY-1999","HU & ddI in Advanced HIV-Infected Subjects Failing Standard Therapy","A5069","11-OCT-2000","In Development"
50958,"Protocol Status","Concluded","15-AUG-2006","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","","Concluded"
50958,"Protocol Status","POS/PAC","02-JUL-2003","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","15-AUG-2006","POS/PAC"
50958,"Protocol Status","Closed to Follow Up","05-FEB-2003","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","02-JUL-2003","Closed to Follow Up"
50958,"Protocol Status","Closed to Accrual","21-JUN-2001","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","05-FEB-2003","Closed to Accrual"
50958,"Protocol Status","Open","30-NOV-2000","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","21-JUN-2001","Open"
50958,"Protocol Status","Pending","22-AUG-2000","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","30-NOV-2000","Pending"
50958,"Protocol Status","In Development","17-JUN-1999","IFN-alfa-2a+Ribavirin vs. PEG-IFN-alfa-2a+Ribavirin for HCV+HIV-1 Infection","A5071","22-AUG-2000","In Development"
50960,"Protocol Status","Withdrawn","15-JAN-2002","Immunologic Recovery after Pot ART & CD34+ Mobilization Following G-CSF","A5072","","Other"
50960,"Protocol Status","Open","14-JUN-2001","Immunologic Recovery after Pot ART & CD34+ Mobilization Following G-CSF","A5072","15-JAN-2002","Open"
50960,"Protocol Status","Pending","28-JUN-2000","Immunologic Recovery after Pot ART & CD34+ Mobilization Following G-CSF","A5072","14-JUN-2001","Pending"
50960,"Protocol Status","In Development","22-JUN-1999","Immunologic Recovery after Pot ART & CD34+ Mobilization Following G-CSF","A5072","28-JUN-2000","In Development"
50963,"Protocol Status","Concluded","27-JUL-2009","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","","Concluded"
50963,"Protocol Status","POS/PAC","05-SEP-2006","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","27-JUL-2009","POS/PAC"
50963,"Protocol Status","Closed to Follow Up","11-JAN-2006","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","05-SEP-2006","Closed to Follow Up"
50963,"Protocol Status","Closed to Accrual","31-JAN-2005","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","11-JAN-2006","Closed to Accrual"
50963,"Protocol Status","Open","16-SEP-2002","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","31-JAN-2005","Open"
50963,"Protocol Status","Pending","03-APR-2002","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","16-SEP-2002","Pending"
50963,"Protocol Status","In Development","06-JUL-1999","Comparison of BID ART vs QD ART and Self-Administered ART vs. DOT ART","A5073","03-APR-2002","In Development"
50965,"Protocol Status","Withdrawn","06-AUG-2003","Short Term ARV Activity of TDF + 3TC & TDF + 3TC + DDI vs. 24 -wks ARV","A5074","","Other"
50965,"Protocol Status","On Hold","31-AUG-2001","Short Term ARV Activity of TDF + 3TC & TDF + 3TC + DDI vs. 24 -wks ARV","A5074","06-AUG-2003","Other"
50965,"Protocol Status","On Hold","31-AUG-2001","Short Term ARV Activity of TDF + 3TC & TDF + 3TC + DDI vs. 24 -wks ARV","A5074","31-AUG-2001","Other"
50965,"Protocol Status","In Development","15-JUL-2001","Short Term ARV Activity of TDF + 3TC & TDF + 3TC + DDI vs. 24 -wks ARV","A5074","31-AUG-2001","In Development"
50965,"Protocol Status","On Hold","16-DEC-1999","Short Term ARV Activity of TDF + 3TC & TDF + 3TC + DDI vs. 24 -wks ARV","A5074","15-JUL-2001","Other"
50965,"Protocol Status","In Development","19-JUL-1999","Short Term ARV Activity of TDF + 3TC & TDF + 3TC + DDI vs. 24 -wks ARV","A5074","16-DEC-1999","In Development"
50970,"Protocol Status","Withdrawn","08-DEC-2000","Study of Adefovir Safety & Efficacy in HIV/HBV-Infected Subjects","A5075","","Other"
50970,"Protocol Status","In Development","13-NOV-2000","Study of Adefovir Safety & Efficacy in HIV/HBV-Infected Subjects","A5075","08-DEC-2000","In Development"
50970,"Protocol Status","On Hold","03-DEC-1999","Study of Adefovir Safety & Efficacy in HIV/HBV-Infected Subjects","A5075","13-NOV-2000","Other"
50970,"Protocol Status","In Development","02-AUG-1999","Study of Adefovir Safety & Efficacy in HIV/HBV-Infected Subjects","A5075","03-DEC-1999","In Development"
50971,"Protocol Status","Concluded","03-FEB-2003","Sequencing vs. Phenotyping for ARV Failure","A5076","","Concluded"
50971,"Protocol Status","Concluded","03-FEB-2003","Sequencing vs. Phenotyping for ARV Failure","A5076","03-FEB-2003","Concluded"
50971,"Protocol Status","Closed to Follow Up","18-JUN-2002","Sequencing vs. Phenotyping for ARV Failure","A5076","03-FEB-2003","Closed to Follow Up"
50971,"Protocol Status","Closed to Accrual","04-JAN-2002","Sequencing vs. Phenotyping for ARV Failure","A5076","18-JUN-2002","Closed to Accrual"
50971,"Protocol Status","Open","20-NOV-2000","Sequencing vs. Phenotyping for ARV Failure","A5076","04-JAN-2002","Open"
50971,"Protocol Status","Pending","05-OCT-2000","Sequencing vs. Phenotyping for ARV Failure","A5076","20-NOV-2000","Pending"
50971,"Protocol Status","In Development","04-AUG-1999","Sequencing vs. Phenotyping for ARV Failure","A5076","05-OCT-2000","In Development"
50972,"Protocol Status","POS/PAC","11-FEB-2010","Virologic Compartment Study in HIV-Infected Subjects Changing or Initiating ART","A5077","","POS/PAC"
50972,"Protocol Status","Closed to Follow Up","30-AUG-2004","Virologic Compartment Study in HIV-Infected Subjects Changing or Initiating ART","A5077","11-FEB-2010","Closed to Follow Up"
50972,"Protocol Status","Closed to Accrual","08-OCT-2002","Virologic Compartment Study in HIV-Infected Subjects Changing or Initiating ART","A5077","30-AUG-2004","Closed to Accrual"
50972,"Protocol Status","Open","20-NOV-2000","Virologic Compartment Study in HIV-Infected Subjects Changing or Initiating ART","A5077","08-OCT-2002","Open"
50972,"Protocol Status","Pending","09-NOV-2000","Virologic Compartment Study in HIV-Infected Subjects Changing or Initiating ART","A5077","20-NOV-2000","Pending"
50972,"Protocol Status","In Development","10-AUG-1999","Virologic Compartment Study in HIV-Infected Subjects Changing or Initiating ART","A5077","09-NOV-2000","In Development"
50977,"Protocol Status","Concluded","18-NOV-2005","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","","Concluded"
50977,"Protocol Status","POS/PAC","04-MAR-2002","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","18-NOV-2005","POS/PAC"
50977,"Protocol Status","Closed to Follow Up","08-JAN-2001","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","04-MAR-2002","Closed to Follow Up"
50977,"Protocol Status","Closed to Accrual","30-AUG-2000","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","08-JAN-2001","Closed to Accrual"
50977,"Protocol Status","Closed to Accrual","30-AUG-2000","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","30-AUG-2000","Closed to Accrual"
50977,"Protocol Status","Open","27-MAY-1999","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","30-AUG-2000","Open"
50977,"Protocol Status","Open","27-MAY-1999","ACTG 328 Substudy: Immunogenicity of Remune + HAART or Remune + HAART + IL-2","A5046s","27-MAY-1999","Open"
50978,"Protocol Status","Concluded","31-MAY-2007","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","","Concluded"
50978,"Protocol Status","POS/PAC","14-DEC-2005","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","31-MAY-2007","POS/PAC"
50978,"Protocol Status","Closed to Follow Up","01-JUN-2005","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","14-DEC-2005","Closed to Follow Up"
50978,"Protocol Status","Closed to Accrual","06-MAY-2002","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","01-JUN-2005","Closed to Accrual"
50978,"Protocol Status","Open","18-DEC-2000","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","06-MAY-2002","Open"
50978,"Protocol Status","Pending","01-AUG-2000","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","18-DEC-2000","Pending"
50978,"Protocol Status","In Development","31-AUG-1999","Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults","A5078","01-AUG-2000","In Development"
50980,"Protocol Status","Concluded","01-MAR-2007","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","","Concluded"
50980,"Protocol Status","POS/PAC","08-MAY-2006","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","01-MAR-2007","POS/PAC"
50980,"Protocol Status","Closed to Follow Up","09-JUN-2005","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","08-MAY-2006","Closed to Follow Up"
50980,"Protocol Status","Closed to Accrual","19-JUL-2004","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","09-JUN-2005","Closed to Accrual"
50980,"Protocol Status","Open","19-JUN-2001","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","19-JUL-2004","Open"
50980,"Protocol Status","Open","19-JUN-2001","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","19-JUN-2001","Open"
50980,"Protocol Status","Pending","29-DEC-2000","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","19-JUN-2001","Pending"
50980,"Protocol Status","In Development","14-SEP-1999","Testosterone Supplement for Reduced Serum Testosterone & Abdominal Obesity","A5079","29-DEC-2000","In Development"
50982,"Protocol Status","Withdrawn","15-MAR-2002","T-20 as Induction Therapy in Subjects with Low CD4 and High Viral Load","A5080","","Other"
50982,"Protocol Status","In Development","13-AUG-2001","T-20 as Induction Therapy in Subjects with Low CD4 and High Viral Load","A5080","15-MAR-2002","In Development"
50982,"Protocol Status","On Hold","05-DEC-2000","T-20 as Induction Therapy in Subjects with Low CD4 and High Viral Load","A5080","13-AUG-2001","Other"
50982,"Protocol Status","In Development","21-SEP-1999","T-20 as Induction Therapy in Subjects with Low CD4 and High Viral Load","A5080","05-DEC-2000","In Development"
50983,"Protocol Status","Withdrawn","31-MAY-2000","PK Interaction/Safety of Dual NNRTIs","A5081","","Other"
50983,"Protocol Status","On Hold","10-APR-2000","PK Interaction/Safety of Dual NNRTIs","A5081","31-MAY-2000","Other"
50983,"Protocol Status","In Development","21-SEP-1999","PK Interaction/Safety of Dual NNRTIs","A5081","10-APR-2000","In Development"
50984,"Protocol Status","Concluded","02-JAN-2007","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","","Concluded"
50984,"Protocol Status","POS/PAC","26-JAN-2006","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","02-JAN-2007","POS/PAC"
50984,"Protocol Status","Closed to Accrual","06-MAR-2004","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","26-JAN-2006","Closed to Accrual"
50984,"Protocol Status","Closed to Follow Up","08-JAN-2004","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","06-MAR-2004","Closed to Follow Up"
50984,"Protocol Status","Open","22-MAY-2001","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","08-JAN-2004","Open"
50984,"Protocol Status","Pending","21-MAR-2001","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","22-MAY-2001","Pending"
50984,"Protocol Status","In Development","30-SEP-1999","Metformin/Rosiglitazone Alone or Combined for Hyperinsulinemia & Waist/Hip Ratio","A5082","21-MAR-2001","In Development"
50986,"Protocol Status","Concluded","26-MAY-2008","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","","Concluded"
50986,"Protocol Status","POS/PAC","31-JAN-2006","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","26-MAY-2008","POS/PAC"
50986,"Protocol Status","Closed to Follow Up","17-MAY-2005","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","31-JAN-2006","Closed to Follow Up"
50986,"Protocol Status","Closed to Accrual","07-SEP-2004","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","17-MAY-2005","Closed to Accrual"
50986,"Protocol Status","Open","15-NOV-2001","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","07-SEP-2004","Open"
50986,"Protocol Status","Open","15-NOV-2001","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","15-NOV-2001","Open"
50986,"Protocol Status","Pending","30-MAY-2001","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","15-NOV-2001","Pending"
50986,"Protocol Status","In Development","12-OCT-1999","Metabolic Complications Associated with ART in HIV-1-Infected Pregnant Women","A5084","30-MAY-2001","In Development"
50988,"Protocol Status","In Development","03-NOV-1999","Impact of HIV Disease & Potent ART on Stem Cell # & Function","A5085s","","In Development"
50989,"Protocol Status","Concluded","02-NOV-2006","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","","Concluded"
50989,"Protocol Status","POS/PAC","19-APR-2004","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","02-NOV-2006","POS/PAC"
50989,"Protocol Status","Closed to Follow Up","22-JAN-2004","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","19-APR-2004","Closed to Follow Up"
50989,"Protocol Status","Closed to Accrual","11-OCT-2002","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","22-JAN-2004","Closed to Accrual"
50989,"Protocol Status","Open","20-FEB-2001","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","11-OCT-2002","Open"
50989,"Protocol Status","Pending","13-DEC-2000","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","20-FEB-2001","Pending"
50989,"Protocol Status","In Development","22-NOV-1999","STI & Resistance Testing-Based Selection of ART for Subjects Failing Current ART","A5086","13-DEC-2000","In Development"
50990,"Protocol Status","Concluded","01-JUL-2010","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","","Concluded"
50990,"Protocol Status","POS/PAC","20-MAY-2003","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","01-JUL-2010","POS/PAC"
50990,"Protocol Status","Closed to Follow Up","18-JUN-2002","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","20-MAY-2003","Closed to Follow Up"
50990,"Protocol Status","Closed to Accrual","28-SEP-2001","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","18-JUN-2002","Closed to Accrual"
50990,"Protocol Status","Open","13-NOV-2000","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","28-SEP-2001","Open"
50990,"Protocol Status","Pending","14-AUG-2000","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","13-NOV-2000","Pending"
50990,"Protocol Status","In Development","30-NOV-1999","Efficacy & Safety of Fenofibrate vs. Pravastatin in Subj w/Lipid Abnormalities","A5087","14-AUG-2000","In Development"
50992,"Protocol Status","Concluded","01-MAR-2005","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","","Concluded"
50992,"Protocol Status","POS/PAC","19-APR-2004","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","01-MAR-2005","POS/PAC"
50992,"Protocol Status","Closed to Follow Up","02-DEC-2003","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","19-APR-2004","Closed to Follow Up"
50992,"Protocol Status","Closed to Accrual","25-JUN-2002","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","02-DEC-2003","Closed to Accrual"
50992,"Protocol Status","Open","29-AUG-2001","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","25-JUN-2002","Open"
50992,"Protocol Status","Pending","14-MAR-2001","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","29-AUG-2001","Pending"
50992,"Protocol Status","In Development","10-DEC-1999","Low Dose IL-2 & Pegylated IFN for HCV/HIV Co-infection","A5088","14-MAR-2001","In Development"
50993,"Protocol Status","Concluded","01-OCT-2006","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","","Concluded"
50993,"Protocol Status","POS/PAC","15-NOV-2000","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","01-OCT-2006","POS/PAC"
50993,"Protocol Status","Closed to Follow Up","06-OCT-2000","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","15-NOV-2000","Closed to Follow Up"
50993,"Protocol Status","Closed to Accrual","25-SEP-2000","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","06-OCT-2000","Closed to Accrual"
50993,"Protocol Status","Open","15-SEP-2000","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","25-SEP-2000","Open"
50993,"Protocol Status","Pending","07-JUL-2000","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","15-SEP-2000","Pending"
50993,"Protocol Status","In Development","10-DEC-1999","Perceived Changes in Body Habitus & Image in  HIV+ Persons on Combination ARV Tx","A5089","07-JUL-2000","In Development"
50994,"Protocol Status","Concluded","13-MAY-2011","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","","Concluded"
50994,"Protocol Status","POS/PAC","14-FEB-2006","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","13-MAY-2011","POS/PAC"
50994,"Protocol Status","Closed to Follow Up","05-DEC-2005","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","14-FEB-2006","Closed to Follow Up"
50994,"Protocol Status","Closed to Accrual","16-DEC-2004","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","05-DEC-2005","Closed to Accrual"
50994,"Protocol Status","Open","17-OCT-2001","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","16-DEC-2004","Open"
50994,"Protocol Status","Pending","31-JAN-2001","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","17-OCT-2001","Pending"
50994,"Protocol Status","Pending","31-JAN-2001","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","31-JAN-2001","Pending"
50994,"Protocol Status","In Development","10-DEC-1999","Selegiline Transdermal System for Tx of HIV-Associated Cognitive Impairment","A5090","31-JAN-2001","In Development"
50997,"Protocol Status","Closed to Follow Up","04-SEP-2002","HCV Kinetics In Subjects Coinfected With HIV-1and HCV-1: Substudy of A5071","A5091s","","Closed to Follow Up"
50998,"Protocol Status","Concluded","01-JUN-2007","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","","Concluded"
50998,"Protocol Status","POS/PAC","16-SEP-2005","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","01-JUN-2007","POS/PAC"
50998,"Protocol Status","Closed to Accrual","16-NOV-2004","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","16-SEP-2005","Closed to Accrual"
50998,"Protocol Status","Closed to Follow Up","16-SEP-2004","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","16-NOV-2004","Closed to Follow Up"
50998,"Protocol Status","In Development","10-FEB-2001","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","16-SEP-2004","In Development"
50998,"Protocol Status","Open","30-NOV-2000","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","10-FEB-2001","Open"
50998,"Protocol Status","Open","30-NOV-2000","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5092s","30-NOV-2000","Open"
50999,"Protocol Status","Concluded","01-FEB-2008","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","","Concluded"
50999,"Protocol Status","POS/PAC","18-APR-2006","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","01-FEB-2008","POS/PAC"
50999,"Protocol Status","Closed to Follow Up","26-MAY-2004","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","18-APR-2006","Closed to Follow Up"
50999,"Protocol Status","Closed to Accrual","29-MAR-2004","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","26-MAY-2004","Closed to Accrual"
50999,"Protocol Status","Open","05-JUN-2001","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","29-MAR-2004","Open"
50999,"Protocol Status","Pending","18-APR-2001","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","05-JUN-2001","Pending"
50999,"Protocol Status","In Development","03-JAN-2000","PK Interactions between DMPA & Selected PIs & NNRTIs in HIV-Infected Women","A5093","18-APR-2001","In Development"
51011,"Protocol Status","Closed to Follow Up","20-FEB-2002","Comparison of Thymus Size in Subjects Randomized to Pot ART vs. Pot ART+I L2","A5094s","","Closed to Follow Up"
51023,"Protocol Status","Concluded","29-SEP-2011","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","","Concluded"
51023,"Protocol Status","POS/PAC","29-JUN-2005","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","29-SEP-2011","POS/PAC"
51023,"Protocol Status","Closed to Follow Up","18-MAR-2005","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","29-JUN-2005","Closed to Follow Up"
51023,"Protocol Status","Closed to Accrual","04-NOV-2002","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","18-MAR-2005","Closed to Accrual"
51023,"Protocol Status","Open","21-FEB-2001","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","04-NOV-2002","Open"
51023,"Protocol Status","Pending","03-JAN-2001","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","21-FEB-2001","Pending"
51023,"Protocol Status","In Development","17-APR-2000","Comparison of Three PI-Sparing Regimens for Initial Treatment of HIV Infection","A5095","03-JAN-2001","In Development"
51026,"Protocol Status","Concluded","01-JUL-2003","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","","Concluded"
51026,"Protocol Status","POS/PAC","23-MAY-2002","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","01-JUL-2003","POS/PAC"
51026,"Protocol Status","Closed to Accrual","12-MAR-2002","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","23-MAY-2002","Closed to Accrual"
51026,"Protocol Status","Closed to Follow Up","11-MAR-2002","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","12-MAR-2002","Closed to Follow Up"
51026,"Protocol Status","Open","30-NOV-2000","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","11-MAR-2002","Open"
51026,"Protocol Status","Pending","26-OCT-2000","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","30-NOV-2000","Pending"
51026,"Protocol Status","In Development","24-APR-2000","SPECT as a Non-Invasive Alternative to Liver Biopsies in Subjects with HIV/HCV","A5096","26-OCT-2000","In Development"
51035,"Protocol Status","Concluded","03-OCT-2011","Neuropsychological Substudy of A5095: Behavior, Mood and Sleep","A5097s","","Concluded"
51035,"Protocol Status","Closed to Follow Up","07-MAR-2005","Neuropsychological Substudy of A5095: Behavior, Mood and Sleep","A5097s","03-OCT-2011","Closed to Follow Up"
51037,"Protocol Status","Withdrawn","08-AUG-2000","Immunologic/Virologic Effects of Mycophenolate Mofetil in Tx of HIV-1 infection","A5098","","Other"
51037,"Protocol Status","In Development","17-MAY-2000","Immunologic/Virologic Effects of Mycophenolate Mofetil in Tx of HIV-1 infection","A5098","08-AUG-2000","In Development"
51038,"Protocol Status","Concluded","01-SEP-2005","Effect of Storage on Plasma Lactate Determinations","A5099","","Concluded"
51038,"Protocol Status","POS/PAC","04-NOV-2004","Effect of Storage on Plasma Lactate Determinations","A5099","01-SEP-2005","POS/PAC"
51038,"Protocol Status","Closed to Follow Up","14-FEB-2001","Effect of Storage on Plasma Lactate Determinations","A5099","04-NOV-2004","Closed to Follow Up"
51038,"Protocol Status","Closed to Accrual","14-FEB-2001","Effect of Storage on Plasma Lactate Determinations","A5099","14-FEB-2001","Closed to Accrual"
51038,"Protocol Status","Open","23-JAN-2001","Effect of Storage on Plasma Lactate Determinations","A5099","14-FEB-2001","Open"
51038,"Protocol Status","In Development","25-MAY-2000","Effect of Storage on Plasma Lactate Determinations","A5099","23-JAN-2001","In Development"
51041,"Protocol Status","Closed to Follow Up","12-JAN-2004","Virology Substudy of A5086","A5100s","","Closed to Follow Up"
51043,"Protocol Status","Closed to Follow Up","10-MAR-2006","Male Genital Secretions Substudy of A5068","A5101s","","Closed to Follow Up"
51049,"Protocol Status","Concluded","23-APR-2008","Restarting ART+/-IL-2 at CD4","A5102","","Concluded"
51049,"Protocol Status","Closed to Follow Up","22-NOV-2004","Restarting ART+/-IL-2 at CD4","A5102","23-APR-2008","Closed to Follow Up"
51049,"Protocol Status","POS/PAC","22-NOV-2004","Restarting ART+/-IL-2 at CD4","A5102","22-NOV-2004","POS/PAC"
51049,"Protocol Status","Closed to Accrual","19-JAN-2003","Restarting ART+/-IL-2 at CD4","A5102","22-NOV-2004","Closed to Accrual"
51049,"Protocol Status","Open","11-JUN-2001","Restarting ART+/-IL-2 at CD4","A5102","19-JAN-2003","Open"
51049,"Protocol Status","In Development","27-JUN-2000","Restarting ART+/-IL-2 at CD4","A5102","11-JUN-2001","In Development"
51050,"Protocol Status","Closed to Follow Up","06-FEB-2002","Switch to PI-Sparing Regimens","A5103","","Closed to Follow Up"
51050,"Protocol Status","Withdrawn","01-FEB-2002","Switch to PI-Sparing Regimens","A5103","06-FEB-2002","Other"
51050,"Protocol Status","Closed to Accrual","07-DEC-2001","Switch to PI-Sparing Regimens","A5103","01-FEB-2002","Closed to Accrual"
51050,"Protocol Status","Open","06-JUN-2001","Switch to PI-Sparing Regimens","A5103","07-DEC-2001","Open"
51050,"Protocol Status","In Development","28-JUN-2000","Switch to PI-Sparing Regimens","A5103","06-JUN-2001","In Development"
51054,"Protocol Status","Closed to Follow Up","06-JAN-2003","Immunology Substudy of A5086","A5104s","","Closed to Follow Up"
51056,"Protocol Status","Withdrawn","12-DEC-2001","Phase I/II Mycophenolate Mofetil + ABC","A5105","","Other"
51056,"Protocol Status","Open","05-NOV-2001","Phase I/II Mycophenolate Mofetil + ABC","A5105","12-DEC-2001","Open"
51056,"Protocol Status","Pending","12-JUN-2001","Phase I/II Mycophenolate Mofetil + ABC","A5105","05-NOV-2001","Pending"
51056,"Protocol Status","In Development","09-AUG-2000","Phase I/II Mycophenolate Mofetil + ABC","A5105","12-JUN-2001","In Development"
51057,"Protocol Status","In Development","10-AUG-2000","Detailed Neuropathy Sub-study of A5069","A5106s","","In Development"
51059,"Protocol Status","Closed to Follow Up","17-FEB-2005","Pharmacology Substudy of A5095","A5107s","","Closed to Follow Up"
51059,"Protocol Status","In Development","14-AUG-2000","Pharmacology Substudy of A5095","A5107s","17-FEB-2005","In Development"
51060,"Protocol Status","Concluded","21-MAR-2006","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","","Concluded"
51060,"Protocol Status","POS/PAC","30-JAN-2004","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","21-MAR-2006","POS/PAC"
51060,"Protocol Status","Closed to Accrual","04-JUN-2002","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","30-JAN-2004","Closed to Accrual"
51060,"Protocol Status","Closed to Follow Up","31-MAY-2002","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","04-JUN-2002","Closed to Follow Up"
51060,"Protocol Status","Temporarily Closed","15-MAR-2002","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","31-MAY-2002","Other"
51060,"Protocol Status","Open","06-AUG-2001","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","15-MAR-2002","Open"
51060,"Protocol Status","Pending","06-APR-2001","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","06-AUG-2001","Pending"
51060,"Protocol Status","In Development","15-AUG-2000","Effect of EFV + NFV on Pharmacokinetics of HMG CoA Reductase Inhibitors","A5108","06-APR-2001","In Development"
51066,"Protocol Status","Closed to Follow Up","04-MAR-2003","Viral Replication on Antigen-Specific Proliferation vs. Cytokine Production","A5109s","","Closed to Follow Up"
51066,"Protocol Status","In Development","11-SEP-2000","Viral Replication on Antigen-Specific Proliferation vs. Cytokine Production","A5109s","04-MAR-2003","In Development"
51067,"Protocol Status","Concluded","29-SEP-2009","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","","Concluded"
51067,"Protocol Status","POS/PAC","06-SEP-2006","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","29-SEP-2009","POS/PAC"
51067,"Protocol Status","Closed to Accrual","09-DEC-2005","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","06-SEP-2006","Closed to Accrual"
51067,"Protocol Status","Closed to Follow Up","21-MAR-2005","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","09-DEC-2005","Closed to Follow Up"
51067,"Protocol Status","Closed to Accrual","08-APR-2004","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","21-MAR-2005","Closed to Accrual"
51067,"Protocol Status","Open","21-MAR-2002","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","08-APR-2004","Open"
51067,"Protocol Status","Pending","16-NOV-2001","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","21-MAR-2002","Pending"
51067,"Protocol Status","In Development","14-SEP-2000","Thymidine Analogue Substitute or NRTI-Sparing Regimen for Peripheral Fat Wasting","A5110","16-NOV-2001","In Development"
51072,"Protocol Status","Closed to Follow Up","18-JUL-2005","Latent Infected T-cell Clearance Substudy of A5068","A5111s","","Closed to Follow Up"
51074,"Protocol Status","Closed to Follow Up","23-DEC-2002","A5079 Substudy of Frequently Sampled IV GTT to Assess Insulin Sensitivity","A5112s","","Closed to Follow Up"
51074,"Protocol Status","In Development","26-SEP-2000","A5079 Substudy of Frequently Sampled IV GTT to Assess Insulin Sensitivity","A5112s","23-DEC-2002","In Development"
51075,"Protocol Status","Concluded","01-NOV-2005","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","","Concluded"
51075,"Protocol Status","Concluded","01-NOV-2005","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","01-NOV-2005","Concluded"
51075,"Protocol Status","POS/PAC","05-FEB-2003","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","01-NOV-2005","POS/PAC"
51075,"Protocol Status","Closed to Follow Up","11-DEC-2001","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","05-FEB-2003","Closed to Follow Up"
51075,"Protocol Status","Closed to Accrual","25-SEP-2001","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","11-DEC-2001","Closed to Accrual"
51075,"Protocol Status","Open","26-APR-2001","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","25-SEP-2001","Open"
51075,"Protocol Status","Pending","19-MAR-2001","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","26-APR-2001","Pending"
51075,"Protocol Status","In Development","27-SEP-2000","Study of Immune Function in Healthy Adults Aged 18-30 & 45","A5113","19-MAR-2001","In Development"
51083,"Protocol Status","Concluded","18-JUN-2011","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","","Concluded"
51083,"Protocol Status","POS/PAC","10-SEP-2004","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","18-JUN-2011","POS/PAC"
51083,"Protocol Status","Closed to Follow Up","07-JAN-2003","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","10-SEP-2004","Closed to Follow Up"
51083,"Protocol Status","Closed to Accrual","26-FEB-2001","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","07-JAN-2003","Closed to Accrual"
51083,"Protocol Status","Open","31-AUG-2000","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","26-FEB-2001","Open"
51083,"Protocol Status","Pending","04-AUG-2000","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","31-AUG-2000","Pending"
51083,"Protocol Status","In Development","12-JUN-2000","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","04-AUG-2000","In Development"
51083,"Protocol Status","Closed to Accrual","06-JUN-2000","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","12-JUN-2000","Closed to Accrual"
51083,"Protocol Status","Open","18-MAY-2000","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","06-JUN-2000","Open"
51083,"Protocol Status","Pending","23-NOV-1999","HIV-Specific Helper/CTL Responses from Therapeutic Vaccination","A5058s","18-MAY-2000","Pending"
51086,"Protocol Status","Concluded","13-MAY-2011","A5090 Substudy:Cognitive Impairment & Oxidative Stress:Proton Magnetic Resonance","A5114s","","Concluded"
51086,"Protocol Status","Closed to Follow Up","03-JUN-2005","A5090 Substudy:Cognitive Impairment & Oxidative Stress:Proton Magnetic Resonance","A5114s","13-MAY-2011","Closed to Follow Up"
51088,"Protocol Status","Concluded","01-FEB-2009","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","","Concluded"
51088,"Protocol Status","POS/PAC","16-SEP-2005","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","01-FEB-2009","POS/PAC"
51088,"Protocol Status","Closed to Follow Up","04-APR-2005","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","16-SEP-2005","Closed to Follow Up"
51088,"Protocol Status","Closed to Accrual","17-MAY-2004","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","04-APR-2005","Closed to Accrual"
51088,"Protocol Status","Open","01-APR-2002","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","17-MAY-2004","Open"
51088,"Protocol Status","Pending","21-FEB-2002","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","01-APR-2002","Pending"
51088,"Protocol Status","In Development","21-NOV-2000","ART Switch at Lower vs Higher HIV RNA Levels in Subjects w/Viral Relapse","A5115","21-FEB-2002","In Development"
51091,"Protocol Status","Concluded","01-JUN-2007","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","","Concluded"
51091,"Protocol Status","POS/PAC","20-DEC-2004","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","01-JUN-2007","POS/PAC"
51091,"Protocol Status","Closed to Follow Up","30-JUN-2004","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","20-DEC-2004","Closed to Follow Up"
51091,"Protocol Status","Closed to Accrual","31-JAN-2003","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","30-JUN-2004","Closed to Accrual"
51091,"Protocol Status","Open","11-JUN-2001","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","31-JAN-2003","Open"
51091,"Protocol Status","Pending","12-MAR-2001","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","11-JUN-2001","Pending"
51091,"Protocol Status","In Development","29-NOV-2000","PI-Sparing Regimen vs. NRTI-Sparing regimen for ACTG 388 participants","A5116","12-MAR-2001","In Development"
51093,"Protocol Status","Concluded","01-NOV-2008","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","","Concluded"
51093,"Protocol Status","POS/PAC","02-JUL-2004","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","01-NOV-2008","POS/PAC"
51093,"Protocol Status","Closed to Follow Up","19-AUG-2003","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","02-JUL-2004","Closed to Follow Up"
51093,"Protocol Status","Closed to Accrual","01-JUL-2002","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","19-AUG-2003","Closed to Accrual"
51093,"Protocol Status","Open","26-OCT-2001","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","01-JUL-2002","Open"
51093,"Protocol Status","Pending","24-MAY-2001","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","26-OCT-2001","Pending"
51093,"Protocol Status","In Development","05-DEC-2000","Distal Symmetrical Polyneuropathy in Advanced HIV-1 for Prior ART Exposure","A5117","24-MAY-2001","In Development"
51094,"Protocol Status","Concluded","01-JUL-2006","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","","Concluded"
51094,"Protocol Status","POS/PAC","04-NOV-2004","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","01-JUL-2006","POS/PAC"
51094,"Protocol Status","Closed to Follow Up","04-NOV-2004","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","04-NOV-2004","Closed to Follow Up"
51094,"Protocol Status","Closed to Accrual","09-FEB-2004","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","04-NOV-2004","Closed to Accrual"
51094,"Protocol Status","Temporarily Closed","23-DEC-2003","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","09-FEB-2004","Other"
51094,"Protocol Status","Open","24-APR-2003","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","23-DEC-2003","Open"
51094,"Protocol Status","Temporarily Closed","14-AUG-2002","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","24-APR-2003","Other"
51094,"Protocol Status","Open","25-JUL-2002","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","14-AUG-2002","Open"
51094,"Protocol Status","Pending","04-DEC-2001","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","25-JUL-2002","Pending"
51094,"Protocol Status","In Development","05-DEC-2000","DAPD vs.Placebo with T-20 and Optimized Background Therapy for Treatment Failure","A5118","04-DEC-2001","In Development"
51095,"Protocol Status","Withdrawn","20-MAY-2003","PK Study of HRT w/NFV, LPV/RTV or EFV in HIV-Infected Postmenopausal Women","A5119","","Other"
51095,"Protocol Status","On Hold","27-AUG-2002","PK Study of HRT w/NFV, LPV/RTV or EFV in HIV-Infected Postmenopausal Women","A5119","20-MAY-2003","Other"
51095,"Protocol Status","Pending","20-JUN-2002","PK Study of HRT w/NFV, LPV/RTV or EFV in HIV-Infected Postmenopausal Women","A5119","27-AUG-2002","Pending"
51095,"Protocol Status","In Development","05-DEC-2000","PK Study of HRT w/NFV, LPV/RTV or EFV in HIV-Infected Postmenopausal Women","A5119","20-JUN-2002","In Development"
51097,"Protocol Status","Withdrawn","19-JUL-2001","Effects of Immunization with HIV-1 Immungen Plus STI on HIV Replication","A5120","","Other"
51097,"Protocol Status","Pending","11-JUL-2001","Effects of Immunization with HIV-1 Immungen Plus STI on HIV Replication","A5120","19-JUL-2001","Pending"
51097,"Protocol Status","In Development","06-DEC-2000","Effects of Immunization with HIV-1 Immungen Plus STI on HIV Replication","A5120","11-JUL-2001","In Development"
51102,"Protocol Status","Closed to Follow Up","18-SEP-2003","PI-Contain/NRTI-Sparing & NRTI-Contain/PI-Sparing Reg. on Visceral Adipose","A5124s","","Closed to Follow Up"
51103,"Protocol Status","Closed to Follow Up","01-JUL-2004","A5116 Substudy:Trunk & Peripheral Adipose Tissue, Bone Density & Metabolic","A5125s","","Closed to Follow Up"
51105,"Protocol Status","Concluded","01-JUN-2009","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","","Concluded"
51105,"Protocol Status","POS/PAC","25-MAY-2007","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","01-JUN-2009","POS/PAC"
51105,"Protocol Status","Closed to Follow Up","06-JUN-2005","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","25-MAY-2007","Closed to Follow Up"
51105,"Protocol Status","Closed to Accrual","01-DEC-2004","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","06-JUN-2005","Closed to Accrual"
51105,"Protocol Status","Open","21-MAR-2002","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","01-DEC-2004","Open"
51105,"Protocol Status","Pending","02-OCT-2001","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","21-MAR-2002","Pending"
51105,"Protocol Status","In Development","18-DEC-2000","Predictive Value of PK-Adj Phenotype on Response to PIs + RTV in PI Failure","A5126","02-OCT-2001","In Development"
51107,"Protocol Status","Concluded","01-NOV-2006","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","","Concluded"
51107,"Protocol Status","POS/PAC","04-MAY-2005","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","01-NOV-2006","POS/PAC"
51107,"Protocol Status","Closed to Follow Up","30-NOV-2004","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","04-MAY-2005","Closed to Follow Up"
51107,"Protocol Status","Closed to Accrual","06-AUG-2004","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","30-NOV-2004","Closed to Accrual"
51107,"Protocol Status","Open","22-MAY-2002","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","06-AUG-2004","Open"
51107,"Protocol Status","Pending","30-JAN-2002","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","22-MAY-2002","Pending"
51107,"Protocol Status","In Development","11-DEC-2000","Adefovir Dipivoxil + Tenofovir Disoproxil Fumarate for HepB/HIV Co-Infection","A5127","30-JAN-2002","In Development"
51108,"Protocol Status","Closed to Follow Up","22-DEC-2010","US Genomics Sample Collection","A5128","","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","21-DEC-2010","US Genomics Sample Collection","A5128","22-DEC-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","15-DEC-2010","US Genomics Sample Collection","A5128","21-DEC-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","02-SEP-2010","US Genomics Sample Collection","A5128","15-DEC-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","31-AUG-2010","US Genomics Sample Collection","A5128","02-SEP-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","24-AUG-2010","US Genomics Sample Collection","A5128","31-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","23-AUG-2010","US Genomics Sample Collection","A5128","24-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","20-AUG-2010","US Genomics Sample Collection","A5128","23-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","19-AUG-2010","US Genomics Sample Collection","A5128","20-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","17-AUG-2010","US Genomics Sample Collection","A5128","19-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","12-AUG-2010","US Genomics Sample Collection","A5128","17-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","10-AUG-2010","US Genomics Sample Collection","A5128","12-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","09-AUG-2010","US Genomics Sample Collection","A5128","10-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","05-AUG-2010","US Genomics Sample Collection","A5128","09-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","04-AUG-2010","US Genomics Sample Collection","A5128","05-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","28-JUN-2010","US Genomics Sample Collection","A5128","04-AUG-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","04-JUN-2010","US Genomics Sample Collection","A5128","28-JUN-2010","Closed to Follow Up"
51108,"Protocol Status","Closed to Follow Up","08-APR-2010","US Genomics Sample Collection","A5128","04-JUN-2010","Closed to Follow Up"
51108,"Protocol Status","Enrolling","13-FEB-2002","US Genomics Sample Collection","A5128","08-APR-2010","Enrolling"
51108,"Protocol Status","Open","31-JAN-2002","US Genomics Sample Collection","A5128","13-FEB-2002","Open"
51108,"Protocol Status","Pending","02-JAN-2002","US Genomics Sample Collection","A5128","31-JAN-2002","Pending"
51108,"Protocol Status","In Development","08-JAN-2001","US Genomics Sample Collection","A5128","02-JAN-2002","In Development"
51110,"Protocol Status","Concluded","01-MAR-2004","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","","Concluded"
51110,"Protocol Status","POS/PAC","26-MAR-2003","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","01-MAR-2004","POS/PAC"
51110,"Protocol Status","Closed to Accrual","23-OCT-2002","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","26-MAR-2003","Closed to Accrual"
51110,"Protocol Status","Closed to Follow Up","10-OCT-2002","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","23-OCT-2002","Closed to Follow Up"
51110,"Protocol Status","Open","30-JAN-2002","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","10-OCT-2002","Open"
51110,"Protocol Status","Pending","11-DEC-2001","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","30-JAN-2002","Pending"
51110,"Protocol Status","In Development","17-JAN-2001","Oral B Vitamin Therapy for Hyperlactatemia in Patients on NRTIs","A5129","11-DEC-2001","In Development"
51113,"Protocol Status","Concluded","09-OCT-2009","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","","Concluded"
51113,"Protocol Status","POS/PAC","12-DEC-2007","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","09-OCT-2009","POS/PAC"
51113,"Protocol Status","Closed to Follow Up","03-OCT-2006","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","12-DEC-2007","Closed to Follow Up"
51113,"Protocol Status","Closed to Follow Up","03-OCT-2006","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","03-OCT-2006","Closed to Follow Up"
51113,"Protocol Status","Closed to Accrual","09-FEB-2006","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","03-OCT-2006","Closed to Accrual"
51113,"Protocol Status","Open","31-MAR-2003","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","09-FEB-2006","Open"
51113,"Protocol Status","Pending","28-MAR-2002","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","31-MAR-2003","Pending"
51113,"Protocol Status","FDA - IND Hold","25-OCT-2001","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","28-MAR-2002","Other"
51113,"Protocol Status","Pending","26-SEP-2001","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","25-OCT-2001","Pending"
51113,"Protocol Status","In Development","24-JAN-2001","Safety/Immunogenicity of ALVAC-Infected Autologous DC SQ vs ALVAC SQ","A5130","26-SEP-2001","In Development"
51114,"Protocol Status","Concluded","02-DEC-2004","EFV Interruption w/o Resistant Virus Selection; Relation to Drug Elimination","A5131","","Concluded"
51114,"Protocol Status","Closed to Follow Up","17-NOV-2003","EFV Interruption w/o Resistant Virus Selection; Relation to Drug Elimination","A5131","02-DEC-2004","Closed to Follow Up"
51114,"Protocol Status","Closed to Accrual","19-AUG-2003","EFV Interruption w/o Resistant Virus Selection; Relation to Drug Elimination","A5131","17-NOV-2003","Closed to Accrual"
51114,"Protocol Status","Open","01-OCT-2001","EFV Interruption w/o Resistant Virus Selection; Relation to Drug Elimination","A5131","19-AUG-2003","Open"
51114,"Protocol Status","In Development","29-JAN-2001","EFV Interruption w/o Resistant Virus Selection; Relation to Drug Elimination","A5131","01-OCT-2001","In Development"
51118,"Protocol Status","Concluded","03-FEB-2011","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","","Concluded"
51118,"Protocol Status","POS/PAC","22-MAR-2007","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","03-FEB-2011","POS/PAC"
51118,"Protocol Status","Closed to Follow Up","03-MAY-2006","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","22-MAR-2007","Closed to Follow Up"
51118,"Protocol Status","Closed to Accrual","01-NOV-2004","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","03-MAY-2006","Closed to Accrual"
51118,"Protocol Status","Open","30-AUG-2002","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","01-NOV-2004","Open"
51118,"Protocol Status","Pending","12-MAR-2002","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","30-AUG-2002","Pending"
51118,"Protocol Status","In Development","31-JAN-2001","IL-2 Effect on HIV-Specific Immunity+ Time to Viral Relapse After ART Withdrawal","A5132","12-MAR-2002","In Development"
51120,"Protocol Status","Withdrawn","04-JUL-2002","NRTI-Sparing Regimen of EFV & LPV/RTV on Venous Lactate & Liver Histology","A5133","","Other"
51120,"Protocol Status","Open","01-MAR-2002","NRTI-Sparing Regimen of EFV & LPV/RTV on Venous Lactate & Liver Histology","A5133","04-JUL-2002","Open"
51120,"Protocol Status","Pending","05-JUL-2001","NRTI-Sparing Regimen of EFV & LPV/RTV on Venous Lactate & Liver Histology","A5133","01-MAR-2002","Pending"
51120,"Protocol Status","In Development","13-FEB-2001","NRTI-Sparing Regimen of EFV & LPV/RTV on Venous Lactate & Liver Histology","A5133","05-JUL-2001","In Development"
51122,"Protocol Status","Withdrawn","01-MAR-2001","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5134","","Other"
51122,"Protocol Status","In Development","20-FEB-2001","Evaluation of the Effects of Ribavirin on ZDV or d4T Triphosphate Formation","A5134","01-MAR-2001","In Development"
51123,"Protocol Status","Closed to Follow Up","10-FEB-2004","Fixed-Dose vs. Concentration-Adjusted PI Therapy for Salvage Therapy","A5135","","Closed to Follow Up"
51123,"Protocol Status","Closed to Accrual","03-JUL-2003","Fixed-Dose vs. Concentration-Adjusted PI Therapy for Salvage Therapy","A5135","10-FEB-2004","Closed to Accrual"
51123,"Protocol Status","Concluded","01-MAR-2003","Fixed-Dose vs. Concentration-Adjusted PI Therapy for Salvage Therapy","A5135","03-JUL-2003","Concluded"
51123,"Protocol Status","Open","15-OCT-2002","Fixed-Dose vs. Concentration-Adjusted PI Therapy for Salvage Therapy","A5135","01-MAR-2003","Open"
51123,"Protocol Status","Pending","01-JUL-2002","Fixed-Dose vs. Concentration-Adjusted PI Therapy for Salvage Therapy","A5135","15-OCT-2002","Pending"
51123,"Protocol Status","In Development","20-FEB-2001","Fixed-Dose vs. Concentration-Adjusted PI Therapy for Salvage Therapy","A5135","01-JUL-2002","In Development"
51130,"Protocol Status","Concluded","29-SEP-2011","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","","Concluded"
51130,"Protocol Status","POS/PAC","06-JUN-2006","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","29-SEP-2011","POS/PAC"
51130,"Protocol Status","Closed to Follow Up","24-JUN-2003","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","06-JUN-2006","Closed to Follow Up"
51130,"Protocol Status","Closed to Accrual","17-JUL-2002","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","24-JUN-2003","Closed to Accrual"
51130,"Protocol Status","Open","27-MAR-2002","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","17-JUL-2002","Open"
51130,"Protocol Status","Pending","06-FEB-2002","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","27-MAR-2002","Pending"
51130,"Protocol Status","In Development","06-MAR-2001","Immunologic Consequences of ARV Tx Intensification: Follow-up to ACTG 315/375","A5136","06-FEB-2002","In Development"
51142,"Protocol Status","Closed to Follow Up","12-MAY-2005","A5137s: Female Genital Secretions Substudy of A5068","A5137s","","Closed to Follow Up"
51143,"Protocol Status","Concluded","25-SEP-2009","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","","Concluded"
51143,"Protocol Status","POS/PAC","24-MAR-2006","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","25-SEP-2009","POS/PAC"
51143,"Protocol Status","Closed to Follow Up","02-MAY-2005","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","24-MAR-2006","Closed to Follow Up"
51143,"Protocol Status","Closed to Accrual","30-APR-2004","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","02-MAY-2005","Closed to Accrual"
51143,"Protocol Status","Open","01-APR-2003","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","30-APR-2004","Open"
51143,"Protocol Status","Temporarily Closed","11-NOV-2002","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","01-APR-2003","Other"
51143,"Protocol Status","Open","31-DEC-2001","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","11-NOV-2002","Open"
51143,"Protocol Status","Pending","03-DEC-2001","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","31-DEC-2001","Pending"
51143,"Protocol Status","In Development","29-MAR-2001","Augmenting Magnitude of HAART-Induced Immune Restoration with Cyclosporine","A5138","03-DEC-2001","In Development"
51145,"Protocol Status","Closed to Follow Up","10-DEC-2003","Mechanism for First Phase Cell Restoration: Substudy of A5138","A5139s","","Closed to Follow Up"
51147,"Protocol Status","In Development","13-APR-2001","Lymph Node Viral Reservoir","A5140s","","In Development"
51150,"Protocol Status","Concluded","16-JUL-2004","Pot. ARV Tx for Subjs w/CD4","A5141","","Concluded"
51150,"Protocol Status","Closed to Follow Up","03-SEP-2003","Pot. ARV Tx for Subjs w/CD4","A5141","16-JUL-2004","Closed to Follow Up"
51150,"Protocol Status","Closed to Accrual","03-JUL-2003","Pot. ARV Tx for Subjs w/CD4","A5141","03-SEP-2003","Closed to Accrual"
51150,"Protocol Status","Open","31-JAN-2002","Pot. ARV Tx for Subjs w/CD4","A5141","03-JUL-2003","Open"
51150,"Protocol Status","Pending","30-OCT-2001","Pot. ARV Tx for Subjs w/CD4","A5141","31-JAN-2002","Pending"
51150,"Protocol Status","In Development","24-APR-2001","Pot. ARV Tx for Subjs w/CD4","A5141","30-OCT-2001","In Development"
51155,"Protocol Status","POS/PAC","07-MAY-2007","LPV/r + EFV vs. LPV/r + 2 NRTIs vs. EFV + 2 NRTIs for Initial Therapy","A5142","","POS/PAC"
51155,"Protocol Status","Closed to Follow Up","09-MAR-2006","LPV/r + EFV vs. LPV/r + 2 NRTIs vs. EFV + 2 NRTIs for Initial Therapy","A5142","07-MAY-2007","Closed to Follow Up"
51155,"Protocol Status","Closed to Accrual","28-MAY-2004","LPV/r + EFV vs. LPV/r + 2 NRTIs vs. EFV + 2 NRTIs for Initial Therapy","A5142","09-MAR-2006","Closed to Accrual"
51155,"Protocol Status","Open","14-JAN-2003","LPV/r + EFV vs. LPV/r + 2 NRTIs vs. EFV + 2 NRTIs for Initial Therapy","A5142","28-MAY-2004","Open"
51155,"Protocol Status","Pending","03-OCT-2002","LPV/r + EFV vs. LPV/r + 2 NRTIs vs. EFV + 2 NRTIs for Initial Therapy","A5142","14-JAN-2003","Pending"
51155,"Protocol Status","In Development","16-MAY-2001","LPV/r + EFV vs. LPV/r + 2 NRTIs vs. EFV + 2 NRTIs for Initial Therapy","A5142","03-OCT-2002","In Development"
51156,"Protocol Status","POS/PAC","19-JUL-2005","LPV/r vs. fAPV+ RTV vs. LPV/r+ fAPV+ TDF + 1 or 2 NRTIs for Virologic Failure","A5143","","POS/PAC"
51156,"Protocol Status","Closed to Follow Up","21-JUN-2004","LPV/r vs. fAPV+ RTV vs. LPV/r+ fAPV+ TDF + 1 or 2 NRTIs for Virologic Failure","A5143","19-JUL-2005","Closed to Follow Up"
51156,"Protocol Status","Closed to Accrual","03-AUG-2003","LPV/r vs. fAPV+ RTV vs. LPV/r+ fAPV+ TDF + 1 or 2 NRTIs for Virologic Failure","A5143","21-JUN-2004","Closed to Accrual"
51156,"Protocol Status","Open","25-JUN-2002","LPV/r vs. fAPV+ RTV vs. LPV/r+ fAPV+ TDF + 1 or 2 NRTIs for Virologic Failure","A5143","03-AUG-2003","Open"
51156,"Protocol Status","In Development","16-MAY-2001","LPV/r vs. fAPV+ RTV vs. LPV/r+ fAPV+ TDF + 1 or 2 NRTIs for Virologic Failure","A5143","25-JUN-2002","In Development"
51157,"Protocol Status","Withdrawn","06-AUG-2004","Phosphorus P31 Nuclear MRS to Evaluate Mitochondrial Dysfunction","A5144","","Other"
51157,"Protocol Status","Temporarily Closed","18-APR-2003","Phosphorus P31 Nuclear MRS to Evaluate Mitochondrial Dysfunction","A5144","06-AUG-2004","Other"
51157,"Protocol Status","Open","06-JUN-2002","Phosphorus P31 Nuclear MRS to Evaluate Mitochondrial Dysfunction","A5144","18-APR-2003","Open"
51157,"Protocol Status","Pending","28-FEB-2002","Phosphorus P31 Nuclear MRS to Evaluate Mitochondrial Dysfunction","A5144","06-JUN-2002","Pending"
51157,"Protocol Status","In Development","16-MAY-2001","Phosphorus P31 Nuclear MRS to Evaluate Mitochondrial Dysfunction","A5144","28-FEB-2002","In Development"
51159,"Protocol Status","Withdrawn","13-NOV-2002","Antioxidants/Thiamine/Riboflavin for Patients recovering from Hyperlactatemia","A5145","","Other"
51159,"Protocol Status","Open","05-APR-2002","Antioxidants/Thiamine/Riboflavin for Patients recovering from Hyperlactatemia","A5145","13-NOV-2002","Open"
51159,"Protocol Status","Pending","15-FEB-2002","Antioxidants/Thiamine/Riboflavin for Patients recovering from Hyperlactatemia","A5145","05-APR-2002","Pending"
51159,"Protocol Status","In Development","30-MAY-2001","Antioxidants/Thiamine/Riboflavin for Patients recovering from Hyperlactatemia","A5145","15-FEB-2002","In Development"
51160,"Protocol Status","Concluded","01-JUL-2011","Effect of TDM on Viral Response to Salvage Regimens","A5146","","Concluded"
51160,"Protocol Status","POS/PAC","10-JUL-2007","Effect of TDM on Viral Response to Salvage Regimens","A5146","01-JUL-2011","POS/PAC"
51160,"Protocol Status","Closed to Follow Up","14-MAR-2007","Effect of TDM on Viral Response to Salvage Regimens","A5146","10-JUL-2007","Closed to Follow Up"
51160,"Protocol Status","Closed to Accrual","05-JUL-2006","Effect of TDM on Viral Response to Salvage Regimens","A5146","14-MAR-2007","Closed to Accrual"
51160,"Protocol Status","Open","17-JUN-2002","Effect of TDM on Viral Response to Salvage Regimens","A5146","05-JUL-2006","Open"
51160,"Protocol Status","In Development","11-JUN-2001","Effect of TDM on Viral Response to Salvage Regimens","A5146","17-JUN-2002","In Development"
51167,"Protocol Status","Closed to Follow Up","10-MAR-2004","Intensive PK Substudy of A5143 to Assess LPV/r & fAPV Interactions","A5147s","","Closed to Follow Up"
51169,"Protocol Status","Concluded","01-DEC-2006","Niacin for HIV dyslipidemia.","A5148","","Concluded"
51169,"Protocol Status","POS/PAC","22-DEC-2005","Niacin for HIV dyslipidemia.","A5148","01-DEC-2006","POS/PAC"
51169,"Protocol Status","Closed to Follow Up","20-JAN-2005","Niacin for HIV dyslipidemia.","A5148","22-DEC-2005","Closed to Follow Up"
51169,"Protocol Status","Closed to Accrual","20-FEB-2004","Niacin for HIV dyslipidemia.","A5148","20-JAN-2005","Closed to Accrual"
51169,"Protocol Status","Open","23-SEP-2002","Niacin for HIV dyslipidemia.","A5148","20-FEB-2004","Open"
51169,"Protocol Status","Pending","31-JUL-2002","Niacin for HIV dyslipidemia.","A5148","23-SEP-2002","Pending"
51169,"Protocol Status","In Development","05-JUL-2001","Niacin for HIV dyslipidemia.","A5148","31-JUL-2002","In Development"
51174,"Protocol Status","Closed to Accrual","12-SEP-2003","ADV, Peg-IFN - Alfa-2A + Ribavirin Treatment in HBV, HIV & HCV Infected Subjects","A5149","","Closed to Accrual"
51174,"Protocol Status","Withdrawn","12-SEP-2003","ADV, Peg-IFN - Alfa-2A + Ribavirin Treatment in HBV, HIV & HCV Infected Subjects","A5149","12-SEP-2003","Other"
51174,"Protocol Status","Open","23-APR-2003","ADV, Peg-IFN - Alfa-2A + Ribavirin Treatment in HBV, HIV & HCV Infected Subjects","A5149","12-SEP-2003","Open"
51174,"Protocol Status","Pending","21-MAR-2003","ADV, Peg-IFN - Alfa-2A + Ribavirin Treatment in HBV, HIV & HCV Infected Subjects","A5149","23-APR-2003","Pending"
51174,"Protocol Status","On Hold","16-JAN-2003","ADV, Peg-IFN - Alfa-2A + Ribavirin Treatment in HBV, HIV & HCV Infected Subjects","A5149","21-MAR-2003","Other"
51174,"Protocol Status","In Development","16-JUL-2001","ADV, Peg-IFN - Alfa-2A + Ribavirin Treatment in HBV, HIV & HCV Infected Subjects","A5149","16-JAN-2003","In Development"
51186,"Protocol Status","POS/PAC","18-APR-2008","Postpartum Virologic & Immunologic Changes in HIV-Infected Women","A5150","","POS/PAC"
51186,"Protocol Status","Closed to Follow Up","24-JAN-2006","Postpartum Virologic & Immunologic Changes in HIV-Infected Women","A5150","18-APR-2008","Closed to Follow Up"
51186,"Protocol Status","Closed to Accrual","13-MAY-2005","Postpartum Virologic & Immunologic Changes in HIV-Infected Women","A5150","24-JAN-2006","Closed to Accrual"
51186,"Protocol Status","Open","22-JUL-2002","Postpartum Virologic & Immunologic Changes in HIV-Infected Women","A5150","13-MAY-2005","Open"
51186,"Protocol Status","Pending","07-JUN-2002","Postpartum Virologic & Immunologic Changes in HIV-Infected Women","A5150","22-JUL-2002","Pending"
51186,"Protocol Status","In Development","21-AUG-2001","Postpartum Virologic & Immunologic Changes in HIV-Infected Women","A5150","07-JUN-2002","In Development"
51187,"Protocol Status","Withdrawn","17-OCT-2001","Concentration-Controlled Tx vs Fixed-Dose Tx  in Treatment-Naive Patient","A5151","","Other"
51187,"Protocol Status","On Hold","18-SEP-2001","Concentration-Controlled Tx vs Fixed-Dose Tx  in Treatment-Naive Patient","A5151","17-OCT-2001","Other"
51187,"Protocol Status","In Development","21-AUG-2001","Concentration-Controlled Tx vs Fixed-Dose Tx  in Treatment-Naive Patient","A5151","18-SEP-2001","In Development"
51188,"Protocol Status","Closed to Follow Up","09-DEC-2004","A5142 Substudy: Endothelial Function Prior to & After Starting ART","A5152s","","Closed to Follow Up"
51188,"Protocol Status","In Development","28-AUG-2001","A5142 Substudy: Endothelial Function Prior to & After Starting ART","A5152s","09-DEC-2004","In Development"
51190,"Protocol Status","POS/PAC","12-SEP-2006","Pharmacology Substudy of A5150","A5153s","","POS/PAC"
51190,"Protocol Status","Closed to Follow Up","14-DEC-2005","Pharmacology Substudy of A5150","A5153s","12-SEP-2006","Closed to Follow Up"
51190,"Protocol Status","Closed to Accrual","20-SEP-2005","Pharmacology Substudy of A5150","A5153s","14-DEC-2005","Closed to Accrual"
51190,"Protocol Status","Open","22-JUL-2002","Pharmacology Substudy of A5150","A5153s","20-SEP-2005","Open"
51190,"Protocol Status","Pending","07-JUN-2002","Pharmacology Substudy of A5150","A5153s","22-JUL-2002","Pending"
51190,"Protocol Status","In Development","29-AUG-2001","Pharmacology Substudy of A5150","A5153s","07-JUN-2002","In Development"
51195,"Protocol Status","Withdrawn","21-MAR-2002","PPAR-gamma Activator Rosiglitazone for Treatment of Lipoatrophy","A5154","","Other"
51195,"Protocol Status","In Development","10-SEP-2001","PPAR-gamma Activator Rosiglitazone for Treatment of Lipoatrophy","A5154","21-MAR-2002","In Development"
51195,"Protocol Status","In Development","10-SEP-2001","PPAR-gamma Activator Rosiglitazone for Treatment of Lipoatrophy","A5154","10-SEP-2001","In Development"
51197,"Protocol Status","Concluded","29-SEP-2011","ARV Treat Intensification on Rate of Decay of Latent Reservoir:Substudy ofA5136","A5155s","","Concluded"
51197,"Protocol Status","Closed to Follow Up","17-JUN-2003","ARV Treat Intensification on Rate of Decay of Latent Reservoir:Substudy ofA5136","A5155s","29-SEP-2011","Closed to Follow Up"
51203,"Protocol Status","Withdrawn","27-SEP-2001","DOT for Patients Experiencing Virologic Failure","A5156","","Other"
51203,"Protocol Status","In Development","25-SEP-2001","DOT for Patients Experiencing Virologic Failure","A5156","27-SEP-2001","In Development"
51205,"Protocol Status","Concluded","01-FEB-2009","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","","Concluded"
51205,"Protocol Status","POS/PAC","20-DEC-2007","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","01-FEB-2009","POS/PAC"
51205,"Protocol Status","Closed to Accrual","19-DEC-2006","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","20-DEC-2007","Closed to Accrual"
51205,"Protocol Status","Closed to Follow Up","08-DEC-2006","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","19-DEC-2006","Closed to Follow Up"
51205,"Protocol Status","Enrolling","09-NOV-2004","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","08-DEC-2006","Enrolling"
51205,"Protocol Status","Open","22-SEP-2004","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","09-NOV-2004","Open"
51205,"Protocol Status","Pending","13-SEP-2002","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","22-SEP-2004","Pending"
51205,"Protocol Status","In Development","26-SEP-2001","Acetyl L-Carnitine for Dideoxynucleoside Associated Distal Peripheral Neuropathy","A5157","13-SEP-2002","In Development"
51206,"Protocol Status","Withdrawn","27-SEP-2001","Suppressive Long-term Antiviral Management of Coinfected Patients (SLAM-C)","A5158","","Other"
51206,"Protocol Status","In Development","26-SEP-2001","Suppressive Long-term Antiviral Management of Coinfected Patients (SLAM-C)","A5158","27-SEP-2001","In Development"
51209,"Protocol Status","Concluded","01-AUG-2005","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","","Concluded"
51209,"Protocol Status","POS/PAC","05-APR-2004","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","01-AUG-2005","POS/PAC"
51209,"Protocol Status","Closed to Accrual","20-MAR-2003","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","05-APR-2004","Closed to Accrual"
51209,"Protocol Status","Closed to Follow Up","17-MAR-2003","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","20-MAR-2003","Closed to Follow Up"
51209,"Protocol Status","Open","30-AUG-2002","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","17-MAR-2003","Open"
51209,"Protocol Status","Pending","24-MAY-2002","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","30-AUG-2002","Pending"
51209,"Protocol Status","In Development","01-OCT-2001","Evaluation of PK Interactions Between PIs & Calcium Channel Blockers","A5159","24-MAY-2002","In Development"
51214,"Protocol Status","Closed to Follow Up","30-JAN-2006","Viral Dynamics Substudy of A5142","A5160s","","Closed to Follow Up"
51223,"Protocol Status","Closed to Follow Up","03-SEP-2003","HAART on Clearance of Pneumocystis Carinii: A Substudy of A5141","A5162s","","Closed to Follow Up"
51226,"Protocol Status","Concluded","30-NOV-2007","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","","Concluded"
51226,"Protocol Status","POS/PAC","01-SEP-2006","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","30-NOV-2007","POS/PAC"
51226,"Protocol Status","Closed to Follow Up","16-FEB-2006","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","01-SEP-2006","Closed to Follow Up"
51226,"Protocol Status","Closed to Accrual","10-MAR-2005","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","16-FEB-2006","Closed to Accrual"
51226,"Protocol Status","Open","27-OCT-2003","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","10-MAR-2005","Open"
51226,"Protocol Status","Pending","16-APR-2003","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","27-OCT-2003","Pending"
51226,"Protocol Status","In Development","03-DEC-2001","Once-Weekly Alendronate for Decreased Bone Mineral Density","A5163","16-APR-2003","In Development"
51227,"Protocol Status","POS/PAC","30-JAN-2008","ART for HIV-Infected Adults with Acute OIs: Immediate vs. Deferred Initiation","A5164","","POS/PAC"
51227,"Protocol Status","Closed to Follow Up","10-AUG-2007","ART for HIV-Infected Adults with Acute OIs: Immediate vs. Deferred Initiation","A5164","30-JAN-2008","Closed to Follow Up"
51227,"Protocol Status","Closed to Accrual","08-SEP-2006","ART for HIV-Infected Adults with Acute OIs: Immediate vs. Deferred Initiation","A5164","10-AUG-2007","Closed to Accrual"
51227,"Protocol Status","Open","26-MAR-2003","ART for HIV-Infected Adults with Acute OIs: Immediate vs. Deferred Initiation","A5164","08-SEP-2006","Open"
51227,"Protocol Status","Pending","31-JAN-2003","ART for HIV-Infected Adults with Acute OIs: Immediate vs. Deferred Initiation","A5164","26-MAR-2003","Pending"
51227,"Protocol Status","In Development","03-DEC-2001","ART for HIV-Infected Adults with Acute OIs: Immediate vs. Deferred Initiation","A5164","31-JAN-2003","In Development"
51228,"Protocol Status","Concluded","01-OCT-2007","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","","Concluded"
51228,"Protocol Status","POS/PAC","04-APR-2006","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","01-OCT-2007","POS/PAC"
51228,"Protocol Status","Closed to Follow Up","04-APR-2006","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","04-APR-2006","Closed to Follow Up"
51228,"Protocol Status","Closed to Accrual","27-APR-2005","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","04-APR-2006","Closed to Accrual"
51228,"Protocol Status","Open","24-FEB-2003","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","27-APR-2005","Open"
51228,"Protocol Status","Temporarily Closed","14-AUG-2002","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","24-FEB-2003","Other"
51228,"Protocol Status","Open","17-JUN-2002","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","14-AUG-2002","Open"
51228,"Protocol Status","Pending","26-APR-2002","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","17-JUN-2002","Pending"
51228,"Protocol Status","In Development","03-DEC-2001","DAPD vs. DAPD + MMF in Treatment Experienced Subjects","A5165","26-APR-2002","In Development"
51229,"Protocol Status","Closed to Follow Up","14-NOV-2002","Viral Dynamics Substudy of A5095","A5166s","","Closed to Follow Up"
51238,"Protocol Status","Withdrawn","03-MAY-2004","LdT Prior to Start of Lamivudine -Containing HAART for Tx of HBV","A5167","","Other"
51238,"Protocol Status","Temporarily Closed","02-APR-2004","LdT Prior to Start of Lamivudine -Containing HAART for Tx of HBV","A5167","03-MAY-2004","Other"
51238,"Protocol Status","Open","17-MAR-2003","LdT Prior to Start of Lamivudine -Containing HAART for Tx of HBV","A5167","02-APR-2004","Open"
51238,"Protocol Status","Pending","19-DEC-2002","LdT Prior to Start of Lamivudine -Containing HAART for Tx of HBV","A5167","17-MAR-2003","Pending"
51238,"Protocol Status","In Development","04-JAN-2002","LdT Prior to Start of Lamivudine -Containing HAART for Tx of HBV","A5167","19-DEC-2002","In Development"
51241,"Protocol Status","Closed to Follow Up","22-OCT-2003","Effect of Acute OI on the Pharmacokinetics of LPV/RTV: Substudy of A5164","A5168s","","Closed to Follow Up"
51241,"Protocol Status","In Development","15-JAN-2002","Effect of Acute OI on the Pharmacokinetics of LPV/RTV: Substudy of A5164","A5168s","22-OCT-2003","In Development"
51243,"Protocol Status","Concluded","20-APR-2010","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","","Concluded"
51243,"Protocol Status","POS/PAC","01-MAY-2006","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","20-APR-2010","POS/PAC"
51243,"Protocol Status","Closed to Follow Up","19-JUL-2005","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","01-MAY-2006","Closed to Follow Up"
51243,"Protocol Status","Closed to Accrual","12-SEP-2003","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","19-JUL-2005","Closed to Accrual"
51243,"Protocol Status","Open","17-OCT-2002","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","12-SEP-2003","Open"
51243,"Protocol Status","Pending","09-SEP-2002","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","17-OCT-2002","Pending"
51243,"Protocol Status","In Development","15-JAN-2002","Immunologic & Clinical Progression in Subjects w/CD4350 Who Stop ART","A5170","09-SEP-2002","In Development"
51248,"Protocol Status","Withdrawn","12-SEP-2002","Proactive vs. Reactive Treatment of Neutropenia & Anemia in Subjects w/HCV & HIV","A5171","","Other"
51248,"Protocol Status","In Development","04-FEB-2002","Proactive vs. Reactive Treatment of Neutropenia & Anemia in Subjects w/HCV & HIV","A5171","12-SEP-2002","In Development"
51249,"Protocol Status","Concluded","15-MAR-2011","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","","Concluded"
51249,"Protocol Status","POS/PAC","28-MAY-2009","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","15-MAR-2011","POS/PAC"
51249,"Protocol Status","Closed to Follow Up","26-MAY-2004","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","28-MAY-2009","Closed to Follow Up"
51249,"Protocol Status","Closed to Accrual","05-AUG-2003","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","26-MAY-2004","Closed to Accrual"
51249,"Protocol Status","Open","16-DEC-2002","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","05-AUG-2003","Open"
51249,"Protocol Status","Pending","30-SEP-2002","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","16-DEC-2002","Pending"
51249,"Protocol Status","In Development","04-FEB-2002","Vaccine-Induced Helper & CTL Responses to Control Viremia w/o ART","A5172","30-SEP-2002","In Development"
51257,"Protocol Status","POS/PAC","02-APR-2009","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","","POS/PAC"
51257,"Protocol Status","Closed to Follow Up","02-MAY-2008","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","02-APR-2009","Closed to Follow Up"
51257,"Protocol Status","Closed to Accrual","11-JUN-2007","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","02-MAY-2008","Closed to Accrual"
51257,"Protocol Status","Enrolling - Temporarily Closed to Accrual","15-NOV-2006","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","11-JUN-2007","Other"
51257,"Protocol Status","Enrolling","06-JAN-2004","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","15-NOV-2006","Enrolling"
51257,"Protocol Status","Open","14-OCT-2003","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","06-JAN-2004","Open"
51257,"Protocol Status","Pending","09-JAN-2003","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","14-OCT-2003","Pending"
51257,"Protocol Status","In Development","19-MAR-2002","Replication-Competent Clearance of HIV in Resting Memory CD4s w/ENF+ART","A5173","09-JAN-2003","In Development"
51264,"Protocol Status","Concluded","01-APR-2010","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","","Concluded"
51264,"Protocol Status","POS/PAC","25-APR-2007","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","01-APR-2010","POS/PAC"
51264,"Protocol Status","Closed to Follow Up","28-MAR-2005","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","25-APR-2007","Closed to Follow Up"
51264,"Protocol Status","Closed to Accrual","27-OCT-2003","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","28-MAR-2005","Closed to Accrual"
51264,"Protocol Status","Open","28-MAY-2003","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","27-OCT-2003","Open"
51264,"Protocol Status","Pending","02-DEC-2002","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","28-MAY-2003","Pending"
51264,"Protocol Status","In Development","02-APR-2002","Improving Immune Function w/Growth Hormone in Subj w/Incomplete CD4 Restoration","A5174","02-DEC-2002","In Development"
51270,"Protocol Status","POS/PAC","15-DEC-2010","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","","POS/PAC"
51270,"Protocol Status","Closed to Follow Up","31-MAY-2010","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","15-DEC-2010","Closed to Follow Up"
51270,"Protocol Status","Closed to Follow Up","30-MAY-2010","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","31-MAY-2010","Closed to Follow Up"
51270,"Protocol Status","Closed to Accrual","01-AUG-2007","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","30-MAY-2010","Closed to Accrual"
51270,"Protocol Status","Enrolling","13-MAY-2005","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","01-AUG-2007","Enrolling"
51270,"Protocol Status","Open","28-APR-2005","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","13-MAY-2005","Open"
51270,"Protocol Status","Pending","22-MAY-2004","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","28-APR-2005","Pending"
51270,"Protocol Status","In Development","08-MAY-2002","Once-Daily PI + Non-NRTI Regimens for Initial Tx  in Resource-Limited Settings","A5175","22-MAY-2004","In Development"
51271,"Protocol Status","POS/PAC","02-SEP-2010","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","","POS/PAC"
51271,"Protocol Status","Closed to Follow Up","17-DEC-2009","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","02-SEP-2010","Closed to Follow Up"
51271,"Protocol Status","Closed to Accrual","21-OCT-2008","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","17-DEC-2009","Closed to Accrual"
51271,"Protocol Status","Enrolling - Re-Opened","04-JUN-2007","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","21-OCT-2008","Other"
51271,"Protocol Status","Enrolling - Temporarily Closed to Accrual","21-MAR-2007","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","04-JUN-2007","Other"
51271,"Protocol Status","Enrolling - Re-Opened","29-SEP-2006","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","21-MAR-2007","Other"
51271,"Protocol Status","Enrolling - Temporarily Closed to Accrual","27-SEP-2006","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","29-SEP-2006","Other"
51271,"Protocol Status","Enrolling","27-FEB-2006","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","27-SEP-2006","Enrolling"
51271,"Protocol Status","Open","27-JAN-2006","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","27-FEB-2006","Open"
51271,"Protocol Status","Pending","28-JUL-2005","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","27-JAN-2006","Pending"
51271,"Protocol Status","In Development","17-FEB-2005","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","28-JUL-2005","In Development"
51271,"Protocol Status","On Hold","19-DEC-2002","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","17-FEB-2005","Other"
51271,"Protocol Status","In Development","06-MAY-2002","Evaluation of the Safety, Tolerability, and Immunogenicity of DermaVir in HIV-1-Infected Subject","A5176","19-DEC-2002","In Development"
51272,"Protocol Status","Concluded","01-AUG-2010","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","","Concluded"
51272,"Protocol Status","Concluded","18-MAR-2010","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","01-AUG-2010","Concluded"
51272,"Protocol Status","POS/PAC","27-JUL-2007","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","18-MAR-2010","POS/PAC"
51272,"Protocol Status","Closed to Accrual","31-MAR-2005","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","27-JUL-2007","Closed to Accrual"
51272,"Protocol Status","Closed to Follow Up","03-MAR-2005","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","31-MAR-2005","Closed to Follow Up"
51272,"Protocol Status","Enrolling","18-FEB-2004","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","03-MAR-2005","Enrolling"
51272,"Protocol Status","Open","03-JUL-2003","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","18-FEB-2004","Open"
51272,"Protocol Status","Pending","05-JUN-2003","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","03-JUL-2003","Pending"
51272,"Protocol Status","In Development","29-APR-2002","The PK of EFV, NVP & LPV/r in HIV Subjects Requiring Hemodialysis","A5177","05-JUN-2003","In Development"
51283,"Protocol Status","POS/PAC","19-MAY-2010","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","","POS/PAC"
51283,"Protocol Status","Closed to Follow Up","12-FEB-2009","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","19-MAY-2010","Closed to Follow Up"
51283,"Protocol Status","Closed to Accrual","02-MAY-2007","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","12-FEB-2009","Closed to Accrual"
51283,"Protocol Status","Enrolling","04-AUG-2004","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","02-MAY-2007","Enrolling"
51283,"Protocol Status","Open","23-JUL-2004","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","04-AUG-2004","Open"
51283,"Protocol Status","Pending","30-JAN-2004","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","23-JUL-2004","Pending"
51283,"Protocol Status","In Development","05-JUN-2003","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","30-JAN-2004","In Development"
51283,"Protocol Status","In Development","27-JUN-2002","Suppressive Long-term Antiviral Management of HCV/HIV Coinfection (SLAM C)","A5178","05-JUN-2003","In Development"
51286,"Protocol Status","Withdrawn","01-MAR-2005","Angiotensin Receptor Blocker (Valsartan) + ART vs. ART Alone for HIV Nephropathy","A5179","","Other"
51286,"Protocol Status","On Hold","20-DEC-2004","Angiotensin Receptor Blocker (Valsartan) + ART vs. ART Alone for HIV Nephropathy","A5179","01-MAR-2005","Other"
51286,"Protocol Status","Pending","26-JUN-2004","Angiotensin Receptor Blocker (Valsartan) + ART vs. ART Alone for HIV Nephropathy","A5179","20-DEC-2004","Pending"
51286,"Protocol Status","In Development","20-JUN-2002","Angiotensin Receptor Blocker (Valsartan) + ART vs. ART Alone for HIV Nephropathy","A5179","26-JUN-2004","In Development"
51287,"Protocol Status","Concluded","01-NOV-2007","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","","Concluded"
51287,"Protocol Status","POS/PAC","15-MAR-2006","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","01-NOV-2007","POS/PAC"
51287,"Protocol Status","Closed to Follow Up","30-MAR-2005","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","15-MAR-2006","Closed to Follow Up"
51287,"Protocol Status","Closed to Accrual","11-MAR-2005","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","30-MAR-2005","Closed to Accrual"
51287,"Protocol Status","Enrolling","09-DEC-2004","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","11-MAR-2005","Enrolling"
51287,"Protocol Status","Pending","03-DEC-2004","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","09-DEC-2004","Pending"
51287,"Protocol Status","Open","03-DEC-2004","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","03-DEC-2004","Open"
51287,"Protocol Status","In Development","27-JUN-2003","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","03-DEC-2004","In Development"
51287,"Protocol Status","On Hold","05-SEP-2002","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","27-JUN-2003","Other"
51287,"Protocol Status","In Development","24-JUN-2002","Efficacy & Safety of Prosaptide for Relief of Neuropathic Pain","A5180","05-SEP-2002","In Development"
51289,"Protocol Status","Concluded","13-OCT-2010","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","","Concluded"
51289,"Protocol Status","POS/PAC","07-SEP-2007","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","13-OCT-2010","POS/PAC"
51289,"Protocol Status","Closed to Follow Up","17-MAR-2005","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","07-SEP-2007","Closed to Follow Up"
51289,"Protocol Status","Closed to Accrual","04-OCT-2004","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","17-MAR-2005","Closed to Accrual"
51289,"Protocol Status","Enrolling","09-SEP-2003","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","04-OCT-2004","Enrolling"
51289,"Protocol Status","Open","21-AUG-2003","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","09-SEP-2003","Open"
51289,"Protocol Status","Pending","23-JUN-2003","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","21-AUG-2003","Pending"
51289,"Protocol Status","In Development","03-JUL-2002","HIV Antigen Specific Immune Responses - Comparison of Alternative in Vitro Assay","A5181","23-JUN-2003","In Development"
51295,"Protocol Status","Withdrawn","10-FEB-2003","Immunologic Effects of AS02A Vaccine when Administered w/HIV Vaccine","A5182","","Other"
51295,"Protocol Status","On Hold","23-OCT-2002","Immunologic Effects of AS02A Vaccine when Administered w/HIV Vaccine","A5182","10-FEB-2003","Other"
51295,"Protocol Status","In Development","30-AUG-2002","Immunologic Effects of AS02A Vaccine when Administered w/HIV Vaccine","A5182","23-OCT-2002","In Development"
51296,"Protocol Status","On Hold","02-JUL-2004","Safety & Immunogenicity of Highly Attenuated Strain of MVA-BN Vaccination","A5183","","Other"
51296,"Protocol Status","Withdrawn","01-JUL-2004","Safety & Immunogenicity of Highly Attenuated Strain of MVA-BN Vaccination","A5183","02-JUL-2004","Other"
51296,"Protocol Status","Pending","21-APR-2004","Safety & Immunogenicity of Highly Attenuated Strain of MVA-BN Vaccination","A5183","01-JUL-2004","Pending"
51296,"Protocol Status","In Development","30-AUG-2002","Safety & Immunogenicity of Highly Attenuated Strain of MVA-BN Vaccination","A5183","21-APR-2004","In Development"
51310,"Protocol Status","POS/PAC","16-FEB-2007","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","","POS/PAC"
51310,"Protocol Status","Concluded","16-FEB-2007","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","16-FEB-2007","Concluded"
51310,"Protocol Status","Closed to Follow Up","25-JAN-2007","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","16-FEB-2007","Closed to Follow Up"
51310,"Protocol Status","Closed to Accrual","11-DEC-2006","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","25-JAN-2007","Closed to Accrual"
51310,"Protocol Status","Enrolling","20-JUN-2006","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","11-DEC-2006","Enrolling"
51310,"Protocol Status","Open","20-APR-2006","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","20-JUN-2006","Open"
51310,"Protocol Status","Pending","20-DEC-2004","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","20-APR-2006","Pending"
51310,"Protocol Status","In Development","23-OCT-2002","ART Impact on PEG IFN Alfa-2A+Ribavirin for HCV in HCV/HIV Coinfection w/High CD","A5184","20-DEC-2004","In Development"
51316,"Protocol Status","POS/PAC","13-AUG-2011","A5175 Genital Compartment Substudy","A5185s","","POS/PAC"
51316,"Protocol Status","Closed to Follow Up","31-MAY-2010","A5175 Genital Compartment Substudy","A5185s","13-AUG-2011","Closed to Follow Up"
51316,"Protocol Status","Closed to Accrual","30-NOV-2006","A5175 Genital Compartment Substudy","A5185s","31-MAY-2010","Closed to Accrual"
51316,"Protocol Status","Enrolling","13-MAY-2005","A5175 Genital Compartment Substudy","A5185s","30-NOV-2006","Enrolling"
51316,"Protocol Status","Pending","13-MAY-2005","A5175 Genital Compartment Substudy","A5185s","13-MAY-2005","Pending"
51316,"Protocol Status","Open","28-APR-2005","A5175 Genital Compartment Substudy","A5185s","13-MAY-2005","Open"
51316,"Protocol Status","Pending","21-MAY-2004","A5175 Genital Compartment Substudy","A5185s","28-APR-2005","Pending"
51316,"Protocol Status","In Development","15-NOV-2002","A5175 Genital Compartment Substudy","A5185s","21-MAY-2004","In Development"
51317,"Protocol Status","Concluded","01-APR-2008","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","","Concluded"
51317,"Protocol Status","POS/PAC","23-SEP-2005","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","01-APR-2008","POS/PAC"
51317,"Protocol Status","Closed to Follow Up","11-JUL-2005","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","23-SEP-2005","Closed to Follow Up"
51317,"Protocol Status","Closed to Accrual","26-JAN-2005","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","11-JUL-2005","Closed to Accrual"
51317,"Protocol Status","Enrolling","16-AUG-2004","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","26-JAN-2005","Enrolling"
51317,"Protocol Status","Open","26-JUL-2004","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","16-AUG-2004","Open"
51317,"Protocol Status","Pending","11-NOV-2003","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","26-JUL-2004","Pending"
51317,"Protocol Status","In Development","18-NOV-2002","Effect of Fish Oil + Fenofibrate on Triglyceride Levels in Subjects on HAART","A5186","11-NOV-2003","In Development"
51318,"Protocol Status","Concluded","10-MAY-2010","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","","Concluded"
51318,"Protocol Status","POS/PAC","09-JUN-2009","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","10-MAY-2010","POS/PAC"
51318,"Protocol Status","Closed to Follow Up","04-SEP-2007","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","09-JUN-2009","Closed to Follow Up"
51318,"Protocol Status","Closed to Accrual","13-APR-2006","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","04-SEP-2007","Closed to Accrual"
51318,"Protocol Status","Enrolling","14-MAY-2004","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","13-APR-2006","Enrolling"
51318,"Protocol Status","Open","19-DEC-2003","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","14-MAY-2004","Open"
51318,"Protocol Status","Pending","29-SEP-2003","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","19-DEC-2003","Pending"
51318,"Protocol Status","In Development","18-NOV-2002","Safety/Immunogenicity of HIV DNA Vaccine VRC-HIVDNA0009-00-VP in Acute Infection","A5187","29-SEP-2003","In Development"
51326,"Protocol Status","Concluded","11-SEP-2010","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","","Concluded"
51326,"Protocol Status","POS/PAC","23-JAN-2009","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","11-SEP-2010","POS/PAC"
51326,"Protocol Status","Closed to Follow Up","31-JAN-2007","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","23-JAN-2009","Closed to Follow Up"
51326,"Protocol Status","Closed to Accrual","12-DEC-2006","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","31-JAN-2007","Closed to Accrual"
51326,"Protocol Status","Enrolling","07-JUL-2005","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","12-DEC-2006","Enrolling"
51326,"Protocol Status","Open","05-MAY-2005","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","07-JUL-2005","Open"
51326,"Protocol Status","Pending","23-JUN-2004","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","05-MAY-2005","Pending"
51326,"Protocol Status","In Development","17-DEC-2002","PK Study of Transdermal & Oral Contraceptive in HIV-1 Women on LPV/r","A5188","23-JUN-2004","In Development"
51331,"Protocol Status","POS/PAC","12-DEC-2006","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","","POS/PAC"
51331,"Protocol Status","Closed to Follow Up","16-OCT-2006","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","12-DEC-2006","Closed to Follow Up"
51331,"Protocol Status","Closed to Accrual","15-SEP-2006","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","16-OCT-2006","Closed to Accrual"
51331,"Protocol Status","Enrolling - Re-Opened","03-AUG-2006","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","15-SEP-2006","Other"
51331,"Protocol Status","Temporarily Closed","23-NOV-2005","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","03-AUG-2006","Other"
51331,"Protocol Status","Open","20-MAY-2005","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","23-NOV-2005","Open"
51331,"Protocol Status","Temporarily Closed","21-MAY-2004","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","20-MAY-2005","Other"
51331,"Protocol Status","Enrolling","03-SEP-2003","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","21-MAY-2004","Enrolling"
51331,"Protocol Status","Open","21-AUG-2003","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","03-SEP-2003","Open"
51331,"Protocol Status","Pending","11-JUN-2003","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","21-AUG-2003","Pending"
51331,"Protocol Status","In Development","31-DEC-2002","Safety and PK among AMD11070 in HIV-Seronegative Men after one or More Doses","A5191","11-JUN-2003","In Development"
51332,"Protocol Status","Concluded","01-JUN-2010","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","","Concluded"
51332,"Protocol Status","POS/PAC","09-MAY-2008","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","01-JUN-2010","POS/PAC"
51332,"Protocol Status","Closed to Follow Up","04-JAN-2007","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","09-MAY-2008","Closed to Follow Up"
51332,"Protocol Status","Closed to Accrual","29-SEP-2006","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","04-JAN-2007","Closed to Accrual"
51332,"Protocol Status","Enrolling","04-APR-2005","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","29-SEP-2006","Enrolling"
51332,"Protocol Status","Open","10-MAR-2005","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","04-APR-2005","Open"
51332,"Protocol Status","Pending","17-FEB-2004","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","10-MAR-2005","Pending"
51332,"Protocol Status","In Development","31-DEC-2002","Antiretroviral Activity & Safety, of PEG IFN Alpha 2-A in HIV Infected Subjects","A5192","17-FEB-2004","In Development"
51333,"Protocol Status","Withdrawn","20-MAR-2007","Safety/Immunogenicity of SQ MVA-mBN32 HIV-1 Vaccine & MVA-BN in HIV-1 Subjects","A5193","","Other"
51333,"Protocol Status","In Development","11-JUL-2006","Safety/Immunogenicity of SQ MVA-mBN32 HIV-1 Vaccine & MVA-BN in HIV-1 Subjects","A5193","20-MAR-2007","In Development"
51333,"Protocol Status","On Hold","27-JUN-2005","Safety/Immunogenicity of SQ MVA-mBN32 HIV-1 Vaccine & MVA-BN in HIV-1 Subjects","A5193","11-JUL-2006","Other"
51333,"Protocol Status","In Development","01-SEP-2004","Safety/Immunogenicity of SQ MVA-mBN32 HIV-1 Vaccine & MVA-BN in HIV-1 Subjects","A5193","27-JUN-2005","In Development"
51333,"Protocol Status","On Hold","27-JUN-2003","Safety/Immunogenicity of SQ MVA-mBN32 HIV-1 Vaccine & MVA-BN in HIV-1 Subjects","A5193","01-SEP-2004","Other"
51333,"Protocol Status","In Development","31-DEC-2002","Safety/Immunogenicity of SQ MVA-mBN32 HIV-1 Vaccine & MVA-BN in HIV-1 Subjects","A5193","27-JUN-2003","In Development"
51337,"Protocol Status","Withdrawn","02-OCT-2003","Neurological Outcomes in Subjects who Stop Antiretroviral Therapy","A5194","","Other"
51337,"Protocol Status","In Development","28-JAN-2003","Neurological Outcomes in Subjects who Stop Antiretroviral Therapy","A5194","02-OCT-2003","In Development"
51344,"Protocol Status","POS/PAC","24-SEP-2010","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","","POS/PAC"
51344,"Protocol Status","Closed to Follow Up","10-MAY-2010","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","24-SEP-2010","Closed to Follow Up"
51344,"Protocol Status","Closed to Follow Up","10-MAY-2010","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","10-MAY-2010","Closed to Follow Up"
51344,"Protocol Status","Closed to Follow Up","10-MAY-2010","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","10-MAY-2010","Closed to Follow Up"
51344,"Protocol Status","Closed to Accrual","15-DEC-2008","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","10-MAY-2010","Closed to Accrual"
51344,"Protocol Status","Enrolling","30-JUN-2006","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","15-DEC-2008","Enrolling"
51344,"Protocol Status","Open","08-MAY-2006","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","30-JUN-2006","Open"
51344,"Protocol Status","Pending","01-FEB-2005","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","08-MAY-2006","Pending"
51344,"Protocol Status","In Development","24-JAN-2003","Safety/Toxicity of Infants of HIV-Infected Women in ART Protocols","A5190","01-FEB-2005","In Development"
51345,"Protocol Status","Withdrawn","14-AUG-2003","Switch from NRTIs (ZDV, d4T, ddC, or ddI) to Study Reversibility of Fatty Liver","A5195","","Other"
51345,"Protocol Status","In Development","07-MAR-2003","Switch from NRTIs (ZDV, d4T, ddC, or ddI) to Study Reversibility of Fatty Liver","A5195","14-AUG-2003","In Development"
51349,"Protocol Status","POS/PAC","25-MAY-2011","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","","POS/PAC"
51349,"Protocol Status","Closed to Follow Up","25-MAY-2011","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","25-MAY-2011","Closed to Follow Up"
51349,"Protocol Status","Closed to Accrual","30-JUN-2006","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","25-MAY-2011","Closed to Accrual"
51349,"Protocol Status","Enrolling","18-AUG-2004","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","30-JUN-2006","Enrolling"
51349,"Protocol Status","Open","30-JUN-2004","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","18-AUG-2004","Open"
51349,"Protocol Status","Pending","05-MAR-2004","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","30-JUN-2004","Pending"
51349,"Protocol Status","In Development","02-APR-2003","Antiretroviral Effect MRK Ad5 HIV-1 Gag Vaccine in HIV Individuals Stopping ART","A5197","05-MAR-2004","In Development"
51354,"Protocol Status","Concluded","01-APR-2010","Effect of Growth Hormone on Thymus Size in HIV Subj on HAART: Substudy of A5174","A5198s","","Concluded"
51354,"Protocol Status","Closed to Follow Up","17-FEB-2005","Effect of Growth Hormone on Thymus Size in HIV Subj on HAART: Substudy of A5174","A5198s","01-APR-2010","Closed to Follow Up"
51354,"Protocol Status","In Development","20-MAR-2003","Effect of Growth Hormone on Thymus Size in HIV Subj on HAART: Substudy of A5174","A5198s","17-FEB-2005","In Development"
51370,"Protocol Status","POS/PAC","28-DEC-2010","International Neurological Study","A5199","","POS/PAC"
51370,"Protocol Status","Closed to Follow Up","31-MAY-2010","International Neurological Study","A5199","28-DEC-2010","Closed to Follow Up"
51370,"Protocol Status","Closed to Accrual","02-AUG-2007","International Neurological Study","A5199","31-MAY-2010","Closed to Accrual"
51370,"Protocol Status","Enrolling","20-FEB-2006","International Neurological Study","A5199","02-AUG-2007","Enrolling"
51370,"Protocol Status","Open","09-FEB-2006","International Neurological Study","A5199","20-FEB-2006","Open"
51370,"Protocol Status","Pending","05-OCT-2004","International Neurological Study","A5199","09-FEB-2006","Pending"
51370,"Protocol Status","In Development","19-NOV-2003","International Neurological Study","A5199","05-OCT-2004","In Development"
51371,"Protocol Status","Concluded","01-APR-2010","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","","Concluded"
51371,"Protocol Status","POS/PAC","02-MAY-2007","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","01-APR-2010","POS/PAC"
51371,"Protocol Status","Closed to Follow Up","09-AUG-2005","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","02-MAY-2007","Closed to Follow Up"
51371,"Protocol Status","Closed to Accrual","15-JUL-2005","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","09-AUG-2005","Closed to Accrual"
51371,"Protocol Status","Enrolling","15-FEB-2005","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","15-JUL-2005","Enrolling"
51371,"Protocol Status","Open","18-JAN-2005","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","15-FEB-2005","Open"
51371,"Protocol Status","Pending","02-NOV-2004","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","18-JAN-2005","Pending"
51371,"Protocol Status","In Development","06-JUN-2003","Anti-HIV Activity/Safety of (VGX-410) Mifepristone at Three Dose Levels","A5200","02-NOV-2004","In Development"
51373,"Protocol Status","POS/PAC","03-MAY-2006","ATV/RTV Maintenance Therapy","A5201","","POS/PAC"
51373,"Protocol Status","Closed to Follow Up","03-MAY-2006","ATV/RTV Maintenance Therapy","A5201","03-MAY-2006","Closed to Follow Up"
51373,"Protocol Status","Closed to Accrual","09-MAY-2005","ATV/RTV Maintenance Therapy","A5201","03-MAY-2006","Closed to Accrual"
51373,"Protocol Status","Enrolling","01-SEP-2004","ATV/RTV Maintenance Therapy","A5201","09-MAY-2005","Enrolling"
51373,"Protocol Status","Open","22-JUL-2004","ATV/RTV Maintenance Therapy","A5201","01-SEP-2004","Open"
51373,"Protocol Status","Pending","03-MAY-2004","ATV/RTV Maintenance Therapy","A5201","22-JUL-2004","Pending"
51373,"Protocol Status","In Development","20-JUN-2003","ATV/RTV Maintenance Therapy","A5201","03-MAY-2004","In Development"
51393,"Protocol Status","Closed to Follow Up","11-NOV-2009","EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects","A5202","","Closed to Follow Up"
51393,"Protocol Status","Closed to Accrual","02-DEC-2007","EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects","A5202","11-NOV-2009","Closed to Accrual"
51393,"Protocol Status","Enrolling","26-SEP-2005","EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects","A5202","02-DEC-2007","Enrolling"
51393,"Protocol Status","Open","21-SEP-2005","EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects","A5202","26-SEP-2005","Open"
51393,"Protocol Status","Pending","23-MAY-2005","EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects","A5202","21-SEP-2005","Pending"
51393,"Protocol Status","In Development","31-OCT-2003","EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects","A5202","23-MAY-2005","In Development"
51395,"Protocol Status","Withdrawn","17-FEB-2005","Switch from ZDV, d4T, ddC, and/or ddI to Study Reversibility of Fatty Liver","A5203","","Other"
51395,"Protocol Status","On Hold","25-OCT-2004","Switch from ZDV, d4T, ddC, and/or ddI to Study Reversibility of Fatty Liver","A5203","17-FEB-2005","Other"
51395,"Protocol Status","In Development","15-OCT-2003","Switch from ZDV, d4T, ddC, and/or ddI to Study Reversibility of Fatty Liver","A5203","25-OCT-2004","In Development"
51396,"Protocol Status","Withdrawn","10-JAN-2006","High Dose PEG-IFN+Ribavirin for HCV Genotype 1 in HIV Co-Infection/Monoinfection","A5204","","Other"
51396,"Protocol Status","In Development","02-DEC-2004","High Dose PEG-IFN+Ribavirin for HCV Genotype 1 in HIV Co-Infection/Monoinfection","A5204","10-JAN-2006","In Development"
51403,"Protocol Status","Concluded","28-JUL-2006","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","","Concluded"
51403,"Protocol Status","Closed to Accrual","23-SEP-2005","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","28-JUL-2006","Closed to Accrual"
51403,"Protocol Status","Closed to Follow Up","20-SEP-2005","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","23-SEP-2005","Closed to Follow Up"
51403,"Protocol Status","Enrolling","31-MAY-2005","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","20-SEP-2005","Enrolling"
51403,"Protocol Status","Open","01-NOV-2004","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","31-MAY-2005","Open"
51403,"Protocol Status","Pending","30-SEP-2004","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","01-NOV-2004","Pending"
51403,"Protocol Status","In Development","11-NOV-2003","Effect of the Levonorgestrel-Releasing IUD on Genital HIV Shedding","A5205","30-SEP-2004","In Development"
51404,"Protocol Status","Concluded","17-JUL-2010","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","","Concluded"
51404,"Protocol Status","POS/PAC","22-MAY-2008","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","17-JUL-2010","POS/PAC"
51404,"Protocol Status","Closed to Follow Up","02-NOV-2007","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","22-MAY-2008","Closed to Follow Up"
51404,"Protocol Status","Closed to Accrual","19-JUL-2007","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","02-NOV-2007","Closed to Accrual"
51404,"Protocol Status","Enrolling","12-SEP-2005","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","19-JUL-2007","Enrolling"
51404,"Protocol Status","Open","02-MAY-2005","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","12-SEP-2005","Open"
51404,"Protocol Status","Pending","30-MAR-2005","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","02-MAY-2005","Pending"
51404,"Protocol Status","In Development","11-NOV-2003","Impact of TDF Added to Stable ART on Dyslipidemia in HIV-Infected Subjects","A5206","30-MAR-2005","In Development"
51410,"Protocol Status","POS/PAC","14-FEB-2012","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","","POS/PAC"
51410,"Protocol Status","POS/PAC","23-NOV-2011","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","14-FEB-2012","POS/PAC"
51410,"Protocol Status","Closed to Follow Up","23-NOV-2011","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","23-NOV-2011","Closed to Follow Up"
51410,"Protocol Status","Closed to Follow Up","23-NOV-2011","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","23-NOV-2011","Closed to Follow Up"
51410,"Protocol Status","POS/PAC","23-NOV-2011","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","23-NOV-2011","POS/PAC"
51410,"Protocol Status","Closed to Accrual","05-JAN-2010","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","23-NOV-2011","Closed to Accrual"
51410,"Protocol Status","Enrolling","16-JAN-2007","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","05-JAN-2010","Enrolling"
51410,"Protocol Status","Open","21-MAR-2006","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","16-JAN-2007","Open"
51410,"Protocol Status","Pending","24-NOV-2004","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","21-MAR-2006","Pending"
51410,"Protocol Status","In Development","09-JAN-2004","3 ART Strategies to Reduce NVP-Resistant HIV After Intrapartum Single Dose NVP","A5207","24-NOV-2004","In Development"
51411,"Protocol Status","POS/PAC","28-FEB-2011","Optimal Combined Therapy After Nevirapine Exposure","A5208","","POS/PAC"
51411,"Protocol Status","Closed to Follow Up","28-FEB-2011","Optimal Combined Therapy After Nevirapine Exposure","A5208","28-FEB-2011","Closed to Follow Up"
51411,"Protocol Status","Closed to Accrual","08-JUL-2008","Optimal Combined Therapy After Nevirapine Exposure","A5208","28-FEB-2011","Closed to Accrual"
51411,"Protocol Status","Enrolling","11-NOV-2005","Optimal Combined Therapy After Nevirapine Exposure","A5208","08-JUL-2008","Enrolling"
51411,"Protocol Status","Open","25-OCT-2005","Optimal Combined Therapy After Nevirapine Exposure","A5208","11-NOV-2005","Open"
51411,"Protocol Status","Pending","12-AUG-2004","Optimal Combined Therapy After Nevirapine Exposure","A5208","25-OCT-2005","Pending"
51411,"Protocol Status","In Development","09-JAN-2004","Optimal Combined Therapy After Nevirapine Exposure","A5208","12-AUG-2004","In Development"
51414,"Protocol Status","Concluded","23-OCT-2009","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","","Concluded"
51414,"Protocol Status","POS/PAC","18-DEC-2008","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","23-OCT-2009","POS/PAC"
51414,"Protocol Status","Closed to Follow Up","09-MAY-2007","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","18-DEC-2008","Closed to Follow Up"
51414,"Protocol Status","Closed to Accrual","30-OCT-2006","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","09-MAY-2007","Closed to Accrual"
51414,"Protocol Status","Enrolling","12-DEC-2005","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","30-OCT-2006","Enrolling"
51414,"Protocol Status","Open","21-NOV-2005","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","12-DEC-2005","Open"
51414,"Protocol Status","Pending","01-DEC-2004","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","21-NOV-2005","Pending"
51414,"Protocol Status","In Development","01-DEC-2003","Safety, Efficacy,Tolerability of Ezetimibe w/Statin for Elevated LDL Cholesterol","A5209","01-DEC-2004","In Development"
51421,"Protocol Status","POS/PAC","02-SEP-2009","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","","POS/PAC"
51421,"Protocol Status","Closed to Follow Up","05-NOV-2008","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","02-SEP-2009","Closed to Follow Up"
51421,"Protocol Status","Closed to Accrual","16-NOV-2006","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","05-NOV-2008","Closed to Accrual"
51421,"Protocol Status","FDA - IND Hold","16-NOV-2006","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","16-NOV-2006","Other"
51421,"Protocol Status","Enrolling - Temp. Closed to Accrual/S.Agents/Prod.","13-SEP-2006","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","16-NOV-2006","Other"
51421,"Protocol Status","Open","25-AUG-2006","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","13-SEP-2006","Open"
51421,"Protocol Status","Temporarily Closed","24-MAR-2006","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","25-AUG-2006","Other"
51421,"Protocol Status","Enrolling","14-MAR-2005","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","24-MAR-2006","Enrolling"
51421,"Protocol Status","Open","30-NOV-2004","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","14-MAR-2005","Open"
51421,"Protocol Status","Pending","16-JUL-2004","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","30-NOV-2004","Pending"
51421,"Protocol Status","In Development","29-DEC-2003","Dose-Finding Safety/Activity Study of AMD11070 (Oral CXCR4 Entry Inhibitor)","A5210","16-JUL-2004","In Development"
51427,"Protocol Status","Closed to Follow Up","25-JAN-2011","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","","Closed to Follow Up"
51427,"Protocol Status","POS/PAC","25-JAN-2011","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","25-JAN-2011","POS/PAC"
51427,"Protocol Status","Closed to Accrual","13-OCT-2005","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","25-JAN-2011","Closed to Accrual"
51427,"Protocol Status","Enrolling","21-JUL-2004","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","13-OCT-2005","Enrolling"
51427,"Protocol Status","Open","26-MAY-2004","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","21-JUL-2004","Open"
51427,"Protocol Status","Pending","21-APR-2004","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","26-MAY-2004","Pending"
51427,"Protocol Status","In Development","21-JAN-2004","Safety/Efficacy of SCH 417690 (Oral HIV Entry Inhibitor) in HIV-1 Subjects","A5211","21-APR-2004","In Development"
51429,"Protocol Status","Closed to Follow Up","23-SEP-2008","Palifermin for inadequate increase in CD4+ cells","A5212","","Closed to Follow Up"
51429,"Protocol Status","Closed to Accrual","10-APR-2008","Palifermin for inadequate increase in CD4+ cells","A5212","23-SEP-2008","Closed to Accrual"
51429,"Protocol Status","Enrolling","12-FEB-2007","Palifermin for inadequate increase in CD4+ cells","A5212","10-APR-2008","Enrolling"
51429,"Protocol Status","Open","12-DEC-2006","Palifermin for inadequate increase in CD4+ cells","A5212","12-FEB-2007","Open"
51429,"Protocol Status","Pending","14-JUL-2006","Palifermin for inadequate increase in CD4+ cells","A5212","12-DEC-2006","Pending"
51429,"Protocol Status","In Development","01-JUL-2005","Palifermin for inadequate increase in CD4+ cells","A5212","14-JUL-2006","In Development"
51429,"Protocol Status","On Hold","06-MAR-2004","Palifermin for inadequate increase in CD4+ cells","A5212","01-JUL-2005","Other"
51429,"Protocol Status","In Development","30-JAN-2004","Palifermin for inadequate increase in CD4+ cells","A5212","06-MAR-2004","In Development"
51430,"Protocol Status","Concluded","01-MAR-2009","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","","Concluded"
51430,"Protocol Status","POS/PAC","24-JAN-2008","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","01-MAR-2009","POS/PAC"
51430,"Protocol Status","Closed to Follow Up","21-DEC-2007","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","24-JAN-2008","Closed to Follow Up"
51430,"Protocol Status","Closed to Accrual","21-DEC-2007","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","21-DEC-2007","Closed to Accrual"
51430,"Protocol Status","Enrolling - Re-Opened","10-OCT-2007","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","21-DEC-2007","Other"
51430,"Protocol Status","Enrolling - Temp. Closed to Accrual/S.Agents/Prod.","30-JAN-2006","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","10-OCT-2007","Other"
51430,"Protocol Status","Enrolling","07-SEP-2005","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","30-JAN-2006","Enrolling"
51430,"Protocol Status","Open","23-AUG-2005","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","07-SEP-2005","Open"
51430,"Protocol Status","Pending","15-OCT-2004","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","23-AUG-2005","Pending"
51430,"Protocol Status","In Development","15-JAN-2004","Safety, Tolerability, & PK Interactions of ATV + Rifampin in Healthy Volunteers","A5213","15-OCT-2004","In Development"
51439,"Protocol Status","POS/PAC","03-JUL-2007","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","","POS/PAC"
51439,"Protocol Status","Closed to Follow Up","20-APR-2007","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","03-JUL-2007","Closed to Follow Up"
51439,"Protocol Status","Closed to Accrual","26-FEB-2007","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","20-APR-2007","Closed to Accrual"
51439,"Protocol Status","Enrolling - Re-Opened","13-JUL-2006","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","26-FEB-2007","Other"
51439,"Protocol Status","Temporarily Closed","19-APR-2006","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","13-JUL-2006","Other"
51439,"Protocol Status","Enrolling","13-JUN-2005","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","19-APR-2006","Enrolling"
51439,"Protocol Status","Open","12-APR-2005","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","13-JUN-2005","Open"
51439,"Protocol Status","Pending","11-NOV-2004","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","12-APR-2005","Pending"
51439,"Protocol Status","In Development","13-FEB-2004","Safety of Single Dose IL-7 in HIV-1-Infected Subjects on ART","A5214","11-NOV-2004","In Development"
51441,"Protocol Status","Withdrawn","27-MAY-2004","PK of Addition of TMC 125 to APV/RTV Regimen in HIV-1 Infected Subjects","A5215","","Other"
51441,"Protocol Status","In Development","02-MAR-2004","PK of Addition of TMC 125 to APV/RTV Regimen in HIV-1 Infected Subjects","A5215","27-MAY-2004","In Development"
51443,"Protocol Status","Closed to Follow Up","26-NOV-2007","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","","Closed to Follow Up"
51443,"Protocol Status","Concluded","26-NOV-2007","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","26-NOV-2007","Concluded"
51443,"Protocol Status","Closed to Accrual","26-JAN-2007","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","26-NOV-2007","Closed to Accrual"
51443,"Protocol Status","Enrolling","24-FEB-2005","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","26-JAN-2007","Enrolling"
51443,"Protocol Status","Open","13-AUG-2004","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","24-FEB-2005","Open"
51443,"Protocol Status","Pending","23-APR-2004","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","13-AUG-2004","Pending"
51443,"Protocol Status","In Development","16-OCT-2003","Cyclosporine A+Trizivir+Kaletra vs.Trizivir+Kaletra alone in Primary Infection","A5216","23-APR-2004","In Development"
51444,"Protocol Status","POS/PAC","31-MAY-2011","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","","POS/PAC"
51444,"Protocol Status","Closed to Follow Up","31-MAY-2011","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","31-MAY-2011","Closed to Follow Up"
51444,"Protocol Status","Closed to Accrual","25-JUN-2009","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","31-MAY-2011","Closed to Accrual"
51444,"Protocol Status","Enrolling","18-MAR-2005","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","25-JUN-2009","Enrolling"
51444,"Protocol Status","Open","27-JAN-2005","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","18-MAR-2005","Open"
51444,"Protocol Status","Pending","09-AUG-2004","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","27-JAN-2005","Pending"
51444,"Protocol Status","In Development","16-DEC-2003","TDF + FTC + LPV/r vs. No ART in Newly Infected Patients","A5217","09-AUG-2004","In Development"
51445,"Protocol Status","Concluded","26-OCT-2011","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","","Concluded"
51445,"Protocol Status","POS/PAC","25-MAY-2011","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","26-OCT-2011","POS/PAC"
51445,"Protocol Status","Closed to Follow Up","02-DEC-2010","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","25-MAY-2011","Closed to Follow Up"
51445,"Protocol Status","Closed to Accrual","18-OCT-2006","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","02-DEC-2010","Closed to Accrual"
51445,"Protocol Status","Enrolling","30-MAR-2006","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","18-OCT-2006","Enrolling"
51445,"Protocol Status","Open","27-MAR-2006","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","30-MAR-2006","Open"
51445,"Protocol Status","Pending","06-AUG-2005","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","27-MAR-2006","Pending"
51445,"Protocol Status","In Development","11-MAR-2004","Therapeutic Immunization with MRK Ad5 in Recently Infected Subjects on ART","A5218","06-AUG-2005","In Development"
51446,"Protocol Status","Withdrawn","11-NOV-2004","LPV/RTV vs. ATV/RTV-Enhanced for First Virologic Failures","A5219","","Other"
51446,"Protocol Status","In Development","15-MAR-2004","LPV/RTV vs. ATV/RTV-Enhanced for First Virologic Failures","A5219","11-NOV-2004","In Development"
51451,"Protocol Status","Concluded","30-MAR-2011","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","","Concluded"
51451,"Protocol Status","POS/PAC","01-APR-2009","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","30-MAR-2011","POS/PAC"
51451,"Protocol Status","Closed to Follow Up","22-SEP-2008","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","01-APR-2009","Closed to Follow Up"
51451,"Protocol Status","Closed to Accrual","24-JUL-2007","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","22-SEP-2008","Closed to Accrual"
51451,"Protocol Status","Enrolling","23-JAN-2007","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","24-JUL-2007","Enrolling"
51451,"Protocol Status","Open","08-DEC-2006","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","23-JAN-2007","Open"
51451,"Protocol Status","Pending","31-JUL-2006","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","08-DEC-2006","Pending"
51451,"Protocol Status","On Hold","13-JAN-2006","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","31-JUL-2006","Other"
51451,"Protocol Status","In Development","01-DEC-2004","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","13-JAN-2006","In Development"
51451,"Protocol Status","On Hold","23-JUL-2004","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","01-DEC-2004","Other"
51451,"Protocol Status","In Development","29-MAR-2004","Response to HBV Vaccine with GM-CSF as a Vaccine Adjuvant","A5220","23-JUL-2004","In Development"
51455,"Protocol Status","POS/PAC","29-OCT-2010","ART Timing in New TB Patients","A5221","","POS/PAC"
51455,"Protocol Status","Closed to Follow Up","30-JUL-2010","ART Timing in New TB Patients","A5221","29-OCT-2010","Closed to Follow Up"
51455,"Protocol Status","Closed to Accrual","25-SEP-2009","ART Timing in New TB Patients","A5221","30-JUL-2010","Closed to Accrual"
51455,"Protocol Status","Enrolling","28-SEP-2006","ART Timing in New TB Patients","A5221","25-SEP-2009","Enrolling"
51455,"Protocol Status","Open","30-AUG-2006","ART Timing in New TB Patients","A5221","28-SEP-2006","Open"
51455,"Protocol Status","Pending","17-MAR-2005","ART Timing in New TB Patients","A5221","30-AUG-2006","Pending"
51455,"Protocol Status","In Development","23-APR-2004","ART Timing in New TB Patients","A5221","17-MAR-2005","In Development"
51461,"Protocol Status","Withdrawn","01-MAR-2005","Treatment Simplification in Patients Who don't Suppress TPV/RTV, T-20, and 3 NRT","A5222","","Other"
51461,"Protocol Status","On Hold","22-SEP-2004","Treatment Simplification in Patients Who don't Suppress TPV/RTV, T-20, and 3 NRT","A5222","01-MAR-2005","Other"
51461,"Protocol Status","In Development","30-APR-2004","Treatment Simplification in Patients Who don't Suppress TPV/RTV, T-20, and 3 NRT","A5222","22-SEP-2004","In Development"
51476,"Protocol Status","Concluded","13-JAN-2011","Differences in LPV/r PK among HIV infected Men and Women","A5223","","Concluded"
51476,"Protocol Status","Concluded","27-OCT-2010","Differences in LPV/r PK among HIV infected Men and Women","A5223","13-JAN-2011","Concluded"
51476,"Protocol Status","POS/PAC","10-NOV-2009","Differences in LPV/r PK among HIV infected Men and Women","A5223","27-OCT-2010","POS/PAC"
51476,"Protocol Status","Closed to Accrual","30-JUL-2007","Differences in LPV/r PK among HIV infected Men and Women","A5223","10-NOV-2009","Closed to Accrual"
51476,"Protocol Status","Closed to Follow Up","30-JUL-2007","Differences in LPV/r PK among HIV infected Men and Women","A5223","30-JUL-2007","Closed to Follow Up"
51476,"Protocol Status","Enrolling - Re-Opened","08-NOV-2006","Differences in LPV/r PK among HIV infected Men and Women","A5223","30-JUL-2007","Other"
51476,"Protocol Status","Enrolling - Temp. Closed to Accrual/S.Agents/Prod.","04-APR-2006","Differences in LPV/r PK among HIV infected Men and Women","A5223","08-NOV-2006","Other"
51476,"Protocol Status","Enrolling","10-OCT-2005","Differences in LPV/r PK among HIV infected Men and Women","A5223","04-APR-2006","Enrolling"
51476,"Protocol Status","Open","06-OCT-2005","Differences in LPV/r PK among HIV infected Men and Women","A5223","10-OCT-2005","Open"
51476,"Protocol Status","Pending","25-JAN-2005","Differences in LPV/r PK among HIV infected Men and Women","A5223","06-OCT-2005","Pending"
51476,"Protocol Status","In Development","14-JUL-2004","Differences in LPV/r PK among HIV infected Men and Women","A5223","25-JAN-2005","In Development"
51477,"Protocol Status","Closed to Follow Up","30-SEP-2009","Metabolic Substudy of A5202","A5224s","","Closed to Follow Up"
51485,"Protocol Status","Closed to Follow Up","14-OCT-2010","High-dose Fluconazole for pre-ART CM Patients","A5225","","Closed to Follow Up"
51485,"Protocol Status","Closed to Follow Up","14-OCT-2010","High-dose Fluconazole for pre-ART CM Patients","A5225","14-OCT-2010","Closed to Follow Up"
51485,"Protocol Status","Withdrawn","16-APR-2010","High-dose Fluconazole for pre-ART CM Patients","A5225","14-OCT-2010","Other"
51485,"Protocol Status","Enrolling","16-APR-2010","High-dose Fluconazole for pre-ART CM Patients","A5225","16-APR-2010","Enrolling"
51485,"Protocol Status","Enrolling","16-APR-2010","High-dose Fluconazole for pre-ART CM Patients","A5225","16-APR-2010","Enrolling"
51485,"Protocol Status","Open","19-FEB-2010","High-dose Fluconazole for pre-ART CM Patients","A5225","16-APR-2010","Open"
51485,"Protocol Status","Pending","08-APR-2009","High-dose Fluconazole for pre-ART CM Patients","A5225","19-FEB-2010","Pending"
51485,"Protocol Status","In Development","07-MAY-2007","High-dose Fluconazole for pre-ART CM Patients","A5225","08-APR-2009","In Development"
51485,"Protocol Status","On Hold","20-JAN-2006","High-dose Fluconazole for pre-ART CM Patients","A5225","07-MAY-2007","Other"
51485,"Protocol Status","In Development","23-AUG-2004","High-dose Fluconazole for pre-ART CM Patients","A5225","20-JAN-2006","In Development"
51491,"Protocol Status","Withdrawn","18-JUL-2007","The International ACTG Longitudinal Linked Randomized Trials (IALLRT)","A5226","","Other"
51491,"Protocol Status","Withdrawn","05-APR-2007","The International ACTG Longitudinal Linked Randomized Trials (IALLRT)","A5226","18-JUL-2007","Other"
51491,"Protocol Status","On Hold","11-FEB-2005","The International ACTG Longitudinal Linked Randomized Trials (IALLRT)","A5226","05-APR-2007","Other"
51491,"Protocol Status","In Development","20-AUG-2004","The International ACTG Longitudinal Linked Randomized Trials (IALLRT)","A5226","11-FEB-2005","In Development"
51506,"Protocol Status","Closed to Follow Up","15-DEC-2010","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","","Closed to Follow Up"
51506,"Protocol Status","POS/PAC","15-DEC-2010","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","15-DEC-2010","POS/PAC"
51506,"Protocol Status","Closed to Accrual","31-DEC-2009","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","15-DEC-2010","Closed to Accrual"
51506,"Protocol Status","Enrolling","01-OCT-2007","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","31-DEC-2009","Enrolling"
51506,"Protocol Status","Open","23-MAY-2007","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","01-OCT-2007","Open"
51506,"Protocol Status","Pending","13-FEB-2007","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","23-MAY-2007","Pending"
51506,"Protocol Status","In Development","17-NOV-2004","Short Course ART for Prev of Maternal/Child Transmission on Subseq Tx Efficacy","A5227","13-FEB-2007","In Development"
51507,"Protocol Status","POS/PAC","10-MAY-2007","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","","POS/PAC"
51507,"Protocol Status","Concluded","10-MAY-2007","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","10-MAY-2007","Concluded"
51507,"Protocol Status","Closed to Follow Up","30-APR-2007","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","10-MAY-2007","Closed to Follow Up"
51507,"Protocol Status","Closed to Accrual","01-APR-2007","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","30-APR-2007","Closed to Accrual"
51507,"Protocol Status","Enrolling","04-FEB-2005","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","01-APR-2007","Enrolling"
51507,"Protocol Status","Open","02-FEB-2005","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","04-FEB-2005","Open"
51507,"Protocol Status","In Development","25-OCT-2004","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","02-FEB-2005","In Development"
51507,"Protocol Status","Pending","23-JUN-2003","Acute HIV Infection & Early Disease Research Program Database Protocol","A5228","25-OCT-2004","Pending"
51514,"Protocol Status","Concluded","23-OCT-2010","Uridine Supplementation in HIV Lipoatrophy","A5229","","Concluded"
51514,"Protocol Status","POS/PAC","11-JAN-2010","Uridine Supplementation in HIV Lipoatrophy","A5229","23-OCT-2010","POS/PAC"
51514,"Protocol Status","Closed to Follow Up","02-DEC-2008","Uridine Supplementation in HIV Lipoatrophy","A5229","11-JAN-2010","Closed to Follow Up"
51514,"Protocol Status","Closed to Accrual","11-JAN-2008","Uridine Supplementation in HIV Lipoatrophy","A5229","02-DEC-2008","Closed to Accrual"
51514,"Protocol Status","Enrolling - Re-Opened","28-FEB-2007","Uridine Supplementation in HIV Lipoatrophy","A5229","11-JAN-2008","Other"
51514,"Protocol Status","Temporarily Closed","17-JAN-2007","Uridine Supplementation in HIV Lipoatrophy","A5229","28-FEB-2007","Other"
51514,"Protocol Status","Enrolling","05-OCT-2006","Uridine Supplementation in HIV Lipoatrophy","A5229","17-JAN-2007","Enrolling"
51514,"Protocol Status","Open","14-SEP-2006","Uridine Supplementation in HIV Lipoatrophy","A5229","05-OCT-2006","Open"
51514,"Protocol Status","Pending","21-FEB-2006","Uridine Supplementation in HIV Lipoatrophy","A5229","14-SEP-2006","Pending"
51514,"Protocol Status","In Development","13-DEC-2004","Uridine Supplementation in HIV Lipoatrophy","A5229","21-FEB-2006","In Development"
51515,"Protocol Status","Closed to Accrual","25-MAY-2010","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","","Closed to Accrual"
51515,"Protocol Status","Closed to Accrual","25-MAY-2010","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","25-MAY-2010","Closed to Accrual"
51515,"Protocol Status","Closed to Accrual","25-MAY-2010","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","25-MAY-2010","Closed to Accrual"
51515,"Protocol Status","Enrolling","06-FEB-2008","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","25-MAY-2010","Enrolling"
51515,"Protocol Status","Open","22-JAN-2008","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","06-FEB-2008","Open"
51515,"Protocol Status","Pending","01-JUN-2006","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","22-JAN-2008","Pending"
51515,"Protocol Status","In Development","06-FEB-2005","Study of LPV/r in Subjects with Virologic Relapse on NNRTI-Containing Regimens","A5230","01-JUN-2006","In Development"
51518,"Protocol Status","Withdrawn","01-JUL-2008","Efficacy of Quadruple NRT I -Based Regimen vs. Standard of Care for Initial Tx","A5231","","Other"
51518,"Protocol Status","On Hold","13-NOV-2007","Efficacy of Quadruple NRT I -Based Regimen vs. Standard of Care for Initial Tx","A5231","01-JUL-2008","Other"
51518,"Protocol Status","In Development","10-MAR-2006","Efficacy of Quadruple NRT I -Based Regimen vs. Standard of Care for Initial Tx","A5231","13-NOV-2007","In Development"
51518,"Protocol Status","On Hold","06-JUL-2005","Efficacy of Quadruple NRT I -Based Regimen vs. Standard of Care for Initial Tx","A5231","10-MAR-2006","Other"
51518,"Protocol Status","In Development","18-JAN-2005","Efficacy of Quadruple NRT I -Based Regimen vs. Standard of Care for Initial Tx","A5231","06-JUL-2005","In Development"
51519,"Protocol Status","POS/PAC","23-SEP-2009","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","","POS/PAC"
51519,"Protocol Status","Concluded","23-SEP-2009","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","23-SEP-2009","Concluded"
51519,"Protocol Status","Closed to Follow Up","28-JUL-2009","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","23-SEP-2009","Closed to Follow Up"
51519,"Protocol Status","Closed to Accrual","10-JUN-2009","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","28-JUL-2009","Closed to Accrual"
51519,"Protocol Status","Enrolling","21-AUG-2007","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","10-JUN-2009","Enrolling"
51519,"Protocol Status","Open","13-AUG-2007","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","21-AUG-2007","Open"
51519,"Protocol Status","Pending","07-SEP-2006","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","13-AUG-2007","Pending"
51519,"Protocol Status","In Development","18-JAN-2005","Optimizing Vaccine Response in HIV-1, HCV, & Co-Infected Subjects","A5232","07-SEP-2006","In Development"
51533,"Protocol Status","Withdrawn","20-NOV-2006","Impact of Early vs. Deferred ART on Incidence of TB and OIs","A5233","","Other"
51533,"Protocol Status","On Hold","01-SEP-2006","Impact of Early vs. Deferred ART on Incidence of TB and OIs","A5233","20-NOV-2006","Other"
51533,"Protocol Status","In Development","05-APR-2005","Impact of Early vs. Deferred ART on Incidence of TB and OIs","A5233","01-SEP-2006","In Development"
51542,"Protocol Status","Closed to Accrual","04-NOV-2011","mDOT vs. Self-Administered Therapy for First Virologic Failure on NNRTI","A5234","","Closed to Accrual"
51542,"Protocol Status","Enrolling","23-APR-2009","mDOT vs. Self-Administered Therapy for First Virologic Failure on NNRTI","A5234","04-NOV-2011","Enrolling"
51542,"Protocol Status","Open","20-MAR-2009","mDOT vs. Self-Administered Therapy for First Virologic Failure on NNRTI","A5234","23-APR-2009","Open"
51542,"Protocol Status","Pending","28-DEC-2007","mDOT vs. Self-Administered Therapy for First Virologic Failure on NNRTI","A5234","20-MAR-2009","Pending"
51542,"Protocol Status","In Development","19-AUG-2005","mDOT vs. Self-Administered Therapy for First Virologic Failure on NNRTI","A5234","28-DEC-2007","In Development"
51543,"Protocol Status","POS/PAC","08-JUL-2010","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","","POS/PAC"
51543,"Protocol Status","Closed to Follow Up","28-JAN-2010","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","08-JUL-2010","Closed to Follow Up"
51543,"Protocol Status","Closed to Accrual","02-OCT-2009","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","28-JAN-2010","Closed to Accrual"
51543,"Protocol Status","Enrolling","27-MAR-2007","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","02-OCT-2009","Enrolling"
51543,"Protocol Status","Open","20-DEC-2006","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","27-MAR-2007","Open"
51543,"Protocol Status","Pending","12-JUL-2006","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","20-DEC-2006","Pending"
51543,"Protocol Status","In Development","07-JUL-2005","Trial of Minocycline for HIV-Associated Cognitive Impairment","A5235","12-JUL-2006","In Development"
51546,"Protocol Status","Withdrawn","30-OCT-2007","Dendritic cell Vaccine Co-transfected w/amplified HIV-1 RNA & huCD40L mRNA","A5236","","Other"
51546,"Protocol Status","On Hold","10-OCT-2007","Dendritic cell Vaccine Co-transfected w/amplified HIV-1 RNA & huCD40L mRNA","A5236","30-OCT-2007","Other"
51546,"Protocol Status","In Development","12-AUG-2005","Dendritic cell Vaccine Co-transfected w/amplified HIV-1 RNA & huCD40L mRNA","A5236","10-OCT-2007","In Development"
51557,"Protocol Status","Withdrawn","08-MAR-2007","ATV/RTV Alone vs. ATV/RTV with Two NRTIs as Maintenance Antiretroviral Therapy","A5237","","Other"
51557,"Protocol Status","On Hold","11-JUL-2006","ATV/RTV Alone vs. ATV/RTV with Two NRTIs as Maintenance Antiretroviral Therapy","A5237","08-MAR-2007","Other"
51557,"Protocol Status","In Development","19-SEP-2005","ATV/RTV Alone vs. ATV/RTV with Two NRTIs as Maintenance Antiretroviral Therapy","A5237","11-JUL-2006","In Development"
51589,"Protocol Status","Withdrawn","31-JAN-2007","Safety & Antiviral Activity of Autologous T Cells Transduced with VRX496","A5238","","Other"
51589,"Protocol Status","In Development","16-MAR-2006","Safety & Antiviral Activity of Autologous T Cells Transduced with VRX496","A5238","31-JAN-2007","In Development"
51600,"Protocol Status","Closed to Follow Up","14-DEC-2011","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","","Closed to Follow Up"
51600,"Protocol Status","Closed to Accrual","18-NOV-2010","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","14-DEC-2011","Closed to Accrual"
51600,"Protocol Status","Enrolling - Temporarily Closed to Accrual","05-NOV-2010","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","18-NOV-2010","Other"
51600,"Protocol Status","Enrolling","31-MAR-2009","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","05-NOV-2010","Enrolling"
51600,"Protocol Status","Open","09-MAR-2009","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","31-MAR-2009","Open"
51600,"Protocol Status","Pending","19-FEB-2008","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","09-MAR-2009","Pending"
51600,"Protocol Status","In Development","10-APR-2007","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","19-FEB-2008","In Development"
51600,"Protocol Status","Withdrawn","02-MAR-2007","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","10-APR-2007","Other"
51600,"Protocol Status","In Development","14-JUL-2006","Pioglitazone Prior to HCV in NonResp. to Peg/IFN & RBV w/ Insulin Resistance","A5239","02-MAR-2007","In Development"
51601,"Protocol Status","Closed to Accrual","06-JUL-2011","HPV Vaccine in Women","A5240","","Closed to Accrual"
51601,"Protocol Status","Enrolling","06-MAR-2008","HPV Vaccine in Women","A5240","06-JUL-2011","Enrolling"
51601,"Protocol Status","Open","15-FEB-2008","HPV Vaccine in Women","A5240","06-MAR-2008","Open"
51601,"Protocol Status","Pending","13-DEC-2007","HPV Vaccine in Women","A5240","15-FEB-2008","Pending"
51601,"Protocol Status","In Development","28-JUN-2006","HPV Vaccine in Women","A5240","13-DEC-2007","In Development"
51602,"Protocol Status","Closed to Accrual","06-JUN-2011","Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US","A5241","","Closed to Accrual"
51602,"Protocol Status","Enrolling","08-FEB-2008","Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US","A5241","06-JUN-2011","Enrolling"
51602,"Protocol Status","Open","31-JAN-2008","Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US","A5241","08-FEB-2008","Open"
51602,"Protocol Status","Pending","14-SEP-2007","Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US","A5241","31-JAN-2008","Pending"
51602,"Protocol Status","In Development","30-JUN-2006","Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US","A5241","14-SEP-2007","In Development"
51623,"Protocol Status","Closed to Follow Up","23-DEC-2010","Non-US Genomics Sample Collection","A5243","","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","10-DEC-2010","Non-US Genomics Sample Collection","A5243","23-DEC-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","10-DEC-2010","Non-US Genomics Sample Collection","A5243","10-DEC-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","31-AUG-2010","Non-US Genomics Sample Collection","A5243","10-DEC-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","31-AUG-2010","Non-US Genomics Sample Collection","A5243","31-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","18-AUG-2010","Non-US Genomics Sample Collection","A5243","31-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","18-AUG-2010","Non-US Genomics Sample Collection","A5243","18-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","18-AUG-2010","Non-US Genomics Sample Collection","A5243","18-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","18-AUG-2010","Non-US Genomics Sample Collection","A5243","18-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","18-AUG-2010","Non-US Genomics Sample Collection","A5243","18-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","26-MAY-2010","Non-US Genomics Sample Collection","A5243","18-AUG-2010","Closed to Follow Up"
51623,"Protocol Status","Closed to Follow Up","08-APR-2010","Non-US Genomics Sample Collection","A5243","26-MAY-2010","Closed to Follow Up"
51623,"Protocol Status","Enrolling","21-DEC-2009","Non-US Genomics Sample Collection","A5243","08-APR-2010","Enrolling"
51623,"Protocol Status","Withdrawn","21-DEC-2009","Non-US Genomics Sample Collection","A5243","21-DEC-2009","Other"
51623,"Protocol Status","Enrolling","21-DEC-2009","Non-US Genomics Sample Collection","A5243","21-DEC-2009","Enrolling"
51623,"Protocol Status","Open","03-NOV-2009","Non-US Genomics Sample Collection","A5243","21-DEC-2009","Open"
51623,"Protocol Status","Pending","25-SEP-2008","Non-US Genomics Sample Collection","A5243","03-NOV-2009","Pending"
51623,"Protocol Status","In Development","18-JAN-2007","Non-US Genomics Sample Collection","A5243","25-SEP-2008","In Development"
51627,"Protocol Status","POS/PAC","12-NOV-2009","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","","POS/PAC"
51627,"Protocol Status","Closed to Follow Up","20-NOV-2008","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","12-NOV-2009","Closed to Follow Up"
51627,"Protocol Status","Closed to Accrual","12-JUN-2008","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","20-NOV-2008","Closed to Accrual"
51627,"Protocol Status","Enrolling","12-DEC-2007","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","12-JUN-2008","Enrolling"
51627,"Protocol Status","Open","14-NOV-2007","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","12-DEC-2007","Open"
51627,"Protocol Status","Pending","26-JUL-2007","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","14-NOV-2007","Pending"
51627,"Protocol Status","In Development","23-OCT-2006","Treatment Intensification w/Raltegravir on level of Persistent Plasma Viremia","A5244","26-JUL-2007","In Development"
51636,"Protocol Status","Closed to Accrual","03-MAY-2010","When to Start ART Outside the U.S","A5245","","Closed to Accrual"
51636,"Protocol Status","In Development","13-SEP-2006","When to Start ART Outside the U.S","A5245","03-MAY-2010","In Development"
51636,"Protocol Status","Open","30-AUG-2006","When to Start ART Outside the U.S","A5245","13-SEP-2006","Open"
51636,"Protocol Status","Enrolling","30-AUG-2006","When to Start ART Outside the U.S","A5245","30-AUG-2006","Enrolling"
51638,"Protocol Status","Closed to Follow Up","23-SEP-2011","Safety & Immunogenicity of Human Papillomavirus Vaccine  in HIV-1-Infected Men","A5246","","Closed to Follow Up"
51638,"Protocol Status","Closed to Accrual","21-NOV-2008","Safety & Immunogenicity of Human Papillomavirus Vaccine  in HIV-1-Infected Men","A5246","23-SEP-2011","Closed to Accrual"
51638,"Protocol Status","Enrolling","09-JAN-2008","Safety & Immunogenicity of Human Papillomavirus Vaccine  in HIV-1-Infected Men","A5246","21-NOV-2008","Enrolling"
51638,"Protocol Status","Open","06-DEC-2007","Safety & Immunogenicity of Human Papillomavirus Vaccine  in HIV-1-Infected Men","A5246","09-JAN-2008","Open"
51638,"Protocol Status","Pending","16-JUL-2007","Safety & Immunogenicity of Human Papillomavirus Vaccine  in HIV-1-Infected Men","A5246","06-DEC-2007","Pending"
51638,"Protocol Status","In Development","19-DEC-2006","Safety & Immunogenicity of Human Papillomavirus Vaccine  in HIV-1-Infected Men","A5246","16-JUL-2007","In Development"
51646,"Protocol Status","Closed to Follow Up","03-JAN-2012","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","","Closed to Follow Up"
51646,"Protocol Status","Closed to Accrual","18-JUL-2011","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","03-JAN-2012","Closed to Accrual"
51646,"Protocol Status","Enrolling - Re-Opened","16-NOV-2009","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","18-JUL-2011","Other"
51646,"Protocol Status","Enrolling - Temporarily Closed to Accrual","21-AUG-2009","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","16-NOV-2009","Other"
51646,"Protocol Status","Enrolling","29-APR-2009","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","21-AUG-2009","Enrolling"
51646,"Protocol Status","Open","16-APR-2009","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","29-APR-2009","Open"
51646,"Protocol Status","Pending","17-JUL-2008","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","16-APR-2009","Pending"
51646,"Protocol Status","FDA - IND Hold","06-FEB-2008","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","17-JUL-2008","Other"
51646,"Protocol Status","Pending","09-JAN-2008","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","06-FEB-2008","Pending"
51646,"Protocol Status","In Development","22-MAR-2007","Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV","A5247","09-JAN-2008","In Development"
51651,"Protocol Status","POS/PAC","26-JUL-2011","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","","POS/PAC"
51651,"Protocol Status","Closed to Follow Up","20-APR-2010","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","26-JUL-2011","Closed to Follow Up"
51651,"Protocol Status","Closed to Accrual","26-JAN-2009","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","20-APR-2010","Closed to Accrual"
51651,"Protocol Status","Enrolling","19-JUN-2008","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","26-JAN-2009","Enrolling"
51651,"Protocol Status","Open","28-MAY-2008","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","19-JUN-2008","Open"
51651,"Protocol Status","Pending","14-MAR-2008","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","28-MAY-2008","Pending"
51651,"Protocol Status","In Development","11-MAY-2007","First-Phase Viral Decay Rates in Tx-Naive Subjects Initiating Tx w/ RAL+FTC+TDF","A5248","14-MAR-2008","In Development"
51659,"Protocol Status","Closed to Follow Up","02-SEP-2008","Intensive Viral Dynamics Substudy of A5248","A5249s","","Closed to Follow Up"
51659,"Protocol Status","Closed to Accrual","26-AUG-2008","Intensive Viral Dynamics Substudy of A5248","A5249s","02-SEP-2008","Closed to Accrual"
51659,"Protocol Status","Enrolling","07-JUL-2008","Intensive Viral Dynamics Substudy of A5248","A5249s","26-AUG-2008","Enrolling"
51659,"Protocol Status","Open","28-MAY-2008","Intensive Viral Dynamics Substudy of A5248","A5249s","07-JUL-2008","Open"
51659,"Protocol Status","Pending","14-MAR-2008","Intensive Viral Dynamics Substudy of A5248","A5249s","28-MAY-2008","Pending"
51659,"Protocol Status","In Development","21-MAY-2007","Intensive Viral Dynamics Substudy of A5248","A5249s","14-MAR-2008","In Development"
51674,"Protocol Status","POS/PAC","23-MAY-2011","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","","POS/PAC"
51674,"Protocol Status","Closed to Follow Up","14-DEC-2010","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","23-MAY-2011","Closed to Follow Up"
51674,"Protocol Status","Closed to Accrual","30-NOV-2010","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","14-DEC-2010","Closed to Accrual"
51674,"Protocol Status","Enrolling","25-AUG-2009","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","30-NOV-2010","Enrolling"
51674,"Protocol Status","Open","20-MAY-2009","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","25-AUG-2009","Open"
51674,"Protocol Status","Pending","27-FEB-2009","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","20-MAY-2009","Pending"
51674,"Protocol Status","In Development","20-SEP-2007","Combination Analgesic Therapy in HIV-associated Painful Peripheral Neuropathy","A5252","27-FEB-2009","In Development"
51679,"Protocol Status","Closed to Follow Up","10-NOV-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","10-NOV-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","10-NOV-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","10-NOV-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","10-NOV-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","10-NOV-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Closed to Follow Up","03-MAR-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Closed to Follow Up"
51679,"Protocol Status","Withdrawn","12-FEB-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","03-MAR-2010","Other"
51679,"Protocol Status","Enrolling","12-FEB-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","12-FEB-2010","Enrolling"
51679,"Protocol Status","Enrolling","12-FEB-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","12-FEB-2010","Enrolling"
51679,"Protocol Status","Open","15-JAN-2010","Durability of Adherence in Self-Management of HIV (DASH)","A5250","12-FEB-2010","Open"
51679,"Protocol Status","Pending","11-SEP-2009","Durability of Adherence in Self-Management of HIV (DASH)","A5250","15-JAN-2010","Pending"
51679,"Protocol Status","In Development","22-OCT-2007","Durability of Adherence in Self-Management of HIV (DASH)","A5250","11-SEP-2009","In Development"
51680,"Protocol Status","Enrolling","21-APR-2011","Enhanced Nursing Support to Improve Self-Management and Outcomes of ART","A5251","","Enrolling"
51680,"Protocol Status","Open","08-OCT-2010","Enhanced Nursing Support to Improve Self-Management and Outcomes of ART","A5251","21-APR-2011","Open"
51680,"Protocol Status","Pending","27-AUG-2009","Enhanced Nursing Support to Improve Self-Management and Outcomes of ART","A5251","08-OCT-2010","Pending"
51680,"Protocol Status","In Development","19-OCT-2007","Enhanced Nursing Support to Improve Self-Management and Outcomes of ART","A5251","27-AUG-2009","In Development"
51682,"Protocol Status","POS/PAC","14-FEB-2012","Sensitivity & Specificity of TB Diagnostics","A5253","","POS/PAC"
51682,"Protocol Status","Closed to Follow Up","06-DEC-2010","Sensitivity & Specificity of TB Diagnostics","A5253","14-FEB-2012","Closed to Follow Up"
51682,"Protocol Status","Closed to Follow Up","06-DEC-2010","Sensitivity & Specificity of TB Diagnostics","A5253","06-DEC-2010","Closed to Follow Up"
51682,"Protocol Status","Closed to Follow Up","06-DEC-2010","Sensitivity & Specificity of TB Diagnostics","A5253","06-DEC-2010","Closed to Follow Up"
51682,"Protocol Status","Closed to Follow Up","06-DEC-2010","Sensitivity & Specificity of TB Diagnostics","A5253","06-DEC-2010","Closed to Follow Up"
51682,"Protocol Status","Closed to Accrual","22-NOV-2010","Sensitivity & Specificity of TB Diagnostics","A5253","06-DEC-2010","Closed to Accrual"
51682,"Protocol Status","Enrolling - Temporarily Closed to Accrual","22-NOV-2010","Sensitivity & Specificity of TB Diagnostics","A5253","22-NOV-2010","Other"
51682,"Protocol Status","Enrolling","05-FEB-2010","Sensitivity & Specificity of TB Diagnostics","A5253","22-NOV-2010","Enrolling"
51682,"Protocol Status","Enrolling","05-FEB-2010","Sensitivity & Specificity of TB Diagnostics","A5253","05-FEB-2010","Enrolling"
51682,"Protocol Status","Open","21-DEC-2009","Sensitivity & Specificity of TB Diagnostics","A5253","05-FEB-2010","Open"
51682,"Protocol Status","Pending","11-FEB-2009","Sensitivity & Specificity of TB Diagnostics","A5253","21-DEC-2009","Pending"
51682,"Protocol Status","In Development","23-OCT-2007","Sensitivity & Specificity of TB Diagnostics","A5253","11-FEB-2009","In Development"
51683,"Protocol Status","Closed to Follow Up","27-DEC-2010","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","","Closed to Follow Up"
51683,"Protocol Status","Closed to Follow Up","27-DEC-2010","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","27-DEC-2010","Closed to Follow Up"
51683,"Protocol Status","Closed to Follow Up","21-DEC-2010","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","27-DEC-2010","Closed to Follow Up"
51683,"Protocol Status","Closed to Follow Up","14-JUN-2010","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","21-DEC-2010","Closed to Follow Up"
51683,"Protocol Status","Enrolling","21-OCT-2009","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","14-JUN-2010","Enrolling"
51683,"Protocol Status","Open","17-SEP-2009","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","21-OCT-2009","Open"
51683,"Protocol Status","Pending","26-MAY-2009","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","17-SEP-2009","Pending"
51683,"Protocol Status","In Development","11-OCT-2007","HIV-Related Oral Mucosal Disease & Use of Saliva in Measuring HIV Viral Load","A5254","26-MAY-2009","In Development"
51688,"Protocol Status","Closed to Accrual","19-OCT-2011","Faster ID of TB and RIF Resistance in non-US HIV-Infected TB Suspects","A5255","","Closed to Accrual"
51688,"Protocol Status","Enrolling","09-SEP-2009","Faster ID of TB and RIF Resistance in non-US HIV-Infected TB Suspects","A5255","19-OCT-2011","Enrolling"
51688,"Protocol Status","Open","25-AUG-2009","Faster ID of TB and RIF Resistance in non-US HIV-Infected TB Suspects","A5255","09-SEP-2009","Open"
51688,"Protocol Status","Pending","06-JAN-2009","Faster ID of TB and RIF Resistance in non-US HIV-Infected TB Suspects","A5255","25-AUG-2009","Pending"
51688,"Protocol Status","In Development","15-NOV-2007","Faster ID of TB and RIF Resistance in non-US HIV-Infected TB Suspects","A5255","06-JAN-2009","In Development"
51692,"Protocol Status","POS/PAC","07-SEP-2010","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","","POS/PAC"
51692,"Protocol Status","Closed to Follow Up","07-APR-2010","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","07-SEP-2010","Closed to Follow Up"
51692,"Protocol Status","Closed to Accrual","27-MAY-2009","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","07-APR-2010","Closed to Accrual"
51692,"Protocol Status","Enrolling","02-FEB-2009","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","27-MAY-2009","Enrolling"
51692,"Protocol Status","Enrolling","14-JAN-2009","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","02-FEB-2009","Enrolling"
51692,"Protocol Status","Open","24-DEC-2008","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","14-JAN-2009","Open"
51692,"Protocol Status","Pending","23-JUN-2008","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","24-DEC-2008","Pending"
51692,"Protocol Status","In Development","27-NOV-2007","MVC for Subjects on ARV tx w/CD4+ T-cell Recovery Despite Virologic Suppression","A5256","23-JUN-2008","In Development"
51698,"Protocol Status","Closed to Accrual","10-JUN-2011","Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers","A5257","","Closed to Accrual"
51698,"Protocol Status","Enrolling","22-MAY-2009","Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers","A5257","10-JUN-2011","Enrolling"
51698,"Protocol Status","Open","18-MAY-2009","Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers","A5257","22-MAY-2009","Open"
51698,"Protocol Status","Pending","04-DEC-2008","Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers","A5257","18-MAY-2009","Pending"
51698,"Protocol Status","In Development","21-DEC-2007","Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers","A5257","04-DEC-2008","In Development"
51699,"Protocol Status","Withdrawn","07-AUG-2011","Issues in the Design of Non-Inferiority Trials Enrolling ARV-Naive Subjects","DACS 247","","Other"
51715,"Protocol Status","Enrolling - Re-Opened","29-NOV-2010","Phase II Study of Chloroquine for Reducing HIV-associated Immune Activation","A5258","","Other"
51715,"Protocol Status","Enrolling - Temporarily Closed to Accrual","23-JUL-2010","Phase II Study of Chloroquine for Reducing HIV-associated Immune Activation","A5258","29-NOV-2010","Other"
51715,"Protocol Status","Enrolling","25-MAR-2009","Phase II Study of Chloroquine for Reducing HIV-associated Immune Activation","A5258","23-JUL-2010","Enrolling"
51715,"Protocol Status","Open","02-MAR-2009","Phase II Study of Chloroquine for Reducing HIV-associated Immune Activation","A5258","25-MAR-2009","Open"
51715,"Protocol Status","Pending","22-DEC-2008","Phase II Study of Chloroquine for Reducing HIV-associated Immune Activation","A5258","02-MAR-2009","Pending"
51715,"Protocol Status","In Development","10-MAR-2008","Phase II Study of Chloroquine for Reducing HIV-associated Immune Activation","A5258","22-DEC-2008","In Development"
51720,"Protocol Status","Closed to Accrual","17-DEC-2010","Weekly Rifapentine/Isoniazid vs. Daily Isoniazid for the Treatment of Latent TB","A5259","","Closed to Accrual"
51720,"Protocol Status","Enrolling","04-FEB-2009","Weekly Rifapentine/Isoniazid vs. Daily Isoniazid for the Treatment of Latent TB","A5259","17-DEC-2010","Enrolling"
51720,"Protocol Status","Open","10-DEC-2008","Weekly Rifapentine/Isoniazid vs. Daily Isoniazid for the Treatment of Latent TB","A5259","04-FEB-2009","Open"
51720,"Protocol Status","Pending","04-AUG-2008","Weekly Rifapentine/Isoniazid vs. Daily Isoniazid for the Treatment of Latent TB","A5259","10-DEC-2008","Pending"
51720,"Protocol Status","In Development","28-JUL-2008","Weekly Rifapentine/Isoniazid vs. Daily Isoniazid for the Treatment of Latent TB","A5259","04-AUG-2008","In Development"
51721,"Protocol Status","Closed to Accrual","19-APR-2011","ARV Initiation with TFV/Emtricitabine plus ATV/r, DRV/r, or RTG:A5257 Substudy","A5260s","","Closed to Accrual"
51721,"Protocol Status","Enrolling","01-JUN-2009","ARV Initiation with TFV/Emtricitabine plus ATV/r, DRV/r, or RTG:A5257 Substudy","A5260s","19-APR-2011","Enrolling"
51721,"Protocol Status","Open","18-MAY-2009","ARV Initiation with TFV/Emtricitabine plus ATV/r, DRV/r, or RTG:A5257 Substudy","A5260s","01-JUN-2009","Open"
51721,"Protocol Status","Pending","04-DEC-2008","ARV Initiation with TFV/Emtricitabine plus ATV/r, DRV/r, or RTG:A5257 Substudy","A5260s","18-MAY-2009","Pending"
51721,"Protocol Status","In Development","29-FEB-2008","ARV Initiation with TFV/Emtricitabine plus ATV/r, DRV/r, or RTG:A5257 Substudy","A5260s","04-DEC-2008","In Development"
51722,"Protocol Status","Withdrawn","22-JUL-2008","Pilot Efficacy Trial of Raltegravir plus Atazanavir for Treatment-Naive Subjects","A5261","","Other"
51722,"Protocol Status","In Development","19-MAR-2008","Pilot Efficacy Trial of Raltegravir plus Atazanavir for Treatment-Naive Subjects","A5261","22-JUL-2008","In Development"
51724,"Protocol Status","POS/PAC","17-MAR-2011","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","","POS/PAC"
51724,"Protocol Status","Closed to Follow Up","15-SEP-2010","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","17-MAR-2011","Closed to Follow Up"
51724,"Protocol Status","Closed to Accrual","27-AUG-2009","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","15-SEP-2010","Closed to Accrual"
51724,"Protocol Status","Enrolling","15-APR-2009","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","27-AUG-2009","Enrolling"
51724,"Protocol Status","Open","02-APR-2009","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","15-APR-2009","Open"
51724,"Protocol Status","Pending","08-JAN-2009","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","02-APR-2009","Pending"
51724,"Protocol Status","In Development","25-APR-2008","RAL plus DRV/RTV in ARV-Naive Subjects","A5262","08-JAN-2009","In Development"
51726,"Protocol Status","Pending","25-OCT-2010","Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","A5263","","Pending"
51726,"Protocol Status","In Development","05-MAY-2008","Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","A5263","25-OCT-2010","In Development"
51727,"Protocol Status","Enrolling","18-NOV-2011","ART Alone or w/Delayed Chemo vs ART w/Immediate Chemo for Limited AIDS-KS","A5264","","Enrolling"
51727,"Protocol Status","Open","17-OCT-2011","ART Alone or w/Delayed Chemo vs ART w/Immediate Chemo for Limited AIDS-KS","A5264","18-NOV-2011","Open"
51727,"Protocol Status","Pending","11-AUG-2010","ART Alone or w/Delayed Chemo vs ART w/Immediate Chemo for Limited AIDS-KS","A5264","17-OCT-2011","Pending"
51727,"Protocol Status","In Development","29-MAY-2008","ART Alone or w/Delayed Chemo vs ART w/Immediate Chemo for Limited AIDS-KS","A5264","11-AUG-2010","In Development"
51736,"Protocol Status","Enrolling","02-AUG-2011","Compare the Efficacy and Safety of Gentian Violet to that of Nystatin (GIVEN)","A5265","","Enrolling"
51736,"Protocol Status","Open","07-JUN-2011","Compare the Efficacy and Safety of Gentian Violet to that of Nystatin (GIVEN)","A5265","02-AUG-2011","Open"
51736,"Protocol Status","Pending","02-APR-2010","Compare the Efficacy and Safety of Gentian Violet to that of Nystatin (GIVEN)","A5265","07-JUN-2011","Pending"
51736,"Protocol Status","In Development","18-JUN-2008","Compare the Efficacy and Safety of Gentian Violet to that of Nystatin (GIVEN)","A5265","02-APR-2010","In Development"
51745,"Protocol Status","Withdrawn","01-MAR-2010","TBV Compared w/RBV in Combination w/PEG-IFN in HCV Genotype I/HIV-Coinfection","A5266","","Other"
51745,"Protocol Status","On Hold","21-JUL-2009","TBV Compared w/RBV in Combination w/PEG-IFN in HCV Genotype I/HIV-Coinfection","A5266","01-MAR-2010","Other"
51745,"Protocol Status","In Development","18-JUL-2008","TBV Compared w/RBV in Combination w/PEG-IFN in HCV Genotype I/HIV-Coinfection","A5266","21-JUL-2009","In Development"
51748,"Protocol Status","POS/PAC","15-JUL-2011","TMC207 & EFV PK Interaction Study","A5267","","POS/PAC"
51748,"Protocol Status","Closed to Follow Up","10-DEC-2010","TMC207 & EFV PK Interaction Study","A5267","15-JUL-2011","Closed to Follow Up"
51748,"Protocol Status","Closed to Accrual","28-OCT-2010","TMC207 & EFV PK Interaction Study","A5267","10-DEC-2010","Closed to Accrual"
51748,"Protocol Status","Enrolling - Temporarily Closed to Accrual","28-OCT-2010","TMC207 & EFV PK Interaction Study","A5267","28-OCT-2010","Other"
51748,"Protocol Status","Enrolling","12-MAR-2010","TMC207 & EFV PK Interaction Study","A5267","28-OCT-2010","Enrolling"
51748,"Protocol Status","Open","15-DEC-2009","TMC207 & EFV PK Interaction Study","A5267","12-MAR-2010","Open"
51748,"Protocol Status","Pending","02-SEP-2009","TMC207 & EFV PK Interaction Study","A5267","15-DEC-2009","Pending"
51748,"Protocol Status","In Development","28-AUG-2008","TMC207 & EFV PK Interaction Study","A5267","02-SEP-2009","In Development"
51753,"Protocol Status","Withdrawn","27-MAY-2009","Interactions when ATV/RTV Dosed is Followed by RIF in Healthy Volunteers","A5268","","Other"
51753,"Protocol Status","In Development","22-SEP-2008","Interactions when ATV/RTV Dosed is Followed by RIF in Healthy Volunteers","A5268","27-MAY-2009","In Development"
51754,"Protocol Status","Closed to Follow Up","12-JAN-2012","NTZ, RBV, and PEG-IFN Alfa-2a for Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","A5269","","Closed to Follow Up"
51754,"Protocol Status","Closed to Accrual","02-AUG-2010","NTZ, RBV, and PEG-IFN Alfa-2a for Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","A5269","12-JAN-2012","Closed to Accrual"
51754,"Protocol Status","Enrolling","07-JAN-2010","NTZ, RBV, and PEG-IFN Alfa-2a for Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","A5269","02-AUG-2010","Enrolling"
51754,"Protocol Status","Open","04-JAN-2010","NTZ, RBV, and PEG-IFN Alfa-2a for Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","A5269","07-JAN-2010","Open"
51754,"Protocol Status","Pending","09-SEP-2009","NTZ, RBV, and PEG-IFN Alfa-2a for Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","A5269","04-JAN-2010","Pending"
51754,"Protocol Status","In Development","15-OCT-2008","NTZ, RBV, and PEG-IFN Alfa-2a for Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","A5269","09-SEP-2009","In Development"
51761,"Protocol Status","Withdrawn","02-JUN-2010","Co-trimoxazole Discontinuation in Adults Receiving ART w/ CD4+ above 200/mm3","A5270","","Other"
51761,"Protocol Status","In Development","12-NOV-2008","Co-trimoxazole Discontinuation in Adults Receiving ART w/ CD4+ above 200/mm3","A5270","02-JUN-2010","In Development"
51765,"Protocol Status","Enrolling","25-FEB-2011","Collection of Comparison Neurocognitive Data in Resource Limited Settings","A5271","","Enrolling"
51765,"Protocol Status","Open","14-FEB-2011","Collection of Comparison Neurocognitive Data in Resource Limited Settings","A5271","25-FEB-2011","Open"
51765,"Protocol Status","Pending","08-JUN-2010","Collection of Comparison Neurocognitive Data in Resource Limited Settings","A5271","14-FEB-2011","Pending"
51765,"Protocol Status","In Development","14-JAN-2009","Collection of Comparison Neurocognitive Data in Resource Limited Settings","A5271","08-JUN-2010","In Development"
51772,"Protocol Status","Enrolling","05-JAN-2010","Oral HPV Shedding and Oral Warts After Initiation of ART","A5272","","Enrolling"
51772,"Protocol Status","Open","17-DEC-2009","Oral HPV Shedding and Oral Warts After Initiation of ART","A5272","05-JAN-2010","Open"
51772,"Protocol Status","Pending","06-NOV-2009","Oral HPV Shedding and Oral Warts After Initiation of ART","A5272","17-DEC-2009","Pending"
51772,"Protocol Status","In Development","05-FEB-2009","Oral HPV Shedding and Oral Warts After Initiation of ART","A5272","06-NOV-2009","In Development"
51785,"Protocol Status","Enrolling","13-MAR-2012","Study of Options for Second-Line Effective Combination Therapy (SELECT)","A5273","","Enrolling"
51785,"Protocol Status","Open","11-JAN-2012","Study of Options for Second-Line Effective Combination Therapy (SELECT)","A5273","13-MAR-2012","Open"
51785,"Protocol Status","Pending","03-DEC-2010","Study of Options for Second-Line Effective Combination Therapy (SELECT)","A5273","11-JAN-2012","Pending"
51785,"Protocol Status","In Development","13-MAY-2009","Study of Options for Second-Line Effective Combination Therapy (SELECT)","A5273","03-DEC-2010","In Development"
51788,"Protocol Status","Enrolling","31-OCT-2011","Reducing Early Mortality & Morbidity w/ Empiric TB Treatment","A5274","","Enrolling"
51788,"Protocol Status","Open","11-OCT-2011","Reducing Early Mortality & Morbidity w/ Empiric TB Treatment","A5274","31-OCT-2011","Open"
51788,"Protocol Status","Pending","09-NOV-2010","Reducing Early Mortality & Morbidity w/ Empiric TB Treatment","A5274","11-OCT-2011","Pending"
51788,"Protocol Status","In Development","13-MAY-2009","Reducing Early Mortality & Morbidity w/ Empiric TB Treatment","A5274","09-NOV-2010","In Development"
51800,"Protocol Status","Enrolling","14-APR-2011","Effect of Atorvastatin on Biomarkers of Inflammation and T-cell Activation","A5275","","Enrolling"
51800,"Protocol Status","Open","07-APR-2011","Effect of Atorvastatin on Biomarkers of Inflammation and T-cell Activation","A5275","14-APR-2011","Open"
51800,"Protocol Status","Pending","23-JUL-2010","Effect of Atorvastatin on Biomarkers of Inflammation and T-cell Activation","A5275","07-APR-2011","Pending"
51800,"Protocol Status","In Development","11-MAY-2010","Effect of Atorvastatin on Biomarkers of Inflammation and T-cell Activation","A5275","23-JUL-2010","In Development"
51800,"Protocol Status","On Hold","28-JAN-2010","Effect of Atorvastatin on Biomarkers of Inflammation and T-cell Activation","A5275","11-MAY-2010","Other"
51800,"Protocol Status","In Development","07-AUG-2009","Effect of Atorvastatin on Biomarkers of Inflammation and T-cell Activation","A5275","28-JAN-2010","In Development"
51803,"Protocol Status","Enrolling","13-DEC-2010","Residual Viremia Substudy of A5001 (ALLRT)","A5276s","","Enrolling"
51803,"Protocol Status","Open","19-NOV-2010","Residual Viremia Substudy of A5001 (ALLRT)","A5276s","13-DEC-2010","Open"
51803,"Protocol Status","Pending","01-DEC-2009","Residual Viremia Substudy of A5001 (ALLRT)","A5276s","19-NOV-2010","Pending"
51803,"Protocol Status","In Development","14-JUL-2009","Residual Viremia Substudy of A5001 (ALLRT)","A5276s","01-DEC-2009","In Development"
51816,"Protocol Status","Closed to Accrual","21-MAR-2012","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","","Closed to Accrual"
51816,"Protocol Status","Closed to Follow Up","28-FEB-2012","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","21-MAR-2012","Closed to Follow Up"
51816,"Protocol Status","Open","24-AUG-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","28-FEB-2012","Open"
51816,"Protocol Status","Enrolling - Re-Opened","24-AUG-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","24-AUG-2011","Other"
51816,"Protocol Status","Enrolling - Temporarily Closed to Accrual","27-JUL-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","24-AUG-2011","Other"
51816,"Protocol Status","Enrolling - Temporarily Closed to Accrual","27-JUL-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","27-JUL-2011","Other"
51816,"Protocol Status","Closed to Accrual","27-JUL-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","27-JUL-2011","Closed to Accrual"
51816,"Protocol Status","Open","21-APR-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","27-JUL-2011","Open"
51816,"Protocol Status","Enrolling - Re-Opened","21-APR-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","21-APR-2011","Other"
51816,"Protocol Status","Enrolling","21-APR-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","21-APR-2011","Enrolling"
51816,"Protocol Status","Enrolling - Temporarily Closed to Accrual","01-APR-2011","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","21-APR-2011","Other"
51816,"Protocol Status","Enrolling","06-DEC-2010","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","01-APR-2011","Enrolling"
51816,"Protocol Status","Open","24-SEP-2010","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","06-DEC-2010","Open"
51816,"Protocol Status","Pending","09-JUN-2010","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","24-SEP-2010","Pending"
51816,"Protocol Status","In Development","08-SEP-2009","Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Mono-Infected Adults","A5277","09-JUN-2010","In Development"
51817,"Protocol Status","Enrolling","15-JAN-2010","HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)","1077HS","","Enrolling"
51817,"Protocol Status","Open","13-OCT-2009","HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)","1077HS","15-JAN-2010","Open"
51817,"Protocol Status","Pending","20-JUL-2009","HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)","1077HS","13-OCT-2009","Pending"
51817,"Protocol Status","In Development","01-FEB-2008","HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)","1077HS","20-JUL-2009","In Development"
51822,"Protocol Status","Enrolling","02-DEC-2011","Pharmacology Substudies of A5263 and A5264","A5278s","","Enrolling"
51822,"Protocol Status","Open","18-NOV-2011","Pharmacology Substudies of A5263 and A5264","A5278s","02-DEC-2011","Open"
51822,"Protocol Status","Pending","30-AUG-2010","Pharmacology Substudies of A5263 and A5264","A5278s","18-NOV-2011","Pending"
51822,"Protocol Status","In Development","29-SEP-2009","Pharmacology Substudies of A5263 and A5264","A5278s","30-AUG-2010","In Development"
51823,"Protocol Status","Pending","20-MAY-2011","Short-course rifapentine/isoniazid for treatment of latent TB in HIV-infected individuals","A5279","","Pending"
51823,"Protocol Status","In Development","22-OCT-2009","Short-course rifapentine/isoniazid for treatment of latent TB in HIV-infected individuals","A5279","20-MAY-2011","In Development"
51823,"Protocol Status","In Development","08-SEP-2009","Short-course rifapentine/isoniazid for treatment of latent TB in HIV-infected individuals","A5279","22-OCT-2009","In Development"
51824,"Protocol Status","Closed to Accrual","02-MAR-2012","High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","A5280","","Closed to Accrual"
51824,"Protocol Status","Enrolling","26-SEP-2011","High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","A5280","02-MAR-2012","Enrolling"
51824,"Protocol Status","Open","15-SEP-2011","High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","A5280","26-SEP-2011","Open"
51824,"Protocol Status","Pending","04-MAR-2011","High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","A5280","15-SEP-2011","Pending"
51824,"Protocol Status","In Development","13-OCT-2009","High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","A5280","04-MAR-2011","In Development"
51825,"Protocol Status","Enrolling","20-APR-2011","Cytokine HIV MAG pDNA Vaccine Delivered via IM/EP or IM Injection","A5281","","Enrolling"
51825,"Protocol Status","Open","31-MAR-2011","Cytokine HIV MAG pDNA Vaccine Delivered via IM/EP or IM Injection","A5281","20-APR-2011","Open"
51825,"Protocol Status","Pending","10-NOV-2010","Cytokine HIV MAG pDNA Vaccine Delivered via IM/EP or IM Injection","A5281","31-MAR-2011","Pending"
51825,"Protocol Status","In Development","23-SEP-2009","Cytokine HIV MAG pDNA Vaccine Delivered via IM/EP or IM Injection","A5281","10-NOV-2010","In Development"
51826,"Protocol Status","Enrolling","04-APR-2012","HPV Test-and-Treat Study","A5282","","Enrolling"
51826,"Protocol Status","Open","12-MAR-2012","HPV Test-and-Treat Study","A5282","04-APR-2012","Open"
51826,"Protocol Status","Pending","22-NOV-2010","HPV Test-and-Treat Study","A5282","12-MAR-2012","Pending"
51826,"Protocol Status","In Development","14-OCT-2009","HPV Test-and-Treat Study","A5282","22-NOV-2010","In Development"
51828,"Protocol Status","Enrolling","01-JUN-2011","PK Interactions between DMPA and LPV/RTV in HIV-Infected Women","A5283","","Enrolling"
51828,"Protocol Status","Open","11-MAY-2011","PK Interactions between DMPA and LPV/RTV in HIV-Infected Women","A5283","01-JUN-2011","Open"
51828,"Protocol Status","Pending","16-DEC-2010","PK Interactions between DMPA and LPV/RTV in HIV-Infected Women","A5283","11-MAY-2011","Pending"
51828,"Protocol Status","In Development","05-OCT-2009","PK Interactions between DMPA and LPV/RTV in HIV-Infected Women","A5283","16-DEC-2010","In Development"
51831,"Protocol Status","Withdrawn","14-NOV-2011","Open-Label Study of GS-9350 and Rifampin in HIV-Uninfected Individuals","A5284","","Other"
51831,"Protocol Status","On Hold","14-JAN-2010","Open-Label Study of GS-9350 and Rifampin in HIV-Uninfected Individuals","A5284","14-NOV-2011","Other"
51831,"Protocol Status","In Development","29-OCT-2009","Open-Label Study of GS-9350 and Rifampin in HIV-Uninfected Individuals","A5284","14-JAN-2010","In Development"
51834,"Protocol Status","Withdrawn","08-JUN-2010","Pharmacokinetics of the Cyclophilin Inhibitor Debio025 and ARV Medications","A5285","","Other"
51834,"Protocol Status","On Hold","25-JAN-2010","Pharmacokinetics of the Cyclophilin Inhibitor Debio025 and ARV Medications","A5285","08-JUN-2010","Other"
51834,"Protocol Status","In Development","04-NOV-2009","Pharmacokinetics of the Cyclophilin Inhibitor Debio025 and ARV Medications","A5285","25-JAN-2010","In Development"
51835,"Protocol Status","Enrolling","03-OCT-2011","Effect of Rifaximin on Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell","A5286","","Enrolling"
51835,"Protocol Status","Open","01-SEP-2011","Effect of Rifaximin on Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell","A5286","03-OCT-2011","Open"
51835,"Protocol Status","Pending","06-DEC-2010","Effect of Rifaximin on Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell","A5286","01-SEP-2011","Pending"
51835,"Protocol Status","In Development","09-NOV-2009","Effect of Rifaximin on Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell","A5286","06-DEC-2010","In Development"
51836,"Protocol Status","Withdrawn","08-JUN-2010","Debio025 + PEG- Interferon + Ribavirin for HCV + HIV infected Subjects","A5287","","Other"
51836,"Protocol Status","On Hold","25-JAN-2010","Debio025 + PEG- Interferon + Ribavirin for HCV + HIV infected Subjects","A5287","08-JUN-2010","Other"
51836,"Protocol Status","In Development","04-NOV-2009","Debio025 + PEG- Interferon + Ribavirin for HCV + HIV infected Subjects","A5287","25-JAN-2010","In Development"
51838,"Protocol Status","Pending","30-SEP-2011","MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After VF","A5288","","Pending"
51838,"Protocol Status","In Development","04-DEC-2009","MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After VF","A5288","30-SEP-2011","In Development"
51839,"Protocol Status","In Development","13-APR-2011","TMC207 in Induction Phase of TB Treatment","A5289","","In Development"
51839,"Protocol Status","On Hold","02-NOV-2010","TMC207 in Induction Phase of TB Treatment","A5289","13-APR-2011","Other"
51839,"Protocol Status","In Development","07-JUL-2010","TMC207 in Induction Phase of TB Treatment","A5289","02-NOV-2010","In Development"
51839,"Protocol Status","On Hold","29-APR-2010","TMC207 in Induction Phase of TB Treatment","A5289","07-JUL-2010","Other"
51839,"Protocol Status","In Development","30-NOV-2009","TMC207 in Induction Phase of TB Treatment","A5289","29-APR-2010","In Development"
51856,"Protocol Status","Pending","17-FEB-2012","Rifampin-Based TB Treatment vs. Rifabutin-Based TB Treatment in HIV","A5290","","Pending"
51856,"Protocol Status","In Development","15-MAR-2010","Rifampin-Based TB Treatment vs. Rifabutin-Based TB Treatment in HIV","A5290","17-FEB-2012","In Development"
51858,"Protocol Status","Withdrawn","21-APR-2011","Lexgenleucel-T in Treatment Experienced Subjects with Multi-drug Resistance","A5291","","Other"
51858,"Protocol Status","On Hold","19-OCT-2010","Lexgenleucel-T in Treatment Experienced Subjects with Multi-drug Resistance","A5291","21-APR-2011","Other"
51858,"Protocol Status","In Development","05-MAR-2010","Lexgenleucel-T in Treatment Experienced Subjects with Multi-drug Resistance","A5291","19-OCT-2010","In Development"
51859,"Protocol Status","Open","30-NOV-2011","A Randomized Trial to Examine and Compare the Effects of HAART vs. Statin Therapy","A5292","","Open"
51859,"Protocol Status","Pending","06-SEP-2011","A Randomized Trial to Examine and Compare the Effects of HAART vs. Statin Therapy","A5292","30-NOV-2011","Pending"
51859,"Protocol Status","In Development","09-MAR-2010","A Randomized Trial to Examine and Compare the Effects of HAART vs. Statin Therapy","A5292","06-SEP-2011","In Development"
52904,"Protocol Status","Enrolling","10-JAN-2012","Endothelial Function, Lipoproteins, and Inflammation with Low HDL: ER Niacin vs. Fenofibrate","A5293","","Enrolling"
52904,"Protocol Status","Open","08-NOV-2011","Endothelial Function, Lipoproteins, and Inflammation with Low HDL: ER Niacin vs. Fenofibrate","A5293","10-JAN-2012","Open"
52904,"Protocol Status","Pending","15-JUN-2011","Endothelial Function, Lipoproteins, and Inflammation with Low HDL: ER Niacin vs. Fenofibrate","A5293","08-NOV-2011","Pending"
52904,"Protocol Status","In Development","26-APR-2010","Endothelial Function, Lipoproteins, and Inflammation with Low HDL: ER Niacin vs. Fenofibrate","A5293","15-JUN-2011","In Development"
52922,"Protocol Status","Open","12-OCT-2011","Boceprevir, Interferon, Ribavirin to Treat HCV/HIV Coinfected Subjects (BIRTH)","A5294","","Open"
52922,"Protocol Status","Pending","12-OCT-2011","Boceprevir, Interferon, Ribavirin to Treat HCV/HIV Coinfected Subjects (BIRTH)","A5294","12-OCT-2011","Pending"
52922,"Protocol Status","In Development","01-JUL-2010","Boceprevir, Interferon, Ribavirin to Treat HCV/HIV Coinfected Subjects (BIRTH)","A5294","12-OCT-2011","In Development"
52941,"Protocol Status","Pending","25-JAN-2012","Xpert MTB/RIF vs Standard TB Diagnostics in TB Suspects","A5295","","Pending"
52941,"Protocol Status","In Development","29-JUL-2010","Xpert MTB/RIF vs Standard TB Diagnostics in TB Suspects","A5295","25-JAN-2012","In Development"
52942,"Protocol Status","Enrolling","29-DEC-2011","Sevelamer for Reducing Endotoxemia and Immune Activation","A5296","","Enrolling"
52942,"Protocol Status","Open","28-NOV-2011","Sevelamer for Reducing Endotoxemia and Immune Activation","A5296","29-DEC-2011","Open"
52942,"Protocol Status","Pending","12-JUL-2011","Sevelamer for Reducing Endotoxemia and Immune Activation","A5296","28-NOV-2011","Pending"
52942,"Protocol Status","In Development","19-OCT-2010","Sevelamer for Reducing Endotoxemia and Immune Activation","A5296","12-JUL-2011","In Development"
52951,"Protocol Status","Pending","06-MAR-2012","Comparing PI-Based to a nNRTI-based ART for Clearance of Pf Parasitemia in HIV-Infected","A5297","","Pending"
52951,"Protocol Status","In Development","26-AUG-2010","Comparing PI-Based to a nNRTI-based ART for Clearance of Pf Parasitemia in HIV-Infected","A5297","06-MAR-2012","In Development"
52962,"Protocol Status","Enrolling","08-MAR-2012","Quadrivalent HPV Vaccine to Prevent Anal HPV Infection in HIV-Infected Men","A5298","","Enrolling"
52962,"Protocol Status","Open","01-MAR-2012","Quadrivalent HPV Vaccine to Prevent Anal HPV Infection in HIV-Infected Men","A5298","08-MAR-2012","Open"
52962,"Protocol Status","Pending","01-SEP-2011","Quadrivalent HPV Vaccine to Prevent Anal HPV Infection in HIV-Infected Men","A5298","01-MAR-2012","Pending"
52962,"Protocol Status","In Development","11-NOV-2010","Quadrivalent HPV Vaccine to Prevent Anal HPV Infection in HIV-Infected Men","A5298","01-SEP-2011","In Development"
52963,"Protocol Status","On Hold","23-SEP-2011","Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Antiviral Efficacy of Ibalizumab","A5299","","Other"
52963,"Protocol Status","Pending","25-AUG-2011","Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Antiviral Efficacy of Ibalizumab","A5299","23-SEP-2011","Pending"
52963,"Protocol Status","In Development","07-OCT-2010","Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Antiviral Efficacy of Ibalizumab","A5299","25-AUG-2011","In Development"
52975,"Protocol Status","On Hold","22-NOV-2011","TB Preventive Therapy for Contacts of Drug Resistant TB-infected individuals","A5300","","Other"
52975,"Protocol Status","In Development","20-OCT-2010","TB Preventive Therapy for Contacts of Drug Resistant TB-infected individuals","A5300","22-NOV-2011","In Development"
52980,"Protocol Status","In Development","22-NOV-2010","Anti-PD-1 Antibody (MK3475) for Reducing the HIV Latent Reservoir","A5301","","In Development"
52981,"Protocol Status","In Development","09-DEC-2010","BioBank for Surrogate Marker Research for TB (B-SMART)","A5302","","In Development"
52982,"Protocol Status","Enrolling","17-JAN-2012","Bone, Immunologic, and Virologic Effects of an ARV Regimen","A5303","","Enrolling"
52982,"Protocol Status","Open","01-DEC-2011","Bone, Immunologic, and Virologic Effects of an ARV Regimen","A5303","17-JAN-2012","Open"
52982,"Protocol Status","Pending","15-JUN-2011","Bone, Immunologic, and Virologic Effects of an ARV Regimen","A5303","01-DEC-2011","Pending"
52982,"Protocol Status","In Development","08-NOV-2010","Bone, Immunologic, and Virologic Effects of an ARV Regimen","A5303","15-JUN-2011","In Development"
53009,"Protocol Status","Closed to Accrual","28-JAN-2012","TB Treatment Shortening with Moxifloxacin","A5304","","Closed to Accrual"
53009,"Protocol Status","Closed to Accrual","28-JAN-2012","TB Treatment Shortening with Moxifloxacin","A5304","28-JAN-2012","Closed to Accrual"
53009,"Protocol Status","Enrolling","04-NOV-2011","TB Treatment Shortening with Moxifloxacin","A5304","28-JAN-2012","Enrolling"
53009,"Protocol Status","Open","15-SEP-2011","TB Treatment Shortening with Moxifloxacin","A5304","04-NOV-2011","Open"
53009,"Protocol Status","Open","15-SEP-2011","TB Treatment Shortening with Moxifloxacin","A5304","15-SEP-2011","Open"
53009,"Protocol Status","In Development","25-JAN-2011","TB Treatment Shortening with Moxifloxacin","A5304","15-SEP-2011","In Development"
53016,"Protocol Status","Pending","18-OCT-2011","HPTN 069/MVC,MVC+FTC,MVC+TDF,or TDF+FTC for PrEP To Prevent HIV in Men Who Have Sex with Men","A5305","","Pending"
53016,"Protocol Status","In Development","28-JAN-2011","HPTN 069/MVC,MVC+FTC,MVC+TDF,or TDF+FTC for PrEP To Prevent HIV in Men Who Have Sex with Men","A5305","18-OCT-2011","In Development"
53027,"Protocol Status","Pending","13-FEB-2012","PA824 and RIF with LPV/r, EFV, and TDF","A5306","","Pending"
53027,"Protocol Status","In Development","21-APR-2011","PA824 and RIF with LPV/r, EFV, and TDF","A5306","13-FEB-2012","In Development"
53042,"Protocol Status","Pending","25-JAN-2012","EBA Study of TB Regimens w/ & w/o INH and Moxifloxacin","A5307","","Pending"
53042,"Protocol Status","In Development","02-MAY-2011","EBA Study of TB Regimens w/ & w/o INH and Moxifloxacin","A5307","25-JAN-2012","In Development"
53043,"Protocol Status","In Development","19-MAY-2011","FTC/RPV/TDF on CD4 Cell Count,Inflammatory Biomarkers,T- Cell Activation and Viral Reservoir","A5308","","In Development"
53059,"Protocol Status","Pending","07-DEC-2011","Pharmacokinetics and Drug Interaction Potential of Boceprevir","A5309s","","Pending"
53059,"Protocol Status","In Development","02-MAY-2011","Pharmacokinetics and Drug Interaction Potential of Boceprevir","A5309s","07-DEC-2011","In Development"
53078,"Protocol Status","In Development","15-JUL-2011","Development of a Neuroimaging Network for the ACTG: Site Screening and Preparation","A5310","","In Development"
53080,"Protocol Status","On Hold","08-AUG-2011","Elevated Cystatin C as a Predictor of Renal Disease in HIV Positive Patients on HAART","DACS 287","","Other"
53081,"Protocol Status","Deferred","11-JUL-2011","Influence of HIV Infection and Viral Burden on ApoL1 Plasma Levels","PR 635","","Other"
53083,"Protocol Status","On Hold","12-JUL-2011","Virologic Correlates of ACTG 5217","NWCS 349","","Other"
53094,"Protocol Status","Pending","29-FEB-2012","PK Study of High-Dose Rifapentine in Healthy Volunteers","A5311","","Pending"
53094,"Protocol Status","In Development","24-AUG-2011","PK Study of High-Dose Rifapentine in Healthy Volunteers","A5311","29-FEB-2012","In Development"
53096,"Protocol Status","Deferred","09-JAN-2012","Interactions between DMPA/TB/ART Drugs in the Treatment of Women Co-Infected with HIV and TB","DACS 291","","Other"
53097,"Protocol Status","Deferred","19-SEP-2011","Antiretroviral Intensification, CNS Penetration and Neurocognitive Impairment","PR 638","","Other"
53107,"Protocol Status","Deferred","27-FEB-2012","Effect of Isotretinoin on Immune Activation among Subjects with Incomplete CD4+ T Cell Recovery","PR 640","","Other"
53107,"Protocol Status","Deferred","05-DEC-2011","Effect of Isotretinoin on Immune Activation among Subjects with Incomplete CD4+ T Cell Recovery","PR 640","27-FEB-2012","Other"
53116,"Protocol Status","In Development","25-OCT-2011","High-Dose Isoniazid Among Adult Patients with Different Genetic Variants of INH-Resistant TB","A5312","","In Development"
53118,"Protocol Status","Withdrawn","15-NOV-2011","Effect of TNF Inhibition on Residual Viremia in Patients Undergoing Antiretroviral Therapy","PR 641","","Other"
53121,"Protocol Status","Withdrawn","16-FEB-2012","Safety and Immunogenicity of High-Dose Influenza Vaccine to Standard-Dose Influenza in Adults","A5313","","Other"
53121,"Protocol Status","In Development","18-OCT-2011","Safety and Immunogenicity of High-Dose Influenza Vaccine to Standard-Dose Influenza in Adults","A5313","16-FEB-2012","In Development"
53122,"Protocol Status","In Development","29-NOV-2011","Lowering Inflammation using Very Low Dose Methotrexate on Cardiovascular Risk in HIV Infection","A5314","","In Development"
53124,"Protocol Status","Deferred","29-NOV-2011","ARV-Nave Women Receiving Atazanavir in Combination with Truvada or Epzicom With or Without RTV","PR 642","","Other"
53125,"Protocol Status","Deferred","21-NOV-2011","Effects of Probenecid on Tenofovir-Associated Renal Proximal Tubulopathy","PR 643","","Other"
53128,"Protocol Status","Deferred","06-DEC-2011","Assessing Differential Screening, Eligibility, Enrollment, and Retention in US Phase III Trials","DACS 296","","Other"
53132,"Protocol Status","Deferred","23-JAN-2012","Determining the Role of Resuscitation Promoting Factors in TB Disease","NWCS 351","","Other"
53133,"Protocol Status","Withdrawn","10-JAN-2012","The Effects of HCV Viral Load Reduction on Renal Markers in HIV-Infected Persons","PR 647","","Other"
53133,"Protocol Status","Deferred","22-DEC-2011","The Effects of HCV Viral Load Reduction on Renal Markers in HIV-Infected Persons","PR 647","10-JAN-2012","Other"
53134,"Protocol Status","Deferred","23-JAN-2012","Long-term Effects of ART on Change in Bone Mineral Density in Subjects in ACTG A5001","PR 648","","Other"
53142,"Protocol Status","Deferred","06-FEB-2012","Telomere Length and Telomerase Reverse Transcriptase Activity of Nucleos(t)ide Inhibitors","NWCS 353","","Other"
53143,"Protocol Status","Deferred","23-JAN-2012","Steady State Population Pharmacokinetics (PK) of Bedaquiline and its M2 and M3 Metabolites","NWCS 354","","Other"
53144,"Protocol Status","Deferred","13-MAR-2012","Biomarkers of B-cell Activation and Risk of HIV-Associated NHL on Suppressive ART","NWCS 355","","Other"
53146,"Protocol Status","Deferred","28-FEB-2012","Virologic Failure and Drug Resistance on Boosted Atazanavir Regimens in A5202","NWCS 356","","Other"
53147,"Protocol Status","Deferred","09-FEB-2012","Monocyte and NK Cell Activation as Predictors of Therapy Response in HCV-HIV Co-Infection","NWCS 357","","Other"
53148,"Protocol Status","Deferred","27-FEB-2012","Proteinuria and Neurocognitive Performance in Participants of ALLRT","DACS 297","","Other"
53152,"Protocol Status","In Development","26-MAR-2012","Romidepsin in Subjects with Viremia on ART to Assess Safety, Tolerability, and Activation of HIV","A5315","","In Development"
53155,"Protocol Status","Withdrawn","29-MAR-2012","Beyond Antiretroviral Treatment: HIV-1 Control Mediated by Interferon Immunotherapy (BEAT HIV)","PR 654","","Other"
53162,"Protocol Status","In Development","27-MAR-2012","Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and ART","A5316","","In Development"
53164,"Protocol Status","In Development","05-APR-2012","Effects of Telmisartan on Fibrotic, Inflammatory,and Metabolic Contributors to End-Organ Disease","A5317","","In Development"
